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Abstract 
Background: 
Screening for prostate cancer is a highly debated public health issue. The evidence base is contested, 
the prostate-specific antigen (PSA) test as a screening technology is limited, no medical body 
recommends a population screening program for prostate cancer screening, local authorities differ in 
the advice they offer on the value of PSA screening in clinical care, and the substantial harms 
associated with PSA screening are well documented. Decisions about PSA screening most commonly 
occur in consultation with a general practitioner (GP). This qualitative study was designed to explain 
how GPs understand, reason about, and use the PSA test to screen men for prostate cancer risk in 
primary care. Australia and the United Kingdom draw on the same evidence base for prostate cancer 
screening yet have notably different rates of PSA screening; they are the two locations of this research 
study. In this thesis I report on GP perspectives on PSA screening.  
Methods: 
This is an empirical study using grounded theory methodology. Data were generated from in-depth 
interviews with GPs in Australia and the United Kingdom, who make decisions about using or not 
using the PSA test as a screening tool. Analysis was developed through transcript coding and detailed 
memo writing, using constant comparison to develop insight and connections between concepts. The 
overall aim of the study was to gain an in-depth understanding of how and why clinicians use the PSA 
test to screen for prostate cancer in primary care.  
Main findings: 
This grounded theory study found that for Australian GPs on the frontline, decision making about PSA 
screening is extremely difficult and complex. There was extensive variation in the clinicians’ accounts 
of their screening behaviour. Different motivations (values and goals) of GPs, context of the clinic and 
specific clinical interactions, opportunity to trust, and responses to uncertainty, were central 
explanations for varied practice. GPs intuitively and/or explicitly drew from multiple, potentially 
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conflicting, types of knowledge (including that from the research evidence) - developed over time – to 
guide their screening decisions. The study included UK GPs as a comparison case to examine the place 
of past and present screening policy, and healthcare system structure and organisation in influencing 
and incentivising particular ways of practicing. The UK experience demonstrates that Australian 
screening practices are not inevitable – things can be done differently. Some Australian clinicians in 
this study experienced significant emotional and cognitive burden, as a result of making screening 
decisions under challenging conditions. The empirical chapters of the thesis focus on four key issues: 
managing the potential for overdiagnosis, responding to uncertainty, practice and policy context, and 
communicating about PSA screening. The Discussion chapter draws these findings together into a new 
explanatory model of GPs’ decision making about PSA screening. 
Conclusion: 
This research provides an in-depth comparative analysis of important drivers of prostate cancer 
screening reported from the perspective of GPs in two locations with diverse screening rates. The 
model produced provides an explanation of the complex and varied process of PSA screening in the 
two jurisdictions. Policy continues to evolve and attract substantial debate in this field in Australia. 
Given that past attempts to intervene in PSA screening practice in Australia seem to have had limited 
effect, a new approach that better reflects the complexity of this issue, including the range of drivers of 
current practice, seems warranted. These findings offer useful empirical guidance for future policy and 
practice, grounded in the experiences of clinicians.  
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Preface 
This thesis describes a qualitative study that investigated how general practitioners (GPs) understand, 
reason about, and use the prostate-specific antigen (PSA) test to screen men for prostate cancer risk in 
primary care. Screening for prostate cancer is a complex and notably controversial public health issue 
(1, 2), regularly encountered by a large number of men and GPs, particularly in Australia.  
Internationally, no clinical guideline recommends a population-screening program for prostate cancer 
screening.  This is because current epidemiological evidence about populations indicates that the 
harms associated with PSA screening, such as false positive tests and overdiagnosis, likely outweigh 
any benefits (3, 4). Yet PSA screening rates remain high (5). Little was known about GPs’ views and 
experiences of PSA screening. I wanted to find out how GPs approach this challenging topic. Are they 
concerned about PSA screening? What are they prioritising? My purpose in asking these questions is to 
better understand those factors that are contributing to the current state of PSA screening practice. 
How this thesis is organised 
This thesis is presented in seven chapters, and written so that each chapter can be read independently. 
Chapter One is the introductory chapter. It is divided into three parts: Part I introduces prostate 
cancer and the PSA test as a screening tool. I briefly discuss the complexities of the evidence base for 
PSA screening and conclude with an overview of current policy and recommendations. Part II is a 
review of the literature on how and why primary care clinicians use the PSA test as a screening tool in 
their clinical practice. Part III details the structure of primary care in Australia and the United 
Kingdom to provide context for this study. I conclude Chapter One with my study aims and research 
questions. In Chapter Two, I describe grounded theory methodology and its application in practice in 
this study. Each of the published or submitted papers in this thesis contain some information about 
methods; this chapter presents the methodology and methods for this empirical study as a whole.  
Chapters Three to Six report the findings of my empirical work. Chapter Three is a study of General 
Practitioners’ approaches to PSA screening and reasoning about overdiagnosis and underdiagnosis in 
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primary healthcare. Chapter Four is an analysis of General Practitioners’ experiences of, and responses 
to, uncertainty in prostate cancer screening. Chapter Five is a comparative study of General 
Practitioners’ perspectives on established differences in prostate cancer screening rates between 
Australia and the United Kingdom. Chapter Six presents findings about differences in communication 
accounted for by General Practitioners’ primary goals and practice situations. Chapter Six is in press at 
and replicates the version accepted for publication. Chapter Seven is a discussion paper.  
Published papers are as they appear in the journal. Each chapter contains its own reference list. The 
journal papers vary from one another in formatting and referencing style, reflecting the requirements 
of the publishing journal. Chapters One, Two, and Seven were written specifically for this thesis rather 
than for journal submission. 
A note on terminology: 
The terminology used to describe prescribing an asymptomatic male a PSA test to screen for prostate 
cancer risk is contentious. In the majority of this thesis I use ‘screening’ to refer to PSA testing of 
ostensibly healthy men who are not considered to be at high risk of prostate cancer for their age, and 
‘testing’ to describe PSA tests prescribed for men who have a diagnosis of prostate cancer or are 
experiencing acute symptoms that may suggest prostate disease. In general, I have used the word 
‘screening’ wherever possible. In the empirical chapters (chapters 3-5), which were published in the 
peer-reviewed literature before this thesis was consolidated and submitted, there is more variation in 
terminology.  Regardless of whether the term ‘testing’ or ‘screening’ is used, this analysis focuses on 
the GPs’ use of the PSA test in men who do not appear to be at higher than population-average risk for 
prostate cancer, as specified in the introduction.   
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CHAPTER ONE.  
Introduction 
 
 17 
Part I: Introduction 
1. Overview of this chapter 
There are three parts to this chapter. Part I introduces prostate cancer and prostate-specific antigen 
(PSA) screening for prostate cancer risk. I describe how the PSA test works as a screening tool and the 
diagnosis and treatment of prostate cancer. I trace the development of the evidence base for PSA 
screening and discuss the complexities of that evidence base. Part I concludes with an overview of the 
current state of prostate cancer screening policy and practice. Part II reviews the published 
international literature on how and why primary care clinicians use the PSA test as a screening tool in 
their clinical practice. Part III details the structure of primary care in Australia and the United 
Kingdom - the two locations of focus for this research project - and concludes with my study aims and 
research questions.  
1.1 Prostate cancer 
The prostate is a gland in the male reproductive system. It is about the size of a small apricot and 
sits at the base of the bladder and in front of the rectum. The prostate gland produces a fluid that 
forms part of semen and the muscles of the gland help propel this seminal fluid into the urethra during 
ejaculation (1). Prostate cancer occurs when abnormal cells in the prostate grow in an uncontrolled 
way. Prostate cancer can put pressure on or obstruct the bladder or urethra (the tube that allows urine 
to be released from the bladder) and cause problems with urination and sexual function.  
  
 18 
Figure 1: Location of the prostate gland 
 
ducu59us/www.shutterstock.com (2) 
Prostate cancer is an important cause of death. It was the third most common cause of cancer 
deaths in Australia in 2014. The age-standardised mortality rate in Australia is 26 deaths per 100,000 
males (2014) (3), and 48.1 deaths per 100,000 males in the United Kingdom (2014) (4). 
Prostate cancer incidence ranges widely between population groups. Prostate cancer is the most 
commonly diagnosed cancer in developed countries (5): a six-fold difference in prostate cancer 
incidence has been reported in more developed countries (56.2 cases per 100,000 population) 
compared to less developed countries (9.4 cases per 100,000 population)(6). Internationally, prostate 
cancer incidence is highest in Australia, North America, Northern and Western Europe, and the 
Caribbean, and lowest in Asia (5). Within Australia, prostate cancer incidence is highest among males 
living in the least disadvantaged and inner regional areas of the country and lowest among males 
living in the most disadvantaged and remote areas (2004-8) (7). Similarly in the UK, the incidence of 
prostate cancer is highest in the least deprived areas (and lowest for males living in the most deprived 
area)(8).  
Prostate cancer mortality ranges widely between population groups. (9). Just as prostate cancer 
incidence varies widely between groups, so does prostate cancer mortality. Prostate cancer mortality 
rates are highest in the Caribbean and lowest in South Central Asia (10). This may partly reflect 
varying data quality worldwide. Within Australia, the age-standardised mortality rate was higher 
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among those living in inner regional and outer regional areas compared to those in major cities in 
2006-2010. There is little difference in mortality between the least and most disadvantaged (26.9 and 
27.7 per 100,000 males, respectively)(7). In the UK, there is some regional variation in prostate cancer 
mortality: in 2007-2009, mortality was higher in the East Midlands and lower in London when 
compared to the England average (11). Mortality rates did not show any difference between 
deprivation groups. 
As discussed later in this chapter, incidence and mortality figures are complicated by the effect of PSA 
screening rates on incidence rates, with contestable effects on mortality. 
The factors that determine the risk of developing prostate cancer are not well known. There are 
three well-established risk factors for prostate cancer:  
1. Age. Prostate cancer is rare in men under 50 years (6). The average age of a [US] man 
diagnosed with prostate cancer is approximately 67 years. 71% of prostate cancer deaths 
occur in men older than 75 years (12).  
2. Family history. A man’s risk for developing prostate cancer is higher than average if a brother 
(2.5-3 times higher) or father and two brothers (9-10 times higher) are diagnosed with 
prostate cancer, particularly if they are younger than 60 years at diagnosis (13).  
3. Ethnicity. Men of African and Caribbean descent have a greater risk of developing prostate 
cancer and more advanced disease upon diagnosis compared to white men (14, 15). US 
studies have found little difference in PSA uptake between black and white men (16, 17). 
Prostate cancer is a clinically heterogeneous disease with a variable natural history. This means 
that tumours can range from small, slow growing lesions to very aggressive tumours. Early, localised 
prostate cancers are confined within the prostate and usually do not produce symptoms; some men 
may experience changes in urinary and sexual function. Locally advanced cancer affects nearby 
tissues, such as the bladder and rectum. Metastatic cancer affects other areas in the body, usually the 
lymph nodes or bone. Locally advanced and metastatic cancers can have a significant effect on 
morbidity, mortality, and quality of life (18).  
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The general population harbours a large pool of predominantly latent prostate tumours. These 
microscopic or indolent tumours progress so slowly that the individual generally dies from other 
causes (e.g. heart disease) before the prostate cancer progresses. Autopsy studies have demonstrated 
a high rate of undiagnosed, asymptomatic prostate tumours in men (19). Welch and Black conducted a 
review of evidence from autopsy studies and estimated that men aged over 60 years have a 30-70% 
lifetime risk of dying with prostate cancer but only a 4% lifetime risk of dying from prostate cancer or 
metastatic disease (20). This is arguably the central problem in prostate cancer early detection and 
management, and I will return to it repeatedly throughout this thesis. 
1.2 Screening for prostate cancer 
Screening for cancer or cancer risk is a well-established feature of secondary preventive 
medical care in high-income countries. The purpose of screening programs is to reduce suffering 
and mortality by enabling early intervention. Cancer screening involves the systematic use of a test to 
find asymptomatic disease or disease risk in healthy populations (7).  
Screening for prostate cancer, accordingly, involves testing men to identify early-stage prostate 
cancers so as to enable early (and effective) intervention. The main goal should be to ensure that 
men live longer and experience less suffering. Because so much prostate cancer is latent and relatively 
indolent, however, the challenge is to find those men whose cancer might otherwise have progressed 
to advanced disease, and distinguish them from the many men who harbour a latent prostate cancer 
that would never have become symptomatic.  
Prostate cancer screening mostly uses the prostate-specific antigen (PSA) test. The PSA test is a 
common blood test that measures the total concentration of PSA protein in a man’s blood. PSA is 
prostate-tissue specific but not prostate cancer-specific; it is found in the epithelial tissue of the 
healthy prostate, in benign hyperplastic tissue, and in prostate cancer. Elevated PSA levels may 
indicate an increased risk for the presence of prostate cancer, but can also be caused by conditions 
such as benign prostatic hyperplasia (BPH) (enlargement of the prostate) and prostatitis 
(inflammation of the prostate). There is no evidence that these benign prostate conditions lead to 
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prostate cancer (21). There are no symptoms that can differentiate early prostate cancer from benign 
prostate conditions such as BPH (22).  
Digital rectal examination (DRE) has sometimes also been used for prostate cancer screening.1 
A digital rectal examination involves manual examination of the prostate gland through the rectum to 
check any abnormality in size, shape, or texture. Irregularities such as a swelling, hardening or lumps 
on the surface of the prostate may be signs of prostate cancer (23). Use of the DRE as a screening tool 
is limited due to poor reliability, sensitivity, and the inability to feel the entire prostate and small 
cancers (24). As the focus of this study is the PSA test, rather than DRE, DRE will not be considered in 
any further detail in this thesis. 
In the following section I present the key features of the PSA test when used as a screening tool.  
How does the PSA test work?  
PSA is measured in nanograms/millilitre (ng/ml).  Because the PSA test is a biomarker, a cutoff or 
threshold value must be set at which a result will be considered ‘abnormal’. However these threshold 
values have varied considerably in the literature and practice. The traditional cut-off level of PSA 
concentration in the blood to be considered an abnormal PSA level has ranged from 2.5ng/ml – 
4.0ng/ml in the major screening studies. It is most commonly recommended that patients be referred 
to specialist services for further investigation if their blood PSA concentration is greater than 4.0ng/ml 
(25), though there is some variation in clinical practice. Some practices use a more stringent level of 
2.5ng/ml. Under these conditions, either a PSA result above 4.0ng/ml, or a PSA result above 2.5ng/ml, 
respectively, would be referred to as a positive or abnormal PSA result to guide further clinical 
investigation.  
                                                             
1 Guidelines vary in relation to whether DRE should be performed alongside PSA. The combination of DRE and PSA testing 
may improve prostate cancer detection rates compared to either test used alone; the USPSTF reports that screening 
programs including DRE alone have not been adequately evaluated in controlled studies. In Australia, the NHMRC does not 
recommend DRE as a routine addition to PSA testing of asymptomatic men in the primary care setting. In the United 
Kingdom, following a recent modification to policy, GPs are advised to consider DRE findings in conjunction with PSA results.  
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Any choice of PSA cut-off involves a trade-off between sensitivity and specificity. With a cut-off 
point of 4.0ng/ml, the PSA test is reported to have sensitivity - the ability to detect cancer if it is there - 
of approximately 21% for detecting any prostate cancer and 51% for detecting high-grade cancers. 
The estimated specificity - the ability to give a true negative test result - is 91% (26). While lowering 
the PSA cut-off would improve test sensitivity and therefore lower the chance of missing clinically 
significant cancers, a lower PSA cut-off would reduce specificity, leading to more false-positive tests 
and unnecessary biopsies (27). This has been the source of considerable disagreement, and will be 
discussed in Section 1.5. 
Age-adjusted PSA values were introduced in 1993 to improve the clinical impact of PSA. 
Different ‘normal’ reference ranges may be a means of improving specificity of the PSA test. PSA levels 
are influenced by the size of the prostate. As men age, it is common for the prostate to become larger, 
leading to higher levels of PSA in the blood and therefore impacting on the diagnostic performance of 
the test. Different normal reference ranges may be appropriate based upon a man’s age (27). Age-
defined PSA levels consider the impact of age on the diagnostic performance of the test. They also aim 
to reduce unnecessary investigation of older patients (28). The usefulness of age-specific PSA ranges 
remains controversial (29). 
Table 1: Upper limits of "normal" serum PSA concentration at different age groups (ng/ml)(30)2 
Age range Upper limit of normal (ng/ml) 
40-49 2.5 
50-59 3.5 
60-69 4.5 
70-79 6.5 
 
In Australia, the National Health and Medical Research Council (NHMRC) and Royal College of 
Pathologists (RCPA) recommend that PSA results be interpreted with reference to age-related 
                                                             
2Oesterling et al were among the first to establish age-specific normalised serum PSA values. They found serum PSA 
concentrations strongly correlated with age and prostatic volume. To define reference ranges, the authors condensed PSA 
values in a set of 471 reference individuals per decade. Using a regression method, the 95th percentile was determined as 
the upper limit of normal (reference range) 
 
 23 
cut-offs (31). This level is quoted on the patients’ results by the pathology laboratory undertaking the 
analysis (32). In contrast, the UK National Health Service (NHS) has recently set PSA >3.0ng/ml for all 
men, regardless of their age (33). Other variations have been suggested to improve detection of 
clinically important cases of prostate cancer, including the use of age-adjusted PSA cut-offs, free PSA, 
and PSA density, slope, and doubling time. No evidence has so far demonstrated that any of these 
testing strategies improve health outcomes (12) and I will not consider them in any detail here. 
Regardless of the threshold chosen, an “abnormal” PSA result does not indicate ill health in a clinical 
sense; PSA levels are an indicator of the possible existence of prostate disease, rather than being a 
reliable indicator of the presence or absence of prostate cancer.  
Some, mostly urological societies, advocate for baseline PSA screening at or after age 40. 
Measuring PSA levels in younger men (45-49 years) may predict long-term risk of developing 
metastatic prostate cancer (34, 35). It is suggested that PSA levels at midlife can be used to stratify the 
intensity of screening over the next two decades of life (36, 37). In Australia, the 2013 Melbourne 
consensus statement recommended baseline PSA screening of men in their 40s to predict the future 
risk of prostate cancer and its aggressive forms (38). Advocates suggest that this risk-adapted 
approach may reduce the cost of screening, decrease over-detection of inconsequential tumours, and 
maintain detection of potentially lethal cancers (39).  
1.3 Diagnosis of prostate cancer 
If a screening test suggests higher than average risk, the next step is generally to refer the person for 
more testing, possibly a repeat of the screening test, and if concerns persist, diagnostic testing. 
A prostate biopsy is the only method by which prostate cancer can be definitively diagnosed. 
TRUS-guided (i.e. under ultrasound guidance) or transperineal biopsy are currently the most common 
follow-up investigative procedures for asymptomatic men with an elevated PSA test result. Both 
procedures use a biopsy gun to collect tissue samples from regions of the prostate through the rectum. 
Generally there is no obvious lump to remove so urologists sample cells from different portions of the 
prostate. In Australia, different providers take different numbers of core samples. Historically, six 
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needle biopsy samples were taken; now, many urologists are advocating 12 or more, noting that the 
more samples that are taken, the more cancer is found (40). In the UK, a TRUS-guided biopsy involves 
taking 10-12 cores of prostatic tissue (41). Some researchers advocate for ‘saturation biopsy’, whereby 
32 to 38 needle biopsy samples are taken, arguing that these increase the detection rate for 
microscopic cancers when compared with repeated normal biopsy procedures (42).  
The diagnosis and grading of prostate cancer is based on histopathological examination of the 
collected biopsy samples. When a cancer is detected, biopsies can provide information about the 
stage and location of the cancer within the prostate, indicate whether the cancer remains localised, 
and how different the tumour looks from normal prostate tissue to suggest how aggressively it is likely 
to behave.  
A prostate cancer’s stage refers to its extent at diagnosis. Staging is important to both estimating 
prognosis and selecting treatment. The most important distinction in staging a prostate cancer is 
whether or not it appears confined to the prostate. T1 and T2 cancers are confined to the prostate (i.e. 
“early stage cancers”). T3 and T4 cancers have grown beyond the prostate into adjacent tissues (i.e. 
“locally advanced cancers”). Prostate cancers that have spread to local lymph nodes or beyond are 
incurable and are referred to as metastatic cancers (22).  
A prostate cancer’s grade refers to how aggressive the cells of the tumour look under a 
microscope. The Gleason score is the standard method of classifying prostate cancers. The pathologist 
looks at the samples and assigns a score from 1 (least aggressive looking or ‘low grade’) to 5 (most 
aggressive looking or high grade) to the most common and second most common pattern they see. 
These grades are combined to produce the Gleason score, ranging from 2 to 10. A lower Gleason score 
(5 or less) indicates a slower growing cancer, less likely to progress, behaving less aggressively, and a 
better prognosis. A higher Gleason score (8 to 10) indicates a faster growing cancer, more likely to 
spread beyond the prostate, and therefore behaving more aggressively. Most men have Gleason scores 
in the middle range (6 or 7). In practice, it is unusual for pathologists to report a Gleason score of less 
than 4 (22). 
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1.4 Treatment of prostate cancer 
Once a man is diagnosed with prostate cancer, making treatment decisions is complex. 
Treatment and management options for the treatment of prostate cancer vary depending on 
the cancer type. There is a broad spectrum of prostatic cancer from slow growing “clinically 
insignificant” tumours to rapidly growing “clinically significant” tumours. Treatment varies from active 
surveillance alone to multimodality treatment. Active treatment options include radical 
prostatectomy, radiation therapy, and androgen deprivation therapy. Table 2 below presents the 
various treatment options available to men who are diagnosed with prostate cancer. I present 
potential harms associated with the various treatment options in Section 1.5.  
Table 2: Treatment options available to men who are diagnosed with prostate cancer 
Treatment pathway About this treatment option 
Active surveillance  Aim: delay curative treatment until there are signs of disease progression to avoid 
unnecessary, potentially harmful, treatments and complications (43) 
 Used in younger, healthy men with low-risk/low-grade cancer  
 Can include PSA screening, digital rectal examination, repeated biopsies, and/or MRI 
(44) 
 Increasingly popular internationally (45) 
Watchful waiting  Aim: delay palliative treatment until there are signs of disease progression 
 Used in men unlikely to benefit from aggressive treatment, such as the elderly, those 
with limited life expectancy, or comorbid conditions (26) 
 A passive management strategy; monitoring may occur regularly depending on the 
patient 
Radical retropubic 
prostatectomy 
 Aim: to remove the prostate gland, part of the urethra, and seminal vesicles  
 Used in men with clinically localised cancer; the most common treatment (46) 
 The use of robotic-assisted prostatectomy (the “da Vinci” robotic surgery machine) 
has surged and has received a lot of publicity 
Radiation therapy  Aim: to kill cancer cells via high-energy rays 
 Used in men with earlier stage cancers (internal and external), or to help relieve 
symptoms such as bone pain if the cancer has spread to a specific area or bone 
 Two main types: external beam radiation therapy (EBRT) and brachytherapy (7)  
Androgen deprivation 
therapy 
 Aim: to keep cancer cells from getting the male hormones they need to grow. Does 
not cure prostate cancer 
 Used in men with advanced disease 
 Involves oral or injection medications, or surgical removal of testicles to lower or 
block circulating androgens (7)  
 
Having presented the basics of prostate cancer disease, PSA screening, and prostate cancer diagnosis 
and treatment, I will now consider the contested evidence for using the PSA test as a screening tool in 
asymptomatic men.  
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1.5 Complexities of the evidence base for prostate cancer screening 
This section presents the complexities of the evidence base for prostate cancer screening practices, 
beginning with a brief discussion of the history and relevance of evidence based medicine (EBM).  
The rise of PSA screening and evidence-based medicine (EBM) 
It is generally accepted that Richard J Ablin first observed the PSA antigen in 1970; it was taken 
up by law enforcement agencies to produce material evidence of sexual assault in criminal cases (47). 
The first commercial PSA test was approved by the US Food and Drugs Administration (FDA) in 1986 
to monitor the progression of prostate cancer in men who had already been diagnosed with the 
disease. A landmark study by Stamey et al published in the New England Journal of Medicine (NEJM) 
correlated higher levels of serum PSA with advancing stages of prostate cancer – establishing PSA as a 
useful marker for residual and recurrent disease (48). A 1991 NEJM study of 1600 men by urologist 
William Catalona reported that PSA screening could increase prostate cancer detection by 20% over 
rectal examination (49). It was highly influential because at the time, nearly 20% of men diagnosed 
with prostate cancer had an advanced form, motivating clinicians towards early detection (50). 
Clinician and patient demand for PSA screening increased dramatically following publication of the 
Catalona study, and its associated publicity and enthusiastic media coverage (51). Mass media 
campaigns were launched nationally in the United States for the ‘ignored male disease’ and there were 
widespread gender equity arguments in support of making the PSA test available (52). 
While no formal screening program existed, PSA testing of asymptomatic men became 
widespread between 1986 and 1994 in the United States and Australia. It was effortlessly 
integrated into clinical care because it was easily accessible, inexpensive, and not invasive. Public 
awareness of PSA was high; in the US, mobile prostate screening vans were launched at sporting 
events and health fairs with the purpose of recruiting asymptomatic men to be screened (53). At this 
time, the PSA test had not yet been approved beyond the purpose of monitoring recurrence of disease. 
But a market for screening had been created (54).  
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Public and professional belief in the value of prostate cancer screening occurred before efficacy 
data from randomised trials was available. Proponents of screening advised clinicians to err on the 
“safe” side and offer screening, with justification that many men would miss out on the benefits of 
screening while waiting for the generation of evidence (55). On this view, the possibility of benefit 
trumped concerns about lack of demonstrated effectiveness.  
In 1994, the FDA approved the use of the PSA test in conjunction with a DRE to test 
asymptomatic men for prostate cancer. Other high-income countries, including Australia and the 
UK, provided similar approval shortly after. 
The PSA has been a controversial screening test since its establishment in clinical care. Before 
the PSA test was approved as a screening tool in the United States, peak medical bodies including the 
American Cancer Society (ACS) (56), American Urological Association (AUA) (57), and the American 
College of Radiology (58), recommended annual PSA screening for all men aged over 50 or for men 
over 40 years of age with a family history or of African American descent. Other professional bodies 
including the American College of Physicians (ACP)(59) and American Academy of Family Physicians 
(AFP) (60) found the evidence questionable and explicitly called for processes of informed consent 
(51). In 1996 the United States Preventive Services Taskforce (USPSTF) declined to recommend in 
favour of PSA screening owing to the as yet unproven benefits of screening asymptomatic men, and 
potential harms (61). Others also declined, citing insufficient evidence, including the National Cancer 
Institute (NCI). In 1997 the American Cancer Society qualified its recommendation for annual PSA 
screening to advise that men be informed of the potential harms of PSA screening as well as the 
benefits prior to being screened (62). 
The Australian Cancer Society (now Cancer Council Australia) consistently advised against 
screening, from the time of its initial policy statement for health professionals released in 1995 (63); 
a position at odds with the American Cancer Society. The Royal Australian College of General 
Practitioners (RACGP) recommended against screening with either DRE or PSA in 1994 (64), despite 
increasing calls for the introduction of a prostate screening program from community groups. The 
growth in de facto screening in Australia alongside conflicting international positions on PSA 
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screening prompted the Commonwealth Government to clarify the purpose of PSA testing in primary 
care. In 1996, the Australian Health Technology Advisory Committee (AHTAC) produced an evidence 
review and report recommending against prostate cancer screening, on the basis that the evidence did 
not meet accepted criteria for benefits, risks, and costs (65). The report did not recommend any policy 
action to reduce the informal screening occurring in primary care. 
In the United Kingdom, policy and health professionals resisted PSA screening from its 
inception. Two systematic reviews commissioned by the National Screening Committee (NSC) in 1996 
each concluded that the available worldwide evidence gave no suggestion that screening would do 
more good than harm (66, 67). However in 1998, in response to public pressure and demand for 
prostate screening, the UK NSC announced that, although a national screening program would not be 
introduced, an informed choice initiative would be developed. The Prostate Cancer Risk Management 
Programme (PCRMP) was subsequently launched in 2002, referred to as the ‘compromise policy’ (68). 
This programme meant that men could receive a PSA test within the NHS if they had been fully 
counselled on the risks and benefits. 
During this period, the evidence-based medicine (EBM) movement was also gaining 
momentum. Evidence-based medicine first emerged in the 1990s, with the aim to improve clinical 
practice with better evidence (69). It represented a shift from medicine’s traditional reliance on 
clinical judgment as the foundation for medical decision-making (70) towards using current evidence 
to guide the process. The stated goal of EBM was to establish a scientific foundation for medical 
practice and medical decision-making (71).  
The EBM movement emphasised empirical evidence from formal and systematic 
epidemiological research (69, 70, 72). Evidence was arranged in a hierarchy, with prospective 
randomised controlled trials (RCTs) and systematic reviews of those trials at the top (69). 
Retrospective and observational studies were less-well respected as forms of evidence. When PSA 
screening became popular, the evidence about it was strongly dominated by observational studies and 
retrospective analyses, not rigorous prospective studies measuring mortality or quality of life 
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outcomes (73). Difficulties in calculating causation and treatment benefits on the basis of 
observational data are well known (74). 
A well-designed randomised controlled trial (RCT) is the gold standard for evaluating whether 
or not screening is making a difference: RCTs allow an accurate estimate of the number of men for 
whom early diagnosis and treatment impact on mortality as an endpoint (12).  
RCTs are necessary because the evaluation of cancer screening is prone to several biases. 
Evidence about screening is particularly subject to lead time and length time bias, which I will discuss 
in relation to PSA screening. Lead time bias (Figure 2) occurs when a PSA test detects the prostate 
cancer before the onset of symptoms but does not change the time of death from the cancer. The 
survival of a patient who would develop symptoms at age 60 and die at age 70 will seemingly double if 
he is diagnosed through screening at age 50 and dies at the same age. The only real effect is that the 
man is aware that he has prostate cancer for a longer time (75). PSA screening (as opposed to 
diagnosis on symptomatic presentation) is more likely to detect a greater proportion of slowly 
progressive cancers, which have a better prognosis even in the absence of screening, including longer 
survival (length time bias). This exaggerates the survival benefits of screening. Survival rates include 
people with non-progressive prostate cancers, who die from something other than the prostate cancer 
(overdiagnosis bias, Figure 3). Overdiagnosis is discussed below and in Chapter 3.  
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Figure 2: Lead-time bias. Even if the time of death is not changed by screening—and thus no life is saved or prolonged—
advancing the time of diagnosis in this way can result in increased 5-year survival rates, causing such statistics to be misleading 
(figure based on the original) (76) 
 
Figure 3: Overdiagnosis bias. Even if the number of people who die is not changed by screening—and thus no life is saved or 
prolonged—screening-detected non-progressive cancers can inflate the 5-year survival rates, causing such statistics to be 
misleading (figure based on the original) (76) 
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Detecting histological prostate cancer even though it may not cause symptoms or death has 
important implications for the interpretation of prostate cancer incidence data (77). Like 
survival rates, incidence rates include life-saving diagnoses as well as those ‘screen-detected’ cancers 
that would not have been diagnosed in the absence of screening nor threatened lives in the absence of 
screening (78) – so it is expected that more screening produces higher incidence (including indolent 
cancers). The age-standardised prostate cancer incidence rate in Australia increased from 80 cases per 
100,000 males in 1982 to 163 cases per 100,000 males in 2012 (79). This is likely to have arisen, at 
least in part, due to the uptake of PSA screening.  
Figure 4: Age-standardised incidence rates for prostate cancer 1982-2013 and age-standardised mortality rates for prostate 
cancer 1968-2014, males, in Australia (79) 
 
 
In situations where cancer overdiagnosis through screening is occurring, the incidence of 
disease will tend to increase without much improvement in mortality from the disease. Many of 
the new cases of early-stage prostate cancer will not cause death if left untreated. Although there has 
been a decrease in prostate cancer mortality over time in Australia, from 36 deaths per 100,000 males 
in 1968 to 26 deaths per 100,000 males in 2014 (Figure 4), the rate has remained relatively stable for 
nearly 50 years (22), despite dramatic increases in prostate cancer incidence. Whether mortality 
trends can be ascribed to PSA screening is debated and difficult to determine. 
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A major development in the evidence base regarding PSA screening was the publication of two major 
RCTs.  
The development of an evidence base for prostate cancer screening 
Although RCTs are necessary to rigorously evaluate screening, conducting them is extremely resource 
intensive, generally taking at least 10-15 years (80). As previously discussed, the popularisation of PSA 
screening ran well ahead of any plans to conduct an RCT.  
The continued debate over PSA screening in the 1990s prompted the initiation of a large, 
randomised controlled trial in the United States (the Prostate, Lung, Colorectal and Ovary 
(PLCO) screening trial) and another in Europe (the European Randomized Study of Screening 
for Prostate Cancer (ERSPC) (Table 3). The trials sought to answer the question of whether 
screening leads to an improvement in overall mortality – Will men over 50 years be likely to live 
longer, and/or be less likely to die of prostate cancer, if they have regular PSA tests? The aim was to 
enable definitive conclusions about the value of PSA screening.  
The two RCTs had different control arms. ERSPC in Europe compared mass PSA screening for 
prostate cancer to no screening. PLCO in the US compared PSA screening to men following their usual 
medical care. However widespread promotion of PSA screening in the US before its effectiveness was 
proven was problematic for the PLCO trial. There was a high contamination rate: 52% of men in the 
control group (no screening) underwent screening, because ‘usual care’ for control group participants 
was opportunistic screening by the time the PLCO trial had begun (81).  
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A difference in the rate of deaths from prostate cancer was the most important endpoint in 
both trials. Additional reported outcomes included prostate cancer diagnosis, all-cause mortality, 
clinical stage, Gleason score, and treatment follow-up. The studies also provided some data on harms 
associated with screening. Given the controversy, the results of the RCTs were much anticipated (51).  
Both study results were published simultaneously in the New England Journal of Medicine 
(NEJM) in 2009, and were among the 15 most frequently cited medical reports of 2009. This attention 
was attributable largely to the intense confusion they created, as their results were apparently 
contradictory. There were major differences between the trials with respect to recruitment 
procedures, screening interventions, PSA cut-off values, and screening intervals. I briefly summarise 
the design, findings, and limitations of the two trials in Table 3. The primary point to note is that the 
ERSPC trial reported a reduction in risk of death from prostate cancer as a result of screening with the 
PSA test while the PLCO trial did not. 
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Table 3: My summary of the PLCO and ERSPC clinical trials 
The Prostate Lung Colorectal and Ovarian Trial 
(PLCO) 
The European Randomized Study of Screening for Prostate Cancer 
( ERSPC) 
 Men from 10 study centres across the USA 
 Trial conducted 1993 – 2001 
 76,685 men aged 55-74 years 
 Men randomised 1:1 to either the screening or control group. Men received either annual 
screening as the intervention or usual care as the control (usual care sometimes included 
screening) 
 Men with a previous history of prostate cancer and men currently receiving cancer 
treatment were excluded from participation  
 The methodological approach was uniform across all sites 
 Men in screening group were offered an annual PSA test for 6 years, of which 4 of the years 
also included an annual digital rectal examination  
 A PSA value greater than 4.0ng/ml was considered to be a positive screening result 
 Compliance: 85% and 86% of men randomised to the screening group complied with the 
screening protocol for PSA screening and digital rectal examination, respectively 
 Contamination: 52% of men assigned to the control group (no screening) underwent 
screening (82) 
 
RESEARCH QUESTION 
 
 Does screening with digital rectal examination plus prostate-specific antigen reduce 
mortality from prostate cancer in men aged 55-74? 
 
 
PRIMARY OUTCOME  
 
 Prostate cancer mortality 
 
FINDINGS 
 
 Did not identify a significant reduction in prostate cancer-specific mortality (RR 1.15, 95% 
CI 0.86 to 1.54) in the screened group, with results at 10 years of follow-up  
 
 
 
 
 
 
 
 Men from sites in 7 European countries (Belgium, Finland, Italy, Netherlands, Spain, 
Sweden, Switzerland) 
 Began in 1991, France joined 2001 
 182,160 men aged 50-74 years 
 Men randomised 1:1 to either the screening or control group, with the exception of 
Finland where randomisation was 2:3 
 Men with a previous diagnosis of prostate cancer were excluded 
 Each country used different recruitment procedures, resulting in variations in the 
selection of participants with respect to age and length of follow-up plus different 
screening interventions, PSA cut-off values, and screening intervals 
 Most countries conducted screening every 4 years with the PSA test alone 
 A PSA value greater than 3.0ng/ml was considered to be a positive screening result; 
this differed between sites 
 Compliance: Rates varied across countries, but overall 82.2% of men in the screening 
group received at least one PSA test 
 Contamination: In the control arm, the contamination rate was 30.7% (86) 
 
RESEARCH QUESTION 
 
 Does prostate-specific antigen screening reduce the risk of death from prostate 
cancer in men aged 50-74? 
 
 
PRIMARY OUTCOME  
 
 Prostate cancer mortality in a core age group (55-69 years) 
 
FINDINGS 
 
 Reported a significant reduction in prostate cancer-specific mortality (RR 0.79, 95% 
CI 0.69 to 0.92) in the screened group over a median follow-up duration of 11 years 
 Reported a significant 21% relative reduction (95% CI 31% to 8%) in prostate 
cancer mortality in the core age group 
 All-cause mortality did not differ between the screening and control groups 
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LIMITATIONS 
 
 Did not exclusively evaluate a screening program for prostate cancer. Men with a history of 
any of the cancer types under investigation (lung, colon, or prostate) were excluded from 
participation 
 High rate of contamination in the control group because the trial occurred in an already 
heavily-screened population. Data indicate that contamination substantially limited the 
ability of the PLCO to identify a clinically significant screening benefit (83) 
 A high rate of men had also already been screened prior to entering the study (84). This is 
likely to have eliminated some cancers detectable on screening, which lowers the power of 
the trial to detect a mortality difference (13) 
 Low rate of compliance for prostate biopsy following a positive screening result (85)   
 Detected cancers were treated according to standard (variable) practice. The decision to 
perform a biopsy was at physician discretion. 
 
LIMITATIONS 
 
 Contamination rate not as high as PLCO but still considerable, which may introduce a 
bias towards not finding a benefit of screening 
 The European population was not as quick to adopt PSA screening as the US, and so 
there were fewer people that had been screened prior to study participation 
 It is difficult to assess the level of homogeneity in screening within the control group 
because the study centres were in different countries 
 The variations in the screening and follow-up methodologies employed across the 
eight participating sites may influence the results (82). Each country in the study 
adopted different recruitment procedures, screening interventions, PSA cut-off 
values, and screening intervals 
 The prostate cancer-specific mortality outcome of the trial was affected more by 
Sweden than any other country (87). This centre included younger participants, a 
lower PSA threshold, shorter screening intervals, and a longer follow-up, all of which 
may have affected the outcome 
 Biopsies of men in the screened group were carried out within the screening centres 
within academic institutions, strictly following defined biopsy indications. This 
raises the question of whether those men received better treatment (88). 
Compliance with biopsy indications was high. 
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Strong criticism of both the ERSPC and PLCO studies and their methodological limitations were 
and remain at the centre of public and professional debate (89). Despite this, results from both have 
been included in major reviews for the development of international policy on PSA screening. The 
Cochrane Collaboration - internationally recognised as the leading evidence synthesis resource – 
conducted a 2013 review and meta-analysis that included data from the PLCO and ERSPC. The authors 
concluded that prostate cancer screening did not result in a statistically significant reduction in all-cause 
mortality compared with no screening (RR 1.00; 95% CI 0.96-1.03) (82). 
Table 4 below presents the summary of the evidence prepared by the RACGP for its members post-ERSPC 
and PLCO 2 (90). It illustrates the complex balance between benefits and harms that GPs and men need to 
consider when making decisions about screening for prostate cancer. Supporting people to understand 
these benefits and harms – which is typically the role of a GP - is no small task (91). 
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Table 4: Risks and benefits of PSA screening; adapted from Harding Centre for Risk Literacy 1000 men graph3 
1000 men aged 55-69 years 
 
WITHOUT annual PSA screening over 11 years WITH annual PSA screening over 11 years 
5 men die from prostate cancer 4 men die from prostate cancer, 1 man is possibly 
saved through screening 
190 men die from other causes 190 men die from other causes 
55 men alive with symptomatic prostate cancer 55 men alive with symptomatic prostate cancer 
782 men alive with no prostate cancer 715 men alive with no prostate cancer 
 87 men learned after biopsy their PSA result was a false 
positive 
28 men have side effects that require healthcare or 
hospitalisation after a biopsy 
25 men will choose to have treatment due to uncertainty 
about which cancers need to be treated. Many of these 
men would do well without treatment (i.e. they are over-
treated) 
37 men with an elevated PSA were found to have slow-
growing cancers (i.e. harmless and therefore over-
diagnosed) 
7-10 men who have treatment will experience impotence 
and/or urinary incontinence or bowel problems. 0.5 men 
have a heart attack due to treatment. 
 
Potential benefits and harms from screening for prostate cancer 
Recommendations against screening for prostate cancer derive from the conclusion that the 
associated harms may outweigh any likely benefits (92). Decision making about PSA screening 
involves weighing up a wide range of potential benefits and harms. 
The primary reported benefits of screening for prostate cancer include: 
 Decreased prostate cancer mortality: PSA screening may have prostate cancer-specific mortality 
benefit among some age groups: the most recent data from the ERSPC trial reports a difference in 
                                                             
3 This fact sheet was developed by Professor Lyndal Trevena, University of Sydney; Professor Paul Glasziou, Bond University; 
Adjunct Associate Professor Leanne Rowe, University of Sydney; and Dr Evan Ackermann, RACGP National Standing Committee 
– Quality Care. Published August 2015. © The Royal Australian College of General Practitioners 
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prostate cancer-specific mortality of 1.3 deaths per 1000 men over 13 years of follow-up (93); no 
data demonstrate a reduction in all-cause mortality (82). 
 Decreased incidence of metastatic prostate cancer: PSA screening may decrease the risk of 
developing metastatic disease; the ERSPC showed that PSA screening almost halved the risk of 
metastatic prostate cancer presentation (82, 94). 
 Reassurance provided by a PSA test result.  
The primary reported harms of screening for prostate cancer include: 
 False positives: About three-quarters of positive PSA test results are false-positives, when cut-offs 
between 2.5 and 4.0ng/ml are used (95). However there is no clear threshold at which prostate 
cancer can be conclusively diagnosed or ruled out from the results of a PSA test (96, 97). 
 Overdiagnosis: The extent of overdiagnosis of indolent nonlethal prostate cancers, combined with 
the frequency and severity of treatment for such cancers, is arguably the most relevant harm 
limiting the acceptability of population screening for prostate cancer (26).  Data from the ERSPC 
show approximately 35 overdiagnosed cases per 1000 men screened (27 additional cases per 
prostate cancer death averted) (93).  
 Overtreatment: Treatment of overdiagnosed cases is considered both unnecessary because it 
does not improve disease outcome and is needlessly harmful because the treatments that follow 
are associated with substantial costs, increased risk of morbidity and compromised quality of life 
(98). Urinary incontinence, and erectile and bowel dysfunction are common harms of treatments 
(12, 82) and may be long lasting (99).  
Limiting estimates of the harms of PSA screening to the harms of having a blood test alone, without 
considering other diagnostic and treatment harms, does not reflect current clinical practice 
because of the propensity by clinicians and patients to treat screen-detected cancer (12). In men 
diagnosed with cancer, 50 to 75% have low-grade disease (Gleason score <6), posing minimal 
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symptomatic or metastatic threat during their lifetime (100). Yet high numbers of men with PSA-detected 
prostate cancer opt to receive early treatment (101). 
There is ongoing debate in the medical and broader community as to the value of PSA screening at 
both the population level and to the individual, with particular concern about the high [over]diagnosis 
rate and overtreatment of prostate cancer, especially low-risk cases (102, 103). The decision to engage in 
or offer PSA screening is almost always made by clinicians in primary care, in consultation, or not, with 
patients. In the following section I summarise explanations for why prostate cancer screening is such a 
challenge for GPs and policymakers. 
1.6 The cultural context for PSA screening 
PSA screening has been heavily debated in healthcare literature and mainstream media. The 
USPSTF decision recommending against screening for prostate cancer in 2012 was widely criticised in the 
media and in the scientific literature (104, 105), including by the American Urological Association (AUA), 
who accused the USPSTF of doing a great disservice to American men (106). 
 
Figure 5: A snapshot of responses: a number of groups discredited recommendations by the USPSTF against PSA screening 
 
Urologists Outraged over Government Panel’s Recommendation to Stop 
Life-Saving Prostate Cancer Testing (107) 
Prostate Cancer, to Screen or Not to Screen: What a Stupid 
Question or How the USPSTF Got it all Wrong (108) 
 
The USPSTF position "condemns tens of thousands of men to die this year and every 
year going forward" (109) 
 
  
 40 
Advocates of screening have been aggressive towards those who have expressed reservations 
about the value of PSA screening. For example, in Australia in 2003, Alan Coates – a senior cancer-
control authority - at 59 years, publicly declared that he personally would not seek PSA screening. Coates’ 
position generated a widespread negative response, despite none of Australia’s key cancer or public 
health bodies endorsing prostate screening at the time (110, 111). Coates was referred to as ‘the apostate 
professor’. It was alleged that it was ‘completely inappropriate for the chief executive of the Cancer 
Council, which runs a message that early detection is the best protection, to say that in his personal case 
he doesn’t believe in it’ [sic] (110, 112). 
GPs are faced with patient demand and medical industrial support for PSA screening within and 
outside of the clinical setting (51). The commercial interests of test manufacturers and urologists have 
likely driven the spread of, and enthusiasm for screening. In 2010, Richard Ablin, the scientist who 
discovered the PSA test in 1970, argued against routine PSA screening, calling it a ‘profit-driven public 
health disaster’ (54). 
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Highly publicised, sometimes misleading messages, have created a screening culture. Many mass 
campaigns urging men to ‘get tested’ have played out over the years in Australia and overseas. Men who 
have had their prostates removed become committed advocates for screening, ‘living proof’ that screening 
can save lives. The websites of advocacy groups that promote the benefits of screening commonly list a 
range of commercial sponsors in the pharmaceutical, medical equipment, and pathology industries, who 
could benefit financially from large numbers of men being screened and treated. 
 
Figure 6: Examples of ads and campaigns promoting PSA screening 
4 5 6
7 8 
                                                             
4 Everyman Cancer campaign, The Institute of Cancer Research. Image available at https://charityuknews.wordpress.com/tag/fumblefriday-
prostatecancer-patricksedgwick-balls/#jp-carousel-25509. Accessed May 08, 2017. 
5 Your Prostate Your Decision campaign, Zero – The End of Prostate Cancer, Prostate Health Education Network and Men’s Health Network with 
support from Genomic Health. Image available at http://www.multivu.com/players/English/7322251-your-prostate-your-decision-joe-torre-talks-
about-prostate-cancer-genomic-testing-treatment-options-psa/. Accessed May 08, 2017. 
6 Ben Stiller Reveals Prostate Cancer Diagnosis, Advocates PSA Tests, NBC Nightly News. Video available at http://www.nbcnews.com/nightly-
news/video/actor-ben-stiller-reveals-he-had-prostate-cancer-advocates-routine-psa-tests-779195459673. Accessed May 08, 2017.  
7 What’s Your Number? campaign, Prostate Cancer Canada. Image available at   http://marketingmag.ca/brands/prostate-cancer-canada-wants-
to-talk-numbers-2395/. Accessed May 08, 2017. 
8 Stand By Your Man campaign, ITV and Prostate Cancer UK. Image available at http://www.itv.com/news/calendar/2013-06-11/stand-by-your-
man-prostate-cancer-awareness-campaign/. Accessed May 08, 2017. 
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Campaigns target men as consumers of health care, encourage individual decisions about screening, 
and thereby add to demand for the test. Messages contained in the ads and slogans can also be false and 
misleading (Figures 6, 7). For example, an Australian campaign featuring young, healthy male sporting 
and acting celebrities, claiming that prostate cancer kills men just like me. Mortality data shows there were 
no cases of men just like them in their 30s who died of prostate cancer in Australia (7, 22).  
 
Figure 7: Examples of persuasive slogans that campaigns have used to encourage men 
to undergo or talk to their GP about PSA screening 
 
 “Man Up!” 9,10 
 “Do it for Dad” 11 
 “Fight for your man” 12 
 “The stats that every real man knows” 13 
 
To complete part 1 of this chapter I present the current state of PSA screening policy and practice. 
  
                                                             
9 Blue September campaign, Prostate Cancer Foundation of New Zealand. http://blueseptember.org.nz/. Accessed May 08, 2017. 
10 Man Up! Australia. http://manupaustralia.org.au/. Accessed May 08, 2017. 
11 Do It For Dads walk run, Prostate Cancer Canada. https://secure.e2rm.com/registrant/LoginRegister.aspx?eventid=213563&langpref=en-
CA&Referrer=https%3a%2f%2fwww.google.com.au%2f. Accessed May 08, 2017.      
12 Fight For Your Man campaign, Janssen Phils. and Healthway Medical Clinics. http://lifestyle.inquirer.net/133143/women-urged-fight-for-
your-mans-prostate/. Accessed May 08, 2017.  
13 STATS campaign, The Prostate Cancer Charity UK. https://www.coloribus.com/adsarchive/prints/the-prostate-cancer-charity-stats-
7891855/. Accessed May 08, 2017. 
 43 
1.7 The current state of practice 
Because population PSA screening is not generally supported (unlike population screening 
programmes such as those for bowel or cervical cancer) prostate cancer screening is not centrally 
organised, there is not a population register or invitation system, and recruitment is primarily via 
clinicians in a primary care setting. In Australia and the United Kingdom, prostate screening is largely 
opportunistic – incorporated as part of a medical consultation and request initiated by the person being 
screened and/or his physician. Routine screening is common, especially in the Australian context, and 
occurs almost always in primary care settings (113). 
GPs are the first point of contact for men wanting to know whether to undertake screening or not 
in Australia and the UK. An important starting point is to understand what the peak medical bodies 
advise GPs to do in their role as gatekeepers to the PSA screening test, and to specialist services. PSA 
screening is a particular case study for which new evidence has prompted the withdrawal of previous 
recommendations; this occurred several times over the course of this thesis (2012-2016). Table 5 
summarises the position of the main relevant health authorities advising GPs on what to do about 
screening men for prostate cancer, in the absence of a national screening programme.  
Most authoritative bodies currently support the concept of patient-informed, shared decision-
making, regardless of whether they support or reject screening for prostate cancer. There is also 
general agreement that (1) PSA screening of older men (>70-75 years) and those with limited life 
expectancy (i.e. <10-15 years) is of limited or no benefit, (2) there are significant downstream harms 
associated with the clinical response to PSA test results, and (3) overtreatment of low-grade tumours is 
problematic (73).  
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While issues with PSA screening are universally acknowledged, some medical bodies have taken 
different positions in terms of the way they advise GPs to approach the issue. For example, while 
both the USPSTF and the AUA acknowledge that existing screening strategies lead to overdiagnosis and 
overtreatment, the USPSTF response is to recommend against screening in all men while the AUA 
recommends limiting screening to specific age ranges and increasing screening intervals. No policy 
position excludes or prohibits PSA screening as an informed choice taken by men in consultation with 
their doctors. 
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Table 5: USA, Australia, and UK recommendations for prostate specific antigen (PSA) screening of asymptomatic males for prostate cancer  
(Note: the USPSTF issued a draft version of updated recommendations shortly before this thesis was submitted; the latest advice, pending public comment, is included in italics) 
 
PROFESSIONAL BODY ADVICE FOR HEALTH PRACTITIONERS SOURCE OF EVIDENCE CONCLUSION ABOUT EVIDENCE 
USA 
United States Preventive Services 
Task Force (USPSTF) (12, 114) 
An independent volunteer panel of 
experts supporting primary care 
practitioners to provide evidence-
based services  
 If men raise PSA screening, or individual 
circumstances warrant, discuss PSA thoroughly 
 If men do not raise/request PSA screening, do not 
feel obligated to offer 
 Do not offer PSA without shared decision making 
 If patient understands benefits/harms, respect his 
preference for screening 
 April 2017: Inform men ages 55 to 69 years about 
the potential benefits and harms of PSA-based 
screening for prostate cancer. Individualise decision 
making following discussion 
 PLCO and ERSPC trials plus 
comprehensive review of the 
evidence examining benefits 
and harms  
 
 
 April 2017: commissioned 
reviews of the evidence of 
screening and treatments, and 
of existing decision analysis 
models 
 The very small mortality 
benefit of PSA-based screening 
for prostate cancer does not 
outweigh the risk of harms 
 
 April 2017: The potential 
benefits and harms of PSA-
based screening for prostate 
cancer in men ages 55-69 years 
are closely balanced 
USA 
American Urological Association 
(AUA) (23) 
A leading advocate for urology 
 If men raise PSA screening, or individual 
circumstances warrant, make individualised 
decision 
 If 55-69 yo man requests PSA screening, use shared 
decision-making 
 Do not routinely screen men aged 40-54 years, men 
>70 years, or with <10-15 year life expectancy 
 ERSPC and PLCO trials plus 
systematic review and meta-
analysis of the published 
literature 1995-2013 
 Screening should still occur, 
but only for certain patients 
 
USA 
American Cancer Society (ACS) 
(115) 
The largest private, not-for-profit 
funder of cancer research. A single 
Board of Directors sets policy and 
related resource allocation 
 Provide men with information about PSA screening 
from 50 years; at 40-45 years for men at higher risk 
 Use discretion to make screening decision for men 
unable to decide  
 DRE may be included 
 A series of systematic evidence 
reviews of published literature 
1950-2009. Results evaluated 
by ACS Prostate Cancer 
Advisory Committee 
 It is not clear if the benefit of 
screening all men for prostate 
cancer outweighs the risks 
 
USA 
American College of Physicians 
(ACP) (116) 
The second-largest physician group in 
the United States  
 Discuss PSA screening thoroughly with men 50-69 
years  
 Do not screen patients who do not express a clear 
preference for screening 
 Do not screen average-risk men under 50 years, 
over 69 years, or with a life expectancy of less than 
10 to 15 years 
 
 Rigorous review of existing 
prostate cancer screening 
guidelines developed by other 
organisations 
 It is important to balance the 
small benefits from screening 
with harms and other side 
effects that result from certain 
forms of aggressive treatment 
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AUSTRALIA 
National Health and Medical 
Research Council (NHMRC) (13) 
Australia’s leading health expert body 
comprising teams of specialists 
providing and promoting evidence-
based public health standards 
 If men raise PSA screening, offer evidence-based 
decisional support  
 Discuss PSA screening thoroughly before making 
screening decisions 
 If informed man requests PSA screening, offer PSA 
test every 2 years from age 50-69 years, and offer 
further investigation if total PSA is greater than 3.0 
ng/ml 
 Do not offer DRE as routine addition to PSA 
 Appraised 7 systematic 
reviews, including PLCO and 
ERSPC trials, plus 
supplementary non-systematic 
review of the literature 
describing benefits and harms 
 
Compared with no PSA screening: 
 There is no effect of PSA 
screening on all-cause 
mortality  
 Present evidence is 
inconsistent as to whether 
there is an effect of PSA 
screening on prostate cancer 
mortality  
 PSA screening reduces the risk 
of prostate cancer metastases 
at diagnosis  
 It is unknown if PSA screening 
affects quality of life due to 
advanced prostate cancer 
AUSTRALIA 
Royal Australian College of General 
Practitioners (RACGP) (117) 
Australia’s largest professional 
general practice organisation; 
supports GPs in patient care 
 Endorsed NHMRC guideline 
 If men do not raise/request PSA screening, do not 
raise this issue 
 If men raise PSA screening, discuss PSA thoroughly 
 Do not offer PSA without shared decision making 
 If a man chooses screening, both PSA and DRE 
should be performed 
 ERSPC and PLCO trials plus 
two systematic reviews (103, 
118) 
 
 Evidence shows the harm of a 
false positive vastly outweighs 
the possible benefit 
AUSTRALIA 
Urological Society of Australia and 
New Zealand (USANZ) (119)  
Peak professional body for urological 
surgeons in Australia and New 
Zealand; works with advocacy and 
support groups such as the Prostate 
Cancer Foundation of Australia 
(PCFA) 
 Endorsed NHMRC guideline. In addition: 
 If younger men (<55yo) are interested, offer single 
PSA test and DRE; individualise follow-up PSA tests 
 If confident, offer DRE to men 55-69 years 
 
 
 ERSPC and PLCO trials 
 
 PSA-based screening, and 
subsequent treatment where 
appropriate, has been shown 
to reduce prostate cancer 
mortality in large randomised 
studies and should be offered 
to appropriately selected 
patients 
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UNITED KINGDOM 
National Health Service (NHS) (120) 
The public health services of England, 
Scotland, and Wales; provides a 
comprehensive range of health 
services 
The National Institute for Health and 
Care Excellence (NICE) advises the 
NHS on effective, good value 
healthcare 
 Do not offer systematic PSA screening 
 GPs should not proactively raise the issue with 
asymptomatic men, but PSA can be provided at 
patient request  
 
 Systematic reviews of the best 
available evidence and explicit 
consideration of cost 
effectiveness 
 When minimal evidence is 
available, recommendations 
are based on the Guideline 
Development Group’s 
experience and opinion of 
what constitutes good practice 
(121) 
 Currently there is no evidence 
that the benefits of a PSA-
based screening programme 
would outweigh the harms 
 More research is needed to 
determine whether a screening 
programme would provide 
men with more benefit than 
harm 
UNITED KINGDOM 
The National Screening Committee 
(NSC) (33) 
The UKNSC reviews screening policies 
every 3 years and makes 
recommendations to ministers in the 
4 UK countries about whether or not a 
screening programme should be set 
up.  
Published the Prostate Cancer Risk 
Management (PCRMP) material for 
GPs 
 Do not offer systematic PSA screening 
 GPs should not proactively raise the issue with 
asymptomatic men, and GPs should use the 
Prostate Cancer Risk Management (PCRMP) 
materials to counsel asymptomatic men aged 50 
and over who ask about PSA screening 
 Any man over the age of 50 years, who asks for a 
PSA test, after careful consideration of the 
implications, should be given one 
 
 Evidence used to support the 
response: PLCO, ERSPC, 
Goteburg subgroup of the 
ERSPC, ProTecT, PROBASE 
Trial 
 Reviewed the evidence 
published between 2010 and 
2014  
 
 Evidence shows a benefit of 
prostate screening to reduce 
prostate cancer deaths by 21%. 
However the evidence is not 
yet sufficient to justify 
introducing a national 
screening programme using 
PSA as the harms still outweigh 
the benefits 
 
UNITED KINGDOM 
The European Association of 
Urology (EAU) (122) 
Leading authority within Europe on 
urological practice, research, and 
education 
 Offer early baseline PSA screening to men at 
elevated risk for prostate cancer (over 50 years, 
men over 45 years with family history, African-
Americans) 
 If man is informed, offer PSA screening and DRE 
 Reviewed the public literature 
1990-2013  
 Included information from the 
ERSPC and PLCO trials, and the 
2013 Cochrane review 
 
 Based on the evidence, an 
individualised risk-adapted 
strategy for early detection 
might be offered to a well-
informed man with at least 10-
15 years of life expectancy.  
 The long term benefit for 
survival and QOL of an early 
baseline screening approach 
remains to be proven at a 
population level  
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PSA screening in general practice 
Since primary care providers play a critical role in screening, it is paramount to examine their 
perspectives on prostate cancer screening in this context of significant controversies and conflicting 
guidelines. GPs in primary care order the majority of PSA screening tests; they have implicitly been given 
the responsibility for guiding men’s decisions about whether or not they should have a PSA test.  
In Part II of this chapter I present a review of the literature about PSA screening in general practice, to 
illustrate existing research interest in this topic and to illuminate gaps in our current understanding of 
these issues. 
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Part II: A review of the literature 
The following section reviews the international literature on how and why primary care clinicians engage 
with, reason about, or use the PSA test for prostate cancer screening in their clinical practice.  
Literature Search 
The review was based on a search of three databases (Medline, Embase, Web of Science). Articles 
published from inception to June 2016 were considered for inclusion. The literature search was 
performed by one researcher (KP). The search was limited to English language. The reference lists of all 
selected articles were also reviewed.  
Search Strategy 
The search strategy, including variations of relevant keywords, was devised with the assistance of a 
university librarian14. 
 
                                                             
14 Medline and Embase: 
1 exp Prostatic Neoplasms/ 
2 prostate cancer.mp. 
3 (cancer adj2 prostate).tw. 
4 exp Prostate-Specific Antigen/ 
5 prostate specific antigen.mp. 
6 (PSA and (test* or screen*)).mp.  
7 exp Primary Health Care/ 
8 general practi*.tw. 
9 GP.tw. 
10 ((family or internal or general) and (doctor or physician or internist)).tw. 
11 (health care and (clinician or professional or provider)).tw. 
12 1 or 2 or 3 
13 4 or 5 or 6 
14 7 or 8 or 9 or 10 or 11 
15 12 and 13 and 14 
Web of Science: 
(prostate cancer) and (prostate specific antigen or PSA) and (screen or screening) and (general practice or primary) and (doctor or physician or 
clinician) 
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Inclusion and Exclusion Criteria 
A study was considered eligible for inclusion if the study participants included primary care providers 
(general practice and/or family practice and/or internal medicine); it reported factors implicated in or 
influencing the use of the PSA test as a screening tool for detecting prostate cancer risk in general 
practice; and it was published in English. Articles were excluded if they were editorials, opinion pieces, 
reviews, or guidelines; focused on patient variables or patients’ point of view; studies on diagnosis, 
treatment and management of prostate cancer; incidence and prevalence studies; and clinical/pathology 
outcome studies. The review was limited to peer-reviewed papers. 
Study Selection and Review Procedure 
The initial selection of papers was based on titles and abstracts using the inclusion and exclusion criteria, 
and was performed by one reviewer (KP). At this stage, all potential studies were included for 
consideration pending full text review. For the next stage, the same criterion was applied to the full texts 
of the studies. Two additional reviewers (my thesis supervisors) applied the criteria to a subset of the 
studies separately; the team discussed and resolved any disagreements.  
Data Extraction and Analysis 
Data was abstracted and recorded in a standardised template by one reviewer (KP), including information 
on author; country of origin; sampling technique; sample size; methodologies; and findings. The research 
question was: What factors explain PSA screening practices in primary care? Data was initially coded to 
encompass all potentially relevant factors involved in PSA screening decision-making and clinical practice. 
Initial codes were collapsed into a shorter list of more inclusive codes. A taxonomy of factors was 
developed based on these revisions. The two additional reviewers applied the codes to a subset of studies 
to clarify and confirm usability of the codes.  
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Findings of the review 
57 studies were identified reporting on prostate cancer screening in general practice, from the GP 
perspective. The majority of studies reported on practice in the United States (n=30). 6 studies were 
conducted in Australia, 5 in the United Kingdom. Four of the studies used qualitative methods (n=1 UK, 
n=3 US). Most data in the quantitative studies was collected via the use of questionnaires alone or 
questionnaires with vignettes. The questionnaires included questions using a Likert scale, questions that 
asked respondents to “choose one of the following”, and yes/no questions. 
11 studies were published in the 1990s, when PSA screening was still relatively new (but being 
enthusiastically adopted), advice to GPs about PSA screening was highly conflicted, and potential harms 
were largely unknown. Less than one-third of the studies were published after 2009, the year that ERSPC 
and PCLO reported preliminary results. In addition, many of the studies published post-2009 report on 
data collected in the years preceding 2009.  
The variations in screening policies and within and between jurisdictions discussed earlier in this chapter 
are relevant to interpretation of these studies. Differences in the epidemiology of prostate cancer between 
populations, and variation in screening modalities (e.g. use of DRE) are also reflected in the study designs. 
For example, two of the included studies focused on African American clinicians (123, 124). The studies 
collectively illustrate the complexity of influences on the PSA screening practice of GPs around the world.  
In this section I present the findings of the international quantitative findings under four broad categories 
reflecting the content of the included literature: determinants of screening practice, PSA screening in the 
clinic, communicating with men about PSA screening, and the place of evidence and guidelines. I then 
present findings from the subset of quantitative work specifically conducted in Australia and the United 
Kingdom, to highlight the most relevant background to this study. I conclude this section with the findings 
of the four qualitative studies and describe the different types of research questions that have been 
investigated using qualitative methods. 
 52 
1.8 Findings of the quantitative literature 
Overall, the quantitative studies confirm the central and influential role of GPs in directing and managing 
decisions and discussions in the clinic about PSA screening.  Although patient request was a common 
driver, GP knowledge, beliefs, characteristics, and practice context strongly shaped screening decisions 
and outcomes.  
Determinants of screening practice 
A number of quantitative studies identified, mostly via surveying clinicians, those factors associated with 
higher or lower rates of PSA screening. These studies were of two kinds. Some asked GPs to report the 
characteristics of patients that changed their practice. Others looked for correlations between GPs’ 
screening practices and their personal or practice characteristics (Table 6).  
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Table 6: Factors associated with higher or lower rates of PSA screening, as reported in the quantitative literature (n=53 studies) 
 
Factors associated with higher likelihood that an individual patient will 
be screened 
Factors associated with lower likelihood that an individual patient 
will be screened 
Patient 
characteristics 
 Patient requests PSA screening (125-136) 
 Age, specifically men >45-50 years (125, 126, 129, 136) 
 Higher risk patients: Family history of prostate cancer (125, 129, 
130, 135, 137-141); African American (139, 142) 
 Anxiety about prostate cancer (140) 
 Lower urinary tract symptoms (132, 134, 137, 142-144) 
 Age, specifically men > 75-80 years and < 40 years (138, 145, 
146)  
Clinician 
characteristics 
 Less knowledgeable about prostate cancer and/or prostate 
cancer screening (125, 135, 136, 142, 147-149)  
 Attitude towards screening or the PSA test (125, 126, 149) 
 Beliefs (that prostate cancer screening represents standard of 
care) (126, 133); belief in PSA test or prostate cancer screening 
efficacy to improve survival (125, 126, 129, 138, 139, 150-155);  
 Older age (126, 131, 133, 144, 148, 152, 154, 156-158) 
 Male gender (126, 130, 147, 148, 156); not associated (129, 159) 
 More years in practice (130, 133, 147, 148, 159) 
 African American (123, 146, 160) 
 Previous experiences, personal and professional (130, 141, 148) 
 Personal screening behaviour (GP has had PSA test, or reports he 
would have the test) (147, 148, 161) 
 Malpractice concerns (149, 150, 162, 163); anticipated regret for 
not ordering 
 Discomfort with uncertainty (134, 163) 
 More knowledgeable about prostate cancer and/or prostate 
cancer screening (125, 135, 136, 142, 147-149, 164)  
 Attitude towards screening or the PSA test (125, 126, 149) 
 Beliefs (lack of scientific evidence, question efficacy of the PSA 
test, concern about treatment side effects)(125, 126, 129, 137, 
139, 150, 162) 
 Younger age (126)  
 Female gender (126)  
 Academic or teaching affiliation, membership in a professional 
association (130, 133, 144, 147, 148, 150, 152, 158, 162) 
 Fewer years in practice (148) (130) 
Contextual 
characteristics 
 Urban or rural practice location (126, 130, 155, 165)  
 Routine health examinations (127, 130, 138, 143, 148) 
 Practice environment: local urology service available (130, 159); 
high volume practice (129, 160); solo practice (rather than multi-
specialty) (160); private practice (166) 
 Form of GP remuneration (fee-for-service) (129, 159)  
 Urban or rural practice location (126, 130, 152, 155) 
 Insufficient time (139, 150, 151) 
 Practice environment: group or multi-specialty (not solo) 
practice (167); academic setting (152) 
 Affiliation with GP College (158)  
 Longer consultations (168)  
 Recommendations from professional organisations (163)  
 Form of GP remuneration (salaried) (129, 159)  
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Patient request was the most consistently reported factor prompting prostate cancer screening. Two-
thirds of the studies reporting on patient request as a primary factor sampled clinicians in North America, 
where PSA screening was quickly adopted in clinical practice and consequently has a significant public 
profile. A patient’s request for screening is reportedly difficult to decline in the United States (134). GP 
participants in New Zealand and the United Kingdom reported not feeling pressured to perform PSA 
screening (153, 130). These findings may reflect differences in policy environments (as presented in Part I 
of this Chapter) and public attitudes towards screening.  
Clinician knowledge about prostate cancer and belief in the utility of the PSA test were important factors. 
As would be expected, clinicians who tested routinely were more likely to accept that the PSA test is a 
good screening tool offering substantial mortality benefit. Clinicians who did not test regularly were more 
likely to question the test’s value and evidence-base, and less likely to believe it offered a mortality 
benefit.  
In many studies, those clinicians who scored higher on tests of knowledge about prostate cancer and PSA 
screening epidemiology screened less frequently or more age-selectively, while lower knowledge scores 
were associated with a higher propensity to screen. Shared decision making (SDM) —generally 
recommended when making PSA decisions—appeared more likely from GPs who had greater knowledge 
scores (147). Physicians in one US study reported low confidence in their knowledge about PSA screening 
and felt uncomfortable with their ability to answer patients’ questions about it, despite recording high 
knowledge scores (135). Knowledge alone may be insufficient to help GPs to make confident 
recommendations.   
GPs more likely to recommend a PSA test were of older age, male gender, and had more years in practice. 
Male GPs who would have a PSA test themselves were up to eight-times more likely to screen men than 
GPs who would not have a test (148). Nearly all GPs 50 years or older in one US study had personally 
received a PSA test (147). Prior professional experiences were also relevant: clinicians who reported 
having an asymptomatic patient diagnosed with prostate cancer following a PSA test were more than 
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three times more likely to screen asymptomatic men compared with their colleagues with no such 
experience (130, 148).  
Lastly, as shown in Table 6, several contextual factors have been associated with prostate screening 
patterns, such as urban clinicians being more likely to screen than rural clinicians. This may be partly due 
to limited access to resources—including urological services—in rural areas. In Australia, GPs in 
metropolitan practice were more likely to discuss PSA screening opportunistically than those GPs in rural 
locations (158). Other studies conducted in the UK and US reported PSA screening highest among GPs in 
rural practices and lowest in urban practices (e.g. (130). These findings likely reflect different structures 
of social demographics in the respective locations. 
PSA screening in the clinic 
A number of studies reported on clinician PSA screening behaviour in the clinic. In most studies, a high 
percentage of clinicians (up to 95% in US studies, 75% in Australia) offered PSA screening routinely or 
recommended screening for prostate cancer using the PSA test (123, 126, 128, 129, 131, 132, 135, 138, 
144, 145, 148-151, 154, 159, 168-171). There was a comparatively low rate of GPs actively arranging 
appointments for PSA testing of healthy men in the United Kingdom (21%) (132) and Denmark (14%) 
(143).  
Several studies reported on clinicians routinely ordering PSA screening for men outside of policy 
recommendations (e.g. >75 years) (145, 146, 149, 172).  
Patient expectation for clinicians to continue screening was the most frequently cited barrier to 
discontinuing PSA screening in the US context, reported by three-quarters (74%) of respondents (146, 
163).  
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Communicating with men about PSA screening 
Because of the complexity of PSA screening decisions, excellent clinical communication is necessary to 
ensure men have the opportunity to make informed screening decisions. Yet comparatively few studies 
have focused on this specific component of the screening process. 
The existing literature suggests considerable variation in whether clinicians communicate with men 
about, or prior to, PSA screening, and also in the nature of that conversation. Overall, the included studies 
suggest that most clinicians at least informed men that their PSA was being checked, but there were 
exceptions. Between 20 and 25% of US physicians surveyed did not engage in pre-screening discussions 
(139, 162, 163); these physicians were more likely to attempt to persuade a reluctant man to be tested 
(139). 
Clinicians who did communicate with men prior to PSA screening took different decision-making roles. 
Some clinicians shared the decision about screening or not screening with the patient (147, 150). Some 
clinicians had a discussion with the patient, and then expected them to decide (137, 139). Some clinicians 
encouraged screening, or attempted to talk patients into having a PSA test (123, 160, 167).  These studies 
were of US physicians, except for one from the UK (137). There is an absence of literature exploring the 
views and communication practices of Australian GPs and their role in that process.  
Some studies asked clinicians about barriers to communicating with men about prostate cancer screening. 
Clinicians reported that dissuading patients from having a PSA test consumes precious consultation time 
(168); patients have difficulty understanding the issues despite the clinician’s best efforts; and most 
patients will elect to get the PSA test anyway (153). GPs in a New Zealand study reported needing more 
knowledge to advise patients, and more than half (56%) felt it was difficult to give a balanced view to 
patients regarding PSA screening (153). Further exploration of these issues is warranted to understand 
communication challenges, and to ascertain whether they can be remedied via clinician education, 
training, or resource development.  
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The place of evidence and guidelines  
Studies have investigated whether clinicians refer to clinical guidelines, whether guidelines influence 
screening decisions and practice, and which guidelines are most influential. Findings relating to 
agreement with guidelines and use in practice need to be interpreted in the context of time and place. For 
example, Lawson et al reported that most clinicians agreed with published guidelines (166); but this study 
was conducted in the USA in 1993, when the American Cancer Society recommended routine screening, so 
cannot be generalised to contemporary clinicians. Similarly, Drummond et al reported that high screening 
GPs were less inclined to apply ‘evidence-based’ information in favour of trusting their salient experience 
and ‘gut feelings’ (148); but this study was reported from Ireland in 2009 when there was no national 
policy or guidelines on prostate cancer screening. 
Most studies included in this review were US-based and referred to the recommendations of the United 
States Preventive Services Task Force (USPSTF), which has advised against prostate cancer screening of 
men of all ages since 2012. Most (93%) US physicians surveyed in 2012 were familiar with the USPSTF 
recommendation (163) and many considered it the most influential clinical guidance (135). However, 
fewer than half (41%) of physicians who agreed with the recommendation (against screening) would no 
longer order routine PSA tests (163).  
The USPSTF recently (April 2017) released an updated draft recommendation 
statement for public comment, from which a final version will be developed. The 
Task Force now recommends offering or providing PSA screening to selected 
patients depending on individual circumstances, rather than discouraging all PSA-
based screening as was previously recommended (114).  
A large number of physicians practicing in the US and Australia disagreed with the 2012 USPSTF 
recommendation (155, 163). I present studies that have specifically investigated Australian GPs’ views on 
Australian policy and recommendations in the following section.  
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The nature of the guideline environment may be reflected in screening behaviour. I explained in Part I of 
this chapter that guidelines in the USA have been notably contradictory since the PSA test was introduced; 
for instance, the USPSTF recommendations were in direct opposition to those published by the American 
Cancer Society in the 1990s and 2000s. In contrast, a single national agency is responsible for formulating 
practice guidelines for all physicians in France and has opposed routine prostate screening since 1998 
(173). A study comparing practice in the USA and France in 2000 identified avoiding regret about 
anticipated ‘bad outcomes’ (i.e. not ordering a PSA test for a patient who was subsequently found to have 
advanced prostate cancer) as the strongest predictor of ordering PSA tests in US physicians. This was not 
a concern for French physicians (134). Clear guidance from one authority may offer GPs important 
support for less frequent screening.  
Next I present quantitative research that has been conducted in Australia and the United Kingdom, 
because this is particularly relevant to the context of this thesis. These studies are a subset of those 
already discussed. 
Quantitative studies conducted in Australia 
There have been six quantitative studies conducted in Australia (128, 144, 155, 158, 165, 174). Two of the 
studies were published in 2015 (128, 155), after publication of the two trials (ERSPC and PLCO) and 
significant international policy changes that ensued (the USPSTF’s D recommendation was made in 2012, 
as was the RACGP’s policy against PSA screening unless specifically requested). The other four studies 
were older: one published in 1995, two in 1998, and one in 2003. No Australia-based research published 
between 2003 and 2015 was identified. All studies concluded significant variation in practice. 
Almost half (43%) of Australian GPs surveyed in 1996 indicated that PSA screening was effective in 
reducing premature mortality from prostate cancer, and more than half (57%) would recommend a PSA 
test during a health check (158). Twenty years later, three-quarters (74%) of Australian GPs surveyed 
indicated that PSA screening is at least ‘somewhat effective’ in reducing prostate cancer mortality in an 
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average risk male (155), and more than half (57%) always or usually offered prostate screening: 
opportunistically (56%) and at patient request (39%) in 2012 (128). So despite significant policy changes 
over the years both within Australia and internationally, GP beliefs in screening and screening behaviour 
may be relatively unchanged.  
In the earlier study, GP awareness of relevant Australian guidelines on prostate cancer screening was low: 
almost half were unable to recall publications from the RACGP or Australian Cancer Society (the two 
existing relevant guidelines at that time). About 40% of the GPs who were familiar with the guidelines 
indicated that they were useful, but most still advocated screening (158), despite that not being the 
recommendation of any of the available guidelines. In the more recent research, GPs were familiar with a 
wide range of Australian guidelines, but most (80%) reported the guidance not clear (128, 155). One-
quarter (28%) did not refer to any guideline (128). 
One study included in this review reported specifically on the concept of overdiagnosis, and it was from 
Australia in 2012. There was clear variation in GP opinion about whether prostate cancer is 
overdiagnosed: one-third of GPs surveyed believed that prostate cancer is overdiagnosed while nearly 
two-thirds (61%) believed prostate cancer is a disease that needs to be diagnosed (128). There are 
ongoing mixed attitudes about overdiagnosis and PSA screening more broadly in the Australian context. 
Quantitative studies conducted in the United Kingdom 
Four studies conducted in the UK context used questionnaires for data collection. Three of the four studies 
were based in Northern Ireland or Ireland (130, 132, 148). Although Northern Ireland has the NHS, it is 
organised differently to the NHS in England and Scotland. As I noted previously, the one study from 
Ireland was conducted at a time when there were no national policy or guidelines for prostate cancer 
screening. These studies are not discussed in any further detail here because they are less relevant to the 
findings of my study.  
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The one remaining study, reported in 2005, used a combination of direct questions and patient vignettes 
(137). Most UK GPs expressed support for policy recommending against routine screening. In contrast to 
the Australian GPs’ reports – which suggested PSA screening is a common feature in primary care – it 
appeared that routine screening in the UK context was rare. The majority of GPs (65%) in this study had 
discussed PSA screening with fewer than 5 men in the past 3 months; one-quarter had not conducted any 
PSA tests for asymptomatic men in this time (137). 83% of the GPs preferred to engage patients in 
thorough discussion of the issues, in comparison to the findings presented earlier regarding US-based 
physicians not engaging in pre-screening discussions (one-quarter of US-based GPs surveyed ordered PSA 
tests without first discussing it with patients). 
1.9 Findings reported in the qualitative literature 
The findings of four qualitative studies (124, 157, 175, 176) are presented separately here to 
contextualise my own qualitative study. Three qualitative studies have been conducted in the United 
States and one in the United Kingdom, reported between 2004 and 2007 (note again no studies post-
2009). One US study collected data only from African American clinicians (124). The qualitative studies 
have focused on determinants of screening practice and GPs’ discussions with men about PSA screening.  
Determinants of screening practice 
In 2001 and 2002, Cooper et al conducted telephone focus groups with US primary care physicians about 
their PSA screening practice and factors influencing those practices. The authors identified two distinct 
practice patterns: “routine screeners”, who recommended and encouraged regular PSA screening for 
asymptomatic men, and “non-routine screeners”. Non-routine screeners were a minority group: they 
neither recommended for or against PSA screening, but rather discussed the implications of PSA screening 
before offering it. Non-routine screeners practiced to guidelines derived from the scientific evidence. 
Routine screeners typically based their practice on their professional and personal experience, rarely 
discussed the test prior to screening, and uniformly believed that PSA screening saves lives (176). 
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Interestingly, both groups reported high screening rates, despite describing considerably different 
practice patterns. One possible explanation is the strength of patient expectation: non-routine screeners 
reported that pre-screening discussions rarely dissuaded patients from having a PSA test. 
Two studies emphasised the powerful influence of personal and professional experiences on PSA 
screening practices (124, 176). Clinicians explained vigilant screening by recounting the diagnoses or 
deaths of family members or friends, deaths of patients who were not screened, survival of patients who 
were screened, or their own personal experience with prostate cancer. Other clinicians reported instances 
of patients undergoing repeated biopsies with no cancer ever found, which served to deter over-screening 
(176).  
Communicating with men about PSA screening 
The discussions that clinicians reported having with asymptomatic men about PSA screening varied 
widely, depending on the personal views held by the clinician about the value or lack of value of the PSA 
test: they placed different emphasis on certain key points, provided different degrees of detail, and were 
more or less impartial in presenting information.  
Some GPs in a UK-based study, where PSA screening is strongly discouraged, emphasised the drawbacks 
of screening to counter men’s primarily positive views of the test. The authors noted that GPs gave 
relatively little attention to the potential benefit of screening for prostate cancer (175). All UK GPs that 
were interviewed in this study said they had some degree of discussion with all men prior to ordering a 
PSA test. 
In contrast, most physicians in Cooper et al’s US-based study routinely recommended that men be 
screened and believed opportunistic screening important. Some reported only having in-depth 
discussions with patients who declined the test, to persuade them to change their mind and agree to be 
screened (176). A number of physicians preferred to avoid in-depth discussions altogether (157, 176), 
reasoning that it would cause patients unnecessary anxiety: one physician likened a discussion about the 
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implications of PSA screening to telling his children there was a possibility that they would be in a car 
accident every time they left home (176).  
African American men have a documented greater burden of prostate cancer than white men, which 
appeared to influence communication approaches: African American physicians described pre-screening 
discussions (with racially mixed patient populations) as typically directed towards explaining the reasons 
the patient should have a PSA test and reported little patient involvement in the screening decision (124). 
These GPs’ were most influenced by evidence highlighting mortality in African American men, and higher 
personal risk for prostate cancer.   
Overall, the literature reviewed provides an array of determinants of screening practice and diversity in 
approaches to PSA screening. These findings highlight the guiding role of the clinician in directing 
screening decisions and action, and the importance of context in explaining screening approaches. 
However there is still little known about doctor’s perspectives on prostate cancer screening in primary 
care, particularly the experiences of Australian GPs. I present the context, rationale, and aims of the study 
in Part III of this Chapter. 
 
 63 
Part III: Context, Rationale and Aims 
1.10 The context of this study 
Primary health care in Australia and the United Kingdom 
This study was undertaken in primary health care in two jurisdictions: Australia and the United Kingdom. 
Some observations about the structure of these two systems, particularly their differences, are necessary 
to frame the methodology and results chapters of this thesis. Detailed information regarding sampling of 
clinicians practicing in the two locations is provided in the methodology section, Chapter 2. 
Primary health care in Australia serves as a gateway to the health system. Australia’s primary health care 
service delivery system has been described as complex, fragmented, and often uncoordinated (177).  
Healthcare in Australia is provided through interdependent public and private sectors, providing both 
equivalent and complementary services. Australia’s health system is funded and administered by several 
levels of government (national, state/territory, and local); in addition 55.6% of the population over 18 
years has private health insurance (2013) (178), encouraged by taxation penalties on those without 
private health insurance who earn over $90,000/year (179). 
Public health care is funded under Medicare, a national public health insurance scheme funded by 
taxation, which provides all Australians with access to free or subsidised healthcare. The Medicare 
Benefits Scheme (MBS) governs the tests, procedures and services that are, or are not, subsidised by the 
Australian government, allocating a Medicare Benefits Schedule number to those services that are 
subsidised. PSA testing is included on the schedule (item 66655), which allows payment of a benefit for a 
PSA test once in a 12 month period for men who do not have previous prostate disease (180). Additional 
item numbers (66656, 66659, 66660) code for patients who have prostatic disease, including follow-up 
testing for previously diagnosed prostate cancer. Up to 4 PSA tests are permitted in a 12-month period 
(180), depending on the purpose of the test and the PSA value.  
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In Australia, general practices essentially operate as private businesses. Most primary health care 
providers charge fee-for-service, including via the MBS. Doctors bill for each item of service they provide, 
and different GPs can charge different fees; any ‘gap’ between the MBS rate and the GP’s fee is paid by the 
patient. Billing policies vary between practices: some practices ‘bulk bill’, where the GP bills Medicare 
directly for the service provided at no cost to the patient, while others bill the patient directly. In the 
period 2012-2013, 82% of GP attendances were bulk-billed (177).  
The United Kingdom has a long-established and highly developed system of generalist, primary care 
delivered by GPs (181), with strong continuity of care (182). Health care in the United Kingdom has been 
centrally funded through the National Health Service (NHS) since 1948. The NHS provides both primary 
and specialist health care which is largely free at the point of delivery. The NHS is generally highly 
regarded by the British public and core features of UK primary care have been constant since its inception 
(182).  
NHS GPs are responsible for a defined population. There is universal registration with a single practice of 
the patient’s choice. Patients may select a GP, but their choice is restricted within geographical areas. The 
incidence of people changing their GPs – other than for reasons of changed residential location – is low. 
Most people have a long-standing relationship with their GP (181). As in Australia, GPs act as gatekeepers 
to specialist care. Specialists work largely in public hospitals. GPs work in practices, which they usually 
own, in partnerships, typically of 4-6 self-employed physicians (182).  
Primary and specialist care is provided by a single payer and is funded nationally from general taxation. 
Practices derive most of their income from contracts to provide NHS care. Approximately 75% of practice 
income comes from capitation, that is, allocation of funding among GPs is determined by patient 
registrations. The remainder is from pay-for-performance fees and contracts for more specialist care. GPs’ 
take-home pay is the practice’s profit. Currently, the average net pay of a GP is slightly more than the 
average NHS income of a specialist (182). All appointments and treatments are free at the point of care, 
paid through taxes. A minority of patients opt out of the NHS system and receive private care. 
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Specific aspects of the respective health care systems are presented in more detail in Chapter 5, a detailed 
empirical analysis of GPs’ perspectives on PSA screening between Australia and the UK, with a particular 
focus on the influence of historical and current organisational and funding structures and rules. The next 
section presents the rationale, aims, and research questions for this study. 
1.11 Rationale for this study 
I have now discussed relevant controversies and uncertainties in PSA screening of asymptomatic men for 
prostate cancer. These concern the PSA test, the evidence base, and the associated harms, and are 
reflected in the inconsistency between numerous guidelines and recommendations. As demonstrated, 
there is substantial variation in screening practice. The quantitative evidence, involving large cohorts of 
GPs from around the world, has shown that certain characteristics of GPs, patients, and contexts can partly 
explain screening behavior, and provided insights into screening patterns and potential drivers of PSA 
screening in general practice. In this study I aimed to produce new knowledge to complement this existing 
evidence base.  
We know from the literature and anecdotally that PSA screening is occurring opportunistically and 
informally in Australian general practice, despite there being no organised prostate cancer screening 
program in this country. We also know that screening rates, and relative screening rates, differ between 
different groups of patients and GPs. At least 20% of Australian men aged 45-74 years have a PSA 
screening test each year, as well as 19% aged over 74 years (183). Recent population-based analyses 
indicate that men undertaking a Medicare-subsidised PSA test decreased by 6% between 2011 and 2014 
(79). One UK study analysed data from patient electronic records in primary care for men aged 45–84 
years and reported that for every 100 men enrolled with a GP for one year, 5.03 (asymptomatic men) 
were tested in 2010, and the rate increased by 8% in 2011 to 5.45 per 100 (184). 
What is less well understood is why these differences might exist. To understand this requires knowledge 
of the PSA screening experience, from the GP perspective. Qualitative research methods are best suited to 
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developing such understanding. The four qualitative studies identified in the literature review reported on 
potential facilitators and barriers to prostate screening and GP-reported discussions with men about the 
PSA test. However these studies provide limited insight into GPs’ reasoning: how and why do GPs decide 
to provide or not provide PSA screening, given the complexities in the evidence base and historical 
contention. I was unable to locate any qualitative research conducted in Australia, and only one qualitative 
study was situated in the UK.  
GPs have primary responsibility for guiding men’s decisions about whether or not to be screened for 
prostate cancer. As I presented earlier in this Chapter, discussions and decisions about PSA screening can 
be complicated due to the complex balance between the benefits and harms of screening, diagnosis, and 
treatment, the mixed advice from professional organisations, and the central controversies. 
This project aimed to generate a rich empirically grounded understanding of what happens in the clinic 
when the topic of PSA screening arises, as explained by GPs. I specifically sought to understand the 
decision-making and screening process and the complexities arising in consultations with asymptomatic 
men about PSA screening, from the GP perspective. I used grounded theory methodology to investigate GP 
explanations of how the PSA test is used for screening purposes in primary care in Australia and the 
United Kingdom, including their reasoning for practicing in this way.  
1.12 Aim of this thesis 
The broad aim of this thesis is to gain an in-depth understanding of how and why general practitioners 
screen for prostate cancer in primary care consultations. 
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1.13 Research questions 
Three core research questions were the starting point for this thesis: 
1 How do GPs approach PSA screening? 
2 What factors influence GP approaches to PSA screening? 
3 What are the consequences of this process? 
I added more refined sub-questions over the course of the project as my understanding about the 
screening process evolved, and theoretical frameworks to explain some of the findings began to develop. 
This is the way of a grounded theory study. I present a full explanation of grounded theory methodology 
and its application to this study in Chapter 2. 
Initially my goal was to identify, understand, and report on the range of positions taken by GPs, and the 
influence of these positions on screening practice.  
1 How do GPs approach PSA screening? 
1.1 How and why do GPs provide, or not provide, the PSA test to their asymptomatic male 
patients?  
1.2 How do GPs describe their communication with men about prostate cancer screening?  
As data collection and analysis developed and progressed, I identified several core concepts from the GP 
accounts.  
2 What factors influence GP approaches to PSA screening? 
2.1 How does concern about under- or over- diagnosis influence GPs’ approaches to PSA 
screening? 
2.2 How does uncertainty influence GPs’ approaches to PSA screening? 
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2.3 How do GPs in Australia and GPs in the UK explain their PSA screening practices? What do 
any similarities or differences suggest about the influence of health systems on GPs’ PSA 
screening practices? 
2.4 What reasons do GPs give for communicating with men about PSA screening as they do? 
3 What are the consequences of this process? 
3.1 How do GPs describe the consequences of their PSA screening practices? 
3.2 How do these described consequences vary? 
Each empirical chapter of this thesis (Chapters 3-6) offers a focused explanation of the core concepts – 
under and over- diagnosis, uncertainty, organisational differences, and communication practices - drawn 
from the developing analysis. The next chapter, Chapter 2, presents the methodology and methods used in 
this study. 
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2. Overview of this chapter 
This chapter presents the methodology and methods used in this study to investigate (a) How GPs 
approach PSA screening, (b) factors that influence GP approaches to PSA screening, and (c) the 
consequences of this process. 
The empirical work was entirely qualitative. Qualitative research methods are concerned with 
understanding phenomena through the meanings people attach to experiences, and are routinely used to 
study the meanings of health and illness and processes of health care (1). This work seeks to explore 
behaviours, processes of interaction, and experiences of individuals and groups in natural settings to 
understand a process or an issue as completely as possible.  
A qualitative approach was appropriate because my aim was to gain in-depth understanding of how and 
why GPs screen for prostate cancer in primary care consultations. I was particularly interested in 
understanding GPs’ reasoning, complexities of the process (including screening practice, communication, 
and decision making), and organisational structures involved in the delivery of this service. As shown in 
Chapter 1, this was a gap in the existing literature. 
In this chapter I provide a detailed description of grounded theory methodology and its application in 
practice during this study. 
Ethics approval and ethical issues 
Study procedures were approved by the Cancer Institute New South Wales and the University of Sydney 
Human Research Ethics Committee [#15245]. GPs had an opportunity to discuss the study with KP prior 
to participation; all GPs provided informed consent to participate and were compensated for their time. 
Participation was voluntary, participants could withdraw at any time, and confidentiality was protected. 
All responses were anonymised before analysis and potentially identifying information removed.   
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2.1 Grounded theory 
I applied a well-established methodology, grounded theory, to guide the collection and analysis of 
qualitative data. It is one of the oldest, most epistemologically sophisticated, and best-described 
methodologies in qualitative health research; and has been used across a range of disciplines since the 
1980s (2). ‘Grounded theory’ refers to both the research product and the analytic method of producing it. 
In a grounded theory study, data are systematically collected and analysed using a specific method. The 
aim is to generate a substantive theory about human behaviour or social processes drawn directly from 
the research data (3). Grounded theory analysis begins inductively. The study is not designed to test pre-
existing theory; rather the researcher looks for new concepts and explanations by studying the 
perspectives of participants within meaningful and relevant contexts, and the findings reflect patterns 
observed within participants’ accounts. While deliberately prioritising the participants’ perspectives as 
much as possible, as analysis progresses the researcher/s bring in conceptual resources from existing 
theory to contextualise and enrich the developing explanation.  
Glaser and Strauss laid the foundations for grounded theory in 1967, publishing a rhetorical defense of 
inductive analysis in their book “The Discovery of Grounded Theory” (4). Their original conception of the 
theory was based on objectivist assumptions about the empirical world, with emphasis on an objective 
reality, neutrality, and providing explanation of a single truth. In their view, sociology had become 
dominated by the use of quantitative methods to operationalise and test existing theories; they argued 
that this was increasingly divorcing sociological research from what mattered to people in the everyday 
world. “Discovery” encouraged researchers to remember how to listen to participants’ own perspectives, 
and develop social theory that adequately reflected participants’ understanding of the world. Abstraction, 
in this original formulation, separated the completed grounded theory from the context and conditions of 
its data collection and analysis. The researcher’s views dominated interpretation of the data. 
Glaser’s original framework was increasingly criticized as researchers began working with the grounded 
theory methodology. Many argued against the idea that the legitimacy of a theory can be determined 
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simply by recourse to its “emergence” from “the data.” Strauss and Corbin (15) advanced the method to 
acknowledge the importance of multiple perspectives, with increasing recognition of the role of social 
constructionism – socially situated meaning, constructed in interaction with others – in knowledge 
production.   
Kathy Charmaz developed a contemporary version of grounded theory that updated the methodology 
epistemologically (3). Charmaz argues that what previous researchers defined as objective data in reality 
reflects partial knowledge and particular perspectives, priorities, and positions. Her constructivist 
grounded theory prioritises the production and quality of data, with close attention to context, actors, and 
actions, to provide an interpretive understanding of the studied phenomenon. Charmaz emphasises that 
both the data and analysis are actively constructed during the research process, involving the work of 
both researcher/s and participants, and requiring careful attention to the quality of data collection and 
analysis processes. I attended grounded theory training with Kathy Charmaz in Melbourne in 2014 and 
2015. 
A longstanding point of contention in grounded theory methodology is the relationship between the 
theory being produced, which is ‘grounded’ in the data collected, and relevant theory existing in the 
literature. Early expressions of grounded theory methodology (4) strongly emphasized the development 
of new theory as opposed to the testing of existent theory and were resolutely inductive. This was likely a 
reflection of the local context: Glaser and Strauss attempted to establish and distinguish qualitative 
methods in the United States in the 1960s, where hypothesis-driven, deductive quantitative research 
prevailed. Contemporary mainstream grounded theorists, in contrast, strongly concur that qualitative 
empirical work must be conducted in the context of existing knowledge (2) and not independently of 
scholarly work. I drew on the theories of various scholars in my interpretive work and have referred to 
them directly in the empirical chapters: examples include Han’s model of uncertainty in Chapter 4 and 
Gabbay and Le May’s mindlines theory in Chapter 5.  
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Fundamental components of a grounded theory study 
Grounded theory methodology provides a specific guiding structure for sampling, data collection, analysis, 
and reporting, designed to support researchers to build theory grounded in collected data. Rigor is 
increased if these phases are iteratively related. The twin foundations of grounded theory are the 
processes of constant comparison (a simultaneous and concurrent process of coding and analysis) and 
theoretical sampling (sampling with the aim of developing the properties of a developing theory). Other 
key features include coding for actions and memo-writing. These methods together guide the systematic 
development of emerging theory, theory construction, and theoretical integration.  
2.2 Sampling  
Initial, purposive sampling 
Grounded theory studies begin broad in scope and researchers presume that they may know little about 
the meanings that drive the actions of participants (5). I began with broad, open research questions: How 
do GPs approach PSA screening? (What is the process, the conditions of practice?), and: What factors 
influence GP approaches to PSA screening? (Why do GPs practice in that way? How is variation explained?). 
Sampling in a grounded theory study begins purposively, that is, recruitment is guided less by traditional 
quantitative concepts of representativeness, and more by the purpose of the study. The researcher seeks 
to recruit those people who are most likely to be able to provide relevant and diverse perspectives on the 
central research questions. I identified GPs as being in the best position to provide insight on my research 
questions, but required a strategic sampling strategy within the population of GPs. The purposive 
component of the sampling was driven by existing quantitative evidence on characteristics of GPs, 
patients and practice contexts associated with higher or lower screening rates (see Section 1.1. Chapter 1). 
I aimed to recruit a set of GPs likely to have diverse practices (especially, frequent versus infrequent 
testers) and to begin to observe how statistically demonstrated variation might work in practice.   
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For the first few interviews, I aimed to gather data from those GPs most likely to face the question of PSA 
screening as part of everyday practice. To begin to understand the process, I wanted to find informants 
who experienced it often and would be able to speak about it readily. I contacted local men’s health clinics 
in Sydney, Australia, particularly in higher socioeconomic suburbs. My background research and literature 
review presented in Chapter 1 indicated that socioeconomic status might be associated with higher rates 
of PSA screening. I broadened my sampling to any GP practicing in Sydney - in regular family practices, 
and in all areas of Sydney. Existing datasets also suggested that PSA screening rates in Australia are higher 
in capital cities than in rural areas (6, 7). To begin to understand this distinction, I targeted the 
newsletters and email lists of regional GP organisations (Medicare Locals) to compare accounts from 
urban areas with those from regional areas. Further advertising in mass and social media, and in medical 
journals (Medical Observer, the Australian Medical Association’s GP Network News, and the 6minutes 
newsletter) extended sampling beyond NSW to other states and territories. This allowed more extensive 
comparison of the influence of different contexts, such as practice location and local culture.  
My evolving research questions continued to drive the process throughout, I constantly returned to these 
questions and asked what extra material I needed to answer my questions more effectively and 
comprehensively.  
Theoretical sampling 
Theoretical sampling is conceptually driven sampling specifically for theory construction. New targets for 
data collection are directed by the results collected from the preceding sample (8). A theoretical sampling 
strategy is only possible as analysis and sampling evolves, informed by coding, comparison, and memo 
writing (5). Questions are raised and gaps in the data set become evident.  
The emphasis of this study evolved as I became increasingly aware of what was important to GPs or issues 
raised by them that alerted me to consider and explore further. For example, I discovered that avoiding 
under-diagnosing prostate cancers was highly valued by some GPs, despite guidelines and the evidence 
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suggesting otherwise. I selected new GPs based on their ability to answer specific analytical questions. My 
interview schedule was modified accordingly. See Section 2.3 for a description of the progression of the 
interview questions. The aim was to clarify uncertainty, test (and attempt to disprove) my interpretations 
of the data, develop the properties of my emerging concepts which were not yet clear, and to better 
support the integrity, focus, and explanatory power of my continuing analysis, including the final product 
(9).  
I scrutinized how issues and processes evident in my analysis might be considered in different contexts 
and under potentially different practice conditions, to refine the scope of my explanations. I invited rural 
and interstate GPs in Australia to answer specific analytical questions; for example, was the variable 
screening practice evident in my initial interviews widespread? What was contributing to variability? Did 
evidence of issues relevant to the first few GPs interviewed appear elsewhere? Regional and rural GPs 
were accessed by phoning practice managers, through colleagues, and advertising with rural Medicare 
Locals. When I encountered GPs whose routine care was divergent from previously-interviewed GP 
norms, I invited more GPs from that practice to attempt to distinguish between personal and institutional 
influences on their practice. Sampling rural GPs also allowed me to test specific provisional explanations, 
that is, that location is relevant to divergent screening patterns.  
For the final phase of theoretical sampling, I interviewed GPs in the United Kingdom. The decision to 
extend my sample to the UK was for a number of reasons, based on my developing analysis of data 
collected from Australian GPs, and in conjunction with information gathered from the existing literature. I 
became interested in exploring whether and how GPs operating under conditions of a contrasting health 
care system may influence PSA screening decisions and behaviour and considerations of the evidence. I 
wanted to find out if screening decisions are any easier for GPs in the UK. I looked for whether uncertainty 
was a common experience, for example (as a provisional explanation of variation in screening practice); 
and how screening guidelines work in UK practice (to further explore possible explanations in conditions 
of practice). I recruited GPs throughout England, Scotland, and Wales. The initial sample of GPs responded 
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to an invitation distributed by academic colleagues through professional networks. I then broadened the 
sample by advertising via email to members of the Royal College of General Practitioners (RCGP), primary 
health care departments, university academic departments, and general practice and research mail lists. I 
also advertised via newsletter including the Society for Academic Primary Care (SAPC) and RCGP 
Scotland’s eBulletin.  
GP demographics 
GPs who received the flyer inviting them to participate in the research were instructed to contact the 
researcher (KP) if they were interested and willing to take part. I included all GPs who expressed interest 
in participating in the research study. Overall, I recruited a sample of 69 GPs, 40 GPs in Australia and 29 
GPs in the UK. Participants were of varying ages, clinical experience, gender, and patient populations. 
 Australia 
 
United Kingdom 
Total 
 n=40 n=29  
Gender  
Male  28 16 44 
Female 12 13 25 
Years in practice  
Mean 19 12  
Range 1-40 1-39  
GP location  
Metropolitan 16 16 32 
Regional, rural 24 13 37 
 
I continued to sample until I reached theoretical saturation. In a grounded theory study, theoretical 
saturation is the point at which gathering more data ceases to yield any further insights about the process 
being studied, so cannot develop the theoretical explanation any further (10). I ceased recruitment once I 
had (1) developed a clear picture of the rationale and practice of GPs in Australia and the UK; (2) felt well 
enough informed to generate an appropriate explanation of specific aspects of that process; and (3) all 
concepts that were important in my developing theories could be substantiated from the data.  
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2.3 Data collection - Interviews  
My aim was to explore how a specific process (prostate cancer screening) occurs in a social context 
(primary care), from a specific perspective (general practitioners). I wanted to know how doctors interact 
with that process, with that medical technology (PSA screening test), in that context, under those 
conditions, and identify patterns and explanations that participants might or might not be aware of.  
I generated data via in-depth semi-structured interviews. Interviewing is the most frequently used form of 
data collection in grounded theory studies (10). I interviewed Australian GPs between March 2013 and 
June 2014 and UK GPs between September and December 2014.  I conducted all interviews, primarily by 
telephone or Skype. They ranged in duration from 18 to 70 minutes.   
Interview questions 
A semi-structured interview guide was prepared to provide general direction and an overview of potential 
question routes. There was sufficient scope for participants to raise issues the interviewer had not 
anticipated. The guide was loosely based on the research questions as well as what I had learned from the 
existing literature on the topic, and covered a broad range of topics, including GPs’ recent clinical 
encounters involving PSA screening decisions; communicating information about PSA screening to 
patients; screening pathways; and overdiagnosis of prostate cancer. I did not rigidly adhere to the 
interview guide when interviewing the GPs; ordering and wording of the questions was contextual and 
responsive to the particular GP and their ability to inform the developing analysis. Questions were open-
ended to encourage in-depth and detailed responses, range and diversity, and to allow for prompting.  
All GPs in Australia and the United Kingdom were asked to think back to their most recent consultation 
involving a discussion about PSA screening or to describe a typical consultation where the topic was 
raised, and were invited to tell the interviewer as much as they could about what happened in the 
consultation (without disclosing patient personal details). The aim of this approach was to open the 
discussion about, and provide context for, conversations about PSA screening, and to use this as a 
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platform to guide prompts and to focus subsequent questions. It also established that the interview was 
about use of the PSA test as a screening tool for asymptomatic men, rather than as a tool to assist in the 
diagnosis or monitoring of prostate cancer. Terminology regarding PSA screening is often difficult to 
interpret. This is in part because similar medical technology is used for both a screening test and a 
diagnostic test.  I wanted to make it clear from the outset that this analysis was concerned with the use of 
the PSA test as a tool for screening only. 
The overall initial interview schedule for Australian GPs was very broad; examples of questions from the 
initial schedule included: 
 How did you come to approach prostate screening in this way? Has this changed over time? 
 How do you decide when to refer a man to a urologist? 
 How well do you think men understand PSA screening? 
Evolution of interview questions 
Responsive and flexible data collection is the methodological standard in qualitative inquiry (11-14). The 
interview guide was reviewed and modified between interviews based on the developing analysis to 
ensure I continued to get the data I needed to inform the ongoing data collection, analysis, and developing 
theory, and to align with the progressing research questions.  
Questions included in the interview guide evolved throughout the entire data collection process as new 
issues arose, driven and informed by theoretical sampling, and as I began to learn what was most 
important to participants. For example, early in the study I identified perceptions of the risk of 
underdiagnosis as a key issue underlying varied clinical practice. In subsequent interviews following this 
discovery, I asked GPs whether this was relevant to them, if they had experienced situations where a 
potentially screen-detected cancer had not been detected in their clinic, and how they reasoned about this 
issue. The interview guide was modified to enrich the quality of the data available to answer my research 
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questions. A flexible and evolving guide also enabled me to continue questioning until each point made by 
each interviewee was fully explained and understood.  
Table 7 demonstrates additional examples of issues that emerged throughout analysis and which were 
further explored in the GP interviews when deemed relevant.  
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Table 7: The evolving interview schedule 
Examples of analytic questions 
arising from analysis 
Empirical evidence that prompted 
further exploration or interest in 
this question 
Examples of questions used to follow-
up issues of potential interest and 
relevance 
 Is the cost of a PSA test 
relevant to screening 
decisions? 
 Interview data indicating 
varied awareness of Medicare 
coverage of the PSA test  
 How often do you order a PSA 
test for an asymptomatic man? 
 Does Medicare coverage of the 
PSA test have any impact when 
you are making decisions about 
ordering a PSA test? 
 Do perceived medico-legal 
implications influence 
screening behaviour?  
 Interview data indicating 
defensive practice due to 
concerns about potential 
litigation 
 Reported attendance at a 
conference in which this issue 
was discussed amongst GPs 
as being a driver of screening 
practice 
 Do you feel there are any 
medico-legal considerations 
around PSA screening? 
 If yes, how is that relevant to 
your screening practice? 
 If no – other GPs have suggested 
this might be an issue, why is 
that not a consideration for you? 
 Do guidelines and the 
information environment 
contribute to variability in 
PSA screening practice? 
 Interview data indicating 
confusion and frustration 
with mixed guidance advising 
on PSA screening 
 Recent update (2012) of 
RACGP Red Book  
 Which guidelines (if any) do you 
refer to when making decisions 
about PSA screening? 
 Why that guideline? 
 Are you familiar with the recent 
RACGP recommendations? What 
do you think of them? 
 Do GPs in rural locations 
explain and use the PSA test 
as a screening tool differently 
to GPs located in urban 
practices? 
Interview data indicating: 
 Urban and rural GPs use the 
PSA test differently  
 The potential influence of the 
availability of urologists on 
screening and referral 
decisions 
 Rural GPs self-manage 
abnormal PSA test results 
more frequently and for 
longer than rural 
counterparts, attributed to 
urology backlog 
 What guides your referral 
decisions, and why?  
 What is your PSA threshold for 
urology referral? 
 Do you access fly-in urologists? 
What is their role in PSA 
screening and in your screening 
decisions? 
 Who or what is your preferred 
source of information about PSA 
screening? 
 
 Is practice protocol relevant 
to GP screening behaviour? 
(in these cases, I tested 
emerging theories by 
interviewing several GPs in 
the same general practice to 
distinguish individual GP 
approaches, practice 
conditions, and context) 
Interview data indicating: 
 Some practices have an 
automatic recall system for 
PSA tests (i.e. a man can 
access PSA screening without 
a GP consultation) 
 Some UK GPs said their 
practice nurses ordered PSA 
tests without the man having 
a GP consultation 
 Does your practice have a 
practice protocol for PSA 
screening? 
 Does your practice have a recall 
system? Why? 
 If yes, how do you use that in 
your practice? 
 What role do practice nurses 
play in PSA screening of 
asymptomatic men? [UK GPs 
only] 
 What is the role of the health 
care system in creating 
particular conditions of 
practice? 
 Interview data indicating 
significant variation in 
Australian GP approaches to 
PSA screening, not entirely 
explainable. Data from a 
different context required to 
confirm, disconfirm, enrich, 
or extend conceptual 
understanding and emerging 
theory 
 How does PSA screening fit into 
the care of male patients over 40 
years in your clinic? 
 Who initiates conversations 
about prostate cancer 
screening? 
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Specific reasons for the inclusion of UK GPs was outlined in Section 2.2. To develop the interview guide 
used in the UK context, I consulted a health services expert in the UK to gain background information and 
identify the most relevant interview questions to that context. The resulting guide began with me asking 
UK GPs to think about the way they typically manage male patients over 40 years and how does PSA 
screening fit into their care, to obtain a general picture of how things worked in the new context. Follow-
up questions included: 
 What do you include in your discussions with men about PSA screening? 
 Is overdiagnosis of prostate cancer considered an issue in PSA screening in your practice / the 
UK? 
 How does referral to urologists work in your practice (i.e. high PSA)? 
 Are you familiar with the Prostate Cancer Risk Management Programme? What effects has the 
PCRMP had on your practice? 
Initial interviews indicated that unlike in some general practices in Australia, PSA screening did not 
appear to be the norm or an accepted standard of care. Following analysis of the initial interviews, I added 
further areas for exploration: 
 What would happen if a GP was screening all asymptomatic men? (to ascertain whether GPs felt 
any pressure to practice in a particular way) 
 What is the place of health checks in the UK? (to ascertain scope for opportunistic screening, as 
was common in Australian practice) 
 Where do GPs access advice about PSA screening in the UK? Why that source? 
 Why do you think the UK has lower PSA screening rates than other localities? (to ascertain 
broader, possibly unexplored, social and political influence) 
In the following section I describe how I analysed the interview data collected from GPs in Australia and 
the UK, guided by the principles of grounded theory methodology. 
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2.4 Data Analysis 
With GP permission, the interviews were digitally recorded. Interview data were transcribed verbatim by 
a professional transcribing service to produce data for analysis. I led the analysis, with support from my 
supervisors. Grounded theory methodology stipulates that data analysis should occur in parallel with data 
collection (10). Analysis begins immediately and is ongoing, and continues in parallel with data collection 
to allow for theoretical sampling (as described in the previous section). Analysis looks for patterns in the 
data that support a comprehensive explanation of the social process being studied (in this case, PSA 
screening). Analysis is conceptual rather than focusing on individual cases. Contexts, contingencies, 
consequences, and conditions are examined (15) to better understand the patterns and relationships 
among these elements and develop an explanation of the social process.  
Developing codes 
Coding data (10) shapes the analytic frame and direction of analysis. Coding is a process of breaking data 
down into small components and labelling the components with a descriptive meaningful label which 
represents key concepts being conveyed in that data. Codes distil and define what the data are about. The 
coding process allows researchers to define what is happening in the data and to begin to grapple with 
what it might mean, to eventually make analytic distinctions.  
Initial coding 
I coded the transcripts. A subset of transcripts were also read and coded by my supervisors independently 
to ensure interpretive rigor; this coding was compared and discussed to inform the development of the 
central concepts in the study. 
I adopted Charmaz’s method of coding for actions and processes, rather than topics, by using gerunds as 
codes, that is, verbs ending in “ing”. Gerunds are used to code in a way that actively captures people’s 
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intentions and concerns, and anchor the analysis. Charmaz recommends coding as quickly and actively as 
possible, keeping codes as similar to the data as possible and preserving event and context (3).  
In my initial coding I worked by principles of inductive reasoning: entire transcripts were coded to 
generate as many ideas as possible from the early data. At this stage, it was not possible to determine 
which concepts would be most important, so I systematically read and considered all GP descriptions. This 
initial or open coding was an important early stage of the analytic process because it focused my attention 
onto things that might otherwise be missed. It also informed my theoretical sampling by highlighting 
areas where data was still needed, shaped the progression of my research questions and the interview 
schedule, and facilitated the emergence and subsequent saturation of an identified core category. I coded 
initially to capture the range of variation and for the conditions that could explain that variation, to be 
built on later in memos. 
Table 8 below is a good example of the type of data I coded as ‘being stuck in a catch-22’. GPs described in 
many different ways being caught in a difficult paradoxical situation, feeling conflicted, but unable to 
escape the dilemma because of conflicting or contradictory rules or conditions. This code, and its various 
iterations, progressively informed the focused code, ‘being uncertain’ which eventually formed the 
backbone of one of my empirical chapters, presenting an analysis of GP experiences of uncertainty (see 
Chapter 4). The example provided in Table 8 of the being stuck in a catch-22 code is from a single GP - a 
very reflective and articulate GP communicating the frustrations of working within the current limitations 
of the evidence and consequent recommendations; and experiencing significant personal conflict as a 
result. 
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Table 8: Example of 'being stuck in a Catch 22' code 
 
Focused coding 
Focused coding is more directive, selective, and conceptual (3) and occurs only after open coding has 
allowed the researcher to alight on a set of analytically important categories. Focused codes were used to 
synthesise, integrate, and organise the large amounts of data in the transcripts; only that data directly 
relevant to the analysis are coded at this stage. I decided which initial codes appeared to be most salient 
or important to the GPs and could usefully contribute most to my analysis, and tested them against more 
extensive data relevant to that code. For example, one of my focused codes – ‘being uncertain’ – was 
abstracted from various versions of this overarching concept evident in my initial coding, such as ‘being 
stuck in a catch-22’, ‘worrying’ and ‘making difficult decisions’. Another example of a focused code from 
my analysis is ‘avoiding underdiagnosis’. The refined focused codes were eventually treated as tentative 
conceptual categories, and were developed and tested in further memos. 
Using constant comparison  
The constant comparative method is an iterative analytic process involving simultaneous and concurrent 
coding and analysis. Data is compared with data, data with codes, codes with codes, codes with categories 
and so on, looking for similarities and differences, confirmation and disconfirmation. The purpose of this 
method is to generate theory systematically and inductively derived directly from the data (4). I compared 
the coded data from my first few interviews with data within the same interviews and between 
But I think that it’s – I do feel that I’ve got men who’ve been treated who need not have been treated and –I 
don’t know that I can weigh up – look, as I said, one – one other factor that I haven’t mentioned is that my 
men who do have – who have been treated for prostate cancer and who now have erection difficulties and 
incontinence, very few of them have very much regret about that.  I mean, that most of them see it as, I’ve been 
cured of cancer and I don’t really mind, I guess – the price you pay for being cured of cancer.   So what’s 
interesting is, as a doctor, I think, well how terrible that you might not be able to have sex again or that you 
have to wear a nappy for the rest of your life, but I’m not sure that that’s as much of a burden for them as it is 
for me – and so – and clearly, a premature death from a horrible cancer is a terrible disaster for a patient and 
for their doctor  and so whether, you know, over-diagnosis and over treatment, I mean, I don’t know how you 
weigh up that against saving – and so what if maybe – maybe 43 incontinent men is worth it for saving one 
man from a premature death,  but I – I don’t – I can’t make that choice, you know, but I – I guess that’s a 
question that I, sort of, contemplate at times. 
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interviews. Selections of data were compared to each other and to existing codes and categories so I could 
gauge their similarity and dissimilarity, including their fit or conflict with my developing explanations of 
the PSA screening process.  
This strategy was an ongoing process maintained for the duration of the research study. It effectively 
ensured active interaction with the data, and helped to identify and clarify variation in the data. 
Provisional explanatory theories were developed, re-developed, and tested with new data, old data, and 
existing knowledge via repeatedly moving to and fro between the collection of data, coding, and memo 
writing. Constant comparison continues until the researcher arrives at the most plausible interpretation 
of the process under study (2).  
Theoretical coding 
Theoretical codes are conceptual connectors, developed through constant comparison. Glaser first 
introduced theoretical coding in grounded theory when he presented a series of theoretical coding 
families that the researcher could draw on to develop conceptual analysis. In his classic version, one 
theoretical code eventually ‘emerged’ that integrated all substantive categories with a core category. 
Charmaz argues that coding in such a way imposes a forced framework on the analysis. I followed 
Charmaz’s variation and used theoretical coding to add precision to relationships between my focused 
codes and to begin theorising about what was actually happening during the PSA screening process (i.e. 
not aiming to “discover” an ultimate theoretical code). Table 9 provides an example of the progression 
from initial coding (being stuck in a catch-22) to focused coding (being uncertain) to the eventual 
development of a theoretical code (experiencing burden). See Section 2.1 regarding using theoretical 
frameworks from the existing literature, such as Han’s taxonomy of uncertainty in health care (applied in 
Chapter 4). 
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Table 9: Illustration of the coding process with examples of initial, focused, and theoretical coding 
(note that some initial codes in this table went on to support the development of other focused and theoretical codes) 
Raw data Initial coding Focused coding Theoretical coding 
I give that explanation to most men – to 
every man who I see about a PSA testing 
and – but I also say that, obviously, PSA 
testing is really the only good way we have 
of finding prostate cancer and I say that we 
also – certainly also know men who die of 
prostate cancer, and I’ve got patients who 
are dying of prostate cancer, and – and it’s 
a very difficult decision as to whether you 
should test for it or not and I say it’s a 
decision that you need to make and I can’t 
make for you, and I find probably a lot of 
my patients choose not to do the test after 
I’ve talked to them about it and I would say 
the significant minority of my patients who 
came in asking for the test decided to do the 
test anyway and I suppose, I mean,– I’ll talk 
a bit more about this, but I think my 
concern is that – is that the – the spiel that I 
give men about this leaves them with 
virtually no ability to make a good decision, 
because I don’t even know what the good 
decision is around PSA testing and I think I 
– I don’t make things easier for people 
because I think it’s an incredibly difficult 
area. 
Explaining: to every 
man; rigorous 
 
Making decisions: 
Recognising difficulty  
 
Making decisions: men 
need to decide 
themselves 
 
Making decisions: men 
changing mind or doing 
test anyway 
 
Being stuck in a catch -
22: Not being able to 
make a good decision 
because there’s no good 
decision to make 
 
Explaining: explanation 
does not making it any 
easier for men 
 
Making decisions: not 
knowing what the good 
decision is 
Being uncertain Experiencing 
personal burden 
 
 
I think prostate cancer screening is, in my 
daily practise, is by far my biggest kind of 
anxiety around cancer screening; I think it 
just seems to – it – we battle in general 
practice with convincing men that they 
need to see the doctor and have health care 
and so the man is – and the man who listens 
to the – the media believes that good self-
care is to have a prostate cancer test and 
then when he comes to me, I tell him that 
that’s actually wrong and so I’m almost, 
sort of, turning away the person who’s 
trying to do the right thing.  So I, you know 
– I don’t achieve a satisfactory balance for 
myself, really, I mean, I just think that, you 
know, I worry – I worry that there are men, 
young men who probably will get prostate 
cancer and die of it because I’m not doing 
enough screening, but I’m not prepared to 
not follow the evidence and I think that the 
evidence says you don’t do it, and I recently 
– I saw even this week, a new guideline 
from the American College of Physicians, 
which was – which supports my view, I 
think, which was to say, frankly, that we 
should not screen men for prostate cancer, 
and that we should only screen those people 
who’ve been given a detailed discussion of 
the risks and benefits of screening – I think 
that that second statement is a copout, I 
think the idea that we should only screen 
those men who’ve been given a proper 
discussion of the risks and benefits, doesn’t 
Framing PSA: worst 
cancer screening 
problem 
 
Being stuck in a catch -
22: contradicting 
ourselves, turning away 
the compliant minority 
 
Being stuck in a catch -
22: not being able to 
satisfy her/himself 
 
Being stuck in a catch -
22 
 
Worrying: that s/he is 
letting young men die 
 
Failing as a doctor 
 
Justifying position: not 
prepared to contradict 
the evidence 
 
Justifying position: 
appealing to authority 
 
Locating 
responsibility: 
explanation / consent is 
a copout – medicine(?) 
needs to find a solution 
 
Being stuck in a catch -
22 
 
 
Being uncertain 
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get away from the fact that we’re still in a 
mess with what we’re actually advising men 
to do and I just think it’s a – we need to 
know quickly, how we decide which men 
need treatment for prostate cancer and 
which men don’t need treatment and until 
we have that answer, this is going to 
remain a big mess, I think, for healthcare. 
Being in a mess 
 
Locating solutions: 
improve knowledge (re 
who should get 
treatment) 
 
Locating 
responsibility: not 
exactly clear but maybe 
the profession? 
 
Writing memos 
Memos are informal analytic notes that detail thinking and analytic work. I used memos during coding, 
collecting, and analysis to document individual cases, categories, and relationships. They create space for 
tracking new ideas and insights, justifying interpretations, documenting outstanding questions to direct 
future data gathering, and for making comparisons and articulating speculations about those 
comparisons.  
Memo writing is a crucial analytic process in grounded theory studies because it prompts early analysis. 
Writing successive memos throughout the research process keeps the researcher involved in the analysis 
and helps to increase the level of abstraction of developing ideas (3). They are an important intermediate 
step between data collection and writing drafts of papers. 
I coded my data in word processing documents with simultaneous memo writing to organise my analysis: 
the memos were the most important way of keeping track of my analysis and thinking and were written 
during and after the data collection period. Throughout the process I asked many questions of the data. 
For example: Under what conditions does this practice occur? How do the GPs think, feel, and act while 
involved in this process? When and how do their actions change? How does this process happen in 
different places, for different people, for the same people at different times? Asking these questions 
encouraged me to examine codes and categories across their dimensions, to develop integrated 
explanatory frameworks, and to focus key messages for paper production and publication.  
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Case-based memos 
Case-based memos were written as soon as convenient after each interview: about how it went, 
information that stood out, what seemed important to that GP, and interesting points to follow up (e.g. 
experiences of uncertainty, distrust, or burden, the place of guidelines). Table 10 provides an example of a 
case-based memo about GPs being stuck in a catch-22, written about an early interview.  
Table 10: A case-based memo, illustrating code ‘Being stuck in a catch-22’ 
 
From this memo I identified new explanations to pursue and subsequently developed the interview 
schedule to find out more about, for example, making impossible decisions, using the evidence, 
thoughtless practice, and feeling burdened.  
Conceptual memos 
I also wrote conceptual memos, to record my thinking about the meaning of initial and focused codes and 
to work out categories and relationships between them in depth. I wrote a number of conceptual memos 
to enrich my understanding of central issues underlying the GPs’ explanations of how things worked in 
This GP provided a very useful, detailed account of the difference between “chucking in a PSA test” versus 
the way it ‘should’ be done (i.e. GP explaining and having rules of thumb about appropriateness of screening 
for individual patients). He does quite a lot of work to position himself and his approach; he is deeply 
committed to being the best GP he can be: he takes his job seriously, and wants to be fully informed, to give 
good advice. His practice is very much in line with the current GP guidelines (Red Book), but he clearly 
articulates the frustration of working within the current limitations of the evidence – and that as a 
profession medicine has not clearly articulated the current position. There was also some important 
information about the emotional effect of the current situation on him as a GP, including that he has to 
carry a burden to protect his patients (e.g. worrying about whether he has made the right decision). The 
most central code for this GP was ‘Being stuck in a Catch-22’. It is not just the GP in a Catch-22, the men are 
also stuck in a Catch-22; a place of personal conflict. This GP has tried to work out what to do about PSA 
screening. But it is impossible to know what to think and the experts have failed him – they cannot give him 
the test or the information that he needs. And if he does think about it, he ends up in an impossible situation: 
he ends up not knowing what to advise, the men end up having to make impossible decisions. And if he tells 
men not to have the test he feels like he is undermining his profession, because it is often a miracle for men 
to see a GP in the first place and so GPs should be offering them anything they can but instead he is telling 
them NOT to have the test. And even when he thinks he has consent from men, he cannot be sure that they 
are actually imagining what they need to imagine to make a good decision. This is why it is a Catch-22. 
Some GPs can deal with this by just chucking in PSA testing (i.e. do it thoughtlessly). Thoughtlessness is a 
highly undesirable quality in decision making. But if you think about it – you find yourself in an impossible 
situation. Because there is no answer, no one can tell you what to think and you cannot work it out for 
yourself, so maybe better off not thinking about it. 
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their practice. Table 11 presents a conceptual memo about ‘being uncertain’. At this stage of analysis, 
researchers using this method pay particular attention to variation in the meaning of concepts – how is 
the identified concept different to different people, different places, how is it similar, how does it compare 
to similar things in the literature – to gain a full grasp of the concept and in turn generate a comprehensive 
explanation of its meaning and relevance to the research question. This is an important step in the move 
towards theory construction.  
Table 11: A conceptual memo about ‘Being uncertain’
 
Being stuck in a catch-22 + Locating responsibility + Making impossible decisions = Being uncertain 
Many different types of *uncertainty* are becoming apparent in different contexts and GPs seem to focus 
on different versions of it, some not so overtly, but overall it doesn’t seem to be a particularly pleasant? 
welcome? experience. I think this concept might offer at least partial explanation of the data on the 
Catch-22 code and repetitive references about locating responsibility, making decisions, and feeling 
burdened by it. Some uncertainties being talked about by GPs: uncertain screening tool; uncertain 
evidence base; uncertain outcomes; uncertain guidelines, recommendations, advice; GP uncertain about 
what they personally would do; how to communicate; do patients know what they’re asking for?; unsure 
what colleagues are doing about it. ‘We don’t know what the hell we’re doing’. Also, overdiagnosis and 
underdiagnosis which I wrote about in a memo before this one are uncertainty. This is why the area of 
overdiagnosis is so uncomfortable and burdensome on GPs too – it’s hard to know right from wrong. The 
true outcome of any screening decision will never be known at an individual level. So what’s a good 
decision and how can you be sure?  
GPs are managing uncertainty in really different ways, in the way they describe it (as a normal part of 
practice, not of concern, rely on gut instinct, very frustrated and concerned) and strategies they use to 
deal with it (assess relevance, seek guidance, consult guidelines, and with patients – provide information, 
test more, test less, ignore, disclose). Some *accept it in their clinic and don’t seem particularly bothered, 
some *negotiate (?) and try to work with it or around it, some throw it away or *transfer it to other 
people, and to organisations too – it is their problem. Should it be the problem of organisations? It seems 
to be a major concern of GPs so needs to be explored further. Paul Han’s model of uncertainty could be 
relevant here? Follow up – suggested by a colleague. Han writes about uncertainty arising from different 
sources: probabilistic, ambiguity, and complexity. These concepts seem to be a good fit here. 
There are two main points about the uncertainty: (1) paradoxically doing PSA test with uncertainty to 
gain certainty, (2) ignoring the technical aspects of uncertainty that the GPs knows from medical 
training etc in their quest for [false] certainty. **Put everything we know about the complexity of the test 
aside – other values and inputs have a stronger pull; there are more compelling reasons that GPs would 
rather do a bad test than not do a test at all. Then there were those GPs that acknowledge the 
uncertainty and feel the burden: because the more you think about it the more you don’t know what to 
do (PSA screening creates exactly the thing they want to avoid; a cascading effect of uncertainty after 
uncertainty). So GPs are caught in dilemma of construction of false certainty. And GPs choose different 
pathways around that.  
BUT, why didn’t this come up in the UK interviews? What is evident in the practice of UK GPs that can 
explain this? I think a lot of it is about whether this is a problem of organisations or of individual GPs. 
More collective responsibility in the UK for what GPs do with the PSA test. I think I have another paper to 
write here about comparing all the conditions that GPs described as relevant to their screening practice 
in the two settings and how that might influence particular ways of practicing. 
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Mapping concepts 
The mapping component of this analysis provided a visual medium to organise and connect ideas. The 
process helped to clarify associations and relationships between topics and developing explanations. 
Consistent with Charmaz, I drew clustering diagrams to visualise the key themes of each memo to see how 
each was connected, or not, and used these images as an outline to additional future memos and in the 
writing process. These conceptual maps are presented in the findings and discussion chapters.  
2.5 Answering my research questions 
Grounded theory focuses on creating conceptual frameworks or theories through building inductive 
analysis from the data: from specific description of the data to more abstract understanding of the 
phenomenon in its entirety. General statements are made about analyses, but are always located in the 
context of their construction –in time, place, and the situation of inquiry (3). At the end of my data 
collection and analysis I had developed a provisional model explaining some aspects of the PSA screening 
process, from the perspective of GPs in Australia and the UK, expressed in diagrams and memos, and built 
around a core set of related categories.  
Generating an explanatory theory 
Grounded theory was explicitly developed to guide researchers to generate new theory rather than to 
verify existing theory (4). The product of a grounded theory study is expressed as a substantive theory: a 
set of concepts that are related to one another in a cohesive whole about an issue or experience that 
works in a particular context; substantive theories should closely reflect what participants experience and 
do.  
Typically a grounded theory study is intended to focus on a central social process (here, prostate cancer 
screening in general practice) and to arrive at a final explanatory theory that explains that process as a 
whole. This study is a good example of this – I have produced four empirical chapters (Chapters 3-6), each 
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focused on a different component of PSA screening in practice: overdiagnosis, uncertainty, context, and 
communication, and concluded with a final discussion cohering these components into a single 
explanation of the process. In Chapter 7 I present a practical working model of the PSA screening process, 
derived from GP accounts of how screening for prostate cancer works in their clinical practice, which 
draws together aspects of all the empirical papers into one model. It reflects significant variation in 
reasoning, practice, and experiences, and provides some explanation of how that variation works, 
including the influence of context. 
2.6 Quality of this grounded theory study 
Quality control is integral to grounded theory procedures and general principles of qualitative research. 
The following points describe process and procedural components of this study that ensured quality and 
rigor at all stages of the process. 
 All interviews were digitally recorded and professionally transcribed 
 Interview transcripts were analysed as soon as possible to focus the progressing data collection, 
particularly theoretical sampling 
 Sampled theoretically, to develop the emerging theoretical categories and make them robust 
 Writing regular, detailed case-based and conceptual memos enriched data analysis and further 
guided focused data collection 
 An evolving interview guide and responsive and flexible data collection ensured that gaps in 
knowledge could be addressed  
 Use of the constant comparative method, described in Section 2.4, ensured the developing theory was 
an accurate and thorough reflection of the process 
 All researchers involved in this project supported analysis activities and attended regular meetings 
to discuss the analysis and emerging interpretations. 
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Quality appraisal similarly applies to the credibility of the final product: the grounded theory. Charmaz 
suggests four characteristics that a grounded theory study should have to be considered a good-quality 
study. These are: credibility, originality, resonance, and usefulness (3). I briefly describe how the criteria 
apply in my study, below. 
Credibility: Charmaz describes research ‘credibility’ as achieving intimate familiarity with the setting or 
topic. My sampling of a large number of GPs across a range of contexts in Australia and the UK has 
provided a useful framework not only to understand how things work in two specific primary care 
contexts, but also to undertake strategic comparison, allowing insights to be generated about how 
different conditions influence practice. 
Originality: ‘Originality’ refers to the social and theoretical significance of the work. This study provides a 
nuanced analysis of how and why GPs test the way they do. I identified what matters to GPs and issues 
that encourage, prevent, and justify practicing in particular ways. Throughout, I compare my analyses 
with relevant theoretical and research literatures, including Han’s taxonomy of uncertainty, Gabbay and le 
May’s mindlines theory, Entwistle et al.’s Consider an Offer framework, and traditional models of 
evidence-based medicine. 
Resonance: In Charmaz’s text, ‘resonance’ is about whether the grounded theory makes sense to the 
participants or people who share their circumstances. I have presented components of this study at local 
and international academic conferences and seminars. Several GPs, academics, and professional 
organisations contacted me following these events to commend the work, and to confirm its relevance and 
applicability to their practice.  
Usefulness: ‘Usefulness’ is achieved if the analysis offers interpretations that people can use in their 
everyday worlds. My conceptual model provides a new way of understanding this complex and 
controversial clinical and public health problem, and has important practical utility. An academic 
representative on the recent Australian PSA guidelines panel advocated for findings from this study to be 
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brought into conversations during the development process. The four empirical chapters were published 
in the peer-reviewed literature, have been cited in academic journals and at international conferences, 
and in Australian medical media, as I noted earlier in the thesis. 
This chapter has provided a detailed explanation of how this study evolved using grounded theory 
methodology. The following chapter is the first of four presenting my empirical work. A summary table on 
the following page orients the reader to the place of each of the following four empirical chapters 
(Chapters 3-6) in relation to components of the final grounded theory, which will be explained in full in 
Chapter 7.
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Components of the final 
grounded theory 
 
Chapter 3. Overdiagnosis 
(n=32 Australian GPs only) 
 
Chapter 4. Uncertainty 
(n=69 Australian & UK GPs) 
 
Chapter 5: Organisational context 
(n=69 Australian & UK GPs) 
 
Chapter 6: Communication 
(n=69 Australian & UK GPs) 
 
Existing theory used in 
development of final 
grounded theory 
 Han’s taxonomy of uncertainty 
 
Gabbay and le May’s Mindlines theory 
 
Entwistle et al’s Consider an offer 
framework 
Research Question 1: How do GPs approach PSA screening? 
Three background 
conditions were central to 
GP descriptions of their 
screening approach: 
-Interpretations of the 
evidence (by GP or others) 
-Relatively stable GP values 
and goals 
-Intuitive patient typologies 
 
 
GPs approached PSA screening…  
 Using one of four heuristics; 
shaped by different values and 
reasoning about the harms of 
under and over diagnosis. 
Considerable diversity. 
 By making an overall judgment 
about the relevance of evidence 
to PSA screening, for this 
individual man, or for all men, 
individually or in interaction 
with the patient 
 Sometimes, by responding to 
patients’ individual preferences, 
shifting their usual screening 
‘rules’ accordingly 
 
GPs approached PSA screening…  
 With more or less uncertainty 
(scientific, practical, personal) 
about professional practice and 
expected standards of care 
 Using different strategies to 
manage different types of 
uncertainty: taking charge, 
engaging others, transferring 
responsibility 
 
GPs approached PSA screening…  
 With GPs’ roles, values, and 
corresponding goals for practice, 
shaped/enabled/disabled by their 
context: 
1. According to professionally-
derived, internalised values and 
goals of the organisation (UK) 
2. According to individual values and 
goals, independent of their 
organisation (AU).  
 By appraising different types of 
evidence, with more or less 
guidance from their organisation  
 
GPs approached PSA screening…  
 With four communication 
patterns: Be screened, Do not be 
screened, Analyse and choose, 
and As you wish 
 By communicating with men in 
line with their primary goals for 
the interaction 
 Sometimes, strongly influenced 
by patient ‘types’  
 Sometimes, framing evidence to 
fit with valued outcomes 
 Sometimes, with little or no 
communication with men prior 
to ordering a PSA 
Research Question 2: What factors influence GP approaches to PSA screening? 
Four sources of 
knowledge (experiential, 
tacit, relational, formal) 
influenced and shaped the 
background conditions 
 
Main factors influencing GP 
approaches included:   
 The GP’s experiences with PSA 
(e.g. missing an aggressive 
cancer): this provided tangible 
evidence; one-off experiences 
trumped formal evidence 
 Relational expectations (e.g. 
patient request, GP reputation): 
GPs discounted or re-shaped 
evidence to respond to these  
 GPs’ interpretations of the 
research evidence (whether 
individually developed or 
received via guidelines) 
Main factors influencing GP approaches 
included:   
 Three different sources of 
uncertainty: probabilistic, 
ambiguity, complexity 
 The GP’s level of uncertainty about 
the PSA screening evidence base: 
some GPs accepted and managed 
on their own, some engaged 
others to help them make sense of 
the evidence, some transferred 
responsibility for interpreting the 
evidence to others 
Main factors influencing GP approaches 
included:   
 History of screening policy and 
agendas; healthcare structures and 
payment models 
 Practice environments that 
encouraged (or discouraged) 
particular approaches, some more 
evidence-based than others 
 Institutional support and 
resources to apply the best 
available evidence in practice (or 
lack of) 
 Screening culture 
 GP mindlines (tacit knowledge, 
developed in-context) 
Main factors influencing GP 
approaches included:   
 GPs’ primary goals for practice 
(developed experientially, 
tacitly, relationally), influenced 
quality and quantity of 
information provision 
 Specific situational and 
relational factors (e.g. man 
screened by another GP) 
 Established norms of 
communicating 
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GPs evaluated the sources 
of knowledge via two 
knowledge filters 
-Trust 
-Uncertainty 
Main factors influencing GP 
approaches included:   
 Lower trust in research evidence 
= GP guided by other sources of 
knowledge, like clinical 
experiences (which provided 
more certainty about the right 
thing to do, not necessarily 
evidence-based) 
 Higher trust in research 
evidence = GP guided by 
epidemiology, and more certain 
about the harms of 
overdiagnosis 
 Some GP uncertainty relating to 
translating overdiagnosis 
statistics to individual patients 
Main factors influencing GP approaches 
included:   
 Type of uncertainty: GPs had more 
trust in their ability to engage in 
‘good’ practice based on 
probabilistic uncertainty than 
uncertainty arising from 
ambiguity or complexity 
 Inconsistent versions of expert 
advice undermined Australian 
GPs’ trust in the system and 
fuelled uncertainty about clinical 
and legal obligations 
Main factors influencing GP approaches 
included:   
 Institutional trust: underpinned 
screening practice of GPs in the 
UK; strongly guiding healthcare 
structures were a proxy for 
relative certainty about the 
evidence and an evidence-based 
approach 
 Interpersonal trust: underpinned 
screening practice of GPs in 
Australia; ambiguity uncertainty 
meant GPs were more likely to 
perceive evidence as uncertain and 
thereby feel uncertain about the 
best approach 
Main factors influencing GP 
approaches included:   
 Trust in, and certainty about, the 
evidence: GPs communicated 
epidemiological perspectives 
 Distrust, and uncertainty about, 
the evidence: GPs framed 
conversations according to 
personal judgments about the 
evidence 
GPs engaged or did not 
engage others in the 
screening interaction 
-Communicating 
-Making a final decision 
(which mediated the final 
outcome) 
Main factors influencing GP 
approaches included:   
 If a GP felt there was a clear 
‘right answer’ they would advise 
patients to take that path, and 
include the patient less 
 If a GP was less clear, they would 
include patients more, case-by-
case, or acted in line with patient 
instructions (e.g. to be screened) 
without question 
 Routine screening behaviours: 
some GPs habitually did not 
engage others (e.g. ‘tick-box’ 
approach) 
 GPs reported communicating 
about overdiagnosis was difficult 
(so most did not discuss it with 
patients)  
Main factors influencing GP approaches 
included:   
 Uncertainty: some GPs took charge 
and managed screening decision 
making on their own 
 Uncertainty: some GPs engaged 
others in managing uncertainty, 
including the medical profession, 
colleagues, and patients 
 Uncertainty: some GPs sought to 
transfer to other parties the 
responsibility for managing or 
reducing some uncertainties 
 Some GPs felt conflicted, or guilty, 
about involving patients in making 
decisions based on uncertainty 
 Some GPs found talking with men 
challenging because of underlying 
uncertainty 
Main factors influencing GP approaches 
included:   
 Institutional arrangements created 
more or less opportunity for 
engagement processes to occur; 
e.g. two-step process, written 
information resource in the UK 
(more opportunity), practice recall 
systems and mailed pathology 
forms in Australia (less 
opportunity) 
Main factors influencing GP 
approaches included:   
 GPs’ ambitions for patient 
understanding: some GPs aimed 
for comprehensive detailed 
information exchange, others 
were satisfied with ‘gist’ 
understanding of the basic 
concepts 
 Patient ‘types’: some GPs 
reverted to intuitive 
understandings of ‘PSA patients’ 
to help them to decide whether 
to involve patients in the process 
and if they did, how that should 
be done 
 Determining that not all patients 
wanted to be active participants 
in decision making 
Research Question 3: What are the consequences of this process? 
There were relevant 
consequences (outcomes) 
for both GP and patient: 
-Screening or not screening 
-Patient outcomes 
-GP outcomes 
Main consequences were:  
 GPs perceived there to be much 
at stake for them individually: 
easy to take ‘wrong’ course of 
action 
Main consequences were:  
 GPs felt insufficiently supported 
professionally, and burdened by 
the complexities of their situation 
and responsibilities to patients 
Main consequences were:  
 Men could receive very different 
care, depending on their GP:  
Institutional norms and 
infrastructure shaped what GPs 
Main consequences were:  
 Consistent communication 
patterns in the UK, variation in 
Australia 
 GPs’ heuristics of patient values, 
rather than actual patient values, 
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 GPs experienced cognitive and 
emotional burden, feeling 
personally responsible for the 
consequences of their approach 
 Because of variation in GP 
practice, men are likely to 
experience unequal access to 
information and consent to 
screening 
 GP anxiety arising from perceived 
incapacity to make good decisions 
without good evidence 
 Continued PSA screening in the 
Australian context, in pursuit of 
certainty 
 
prioritised as an outcome for a 
patient 
 Promoting a market for PSA 
screening: Australia’s fee-for-
service payment system continues 
to reward GPs for activity in 
primary care 
commonly transpired to inform 
decision making  
 A spectrum of patient 
involvement: GP 
conceptualisations of the ‘ideal’ 
patient outcome varied  
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CHAPTER THREE. 
Doctors’ approaches to PSA testing and 
overdiagnosis in primary healthcare:  
A qualitative study 
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3. Overview of this chapter 
This chapter presents an analysis of how and why GPs provide, or do not provide, the PSA test to their 
asymptomatic male patients (Research Question 1.1), with a focus on under- and over- diagnosis. GP 
considerations of under- and over- diagnosis were identified as significant sources of variation in 
reasoning (Research Question 2.1), and having a substantial impact on GPs, personally and professionally 
(Research Question 3.1, 3.2). 
PSA screening has significantly increased the detection of prostate cancers. Some cancers found through 
PSA screening grow so slowly that they may never become clinically relevant or impact on a man’s life. 
Men with such cancers do not benefit from detection and treatment. Overdiagnosis is thus particularly 
pertinent to prostate cancer. Overdiagnosis is widely considered the most concerning potential harm of 
PSA screening. But overdiagnosis is a complex concept to understand and explain for health care 
professionals and the public. Responsibility for guiding men’s decisions about whether or not to be 
screened for prostate cancer has largely been placed in the hands of individual clinicians. A conundrum 
for clinicians is that it is not possible for them to know which cases represent overdiagnosis at the time of 
screening. Few publications have reported on clinician views on overdiagnosis.  
3.1 Publication details 
Pickles K, Carter SM, Rychetnik L. Doctors’ approaches to PSA testing and overdiagnosis in primary 
healthcare: a qualitative study. BMJ Open 2015;5: e006367. doi:10.1136/bmjopen-2014-006367 
3.2 Authors’ contributions 
KP, SC, and LR conceived the study and were involved in designing the study and developing the methods. 
SC & LR obtained funding and are CIs on the NHMRC funded project grant. KP conducted the interviews 
and led the analysis, had full access to all data in the study, and takes responsibility for the integrity of the 
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data and the accuracy of the data analysis. KP, SC, and LR drafted the manuscript. All authors contributed 
to the interpretation of the analysis and critically revised the manuscript.  
3.3 Abstract 
This was a qualitative study that sought to explain how PSA screening works in clinical practice. Data 
were analysed using grounded theory methods. We interviewed 32 Australian GPs to illuminate the issues 
from the GP perspective. We found significant variation in the GPs’ approaches to screening for prostate 
cancer, which were strongly related to their personal view on how underdiagnosis and overdiagnosis 
should be balanced. We identified four heuristics to describe GP preference for, and approaches to, PSA 
screening and overdiagnosis: (1) GPs who prioritised avoiding underdiagnosis, (2) GPs who weighed 
underdiagnosis and overdiagnosis case by case, (3) GPs who prioritised avoiding overdiagnosis, and (4) 
GPs who did not engage with overdiagnosis at all. Many GPs gave considerable weight to concerns about 
missing cancers. Some GPs described feeling conflicted about the right thing to do which created 
considerable burden. We look at GP responses to navigating this complex situation. These findings offer 
important guidance for future efforts to address the problem of prostate cancer overdiagnosis. 
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ABSTRACT
Objectives: (1) To explain general practitioners’
(GPs’) approaches to prostate-specific antigen (PSA)
testing and overdiagnosis; (2) to explain how GPs
reason about their PSA testing routines and (3) to
explain how these routines influence GPs’ personal
experience as clinicians.
Setting: Primary care practices in Australia including
men’s health clinics and rural practices with variable
access to urology services.
Participants: 32 urban and rural GPs within Australia.
We included GPs of varying ages, gender (11 female),
clinical experience and patient populations. All GPs
interested in participating in the study were included.
Primary and secondary outcome measure(s):
Data were analysed using grounded theory methods to
determine how and why GPs provide (or do not provide)
PSA testing to their asymptomatic male patients.
Results: We observed patterned variation in GP
practice, and identified four heuristics to describe GP
preference for, and approaches to, PSA testing and
overdiagnosis: (1) GPs who prioritised avoiding
underdiagnosis, (2) GPs who weighed underdiagnosis
and overdiagnosis case by case, (3) GPs who prioritised
avoiding overdiagnosis and (4) GPs who did not engage
with overdiagnosis at all. The heuristics guided GPs’
Routine Practice (usual testing, communication and
responses to patient request). The heuristics also
reflected GPs’ different Practice Rationales (drawing on
experience, medicolegal obligations, guidelines and
evidence) and produced different Practice Outcomes
(GPs’ experiences of the consequences of their PSA
testing decisions). Some of these heuristics were more
responsive to patient preferences than others.
Conclusions: Variation in GPs’ PSA testing practices is
strongly related to their approach to overdiagnosis and
underdiagnosis of prostate cancer. Men receive very
different care depending on their GP’s reasoning and
practice preferences. Future policy to address
overdiagnosis will be more likely to succeed if it
responds to these patterned variations.
INTRODUCTION
Prostate-speciﬁc antigen (PSA) testing for
prostate cancer in healthy men is an
emotive, controversial1 and hotly debated
issue. Evidence suggests that harms of PSA
testing for prostate cancer in asymptomatic
men can outweigh beneﬁts.2–4 Most guide-
lines recommend against population screen-
ing;3 5–7 however, some professional societies
do recommend selective PSA testing8–10
(table 1). In Australia, and internationally,
many men continue to be tested despite
guidelines advising not to screen.16–18 This
article presents an empirical qualitative study
of how Australian general practitioners (GPs)
reason about PSA testing of asymptomatic
men for prostate cancer, who they test and
why, with a particular focus on how GPs
manage the risk of overdiagnosis.
Overdiagnosis and/or overtreatment are
considered the main potential harms of PSA
testing. Overdiagnosis occurs when people
without symptoms are correctly diagnosed
Strengths and limitations of this study
▪ Most previous research has examined which
general practitioner (GP) characteristics are asso-
ciated with frequent or infrequent testing, and
has been predominantly quantitative. This
in-depth qualitative study offers a unique exam-
ination of GPs’ approaches to prostate cancer
overdiagnosis, from the GP perspective. It is the
first study to systematically map prostate-specific
antigen (PSA) testing with GPs’ reasoning and
understanding of prostate cancer screening and
overdiagnosis.
▪ We identified and interviewed highly informative
participants (GPs) and have developed valuable
detailed insights into how the PSA testing
process works in everyday practice.
▪ There may be value in knowing the prevalence of
the four heuristics we have discovered across the
population: a next step could be a population-
based survey to ascertain the prevalence of these
heuristics at a population level.
▪ Since physicians with strong opinions may have
been more likely to volunteer, some selection
bias is possible. However, diverse opinions and
approaches were reported, suggesting that
strong selection bias is unlikely.
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Table 1 The US, UK and Australian recommendations for prostate-specific antigen (PSA) testing of asymptomatic men for
prostate cancer
Professional body
Advice for health practitioners (see original documents for exact
phrasing)
Population US Preventive Services Task Force
(USPSTF)3
▸ Discuss PSA screening thoroughly with men who raise the issue or
if the man’s individual circumstances warrant consideration of PSA
testing. Do not feel obligated to offer PSA testing if a patient does
not raise the issue or request the test
▸ The decision to start or continue PSA screening should reflect the
patient’s understanding of the possible benefits and expected harms
and should respect his preferences
National Health and Medical
Research Council (NHMRC)11
▸ Before ordering a PSA test, health practitioners should talk to men
about the potential benefits and harms of PSA testing
National Health Service (NHS)12 ▸ Screening not recommended. An informed choice programme,
Prostate Cancer Risk Management aims to provide high-quality
information about the risks and benefits to men who ask about
screening in order to enable them to decide whether to have the test
National American Cancer Society (ACS)10 ▸ Provide men the opportunity to make an informed decision; for men
who are unable to decide, the screening decision can be left to the
discretion of the healthcare provider
▸ Men at average risk and expected to live at least 10 more years
should receive this information beginning at age 50 years. Men in
higher risk groups should receive this information at age 40–
45 years
Cancer Council Australia (CCA) and
Australian Health Ministers’ Advisory
Council (AHMAC), 2010*13
▸ Speak to men about the benefits and harms of testing and treatment
so that they can make an informed choice
Specialist American Urological Association
(AUA)8
▸ Shared decision-making for men aged 55–69 years based on a
man’s values and preferences
▸ Routine screening is not recommended in men aged 40–54 years at
average risk, or in men over 70 years or with less than a 10–15-year
life expectancy; decisions should be individualised for men younger
than 55 years at higher risk
Urological Society of Australia and
New Zealand (USANZ)14
▸ PSA and digital rectal examination (DRE) should be offered to men
55–69 years, after providing information about the risks and benefits
of such testing
▸ Interested men in younger age groups (under 55 years) could have a
single PSA test and DRE performed at or beyond age 40 to provide
an estimate of their prostate cancer risk over the next 10–20 years,
with the intensity of subsequent monitoring being individualised
accordingly
Primary
Care
American College of Physicians
(ACP)15
▸ Inform men 50–69 years about the limited potential benefits and
substantial harms of screening for prostate cancer
▸ Base the decision on the man’s risk for prostate cancer, a
discussion of the benefits and harms of screening, the patient’s
general health and life expectancy and patient preferences
▸ Advised not to screen patients who do not express a clear
preference for screening
▸ Advised not to screen average-risk men under 50 years, over
69 years, or with a life expectancy of less than 10 to 15 years
Royal Australian College of General
Practitioners (RACGP)6
▸ Not recommended unless the man specifically asks for it, and he is
fully counselled on the pros and cons
▸ General practitioners need not raise this issue, but if men ask about
prostate screening they need to be fully informed of the potential
benefits, risks and uncertainties of prostate cancer testing
▸ When a patient chooses screening, both PSA and DRE should be
performed
▸ Responding to the patient’s concerns and fulfilling medicolegal
responsibilities are considerations in discussion with patients
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with a disease that would not cause them to experience
symptoms or early death.19 It is hard to understand and
explain,20 and difﬁcult to quantify; estimates range from
15% to more than 84% of screen-detected prostate
cancers.21–26 Overdiagnosis may lead to overtreatment:27
treatment a person did not need. PSA testing often trig-
gers a cascade of diagnostic tests and active treat-
ment,28 29 potentially compromising a well person’s
quality of life.30 31 Advocates of testing argue that PSA
testing may, in some cases, lower the stage and grade of
cancer at diagnosis, and reduce the risk of being diag-
nosed with metastatic prostate cancer, for which there is
no cure.32–34 However, across the population of asymp-
tomatic men, PSA testing does not decrease all-cause
mortality, and some men will progress and develop meta-
static disease even if they are screened (despite earlier
diagnosis).35
Responsibility for guiding men’s decisions about
whether or not to be screened for prostate cancer has
largely been placed in the hands of individual physi-
cians. In Australia, GPs are the primary point of
contact to access a PSA test. There is no organised
screening programme; PSA testing is opportunistic but
prevalent.18
Empirical work exploring prostate cancer screening in
general practice has primarily focused on: (1) the
reasons GPs give for ordering PSA tests; (2) the
characteristics of GPs (such as age, gender, location)
associated with more or less frequent testing and
(3) how GPs communicate with patients about the PSA
test.36–44 The predominantly quantitative evidence pro-
vides insights into the patterns and potential drivers of
PSA testing in general practice but does not illuminate
the dilemmas of PSA testing from the GP’s perspective,
and in particular how GPs reason about overdiagnosis.
To ﬁll this gap, we conducted a qualitative study to
explore how and why GPs provide (or do not provide)
PSA testing to their asymptomatic male patients. We
report on the signiﬁcance and impact of overdiagnosis
in GPs’ clinical reasoning about PSA testing.
METHODS
Design
We used the well-established, systematic qualitative
research methodology of grounded theory45 to guide
our sampling and analysis. We collected data via
in-depth interviews. GPs had an opportunity to discuss
the study, and gave consent prior to participation.
Participants and setting
We recruited 32 urban and rural GPs throughout
Australia (11 female). Our initial purposive sample was
of GPs working in men’s health clinics in Sydney (n=2).
We advertised via the newsletters and email lists of
regional GP organisations (Medicare Locals) in Sydney
(n=8). GPs were invited to contact KP if they were inter-
ested and willing to participate in the research. We then
broadened our sampling by advertising in mass and
social media, and in medical journals (Medical Observer,
the Australian Medical Association’s GP Network News,
and the 6 min newsletter). As analysis and sampling
evolved, we invited additional rural and interstate GPs to
answer speciﬁc analytical questions (n=11). Rural GPs
were accessed by phoning practice managers, through
colleagues, and advertising with rural Medicare Locals,
adding eight further GPs. When we encountered GPs
whose routine care was divergent from previously inter-
viewed GP norms, we invited more GPs from that prac-
tice to attempt to distinguish between personal and
institutional inﬂuences on their practice. An additional
three GPs were recruited in this ﬁnal phase of theoret-
ical sampling. GPs of varying ages, clinical experience,
gender and patient populations were all included. All
GPs interested in participating in the study were
included. GPs were compensated for their time.
Interviews/data collection
A semistructured interview schedule was developed with
a focus on GPs’ current approaches to, and reasoning
about, PSA testing. The schedule covered a broad range
of topics, including GPs’ recent clinical encounters
involving PSA testing decisions; communicating informa-
tion; screening pathways; and the central theme of this
paper, overdiagnosis. The interview schedule was modi-
ﬁed between interviews, informed by the developing
analysis. Interviews took place between March and
September 2013. They were conducted by KP, mostly by
telephone, and ranged in duration from 18 min to 1 h
and 10 min. All interviews were audio-recorded,
de-identiﬁed and transcribed verbatim.
Examples of questions GPs were asked about overdiag-
nosis included the following:
▸ Are you familiar with the term ‘overdiagnosis’?
▸ Do you think about the issue of overdiagnosis in your
practice?
▸ How do you manage overdiagnosis in your practice?
▸ Overdiagnosis must be a challenging concept to talk
about with your patients; how do you manage that
challenge?
Data coding and analysis
The analysis was led by KP, who coded the transcripts
and wrote detailed memos which were reviewed and dis-
cussed by the authors in analytical meetings. A subset of
transcripts was read and coded by all three authors inde-
pendently; this coding was compared and discussed to
inform the development of the central concepts in the
study. This paper focuses on how GPs dealt with the
concept of overdiagnosis.
RESULTS
Most GPs felt uncertain and/or conﬂicted regarding
what to do about PSA testing of asymptomatic men.
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In the following section, we will explain overall patterns
and then outline four heuristics used in practice.
GPs considered underdiagnosis as well as overdiagnosis
GPs discussed the harms of underdiagnosis (the missed
opportunity to intervene in potentially preventable
deaths) as much as those of overdiagnosis (the psycho-
logical and physical harms and ﬁnancial costs of
unnecessary diagnosis and treatment). Since both harms
are salient and serious, PSA testing decisions were
described as a “balancing act” (GP21) or gamble. GPs
reported the difﬁculties of needing to choose between
potential harms (eg, incontinence and impotence) and
the chance of saving lives.
Testing decisions were described as a personal burden
Uncertainty about PSA testing created a ‘personal
burden’ for some GPs; they felt personally responsible
for the consequences of their PSA testing approach, and
experienced guilt and self-blame as a result.
Many GPs used personal or professional experiences
with the PSA test, both positive and negative, as powerful
anchors for their current practice: these experiences
often explained GPs’ perception of personal burden. We
will return to the personal burden of PSA testing
throughout the following sections.
GPs’ communication practices varied
GPs varied in the conversations they had with men spe-
ciﬁcally about overdiagnosis. Some deliberately avoided
raising the issue, or talked men into or out of having a
PSA test. GPs described several important contextualis-
ing factors.
1. Cancer is widely feared and difﬁcult to talk about.
2. Overdiagnosis is hard to understand for GPs and for
the public—and it is contradictory to many people’s
existing health beliefs.
3. Both doctors and patients often have a strong belief
that cancer screening is, in general, a worthwhile and
important strategy to combat the risk of getting
cancer.
GPs employed four heuristics to manage PSA testing
GPs’ responses to this difﬁcult situation depended on
how they viewed an implicit continuum between over-
diagnosis and underdiagnosis. They considered which
end of the spectrum would cause the greatest harm to
each patient and/or their patients in general.
Four broad patterns (‘heuristics’) were employed.
1. Some GPs preferred to offer PSA testing to avoid
underdiagnosis.
2. Some GPs were strongly oriented to avoiding over-
diagnosis, and so tried to test as little as possible.
3. Some GPs made case-by-case individualised decisions.
4. Some GPs did not think about underdiagnosis or
overdiagnosis at all.
These four heuristics represent observed patterns of
GPs’ preferred or dominant practice orientations; that is, each
GP seemed to prefer one of these four heuristics as their
overall approach to PSA testing. Some of these heuristics
were more responsive to patient preferences than others
(table 2).
The GPs’ Dominant Practice Orientation guided their
Routine Practice (usual testing, communication and
responses to patient requests). GPs also described their
Practice Rationale (drawing on experience, medicolegal
obligations, guidelines and evidence) which inﬂuenced
testing decisions and justiﬁed why they adopted their
particular practice orientation. Their orientation pro-
duced a Practice Outcome: GPs’ experiences of the conse-
quences of their PSA testing decisions. The four
dominant practice orientations (heuristics) are sum-
marised in table 2 and described below.
Heuristic 1: GP preference to offer PSA testing to avoid
underdiagnosis
GPs employing heuristic 1 thought testing was necessary
because there was a possibility it might prevent a man’s
death. Overdiagnosis was perceived as (1) a natural con-
sequence of PSA testing; (2) better than dying and (3) a
justiﬁable source of harm (harms being a regrettable
but necessary price of ‘cure’).
These GPs focused on cancer as life-threatening, and
prostate cancer as a terrible death. They saw preventing
death as the primary duty of the GP. This heightened
their responsibility to do anything that may diagnose
cancer early: “Because if you don’t overdiagnose, the
alternative is to underdiagnose” (GP28). Underdiagnosis
was perceived to be a medicolegal risk, and for some
GPs, legal risk was uppermost in their minds during the
decision-making process. GPs concerned with missing
diagnosing cancers practised more defensively; “I’m
often a bit defensive…I guess that’s partly that legal
thing” (GP5).
GPs with this practice orientation advised men to have
a PSA, emphasising beneﬁts of early detection, and did
not discuss overdiagnosis.
Some of these GPs thought decisions about postdiagno-
sis management (eg, active surveillance) could limit the
harms of potential overdiagnosis. This allowed them to
deﬁne testing without invasive procedures as inconse-
quential: “it’s not terribly onerous to have a blood test
every six months” (GP3). Although many of these GPs
accepted that the PSA test was not perfect, they preferred
to test because “clearly, people’s lives are saved” (GP8).
These GPs anchored their practice orientation to per-
sonal experiences. Their approach was supported by
stories of men still being alive following active testing
and treatment.
Another anchor for this heuristic was having experi-
enced caring for patients with metastatic cancers, “I’ve
had two recently where their GP refused to actually test
the PSA level over the last ten years and both presented
with metastatic prostate cancer” (GP24), and witnessing
the horrors of prostate cancer deaths: “dying from pros-
tate cancer would probably rank amongst one of the
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worst ways to die…pain that is almost not able to be alle-
viated by narcotics” (GP29).
Despite their convictions, GPs experienced some per-
sonal struggle when they witnessed side effects of pros-
tate cancer treatment. Such cases were often recalled in
detail. For example, one GP describes this as “a heavy
burden if a person is left with side effects” but accepted
that “that’s just part of being a GP, you have to walk
around with this” (GP29). They tried not to take it per-
sonally, “oh, well, it happens. I mean, unfortunately, no
matter how good a doctor [I am], now and then this is
going to happen” (GP19). Overall, though, the personal
burden felt by this group was relatively small and did not
challenge the GP’s belief in PSA testing, which they said
fulﬁlled their role as a clinician to save lives. Many also
regarded testing as consistent with specialists’ advice,
which allowed them to reduce their personal burden;
that is, the responsibility of decisions about PSA testing
was shared with these specialists (but not with their
patients).
Heuristic 2: GP preference to not offer PSA testing to avoid
overdiagnosis
GPs employing heuristic 2 preferred not to conduct PSA
testing. Their primary justiﬁcation was preventing harms
caused by overdiagnosis. However, while they would try
to talk patients out of having the test, they would never
refuse a PSA test. These GPs also recognised that PSA
testing has saved lives; “we know that happens. The
problem is, it just doesn’t happen often enough to
balance out…all the damage that we do” (GP17).
This group of GPs emphasised the harms of PSA
testing (including overdiagnosis) when advising their
patients; and said many patients chose not to be tested
following discussion. These GPs, who fully explain over-
diagnosis, described themselves as “taking the risk of
doing the hard work, hard yards” (GP23). They resisted
medicolegal fears by engaging in detailed discussions of
beneﬁts and harms, and felt covered from legal prosecu-
tion by the Royal Australian College of General
Practitioners (RACGP) guidelines.
GPs committed to avoiding overdiagnosis particularly
drew on and trusted the research evidence to guide and
inform their testing decisions. However, practising
accordingly could be compromised by situational
factors, such as a patient who had not been tested dying
of prostate cancer. GPs said it was incredibly challenging
to ignore personal (anecdotal) experiences, yet some
were adamant that their practice would not be inﬂu-
enced by these experiences.
GPs found it hard knowing some cancers would be
missed because of their decision not to test: for
example, one described this as “a burden that I carry”
(GP8). GPs most concerned about overdiagnosis experi-
enced the highest levels of personal burden because,
although relatively rare, death as the potential conse-
quence of not testing was seen as the worst possible
outcome. Some suspected that overdiagnosis and
overtreatment were not as much of a burden for the
patient as they were for the doctor.
Heuristic 3: GP thinks of each patient as an individual
and makes case-by-case decisions
GPs employing heuristic 3 had no preconceived attitude
towards avoiding underdiagnosis or overdiagnosis. They
tailored PSA testing decisions speciﬁcally for the per-
sonal circumstances of each patient, according to the
patient’s risk proﬁle (age, family history), life expect-
ancy, interest, motivation, reason for wanting a PSA test,
cancer anxiety, or intention and ability to act on abnor-
mal test results. These GPs were particularly responsive
to patients’ individual preferences, so the outcome of
the consultation was largely unpredictable: “You have to
try and work out what’s best for the—that one particular
patient that you are talking to at the time” (GP18).
Testing ‘rules’ shifted according to the patient and the
GP; “it’s so easy to just learn what you do from a book
but once you are actually faced with someone you know
you can’t—it’s difﬁcult to apply the same rule” (GP6).
These GPs approached communication in several dif-
ferent ways. Some made their own decision about the
‘right’ approach for each particular patient, and advised
that patient accordingly. This could include not discuss-
ing overdiagnosis at all, on the grounds that it was irre-
sponsible to expect patients to understand complex
information; “if you start going down that road and—
and to what end?” (GP7). Other GPs tailored their dis-
cussion about overdiagnosis to the needs of the individ-
ual patient, their perceived level of understanding and
time pressures: “it gets more complicated depending on
how interested the person is” (GP4). Thus, the GP’s
communication depended entirely on the individual
patient in front of them.
GPs who approached PSA testing case by case gener-
ally agreed that overdiagnosis statistics do not, or cannot,
apply to individuals; “those like statistical issues don’t
apply to the individual…because…they make their deci-
sions on a set of complex, but perhaps irrational basis,
you know, anxiety and…” (GP7). Accordingly, they tai-
lored their testing and patient communication but
expressed some difﬁculties in translating population-
based information to individuals.
The personal burden experienced by these GPs was
minimal as in most consultations the burden of decision-
making was shared with their patients. GPs sought to
reach a mutual understanding of PSA testing if they
thought the patient was able to understand the informa-
tion required, and shared the responsibility of decisions
and outcomes of the consultation with the individual
man. They tended to consider decisions about PSA
testing as neither right nor wrong and so could be
swayed either way depending on the patient and their
needs. These GPs had minimal legal concern because
they perceived patients to have made informed decisions
based on their individual needs.
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Heuristic 4: GP preference to avoid thinking about
underdiagnosis or overdiagnosis
GPs not thinking about underdiagnosis or overdiagnosis
did not have a preference or priority for avoiding one
harm over another. For these GPs, the PSA test was con-
sidered just another form of routine screening and
underdiagnosis or overdiagnosis was not an issue of
concern.
The majority of GPs in this group did not engage with
considering the implications of underdiagnosis or over-
diagnosis and what that meant for their patients. Some
of these GPs felt explaining overdiagnosis was the
responsibility of urologists, and preferred to simply
inform men that a PSA test may lead to them having a
biopsy. These GPs also said they preferred to be guided
by urologists on what to do about PSA testing overall.
Personal burden associated with underdiagnosis or
overdiagnosis was therefore not a signiﬁcant feature for
this group of GPs. For some, their priority was being
regarded as a ‘good’ GP by their patients: they focused
on how their testing decisions might inﬂuence their
reputation and rapport with their patient. They reported
that a ‘good’ GP was in many cases deemed to be
someone who actively tested.
DISCUSSION
Overdiagnosis of indolent cancers in cancer screening is
now recognised as a signiﬁcant problem, but solutions to
this problem (eg, communication, public awareness) are
as yet uncertain, including in primary care. Most previ-
ous research has examined associations between GP
characteristics and frequency of PSA testing. Fewer
studies have sought to explain variation in GPs’ PSA
testing practice. Ilic and colleagues46 differentiated
‘reactive screeners’ (GPs who screened only at the
patient’s request) from ‘proactive screeners’ (GPs moti-
vated to test, believed screening was beneﬁcial, and
feared missing cancer, including for medicolegal
reasons). Our study provides a more nuanced analysis of
how and why GPs test the way they do, and offers a
unique examination of GPs’ approaches to prostate
cancer underdiagnosis and overdiagnosis. It is the ﬁrst
study to systematically examine the relationship between
GPs’ reasoning and behaviour in relation to PSA testing.
We identiﬁed four distinct approaches, each associated
with different practices, rationales and outcomes. Our
ﬁndings explain why men so often receive different
advice and clinical care: this depends on their GP’s PSA
testing practice orientation.
There is value in understanding the reasoning behind
actual practice. GPs’ reasoning makes sense of variation
in practice: it explains why different GPs are making dif-
ferent testing decisions in similar cases. GPs’ experiences
with PSA testing (positive and negative), values, percep-
tions (of the GP role, the patient role, of the PSA test
and overdiagnosis), considerations of evidence and
guidelines, and their sense of personal burden
(anticipated or experienced) all uniquely contribute to
PSA testing patterns. Variation in practice has ethical
implications, as men are experiencing unequal access to
information and consent to PSA testing. Yet these GPs
were not acting arbitrarily; most were simply doing the
best they could in an almost impossible situation. The
difﬁcult position GPs are in should be recognised in
future efforts to address the problem of prostate cancer
overdiagnosis.
Policy implications
Guidance used by Australian GPs about PSA testing
varies widely (see table 1). This also contributes to the
diversity of practice revealed in this study. Although it
would be unrealistic to expect the mere existence of a
guideline to change practice,39 it does seem reasonable
for GPs to expect that expert bodies will provide clear
guidance wherever possible. A community jury on PSA
testing reported men’s experiences of variable and
inconsistent advice from GPs, and recommended pro-
grammes to support GPs to provide patients with better
quality and consistent information about PSA screen-
ing.47 The Australian Medical Health and Research
Council (NHMRC) has recently produced an authorita-
tive summary of PSA testing beneﬁts and harms for GPs
to discuss with their patients.
The ﬁndings of this study offer important guidance
for the implementation of such recommendations in
practice. We recommend that agencies seeking to
promote the uptake of guidance for practitioners must
take account of the different motivations of GPs and rec-
ognise the signiﬁcant diversity in the approaches that
GPs are taking towards PSA testing of asymptomatic
men. GPs who employ heuristic 2, for example, were
already attentive to the epidemiological evidence, and so
are likely to be receptive to recent NHMRC guidance.
However, GPs who are employing heuristic 1 may need
very active knowledge translation strategies if they are to
change their practice. These GPs were deeply concerned
that by their failure to screen they might allow a man to
die of prostate cancer. It seems unlikely that they will
change their practice unless this concern is recognised
and responded to. Communications, workshops and new
incentives therefore need to consider variation in GP
perspectives and the range of drivers of current practice
as identiﬁed in this research (address legal concerns,
the need for consent due to potential harms and
acknowledge burden).
Limitations
Since physicians with strong opinions may have been
more likely to volunteer, some selection bias is possible.
However, diverse opinions and approaches were
reported, suggesting that strong selection bias is unlikely.
Conclusions
Future strategies for addressing the problem of prostate
cancer overdiagnosis in general practice should be
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underpinned by empirical evidence about how GPs
approach PSA testing, and the reasons they give for their
actions. Explicit consideration in practice guidelines of
the challenges faced by GPs when balancing underdiag-
nosis and overdiagnosis, including GPs experiences of
personal burden, medicolegal concerns and communi-
cation strategies, will better support GPs to inform and
guide men’s decisions on whether or not to have a PSA
test. Further public deliberation on how the inevitable
trade-offs could and should be managed in primary care
could also inform such discussions between clinicians
and their patients.48
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CHAPTER FOUR. 
General Practitioners’ experiences of, and responses 
to uncertainty in prostate cancer screening:  
Insights from a qualitative study 
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4. Overview of this chapter 
We focused on accounts generated from interviews with 69 GPs practicing in Australia and the UK about 
how they approach PSA screening (Research Question 1). Uncertainty about prostate screening was 
identified as a core issue. This chapter presents an analysis on GP experiences of uncertainty, answering: 
How does uncertainty influence GPs’ approaches to PSA screening? (Research Question 2.2). What are the 
consequences of this process? (Research Question 3). 
Much of the controversy described in the current prostate screening debate, presented in Chapter 1, 
appears to arise from prevailing uncertainty about the utility of the PSA test as a screening tool. There are 
unresolved tensions and disagreements amongst experts, high patient demand, complex cultural factors, 
and inconsistent clinical recommendations. Collectively this reflects and generates significant uncertainty 
about the appropriateness of screening. We explored how GPs in Australia and the United Kingdom 
described and responded to uncertainty in the context of PSA screening. 
4.1 Publication details 
Pickles K, Carter SM, Rychetnik L, McCaffery K, Entwistle VA (2016) General Practitioners’ Experiences of, 
and Responses to, Uncertainty in Prostate Cancer Screening: Insights from a Qualitative Study. PLoS ONE 
11(4): e0153299. doi:10.1371/journal.pone.0153299 
4.2 Authors’ contributions 
All authors contributed equally to this work. 
4.3 Abstract 
This paper draws on our empirical data to explain the primary sources of uncertainty described by GPs in 
this context, and how they experience and respond to uncertainty about PSA screening. We found that 
Australian GPs reported experiencing substantially more uncertainty than UK GPs. This seemed partly 
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explainable by notable differences in conditions of practice between the two countries. Using Han et al’s 
taxonomy of uncertainty as an initial framework, we first outline the different sources of uncertainty GPs 
(mostly Australian) described encountering in relation to prostate cancer screening and what the 
uncertainty was about. We then suggest an extension to Han et al’s taxonomy based on our analysis 
relating to the varied ways that GPs manage uncertainties in the context of PSA screening. We consider the 
burden of uncertainty on GPs and the role of the health care system in supporting GPs to practice in a way 
consistent with evidence-based professional standards. 
4.4 Manuscript 
The published version of the manuscript follows. 
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Abstract
Background
Prostate-specific antigen (PSA) testing for prostate cancer is controversial. There are unre-
solved tensions and disagreements amongst experts, and clinical guidelines conflict. This
both reflects and generates significant uncertainty about the appropriateness of screening.
Little is known about general practitioners’ (GPs’) perspectives and experiences in relation
to PSA testing of asymptomatic men. In this paper we asked the following questions: (1)
What are the primary sources of uncertainty as described by GPs in the context of PSA test-
ing? (2) How do GPs experience and respond to different sources of uncertainty?
Methods
This was a qualitative study that explored general practitioners’ current approaches to, and
reasoning about, PSA testing of asymptomatic men. We draw on accounts generated from
interviews with 69 general practitioners located in Australia (n = 40) and the United Kingdom
(n = 29). The interviews were conducted in 2013–2014. Data were analysed using grounded
theory methods. Uncertainty in PSA testing was identified as a core issue.
Findings
Australian GPs reported experiencing substantially more uncertainty than UK GPs. This
seemed partly explainable by notable differences in conditions of practice between the two
countries. Using Han et al’s taxonomy of uncertainty as an initial framework, we first outline
the different sources of uncertainty GPs (mostly Australian) described encountering in rela-
tion to prostate cancer screening and what the uncertainty was about. We then suggest an
extension to Han et al’s taxonomy based on our analysis of data relating to the varied ways
that GPs manage uncertainties in the context of PSA testing. We outline three broad strate-
gies: (1) taking charge of uncertainty; (2) engaging others in managing uncertainty; and (3)
transferring the responsibility for reducing or managing some uncertainties to other parties.
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Conclusion
Our analysis suggests some GPs experienced uncertainties associated with ambiguous
guidance and the complexities of their situation as professionals with responsibilities to
patients as considerably burdensome. This raises important questions about responsibility
for uncertainty. In Australia in particular they feel insufficiently supported by the health care
system to practice in ways that are recognisably consistent with ‘evidence based’ profes-
sional standards and appropriate for patients. More work is needed to clarify under what cir-
cumstances and how uncertainty should be communicated. Closer attention to different
types and aspects of the uncertainty construct could be useful.
Introduction
Prostate-specific antigen (PSA) testing for prostate cancer is controversial. There are unre-
solved tensions and disagreements amongst experts, and clinical guidelines conflict. This both
reflects and generates significant uncertainty about the appropriateness of testing, especially in
asymptomatic men. The United States Preventive Services Taskforce (USPSTF) recommends
physicians should not offer or order PSA screening unless they are prepared to engage in
shared decision making (SDM) that enables an informed choice by the patient; this includes
providing information about the associated uncertainties [1]. The Royal Australian College of
General Practitioners (RACGP) advises GPs not to raise the issue of PSA testing unless men
specifically ask, in which case they should provide full information regarding the benefits,
risks, and uncertainties (about benefits and risks) [2]. The UK’s National Screening Committee
(UK NSC) policy similarly does not recommend universal screening for prostate cancer.
Instead there is an informed choice program in place where men who request PSA testing can
have it following detailed information exchange to aid shared decision making.
Primary care clinicians advise on and are gatekeepers to the PSA test. In practice, they vary
in what they disclose to patients about the uncertainty and controversy that surrounds it. Rec-
ognition of uncertainty may in general be ethically preferable, facilitating more completely-
informed consent [3] and promoting realistic patient expectations about medical care [4,5].
However, research from the US and UK suggests communication of uncertainties with patients
in the context of PSA testing is infrequent and complex [6–8].
Uncertainty is a common but under-researched issue in general practice and clinical deci-
sion making [9,10]. Some research about communication in various clinical settings indicates
that doctors can be reluctant to disclose uncertainty, preferring to present the appearance of
certainty to their patients [11,12], and to avoid being judged as inadequate or ineffective [13].
There are different findings (and suggestions about the implications of) communicating uncer-
tainty. Communicating uncertainty can have a negative effect on patients, including heighten-
ing perception of risk, causing unnecessary worry [14], and decreasing ability to make
decisions about care [15]. In contrast, other research suggests honest expressions of uncertainty
may improve the doctor patient relationship [13], facilitating trust [11], therapeutic effective-
ness [16] and patient confidence [10], and decreasing patient interest and participation in med-
ical screening [6,17,18].
Studies investigating doctors’ experiences of uncertainty, specifically in the context of PSA
testing, are scarce. The experience of uncertainty is a challenging phenomenon to explore [14];
yet it is central to much of medical practice. Some argue that tolerance of uncertainty is an
essential dimension of professional competence [19]. Others have suggested that changing
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professional and public attitudes towards medical error and uncertainty is key to reducing
overdiagnosis and overtreatment [20].
Han’s taxonomy of uncertainty [14] makes a valuable contribution to its conceptualisation
in health care. As shown in Box 1 (modified), the taxonomy has three dimensions: sources of
uncertainty (where uncertainty comes from), issues of uncertainty (what uncertainty is about),
and locus of uncertainty (who is uncertain).
In this paper we first report on clinician perspectives and experiences of uncertainty in rela-
tion to PSA testing using Han’s framework. We then add to Han’s taxonomy an outline of the
strategies that GPs use to manage uncertainty in PSA testing.
We use data from a qualitative study that explored general practitioners’ current approaches
to, and reasoning about, PSA testing of asymptomatic men. Uncertainty in PSA testing was
identified as a core issue, and we draw on this data to address the following questions:
1. What are the primary sources of uncertainty as described by GPs in the context of PSA
testing?
2. How do GPs experience and respond to different sources of uncertainty?
Methods
Design
We applied the well-established, systematic qualitative research methodology, grounded theory
[21]. All study procedures were approved by the Cancer Institute NSW and the University of
Sydney Human Research Ethics Committee [#15245]. GPs had an opportunity to discuss the
study, and gave written consent, prior to participation.
Box 1. Han’s (2011) taxonomy of uncertainty: a summary.
Sources of uncertainty:
1. Probabilistic uncertainty generated from the indeterminacy of a phenomenon’s future
outcome, such as the probability of benefit (or harm) from a test or treatment
2. Ambiguity signifies the lack of reliability, credibility, or adequacy of information
about a phenomenon of interest, and includes imprecision (e.g. wide probability esti-
mates of benefit /harm from treatment), conflicting opinions/evidence, and lack of
information
3. Complexity is uncertainty arising from aspects of a phenomenon itself, which make it
difficult to comprehend; e.g. numerous potential outcomes from a medical test or
treatment or the existence of varied risk factors, symptoms, or signs of a given disease.
Issues of uncertainty:
1. Scientific uncertainty is disease-centred. Encompasses uncertainties about diagnosis,
prognosis, causal explanations, treatment recommendations
2. Practical uncertainty is system-centred. Applies to the structures and processes of
care (competence, quality, responsibilities)
3. Personal uncertainty is patient-centred. Psychosocial and existential issues (relation-
ships, impact on life goals)
Locus of uncertainty:
Where the uncertainty resides: with the clinician or the patient
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Participants and Setting
We recruited a sample of 69 GPs (40 Australian, 29 UK) for this study. In Australia we adver-
tised via the newsletters and email lists of GP organisations (Medicare Locals) in Sydney, in
mass and social media, and in medical journals. Rural GPs were accessed by phoning practice
managers, through colleagues, and advertising with rural Medicare Locals [22].
We included GPs from the United Kingdom to also explore PSA testing reasoning and prac-
tice in a jurisdiction with comparatively lower rates of prostate cancer screening than Australia.
We subsequently recruited 29 GPs throughout England (n = 24) and Scotland (n = 5). Our initial
sample of GPs responded to an invitation distributed by academic colleagues through profes-
sional networks. We then broadened our sample by advertising via email to members of the
Royal College of General Practitioners (RCGP), primary health care departments, university aca-
demic departments, and general practice and research mail lists. We also advertised via newslet-
ter including the Society for Academic Primary Care (SAPC) and RCGP Scotland’s eBulletin.
GPs were invited to contact KP if they were interested and willing to participate. Participat-
ing GPs were of varying ages, clinical experience, gender, and patient populations. All GPs who
expressed interest in participating were included. GPs were compensated financially for their
time.
Interviews / Data Collection
We generated data via in-depth interviews. The semi-structured interview schedule covered a
broad range of topics, including GPs’ recent clinical encounters involving PSA testing deci-
sions; communicating information; screening pathways; and overdiagnosis. The schedule was
modified between interviews, informed by the developing analysis. Uncertainty was not specifi-
cally included as a topic for discussion in the schedule; rather it was a recurring concept that
was identified during data analysis. Interviews with Australian GPs took place between March
2013 and June 2014 and with UK GPs between September and December 2014. They were all
conducted by KP, mostly by telephone and Skype, and ranged in duration from 18 to 70 min-
utes. All interviews were audio-recorded and transcribed verbatim.
Data Coding and Analysis
The analysis was led by KP, who coded the transcripts and wrote detailed memos which were
regularly reviewed and discussed by the authors in analysis meetings. A subset of transcripts
was read and coded by three authors independently; this coding was compared and discussed
to inform the development of the central concepts in the study.
A longstanding point of contention in grounded theory methodology is the relation between
the theory being produced, which is ‘grounded’ in the data collected, and existing relevant the-
ory. While early expressions of grounded theory methodology [23] strongly emphasised the
development of new theory as opposed to the testing of existing theory, contemporary main-
stream grounded theorists strongly concur that qualitative empirical work must be conducted
in the context of existing knowledge [24]. As uncertainty was identified as a core category in
our data analysis, we turned to the literature to develop a better understanding of the concept,
and identified Han’s taxonomy of uncertainty in health care [14]. This taxonomy resonated
with our interpretation of the data and suggested face validity for our early analysis of the
sources and issues of uncertainty. We used Han’s taxonomy to develop our analysis of GPs’
experiences with uncertainty and categorised our data according to the ‘sources’ and ‘issues’ of
uncertainty as described in the framework. In addition, we developed a new set of concepts
related to how GPs respond to uncertainty in PSA testing, an issue that was not included in
Han’s typology.
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Results
We identified considerable variation in GPs’ interpretation, management, and experiences of
uncertainty in terms of the source of the uncertainty they described, its impact on usual prac-
tice, and GPs perception of who should respond to uncertainty.
There seemed to be substantially more uncertainty experienced among Australian than UK
GPs, perhaps partly explainable by the notable differences in conditions of practice for PSA
testing between the two countries. The United Kingdom system is structured in several ways
likely to decrease uncertainty. There is a clear policy directive against screening asymptomatic
men for prostate cancer. There is an established norm of communicating with men who ask
about PSA testing, and a structured approach to communication including a written informa-
tion resource. In addition, referral pathways following particular test results are well-defined.
In contrast, Australian policy is not clearly defined or directive, and at the time of this study
there was no single authoritative document advising GPs how or what to communicate to men.
The lack of policy clarity seems likely to contribute to the considerable variation in GP
approaches to PSA testing [22].
Unsurprisingly, given these differences, Australian and UK GPs talked differently about
prostate cancer screening. Asymptomatic men ask about prostate cancer screening frequently
in Australian practice. Yet Australian GPs said they felt unsure about what is the “right” thing
to do about PSA testing, expressed frustration about the lack of formal guidance to direct their
practice, and many found talking with men about PSA testing a challenging experience because
of underlying uncertainty. In contrast, the majority of GPs practicing in the UK were not rou-
tinely having discussions with asymptomatic men about PSA testing. They explained that
screening men for prostate cancer is not a widely supported process, nor a common request
from patients. When men did want a PSA test, GPs favoured providing them a standard gov-
ernment-produced information leaflet, to promote informed decisions. UK GPs considered
conversations about PSA testing with asymptomatic men to be of low priority unless men
asked, and overall did not express any notable uncertainty about whether to test men or not.
As a result, there was comparatively less UK data about UK GP experiences of uncertainty. The
results described below therefore predominantly describe the Australian data. We will return
to the implications of this in the discussion.
Where Does GPs’ Uncertainty Come from andWhat Is the Uncertainty
About?
Table 1 outlines sources of GPs’ uncertainty about PSA testing. We have included Han’s defini-
tion of each source of uncertainty followed by a summary of how GPs described this type of
uncertainty manifesting in their practice.
Table 2 captures the issues of uncertainty, again presented with Han’s definition of the
issues followed by specific examples in each cell from our data. Han’s framework characterises
‘personal uncertainty’ as patient-centred. However because this study focused on the perspec-
tive of GPs, our data also includes personal uncertainty with a locus in GPs.
Our data indicate that GPs may experience a diverse range of uncertainties with respect to
PSA testing. There were important differences however, between Australian and UK GPs’
descriptions regarding what their uncertainty was about. Australian GPs’ uncertainty was
related to all three of the issues described above: scientific, practical, and personal. UK GP
experiences of uncertainty were mostly about personal issues, because (a) GPs were clear about
procedural expectations coming from government and medical bodies about PSA testing, and
scientific uncertainty was dealt with via clear guidelines and norms; and (b) UK GPs expressed
a sense that the medical profession was collectively managing the uncertainty so individual
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GPs were facing less practical uncertainty because the UK system has processes in place to help
them manage it. Thus the UK GPs’ uncertainty was predominantly patient-centred; they were
mostly concerned that when their patients sought or asked about PSA testing, they were then
burdened with uncertainty due to the uncertain nature and quality of the available information.
UK GPs did not feel uncertain themselves but worried that their ‘patients have to make well-
informed decisions and I suppose that’s where it’s such a minefield of uncertainty, it must be very
difficult for people to say that they’ve made a well-informed decision’ (UKGP26).
Below we outline strategies GPs described using to handle uncertainty in the context of PSA
testing of asymptomatic men. The information below draws primarily from the Australian
data; where observations are based on UK data this is noted.
What Strategies Do GPs Use to Manage Uncertainty?
We identified three main approaches GPs used when faced with uncertainty around PSA test-
ing, specifically about decision-making and responsibility:
Table 1. Sources of uncertainty (where is GP uncertainty coming from?).
Han’s SOURCES of uncertainty How does this taxonomy manifest in the context
of PSA testing?
PROBABILISTIC UNCERTAINTY Generated from
the indeterminacy of a phenomenon’s future
outcome, such as the probability of beneﬁt (or harm)
from a test or treatment
Several important potential outcomes may follow
from PSA testing. Early diagnosis and treatment
may decrease prostate cancer death for a small
number of men. For the majority, any mortality
beneﬁt is outweighed by risk of harm: testing and
treatment is associated with substantial harms,
including impotence, incontinence, and anxiety.
Although the probabilities of some of these
outcomes can be estimated for populations, there is
no way of knowing which individual patient will
experience which outcomes.
AMBIGUITY Lack of reliability, credibility, or
adequacy of information about a phenomenon of
interest; includes imprecision (e.g. wide probability
estimates of beneﬁt /harm from treatment),
conﬂicting opinions/evidence, and lack of information
The PSA test performs poorly as a screening tool. It
is known that some screen-detected prostate
cancers are more aggressive than others, but the
PSA test cannot differentiate aggressive from non-
aggressive cancers. This, together with
uncertainties about treatment effects, uncertainty
about how particular patients might react to
different biomedical clinical outcomes (physically
and psycho-socially), and how patients may
respond differently to the risk of these outcomes,
means it is unclear what test results might actually
mean for each individual patient both at the point of
testing and following an abnormal test result
COMPLEXITY Arising from aspects of a
phenomenon itself, which make it difﬁcult to
comprehend; e.g. numerous potential outcomes
from a medical test or treatment or the existence of
varied risk factors, symptoms, or signs of a given
disease. Confounding, interacting factors add
complexity and complicate interpretations and
outcomes. Personal judgment and clinical
experience informs decisions.
The multiple-stage, multiple possibility sequence of
testing and treatment outlined above add
complexity to an evaluation of testing. Although the
patient descriptors used in research studies and
guidelines may seem simple (e.g. age 70+,
asymptomatic) in general practice many individual
patients are complex in ways not reﬂected in the
evidence base. This includes the presence of
comorbidities, and the difﬁculty in distinguishing
symptomatic from asymptomatic men because of
the multiplicity of causes of the symptoms
commonly associated with prostate cancer. GPs
consequently feel uncertain about how clinical
descriptors should be applied.
doi:10.1371/journal.pone.0153299.t001
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1. Sometimes GPs took charge of uncertainty, considered it a usual feature of their daily prac-
tice, and managed (at least some) uncertainties on their own
2. Sometimes GPs engaged others in managing uncertainty: they accepted some uncertainty as
a challenge and used it as an opportunity to engage the medical profession, colleagues, and
patients about how the uncertainty would be handled, to enable them to better support
patients and find shared solutions
3. Sometimes GPs sought to transfer to other parties the responsibility for reducing or manag-
ing some uncertainties.
Some GPs tended to manage all types of uncertainty about PSA testing in a relatively consis-
tent way, adopting one of the three approaches described above (i.e. some GPs usually took
charge, usually accepted and engaged, or usually transferred, although this was never absolute).
Other GPs were more variable in their approach, applying different management strategies in
Table 2. Issues of uncertainty (what is the uncertainty ABOUT?).
Han’s ISSUES of uncertainty
(what is the uncertainty about?)
Probabilistic material as a Source
of uncertainty (uncertainty
arising from the probabilistic
nature of information)
Ambiguity as a Source of
uncertainty (uncertainty arising
from the ambiguity of evidence or
expert guidance):
Complexity as a Source of
uncertainty (uncertainty arising
from the interaction of multiple
factors, some unknown):
SCIENTIFIC UNCERTAINTY
Disease-centred. Uncertainties
about diagnosis, prognosis, causal
explanations, treatment
recommendations
• GPs concerned about their
inability to predict clinical outcomes
(such as incontinence or impotence)
following testing and treatment at
the individual patient level.
Probabilities can predict aggregate
outcomes in a population, but
cannot specify their exact
distribution, or the probable severity
of potential outcomes in any given
individual.
• GPs concerned about conﬂicting
estimates for particular outcomes for
particular populations GPs uncertain
about the conclusions that should be
drawn from the evidence base for/
against screening for prostate cancer
• Interpretation of the beneﬁts and
risks of testing and treatment can
change over time and depend on
various assumptions (e.g. about
patient values and current state).
GPs concerned about evaluating
beneﬁts and risks and making
treatment decisions relating to
individual patients because of this
complexity.
PRACTICAL UNCERTAINTY
System-centred. Uncertainties
about the structures and processes
of care (competence, quality,
responsibilities)
• GPs described probabilities as
challenging to think about and apply
in individual clinical encountersGPs
unsure how urologists will work with
patients referred with a high PSA
result
• GPs uncertain about professional
practice due to disagreement
between guidelines GPs concerned
about conﬂicting guidance from
medical authority: professional
organizations and colleagues vary in
the recommendations they make
about whether or not (and under what
circumstances) to screen with
PSAGPs unclear under what
conditions they could be medically
liableGPs concerned about
inconsistent referral pathways and
advice
GPs ﬁnd communicating
probabilistic information with
speciﬁc patient types (e.g. health
illiterate, anxious, determined to
have the test) difﬁcultGPs seeing a
patient who usually consults a
different GP found this a complex
and ‘awkward’ situation in which to
practice if their testing preferences
were dissimilar to the GP they were
replacing
PERSONAL UNCERTAINTY GP/
patient-centred. Uncertainties about
psychosocial and existential issues
(relationships, impact on life goals)
GPs concerned about their inability
to predict the psychological and
existential outcomes of testing and
treatment that would be
experienced by the patient
• GPs consider what is at stake for
them as an individual clinician—
legally, psychologically, professionally
and socially—if they do or do not
testGPs uncertain about what is the
right thing to do in this context in
order to be considered a ‘good GP’
and preserve relations with their
patientsGPs concerned about
whether it is ok to change PSA
testing practice following personal
and practice experiences
• GPs concerned about their ability
to judge how ‘good’ any individual
patient’s consent/decision might be,
and what the outcomes of poor/
inaccurate judgment may mean for
them and their patientsGPs
uncertain about individual patient
tolerability of potential
consequences of their
decisionsGPs feel conﬂicted when
their own personal preferences for
testing/not testing conﬂict with
advice they provide
doi:10.1371/journal.pone.0153299.t002
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different situations. Particular sources of uncertainty also tended to elicit particular types of
responses. So GPs who tended to use different strategies to manage different types of uncertain-
ties may call upon one or all of the techniques depending on the type of uncertainty, the partic-
ular situation, and the GPs individual interpretation of it and level of tolerance.
We describe the three categories of GPs approaches below.
1. GPs taking charge of uncertainty. When we describe GPs as “taking charge of uncer-
tainty” we refer to circumstances when they recognised uncertainty, tolerated it, and accepted
it as a lasting presence in their practice. They found ways through the uncertainty for them-
selves according to their ‘own protocol’ (GP24) because ‘the scientists and the doctors cannot tell
you what’s going to happen’ (GP17). GPs taking charge had settled into ways of dealing with
some kinds of uncertainty and now just got on with it, acting confidently as lead decision-mak-
ers. It depended on the individual GP whether “taking charge” occasioned active recommenda-
tion of PSA testing or not.
Although these GPs might seek more medical information to inform further decisions fol-
lowing initial testing (e.g. actively PSA testing including repeat testing, ordering alternative
tests), this was independent of external parties: they did not describe feeling any pressure to
consult patients or recommendations before making decisions. Some GPs preferred to practice
using a ‘gut feeling sort of approach’ (GP21), because ‘nobody really knows the right answers to
any of these questions’ (GP18). For them, ‘because the science is imperfect, then personality and
medical judgement have. . .more of an important role’ (GP17). These GPs directed their PSA
testing practice according to their clinical experience.
When GPs took charge of uncertainty about testing decisions, they did not routinely discuss
uncertainty comprehensively with patients. Sometimes they believed a patient did not have the abil-
ity to cope with the complex information, and sometimes they assumed a position of making deci-
sions on behalf of patients to protect them from navigating uncertain decisions, ‘I think it’s a lot
easier for the patient to not be in that position [of making decisions grounded in uncertainty] at all’
(GP17). There were some GPs who disagreed with this as an appropriate approach; however the
GPs using it as a strategy did so to protect their patients from the uncertainty in current knowledge.
When GPs took charge, they did not perceive or experience uncertainty as burdensome:
they simply accepted that ‘it’s not clear and that’s just the way it is’ (GP20), or ‘[the PSA test is]
not perfect but it’s all we’ve got’ (GP26). One GP commented that all doctors should have the
capacity to make decisions about the evidence around PSA testing, despite its uncertainty ‘if
you think it’s too hot in the kitchen, get out. . .I have no sleepless nights worrying about missing
one, I think that’s just–just life’ (GP18). Ultimately, these GPs were comfortable acknowledging
that GPs ‘don’t have to have the answers to everything in medicine’ (GP3).
Interestingly, how to handle normal PSA test results was a source of uncertainty for some
UK GPs because all guidance following PSA testing is for symptomatic patients or abnormal
test results. UK GPs really relied on having guidelines to direct their practice. These guidelines
are, roughly: 1) don’t test; 2) if someone happens to ask, give them this information; 3) if
abnormal PSA result, refer to this hospital (clear procedure). As a result GPs said they were
uncertain about how to proceed following normal PSAs. Should they, for example, tell the man
that they could now stop worrying altogether, or that they should come back in x years? They
wanted to avoid being in this position of uncertainty so their strategy was to, wherever possible,
not test in the first place. In comparison, some Australian GPs described normal results as a
source of relief and reassurance for them and their patients, because for them, the uncertainty
of not knowing was greater than knowing a test result (abnormal of not). GPs told of how most
patients in Australia receiving PSA testing expect to be tested annually, so GPs actively test
them year-to-year in the hope of finding another normal result.
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2. GPs engaging others in managing uncertainty. In some situations, GPs were commit-
ted to engaging others in managing uncertainty about PSA testing. They took uncertainty as a
challenge, and engaged the medical profession, colleagues, and patients in their quest to make a
good decision in the context of shared uncertainty. Engaging others occurred via relationships
and communication. These GPs took it as their duty to grapple with the uncertainty and felt a
sense of responsibility to share it with the profession (usually as a member of an organisation
of GPs and specialists), and with patients: to inform them of uncertainty, ongoing debate and
lack of consensus. They expected to be supported by GP and specialist colleagues to help man-
age their own emotional and informational needs (e.g. consulting colleagues and specialists for
advice), and to in turn effectively support patients to make decisions.
Some GPs negotiating uncertainty felt more comfortable than others managing the uncer-
tainty of the ‘grey zone’ of PSA test results. In this zone (>4ng/ml,<10ng/ml) the clinical
implications of test results, and decisions about what to do, are most contested. GPs comfort-
able with managing the grey zone themselves via repeat testing or active surveillance (rather
than external referral to a specialist) had ‘no hesitation’ (GP31) to contact colleagues or special-
ists for advice and ‘reassurance. . .of what to tell the patient’ (GP5) once uncertainty moved
beyond the GPs’ ‘own level of comfort and expertise’ (GP31).
GPs who negotiated uncertainty were more inclined to talk about the uncertainty of PSA
testing with their patients. They reported telling their patients that it is not possible to be sure
about aspects of PSA testing, including probabilistic outcomes and individual prognosis, and
therefore any advice offered had some degree of underlying uncertainty. GPs told patients they
themselves don’t know what to do about PSA testing of asymptomatic men and don’t ‘pretend
to fully understand it’ (GP31), ‘so I don’t expect patients to have the capacity to–we say fully
informed, but really we’re not, so how can the patient be?’ (GP26). Yet these GPs were adamant
that regardless of the limitations of the available knowledge base, ‘the information needs to be
on the table’ (GP31).
GPs who talked to patients about the uncertainties of PSA testing said they acknowledged the
discord in professional opinion about what should be done with their patients. For many GPs
this was a source of considerable frustration: ‘every week and I’m like, for God’s sake, can someone
make a decision so I know what to do?’ (GP26). They often did not feel supported by the medical
profession: ‘It’s up to individual GPs to sort it out himself–I mean it shouldn’t happen this way,
but we’re not getting really helpful information from our so-called experts’ (GP28). The RACGP
guidelines (as outlined in the introduction) were described as unhelpful, ‘a blanket ethical state-
ment’ (GP28) and GPs said they felt ‘we’re still in a mess with what we’re actually advising men to
do. . .we don’t know what the hell we’re doing’ (GP8). Some of these GPs reported clear ideas
about how authorities should respond to support GPs and to support patients. This centred on
consensus, talking the same language, and telling GPs exactly what information they should pro-
vide patients. Some GPs did, however, recognise the difficult position authorities are in when try-
ing to produce policy in a complex situation; ‘the opinions and the spectrum. . .it just reflects that
it’s unclear and that opinion is divided depending on who you talk to’ (GP20).
For many GPs an element of discomfort with uncertainty was ever-present. GPs felt guilty
about possible negative psychosocial effects on their patients of understanding how messy and
complex the situation is; ‘the spiel that I give men about this leaves them with virtually no ability
to make a good decision. . .I don’t make things easier for people’ (GP8). GP attempts to share
their knowledge of the uncertainties and experience of being uncertain about what to do with
patients sometimes proved futile: for example if the patient wanted the GP to decide what to do
on their behalf and preferred not to be engaged in/take on the lead role in decision making.
Of the three approaches, it was the GPs engaging others in the uncertainty of PSA testing
who were most likely to experience that uncertainty as burdensome. They worked hard to
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make an impossible situation as good as possible. But their work to mitigate the uncertainty
was unrecognised and unrewarding; the more GPs tried to wrestle with the uncertainty, the
more uncertain the situation appeared. Yet these GPs continued to take on some uncertainty as
a challenge because doing something–engaging patients and the profession–felt appropriate
and ‘right’ to them as GPs.
3. GPs transferring uncertainty. Finally, some GPs employed strategies of “transferring”
responsibility for decision making in the face of uncertainty. They perceived uncertainty as
problematic and uncomfortable and sought out other parties to reduce their experience of
uncertainty. The external authorities could include: urologists, those researching the test, legal
authority, or the health system. One GP described this process of transferring responsibility for
decision-making as ‘handballing it to somebody else’ (GP26).
In practice, GPs in this category were not likely to repeat PSA test results that returned in
the grey zone, rather preferring to refer those patients immediately to specialists to make deci-
sions about the next stage of management. In fact a subset of GPs were committed to immedi-
ate referral regardless of what the PSA test result was: ‘even though it’s [PSA] still well within
the normal range for their age—I just think that’s a specialist’s [urology] decision, not mine’
(GP26). For GPs, having urology as a backup meant they could regard uncertain PSA results as
‘not my problem, quite frankly’ (GP25).
Some GPs engaged in active PSA testing as a strategy for managing their uncertainty, partic-
ularly about potential legal ramifications of not testing; ‘I would probably still send him for the
test because I’d be worried somebody would sue me if I didn’t’ (GP22). One GP said that when
in a position of not knowing what to do ‘I think medico-legal comes into that. . .you’re more
defensive in your acting’ (GP34). This subgroup of GPs looked to legal authority to protect
them and justify their practice, and perceived medico-legal obligations influenced their practice
particularly when they felt uncertain about what to do.
Some GPs left decision making entirely up to the individual patient to deal with; ‘so I say
well it’s your decision and if you want to have it, you can. If you don’t want to worry about it,
that’s ok with me too. So I let them decide basically’ (GP21). A number of practices in Australia
had implemented their own policy: a recall system whereby patients would be automatically
notified when due for a PSA test with an accompanying pathology form. In these instances,
GPs minimised repeated engagement with the uncertainties of PSA testing and personal
responsibility for patient decision-making. By automating the process they effectively trans-
ferred responsibility for follow-up to a practice management system, and their patients would
in turn choose how to respond to the automated invite.
Those GPs whose default-practice was to transfer responsibility had worked out a way of
practicing which relieved them of the burden of advising and making practice decisions based
on uncertain foundations (at least until their next consultation involving a PSA test). This risk-
averse approach–transferring uncertainty to external authority as soon as possible–was per-
ceived by GPs as a way to save patients from being burdened by GP uncertainty and meant the
GP did not have to engage with what they considered an unresolvable situation.
How Do GPs Respond to Different Sources of Uncertainty?
Probabilistic uncertainty was identified as a major source of uncertainty by the GPs, yet they
tended to speak of it as being more tolerable than uncertainties arising from ambiguity and
complexity. Overall, GPs accepted responsibility for probabilistic uncertainty and shared their
knowledge about it; it was not as common for GPs to attempt to transfer responsibility for this
source of uncertainty. Many GPs described handling probabilistic uncertainty reasonably com-
fortably on their own. They saw it as central to the GP role and to clinical judgment, which
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necessarily involves interpreting scientific evidence and probabilities. Individuals or organisa-
tions were not blamed or held directly responsible for probabilistic uncertainty. GPs described
probabilistic uncertainty as challenging (e.g. indeterminate medical outcomes), but had mostly
found a relatively settled way of dealing with it because they had few alternatives.
The two other types of uncertainty invoked different responses: uncertainty arising from
ambiguity—for example, varied recommendations—and complexity—the vagueness of clinical
descriptors, or the difficulty in judging patient understanding. Many GPs preferred to negotiate
or transfer responsibility for these uncertainties. For example, a GP experiencing uncertainty
in a testing decision might tell the patient about discordant recommendations to justify their
uncertainty and immediately refer to specialists for further opinion. Some GPs appeared to
hold that responsibility for ambiguity or complexity should be collective and others should be
involved in negotiating decisions, or they preferred to transfer those decisions to specialists.
Ambiguity and complexity commonly led to practical issues for GPs arising from this uncer-
tainty–how to engage in ‘good’ practice and appropriate communication based on complex evi-
dence and ambiguous guidance. Ambiguity and complexity were also a foundation for GPs’
sense of personal burden, as some GPs expressed anxiety about their capacity to make ‘good’
decisions without good evidence, and ability to judge what level of information was suitable to
support consent. Theoretically these sources of uncertainty could be modified or improved
with system change (for example, consistent recommendations, established consent protocols)
but GPs felt limited in their capacity to make changes at the clinical level.
Discussion
GPs described experiencing considerable and, at times, burdensome uncertainty in the context
of PSA testing of asymptomatic men for prostate cancer. Locating and describing sources or
types of uncertainty (Table 1) as per Han is important in this context because the various types
of uncertainty produced different issues (Table 2), which GPs responded to and managed
using distinct strategies (our 3 strategies outlined above).
Sources, Issues, and Management of Uncertainty
GPs in our study appeared to manage uncertainty arising from probabilistic information with
reasonable confidence when compared to the other sources of uncertainty. One possible expla-
nation for this finding is that GPs are familiar with probabilities and are trained to interpret
and manage probabilistic information in the clinical setting. Numerous resources are available
presenting probabilistic and statistical information in multiple formats (numerically, graphi-
cally) to assist GPs and to support the decision making capacity of their patients. While proba-
bilistic uncertainty is particularly challenging in relation to PSA testing and cannot be readily
resolved with leaflets or information sheets, we propose that such resources ‘normalise’ the
probabilistic uncertainty inherent to this context. It is possible that GPs feel more comfortable
taking charge or engaging with others about probabilistic uncertainty because they are better
able to get a handle on the uncertainty they are dealing with because it is an ongoing and famil-
iar type of uncertainty. Probabilistic information about outcomes is also the typical kind of
information assumed to be shared in processes of shared decision-making.
It is clear from our results that uncertainty from ambiguity on the other hand was extremely
frustrating for GPs; GPs were uncertain about guidance from medical authorities and were
unclear of their clinical and legal obligations. These uncertainties are grounded in ambiguity,
which, as the decision psychology literature has shown, people generally prefer to avoid (e.g.
[25]. Ambiguity is more directly related to uncertainties about what to do in practice than
probabilistic uncertainty, and perhaps leaves more scope for GPs to take a “wrong” course of
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action. Aspects of ambiguity in this context are potentially modifiable, which could reduce
some uncertainty for GPs. For example, clearer and more consistent expert guidance may
assist. Yet even if more ‘certainty’ was implemented at the system-level via clear guidelines or
consistent advice from authoritative sources, clinicians will inevitably still experience some per-
sonal uncertainty stemming from the complexity of this information, and because of diverse
GP and patient value systems in the clinical context (e.g. questioning appropriateness of
recommendations).
Complexity was also experienced as particularly uncomfortable for GPs; some GPs described
feeling uncertain about their own clinical judgment. Complexity is essentially a source of uncer-
tainty amenable to individual value judgment, interpretation, and assumptions. It is therefore dif-
ficult to offer training or advice to GPs about ideal management of complexity uncertainty in
relation to PSA testing. While clearer expert opinion may lessen ambiguity, GPs are left to deal
with complexity at the clinical level with the individual patient. Our data from UKGPs illustrates
that even with system-level guidance and clear ‘best practice’ formulations, GPs continue to expe-
rience personal uncertainty because every patient and consultation involving PSA testing is dif-
ferent and involves difficult value judgments. Clinicians will invariably face ongoing uncertainty
about the nature of medical evidence and individual and distributive health care [26].
The Burden of Uncertainty
Ordering PSA tests for screening purposes is paradoxical in relation to uncertainty. Testing is a
response to uncertainty: an attempt to better predict a man’s risk of developing prostate cancer.
Yet while PSA testing aims to reduce uncertainty, the characteristics of the test when used as a
screening tool mean that it tends to introduce more scientific, practical, and personal uncer-
tainty than it eliminates. Faced with a PSA test result, the clinical significance of which is
intrinsically uncertain, some GPs actively tried to lessen uncertainty by looking to guidelines
on which to base decisions, or by sharing their knowledge with patients. However these strate-
gies also tended to compound uncertainty, piling up knowledge about the uncertainties regard-
ing outcomes, and GPs felt further burdened as a result. This is the great paradox of the PSA. If
GPs chase certainty via more and more testing and investigation, this may create more uncer-
tainty. Testing can undoubtedly create certainty for some GPs and patients at the individual
level, but it comes at a cost of lots of uncertainty, including GPs’ top line uncertainty about
using the PSA test at all. This, as our research has demonstrated, is what inflicts considerable
burden on GPs: because they have burdened patients with information which cannot provide
any clear answer, because their efforts to locate certainty have gone unrewarded, and because
of remaining uncertainty about what counts as good practice.
Uncertainty and the associated struggle is not just a burden to be borne by individual practi-
tioners. There is an expectation that GPs will practice in line with professional standards and
evidence-based medicine. If GPs are expected to act according to these standards, it would be
reasonable to suppose that the health care system might owe GPs some reciprocal supports to
make it possible for them to do so.
Ethical Considerations
There are judgments to be made about how best to involve men in PSA testing decisions. Our
data touches on uncertainties about whether, when, and in what forms communicating about
uncertainty is considered appropriate. Communicating uncertainty is not simply about proba-
bilities; ambiguity and complexity are also key sources of GP uncertainty and subsequent bur-
den. Any attempt to guide communication about uncertainty in PSA testing practice may be
more effective if it addresses all three sources of uncertainty.
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Ethical questions remain in relation to presenting uncertainty to patients who wish to avoid
making medical decisions; coping with uncertainty is known to be a source of substantial stress
and anxiety for many patients (e.g. [27]. Manson and O’Neill argue that a trusting and respon-
sive relationship might be more valued by patients than detailed information exchange [28].
Perhaps in some situations, a “taking charge” approach, whereby GPs call on their professional
experience and apply ‘rules of thumb’ to direct their practice might be appropriate, while in
more complex situations, GPs may need to discuss and reach agreement with others regarding
how decisions based on uncertainty will be allocated and resolved.
More work is needed to clarify under what circumstances uncertainty should be communi-
cated to patients, and if so what aspect of the uncertainty construct should be addressed. Para-
scandola et al argue that respectful interaction with patients requires disclosure about
uncertainty even when it is not offered to gain consent or in the service of patient decision
making; as long as patients understand the general decision making context [29]. Ideally, doc-
tors need to feel supported in their dealings with uncertainty. Research suggests that when doc-
tors are comfortable with uncertainty and collaborate with patients in their medical care,
patient trust and satisfaction are high [29].
Limitations
This analysis was inductive rather than commencing with research questions about uncer-
tainty. Further research could test our findings and explore the impacts of uncertainty in more
depth.
Conclusions
These important aspects of uncertainty require further and specific investigation, including the
potential implications of clinician uncertainty for cost and quality of health care [30].
This study is a first step in mapping how clinicians practice under conditions of uncertainty.
Our unique findings identified what doctors actually do in response to the different types of
uncertainty encountered. These results have practical value: the GPs in our study responded to
the various types of uncertainty and their associated issues differently. It seems likely that GPs
and their patients will benefit from greater acknowledgment by the profession of specific
sources of uncertainty and their unique implications, and in particular the often-neglected
uncertainty arising from ambiguity or complexity. Achieving this would be an essential step in
promoting GP engagement with uncertainty, and ultimately patient involvement in better
informed decisions about PSA testing for prostate cancer.
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CHAPTER FIVE. 
Doctors’ perspectives on PSA testing illuminate 
established differences in prostate cancer screening 
rates between Australia and the United Kingdom:  
A qualitative study 
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5. Overview of this chapter 
The United Kingdom was identified as an interesting and relevant comparison case for this study. The 
prostate cancer screening policies of Australia and the UK draw on the same international research 
literature, and report similar rates of prostate cancer mortality, yet these jurisdictions have notably 
different rates of PSA screening in primary care.  
The aim of the analysis presented in this chapter was to compare GPs’ reasoning about prostate screening 
in two jurisdictions with different PSA policy environments to further understand the influence of 
different conditions of practice. We asked, how do GPs in Australia and GPs in the UK explain their PSA 
screening practices? What do any similarities or differences suggest about the influence of health systems 
on GPs’ PSA screening practices? (Research Question 2.3). The GPs’ accounts suggested that the 
organisation and structure of health care systems can contribute to explaining varied use of the PSA test 
as a screening tool in clinical practice. 
5.1 Publication details 
Pickles K, Carter SM, Rychetnik L, et al. Doctors’ perspectives on PSA testing illuminate established 
differences in prostate cancer screening rates between Australia and the UK: a qualitative study. BMJ Open 
2016;6:e011932.doi:10.1136/bmjopen-2016-011932 
5.2 Authors’ contributions 
All authors conceived the study and were involved in designing the study and developing the methods. SC 
& LR obtained funding and are CIs on the NHMRC funded project grant. KP conducted the interviews, had 
full access to all data in the study, and takes responsibility for the integrity of the data and the accuracy of 
the data analysis. KP drafted the manuscript. All authors contributed to the interpretation of the analysis 
and critically revised the manuscript. 
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5.3 Abstract 
In this grounded theory study, GPs in Australia and the UK were interviewed about their use of the PSA 
test as a screening tool in primary care. The GPs’ accounts revealed fundamental differences in whether 
and how prostate cancer screening occurred in their practice and in the broader context within which 
they operate. We found important drivers of more screening (Australia) and less screening (UK), including 
the history of prostate screening policy, organisational structures, and funding models. In Australia, 
screening processes and decisions were mostly at the discretion of individual clinicians, and varied 
considerably. In the UK, GP accounts reflected a consistent, organisationally embedded approach based on 
local evidence-based recommendations to discourage screening. We discuss these findings with reference 
to Gabbay and le May’s mindlines theory, which considers the influence of local context on GP use of 
formal knowledge such as clinical guidelines. 
5.4 Manuscript 
The published version of the manuscript follows. 
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ABSTRACT
Objectives: To examine how general practitioners
(GPs) in the UK and GPs in Australia explain their
prostate-specific antigen (PSA) testing practices and to
illuminate how these explanations are similar and how
they are different.
Design: A grounded theory study.
Setting: Primary care practices in Australia and the UK.
Participants: 69 GPs in Australia (n=40) and the UK
(n=29). We included GPs of varying ages, sex, clinical
experience and patient populations. All GPs interested in
participating in the study were included.
Results: GPs’ accounts revealed fundamental
differences in whether and how prostate cancer
screening occurred in their practice and in the broader
context within which they operate. The history of
prostate screening policy, organisational structures and
funding models appeared to drive more prostate
screening in Australia and less in the UK. In Australia,
screening processes and decisions were mostly at the
discretion of individual clinicians, and varied
considerably, whereas the accounts of UK GPs clearly
reflected a consistent, organisationally embedded
approach based on local evidence-based
recommendations to discourage screening.
Conclusions: The GP accounts suggested that
healthcare systems, including historical and current
organisational and funding structures and rules,
collectively contribute to how and why clinicians use the
PSA test and play a significant role in creating the
mindlines that GPs employ in their clinic. Australia’s
recently released consensus guidelines may support
more streamlined and consistent care. However, if GP
mindlines and thus routine practice in Australia are to
shift, to ultimately reduce unnecessary or harmful
prostate screening, it is likely that other important
drivers at all levels of the screening process will need to
be addressed.
BACKGROUND
Prostate-speciﬁc antigen (PSA) testing of
asymptomatic men for prostate cancer risk is
a contested issue internationally. In this
paper, ‘asymptomatic’ will refer to those men
attending clinical practice with no prior indi-
cations associated with prostatic disease. This
is in contrast to the detection of prostate
cancer in symptomatic men: men who have
symptoms that could be related to locally
advanced or metastatic prostate cancer such
as frequency of urination, new onset bone
pain and/or neurological symptoms involv-
ing the lower extremities.1 PSA testing of
asymptomatic men is not recommended as a
population-screening programme in Australia
or the UK, the two countries on which our
analysis focuses.
Prostate cancer incidence varies more than
25-fold worldwide. Incidence ﬁgures, which
incorporate both life-saving diagnoses and
Strengths and limitations of this study
▪ The published literature about prostate cancer
screening in general practice is replete with
quantitative studies: They have identified clinician
and patient demographics associated with more
or less screening, and have analysed rates of
screening and frequency of discussions about
prostate-specific antigen (PSA) testing. Our
research is complementary to existing quantita-
tive findings: We asked how PSA testing of
asymptomatic men occurs in clinical practice,
from the general practitioner (GP) perspective.
▪ This study applied grounded theory methodology
to explore how clinicians describe their prostate
screening practice, and relate these to points of
variation in the respective healthcare systems.
Grounded theory is a suitable approach for the
investigation of complex multifaceted processes
(like PSA screening) occurring in context.
▪ We interviewed a large number of highly inform-
ative participants (GPs) in Australia and the UK
with diverse opinions and approaches.
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overdiagnosed cancers,2 vary between Australia, where inci-
dence is 115.22 cases per 100 000 population, and the UK,
where incidence is 73.19 per 100 000. Despite this differ-
ence in reported incidence, the two countries have roughly
equivalent prostate cancer mortality ﬁgures: 12.88 and
13.07 per 100 000, respectively.3 There are many reasons
for variation in incidence and mortality rates, which could
be due to underlying differences in prostate cancer risk
and population age structures, men presenting for testing,
access and availability of treatment options, cancer coding
and registration and diagnostic processes (such as availabil-
ity of PSA testing and improved diagnosis).
An important factor inﬂuencing reported prostate
cancer incidence in a population is PSA testing rates:
higher testing rates produce higher incidence. Testing
rates may be inﬂuenced by differences in professional
and organisational policies, media, cultural beliefs and
values. Annual PSA testing rates of asymptomatic men in
general practice are difﬁcult to ascertain. The data col-
lected often do not distinguish men who have had a
PSA for prostate cancer screening from those in whom
established disease is being monitored.
Clinical practice in the UK and Australia is grounded
in the same evidence base and international literature,
yet the two jurisdictions have notably different rates of
PSA testing. In the UK, a study in six English cities
reported the annual practice-based PSA testing rate for
2007 (in men aged 45–89 years) to be 6.2%.4 A more
recent study analysed data from patient electronic
records in primary care for men aged 45–84 years. It
reported that for every 100 men enrolled with a general
practitioner (GP) for one year, 5.03 (asymptomatic
men) were tested in 2010, and the rate increased by 8%
in 2011 to 5.45 per 100.5 Note that the data this analysis
was based on represent only 5% of the population in
England and may not be representative of all practices.
Analysis of Medicare Australia’s Medical Beneﬁts
Scheme records suggests that each year at least 20% of
men aged 45–74 years have a PSA test, presumably for
the purpose of early diagnosis of prostate cancer.6 This
number underestimates the actual number of PSA tests
performed, by up to 40%.7 The prevalence of PSA
testing in men over 50 years in Australia was reported at
63% in 2003; that is, 63% of men >50 years had ever had
a PSA test.8 This proportion is likely to have risen since.9
This raises questions about how practice in the two jur-
isdictions, while drawing on the same evidence base,
could be so markedly different. In table 1, we set out
some important differences in the organisation and
funding of primary healthcare between Australia and
the UK, including subtle variance in the advice offered
to GPs from expert authorities in relation to how actively
physicians should offer testing. Any or all of these differ-
ences conceivably inﬂuence testing rates.
Here, we report on a comparative qualitative study of
Australian and UK GPs’ current approaches to, and rea-
soning about, PSA testing of asymptomatic men to
address the following questions:
▸ How do GPs in the UK and GPs in Australia explain
their PSA testing practices?
▸ How are these explanations similar and different?
Our analysis draws on Gabbay and le May’s14 concept
of ‘mindlines’, which they developed to explain how GPs
use research evidence in practice. They describe mind-
lines as ‘collectively reinforced, internalised, tacit guide-
lines’,15 mainly grown and reﬁned via training,
experience and interaction with trusted sources, and
mediated by features of primary care organisations,
including their ethos and ﬁnancial and structural ele-
ments. Their mindlines theory makes a valuable contri-
bution to the evidence-based medicine (EBM) and
knowledge translation literatures because the theory
considers the inﬂuence of local context on GP adhe-
rence and use of formal knowledge like guidelines. We
use our analysis of data collected from GPs practising in
Australia and the UK to extend Gabbay and le May’s
theory of mindlines.
METHODS
Design
We applied the well-established, systematic qualitative
research methodology of grounded theory.15 Grounded
theory is a method of conducting qualitative research
that focuses on creating conceptual frameworks or the-
ories through building inductive analysis from the
data.16 Grounded theorists are led by the experiences of
the people in their inquiry and the substantive theories
they develop closely reﬂect what those people experi-
ence and do. Speciﬁc methods of data collection and
analysis are used to identify patterns in the research
data. The twin foundations of grounded theory are the
processes of constant comparison (a simultaneous and
concurrent process of coding and analysis) and theoret-
ical sampling (sampling with the aim of developing the
properties of a developing idea or theory). These
methods together guide the systematic development of
emerging theory, and ensure ﬁndings remain ﬁrmly
grounded in the collected data. All study authors have
been formally trained in the methods described; SC has
particular expertise in grounded theory methodology.
Participants and setting
We purposively recruited a sample of 69 GPs (Australia,
n=40; the UK, n=29) for this study. In Australia, we
advertised via the newsletters and email lists of GP orga-
nisations (Medicare Locals) in Sydney, and in mass and
social media, and in medical journals. As analysis and
sampling evolved, we invited additional rural and inter-
state GPs to answer speciﬁc analytical questions; for
example, the inﬂuence of GP proximity to specialist ser-
vices. Rural GPs were accessed by phoning practice man-
agers, through colleagues, and advertising with rural
Medicare Locals.17 When we encountered GPs whose
routine care was divergent from previously interviewed
GP norms, we invited more GPs from that practice to
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Table 1 A comparison of Australian and UK health systems and PSA testing context
Australia The UK
How is primary
healthcare provided?
The Australian Medicare system is
predominantly based around private practice
and fee-for-service funding, that is, private
practitioners in independent businesses are paid
for each instance of service, mainly using public
funds through the MBS, sometimes
supplemented by patient copayments.
Some GPs bulk bill, that is, GPs charge the
Government (Medicare) directly for any medical
service that their patient receives. In these
practices, GPs receive the Medicare rebate (a
fixed sum for each type of service) as payment,
and patients pay nothing. There is considerable
geographical variation in bulk billing practice
depending on where the GP is based (less in
more affluent areas and in rural, regional and
remote areas,10–12 where there is a greater
shortage of doctors and healthcare services).
There are standards but GPs are mostly free to
set their own fees for consultations and
procedures. Some charge substantially more
than the value of the Medicare rebate.
Australians can consult any GP they choose,
including seeing multiple GPs in multiple
practices.
The countries of the UK have centralised health
systems—the NHS. General practices mostly
operate as independent businesses managed
by GPs delivering care under contract to the
NHS and free to the patient at point of use.
GPs receive some payment on a capitation
basis (practices receive a fixed amount to
manage a set of potential patients).
There is virtually no fee for service element, but
some of the money practices receive from the
NHS is dependent on them supplying evidence
that certain quality standards have been met
(eg, that at least n% of people with a diagnosis
of x have received intervention y).
Almost all residents in the UK are registered to
a GP practice near their usual home, and will
consult GPs within that practice.
Are GPs advised to
offer PSA testing?
RACGP advises its members not to raise the
issue of PSA testing with patients, but if men
ask, to fully inform them about the potential
benefits, risks and uncertainties.
USANZ advises for men at average risk of
prostate cancer, who have been informed of the
benefits and harms of testing and who decide to
undergo regular testing for prostate cancer, offer
PSA testing every 2 years from 50–69 years,
and offer further investigation if total PSA is
greater than 3.0 ng/mL.
Universal screening for prostate cancer is not
recommended; however, PSA testing can be
provided at patient request (UK National
Screening Committee).
EAU advises that informed men requesting an
early diagnosis should be given a PSA test and
undergo a DRE. A risk-adapted strategy might
be considered based on the initial PSA level.
How should men be
tested (if they choose to
be tested)?
GPs advised to discuss the pros and cons of
testing with eligible men.
2012 RACGP Red Book guidance advises GPs
to perform PSA and DRE when a patient
chooses screening, whereas Australian NHMRC
guidelines do not recommend DRE for
asymptomatic men in the primary care setting.
USANZ suggests that GPs confident in
performing DRE are still encouraged to do so.
GPs advised to discuss the pros and cons of
testing with eligible men.
DRE is not recommended as a screening test in
asymptomatic men in the UK (NHS PCRMP).
Men aged >50 years who request a PSA test
can access the NHS PCRMP, an informed
choice programme introduced by the
Government in 2002 to ensure that men
concerned about prostate cancer receive clear
and balanced information. The PCRMP
provides GPs with information to counsel any
man who asks about PSA testing. It is an
English initiative, but Wales, Scotland and
Northern Ireland have adopted the same
approach and use the same materials
Is the PSA test funded? The Australian Government has subsidised PSA
tests for men 50 years and over since 1989
through the MBS.13
PSA testing can be provided free on the NHS
for men over 50 years on the condition they
have made an ‘informed choice’ following a GP
consultation.
DRE, digital rectal examination; EAU, European Association of Urology; GP, general practitioner; MBS, Medicare Benefits Schedule; NHMRC,
National Health and Medical Research Council; NHS, National Health Service; NHS PCRMP, National Health Service Prostate Cancer Risk
Management Programme; PSA, prostate-specific antigen (test); RACGP, Royal Australian College of General Practitioners; USANZ,
Urological Society of Australia and New Zealand.
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attempt to distinguish between personal and institu-
tional inﬂuences on their practice.
We recruited 29 GPs throughout England (n=23),
Scotland (n=5) and Wales (n=1) to explore PSA testing
reasoning and practice in a jurisdiction with compara-
tively lower rates of prostate cancer screening than
Australia. The initial sample of GPs responded to an
invitation distributed by academic colleagues through
professional networks. We then broadened the sample
by advertising via email to members of the Royal College
of General Practitioners (RCGP), primary healthcare
departments, university academic departments and
general practice and research mail lists. We also adver-
tised via newsletter including the Society for Academic
Primary Care and RCGP Scotland’s eBulletin.
GPs were invited to contact KP if they were interested
and willing to participate. An information sheet outlin-
ing the research project was emailed to all respondents.
Participants were of varying ages, clinical experience,
sex and patient populations: all GPs who expressed
interest in participating were included. GPs were com-
pensated for their time.
Interviews/data collection
We generated data via in-depth interviews. The semi-
structured interview schedule covered a broad range of
topics, including GPs’ recent clinical encounters involv-
ing PSA testing decisions, communicating information
about PSA testing to patients, screening pathways for
PSA and overdiagnosis of prostate cancer. The schedule
was modiﬁed between interviews based on the develop-
ing analysis to enrich the data available to answer our
research questions. All GPs were asked to think back to
their most recent consultation involving a discussion
about PSA testing or to describe a typical consultation
where the topic was raised. The aim of this approach
was to open the discussion about, and provide context
for, conversations about PSA testing and to use as a plat-
form to guide prompts and to focus subsequent
questions.
Interviews took place between March 2013 and June
2014 (Australian GPs) and between September and
December 2014 (UK GPs). We continued to interview
GPs until we judged we had reached theoretical satur-
ation, that is, the point at which gathering more data
ceases to yield any further insights about the emerging
grounded theory. All interviews were conducted by KP,
primarily by telephone or Skype, and ranged in duration
from 18 to 70 min. All interviews were audio-recorded,
and were transcribed verbatim.
Data coding and analysis
The analysis was led by KP, who coded the transcripts
and wrote detailed memos which were reviewed and dis-
cussed by the authors in analysis meetings. A subset of
transcripts was read and coded by three authors inde-
pendently; this coding was compared and discussed to
inform the development of the central concepts in the
study. All concepts were derived directly from the data.
Transcripts were not returned to participants for
comment; all participants will receive a written summary
of the research ﬁndings on study completion.
Role of the funding source
This study was funded by Australia’s National Health
and Medical Research Council (NHMRC) through a
peer-reviewed competitive process. The funder had no
role in the design, conduct or reporting of the study.
RESULTS
We identiﬁed notable differences in GPs’ explanations
of PSA testing in their individual practices, and within
GPs’ descriptions about the conditions of the respective
health systems in Australia and the UK. One striking dif-
ference was that Australian GPs reported that they fre-
quently spoke with asymptomatic men about being
screened for prostate cancer, while UK GPs reported
that they did this rarely. Another was that the process by
which PSA testing occurred in each country appeared to
be quite different. We explore below potential explana-
tions for these differences.
How did UK and Australian GPs’ descriptions of their
practices differ?
Testing as an exception versus testing as routine
GPs’ descriptions of a ‘typical’ consultation with a
PSA-age man were very different in the two jurisdictions.
Most GPs practising in the UK commented that PSA
testing is quite uncommon and is certainly not consid-
ered routine practice. GPs said it would be ‘rare’ or
‘unusual’ for asymptomatic men to request PSA testing.
UK GPs noted they may only receive a few PSA requests
a year and some could not recall an example to refer to
in the interview. The idea that a GP might introduce
PSA testing as an issue for consideration for an other-
wise healthy man was seen as strange; “if they’re coming in
with other issues, then we wouldn’t say, oh by the way, you
don’t want a PSA test, do you? That just wouldn’t happen”
(GP1). UK GPs tended not to order the test unless spe-
ciﬁcally asked to do so, and some would “work quite hard
to talk [asymptomatic] people out of it” (GP12).
In stark contrast, many Australian GPs talked about
PSA testing as an everyday, usual part of consultations,
and all reported that they commonly received requests
for the test. Some said that on a typical day, they
ordered several PSA tests for asymptomatic men. A sig-
niﬁcant proportion of the Australian GPs interviewed
said that they might also raise PSA testing with a patient,
unprompted. They reported that they would suggest
testing because of a man’s age, or raise it in the context
of a health check. To quote one GP: “people are used to
sort of being screened…so we’re tacking this onto the discussion
basically” (AGP21). Some GPs said their patients “don’t
get a chance” to initiate a discussion about PSA testing
before the GP “talks them into it there and then” (AGP29).
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How PSA testing occurred: immediate testing versus a
cooling-off period with extra information
The main difference between UK and Australian GPs’
descriptions of how PSA testing occurred was that for
Australian men, a decision about testing, and the order-
ing of a PSA test, was likely to occur in the consultation
in which it was ﬁrst raised. In contrast UK GPs described
a two-step process, with a ‘cooling-off’ period between
discussion and testing (if testing occurred at all).
UK GPs consistently reported the use of written informa-
tion leaﬂets (mostly from www.patient.co.uk). They would
give these to men who asked about PSA testing to take
away and read to help them decide whether they wanted
to be tested. GPs said that verbal discussions within the
consultations were relatively brief because of the compre-
hensiveness of this resource. GPs noted that having a
built-in ‘cooling-off period’ effectively (1) demonstrates
that PSA testing is not something to rush into, and (2)
allows patients to absorb the information in the leaﬂet
before making a decision. A number of GPs said that men
decided not to have PSA testing after receiving the infor-
mation, “but whether that is because they’ve really understood the
information or whether they’ve just picked up on the vibe, I
couldn’t really give you a good answer on that” (GP15).
GPs in Australia did not commonly report providing
written information to their patients; they predomin-
antly described having a verbal discussion only. Some
GPs described engaging men in quite a detailed explan-
ation about PSA testing, while other GPs said their dis-
cussion was “very, very brief” (AGP14). One GP, for
example, reported: ‘I give them next to none [information].
I say ‘Do you want to ﬁnd out if you’ve got prostate cancer?”’
(AGP9). Sometimes there was no discussion prior to
testing. Other GPs apparently tried—and said they
would sometimes succeed—to counsel men out of
having a PSA test, reporting, for example, that “nine out
of ten will choose not to have the test after appropriate explan-
ation” (AGP23). These examples illustrate the consider-
able diversity of practice in Australia compared with the
relative consistency of practice in the UK.
What practice conditions did GPs report that might help
explain differences in practice?
We explored GPs’ descriptions of training, structures and
availability of resources, which served as anchors for their
use of PSA testing as a screening tool. We outlined the simi-
larities and differences we observed in UK and Australian
GPs’ accounts of the conditions under which they prac-
ticed. Table 2 is a representation of the ‘system’: not just
the health system but the broader social and funding struc-
tures, comprising several interacting components.
Figure 1 illustrates the direction in which the system
factors presented in table 2 potentially inﬂuence pros-
tate screening: towards more PSA testing or towards less
PSA testing, and including those system factors with no
reported impact on testing rates.
Here, we present three overarching themes we subse-
quently identiﬁed as underlying and likely contributing
to the variation evident in the GP’s accounts: (1) history
of PSA testing policy, (2) healthcare structures and
incentives and (3) GP’s preferred source of knowledge.
The history of PSA testing policy in the two countries is an
important distinguishing factor
A number of GPs in the UK reported the long-standing
consistency of a central authoritative position discour-
aging prostate cancer screening. The policy could be
summarised as ‘don’t raise it, and inform if asked’. From
the mid-1990s all GPs in the UK were sent relatively
easy-to-read summaries of the evidence together with
written information to hand out to men who asked
about the PSA test.18 Dissemination of similar informa-
tion has been used continuously since.
In contrast, in the Australian context, some GPs
recalled the positive publicity that accompanied PSA
testing when it was ﬁrst introduced. Online documents
indicate that, simultaneously, some Australian authorities
actively encouraged and promoted PSA testing of asymp-
tomatic men, while other ofﬁcial guidelines, released as
early as 1995, recommended against prostate screen-
ing.19 20 As shown in table 2, Australian GPs reported
that the guideline environment is challenging to navi-
gate, making it difﬁcult for GPs to ﬁnd consistent and
centrally issued directive advice.
The early messaging to GPs seems to have had long-
lasting implications. GPs in both countries commented
on the tendency to continue practising in the manner
in which they began. One UK GP explained, “it’s quite
difﬁcult to change your practice. I think if you’re a GP who’s
never been doing the PSA test then it’s easier for you to carry on
not doing them” (GP9). An Australian GP said,
I guess we learn from our initial experiences and it’s very
hard to change your initial thoughts on a particular test.
So my initial understanding was it’s an amazing test, that
it should be done, that it’s very useful, that you’re almost
neglectful not to do it… the initial thing was PSA is
useful and that has basically stuck in my head, that PSA
testing is useful. (AGP1)
How healthcare structures and incentives drive practice
The clinicians’ accounts clearly reﬂected the known dif-
ferences in healthcare payment models between the two
locations. In Australia, GPs are paid fee-for-service—a
scheme dependent on the quantity of instances of
patient care—thus more patients, procedures and
appointments generate greater income for GPs. One GP
commented on the implications of fee-for-service,
If I went around having my 10 minute discussion with all
my patients about why not to do PSA testing, I will make
less money than [a GP] who does the 30 second—here
Jack, that’s a good idea, here, have the PSA test, we’ll see
you in a fortnight to check the result…one of the conse-
quences of the current health system is that it feeds itself
to making more diagnoses and being more busy, not less
busy. (AGP23)
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Table 2 Practice conditions reported by GPs that might explain differences in practice
Situation in the UK Situation in Australia Differential effect on PSA testing
Prostate
screening culture
Doctors screening healthy people, or healthy
people demanding this, considered strange; ‘it
doesn’t happen. People don’t come in and say
“they feel fine, they just want all their blood
checks”…I don’t think the NHS could really do
that’ (GP21).
GPs report routinely offering (and encouraging)
patients to have multiple tests, perhaps including
PSA; healthy patients request health checks
regularly. Some considered this ‘normal’ and/or
‘responsible’.
‘Screening culture’ likely influences default
screening practices; in Australia PSA has
“become a fairly entrenched part of the male
[annual] health check up” (AGP17).
GP training UK GPs felt trained to avoid PSA testing, a
‘really big topic’ and ‘classic case’ in medical
exams and training. “The training that we
received is … how you would have a discussion
… when we’re asked for [the test], and you
almost felt like they were sort of trying to
dissuade asymptomatic men from having it…
that was definitely the sort of slant” (GP16).
GPs in Australia did not comment much about
their medical training and PSA testing; one GP
who did said “it’s one of the areas where it’s pretty
much self-taught and you develop your own
opinion” (AGP4).
GPs in the UK are specifically trained how to
advise asymptomatic men against screening,
so seem likely to have more skills to do so, and
to default to this practice.
Funding models UK GPs spaced appointments to allow for
appropriate care, because “the expectation from
the UK government as purchasers of the care
would be that [men] be counselled around the
limitations” (GP15). They were acutely aware of
“a responsibility [for] spending the finite [NHS]
resources” (GP23). UK GPs and practices did
not gain financially from test-ordering.
Conversely: PSA testing “just creates more
work” (GP6).
Some Australian GPs had systems to shorten
consultations about PSA testing, for example,
including PSA in routine bloodwork/‘bucket
testing’, automatic recall so patients could be
tested without seeing the GP. Some GPs blamed
Australia’s fee-for-service health system, which
encouraged seeing (and testing) more patients:“it
feeds itself to making more diagnoses” (AGP23).
The Australian fee-for-service funding model
incentivises [over]servicing; the UK’s NHS
scarce resources model incentivises caution in
creating burden on a limited system.
Guidelines UK GPs saw NICE guideline (a clear policy
directive) as authoritative, trustworthy, impartial
advice against testing; the national guideline
influenced practice. “I think people are wary of
practicing not in line with that and then they
have potential then for criticism” (GP3). The
established norm is structured communication
with men who ask about testing, using a written
information resource.
GPs found Australia’s competitive information
environment about PSA testing hard to navigate:
“there’s plenty of guidelines, but they’re all
different and there’s nothing official…there’s no
hard and fast rule” (AGP9). “It’s a very tricky area
because…opinion is divided depending on who
you talk to” (AGP20). Many GPs did not use a
guideline, citing patient demand, lack of time,
unfamiliarity or a preference for their own
judgement; some said RACGP guidance was an
unclear ‘cop-out’.
Having one authoritative guideline seems to
encourage consistent practice. At the time of
this study, such guidance did not exist in
Australia, probably contributing to variation in
PSA testing practice.17
Mass media and
public profile
UK GPs reported that prostate cancer is
sometimes in the news media but is “certainly
not something which is on the front page of
newspapers everyday” (GP8) and “doesn’t
translate into a lot of men coming and asking
Australian GPs said “there has been a lot of
media attention to PSA testing over the years”
(AGP15), a “part of the big problem with the
prostate cancer stuff” (AGP23). Requests
increased after media coverage;
Conflicting messages and promotion of PSA
testing in Australia drives demand from
patients; this is absent in the UK.
Continued
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Table 2 Continued
Situation in the UK Situation in Australia Differential effect on PSA testing
for PSA tests” (GP1). Many said patients would
only hear about PSA testing from their doctor.
‘media-influenced’ patients had preconceived
ideas, assuming screening was widely endorsed if
sanctioned on TV, “so they see it as their right to
have it” (AGP15). “Men know that it’s available…
so it’s hard not to bring it up” (AGP2).
Practice protocols All GPs within a single practice in the UK
tended to test in a similar way: they “practice as
a group and with group support” (GP20). This
occurred via ‘verbal agreement’ rather than
formal written protocols. Internal practice
protocols sometimes permitted practice nurses
to PSA-test asymptomatic men without GP
involvement.
In the absence of Australian consensus
guidelines, GPs developed their own testing
protocol over years, “I have built up my own idea
of practice” (AGP36). Practices need not have
formal protocols as “it is a judgement call at the
moment” (AGP39).
Presence or absence of protocols at practice
level does not seem to explain differences
between the two countries: both lacked
protocols.
Method of
screening
When UK GPs screened (rarely) they often did
DRE before or instead of PSA. They thought
DRE good or standard practice, and valued the
information it provided: “the two tests go
together” (GP14), “it’s a two-part process”
(GP23), “doing a PSA alone is worse than
doing nothing at all” (GP7). UK urologists
reportedly expect GPs to do DRE (although
urologists will repeat it).
Australian GPs reported rarely doing DRE in
asymptomatic men. Australian GPs were unsure
they could detect abnormality via DRE.
In the UK, DRE was used prior to or instead of
PSA, but was not recommended; conversely,
until recently Australian guidelines
recommended DRE with PSA but it was rarely
done.
Referral systems
for men with
abnormal results
In the UK, referral pathways following particular
test results are well defined: if PSA was
abnormal, GPs would always refer to NHS
urology to see the next available (possibly
unnamed) consultant, entirely publicly funded.
GPs’ cancer referrals were audited and GPs
made accountable for referrals.
After abnormal PSA test results, Australian GPs
varied greatly in when, how and to whom they
referred. In urban Australia, where there were
more urologists, immediate referral after abnormal
PSA was common; in rural Australia (fewer
urologists) GPs managed abnormal PSA tests for
months or years before referral. Australian
urologists may be seen publicly or privately;
private urology is a competitive marketplace.
Australia lacked a clear referral pathway for
PSA testing, so decisions were made by
individual GPs and patients, influenced by a
business model of healthcare and a private
health sector. In the UK, referral was
streamlined and publicly funded.
Position taken by
urology as a
profession
UK GPs said urologists “certainly do not push
us to screen men who are otherwise well—if
you asked any of them they’ll probably say it’s
actively discouraged” (GP1). (While not
reported by these GPs, we know anecdotally
and from the literature that some UK urologists
have advocated PSA screening.) GPs
described close communication and ‘strong
Australian GPs said urologists “encouraged PSAs
to be done a lot more urgently” (AGP37). Some
GPs accepted this advice; others “politely ignore
[d] the advice from urologists in that respect. And
from their organizations” (AGP19), as “they have
made life very difficult because they’re being very
unfair on the evidence that’s out there” (AGP18).
In rural areas, fly-in urologists ran monthly clinics,
and influential seminars encouraging testing.
There was strong variation in GP perceptions
and collaborations with urologists, within and
between countries. Some Australian GPs were
strongly sceptical of some urologists’ position;
UK GPs were less sceptical.
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UK GPs reported that the focus of the UK capitation
system is on quality of care rather than quantity of care.
They described processes in place to support GPs to
provide detailed evidence-based information to men
who ask about prostate screening; “What happens is you
type it [PSA] in and because we have web-based patient data
systems, they link…to the patient information stuff, so you tend
to use what comes to hand very easily…and because it’s
online…it’s as up to date as it can possibly be” (GP28).
Appointments about PSA testing in the UK are (or can
be) a two-step process; a ‘cooling-off period’ is built into
usual practice. A policy environment that encourages a
two-step process serves to avoid overuse and to ensure
decisions are well informed. The UK system looked to
be built on an underlying assumption that men who
know the facts about PSA testing are less likely to want
it. UK GPs reported “feeling quite supported over what we
are doing” (GP28) and seemed inclined to operate within
the bounds of their health system, while Australian GPs
often practiced according to individual standards.
In the UK, referral pathways following particular test
results are well deﬁned. GPs reported that the urology
departments in their local hospitals had issued referral
guidelines for GPs. These were often simpliﬁed versions
of The National Institute for Health and Care
Excellence (NICE) guidance and were seen as prescrip-
tive: as one GP said, “it’s a very clear path, it’s not a clinical
decision” (GP2). Most patients with abnormal PSA results
in the UK are referred to a National Health Service
(NHS) urology team and see the next available consult-
ant initially on an unnamed basis. It is publicly funded
(there are some private urologists, but they are a minor-
ity). These urologists therefore do not compete with one
another for business to any great extent.
Urologists in Australia serve the public and private
sectors: patients can be seen privately or as public outpa-
tients, and private urology, in particular, is a competitive
marketplace. The GPs who participated in this study
often spoke of patients as consumers, who maintained
substantial individual choice in healthcare decisions.
Australian GPs reported selecting (with or without the
patient) which individual, named urologist a patient will
see. They described making this choice based on factors
including the ‘personalities’ of the patient and urologist,
and how ‘interventionist’ they perceived the urologist to
be. The GPs varied greatly in when, how and to which
specialist they referred abnormal PSA test results. Men
could thus potentially receive very different care
depending on their GPs approach to PSA testing and
urology referral.
GPs appear to rely on different kinds of knowledge in
determining their practice
Accountability, clear expectations set in central policy
and support to apply best available evidence meant that
UK GPs were equipped to practice in a relatively predict-
able and standardised way, including when directly asked
about PSA testing by their patients. A number of GPs
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from the UK commented throughout the interviews that
they had never before reﬂected on why they approach
consultations about PSA testing in the way that they
described. They had never really had to grapple with
what to do as in regular practice they could conﬁdently
follow the available authoritative, evidence-based
guidance.
Many GPs in Australia also aimed to practice EBM by
following a published guideline. However, there was a
proportion who were more likely to practice according
to a different idea of evidence: for whom the ‘evidence’
from their own experience or the experiences of collea-
gues was critically important in directing their approach
to PSA testing. In the Australian context, ambiguity and
contestability surround interpretations of the evidence,21
and are accompanied by vague professional guidance.
Some GPs described research-based directives as incom-
patible with their day-to-day practice and preferred to
deal with what they described as routine cases using
their own experience. We reﬂect on these issues further
in the Discussion.
DISCUSSION
Australia and the UK draw on the same evidence base
for prostate cancer screening. The PSA test is in prin-
ciple available free to eligible men in both countries,
and prostate cancer mortality is roughly equivalent. Yet,
the rates of PSA testing for prostate cancer risk in the
two countries are strikingly different. We identiﬁed fun-
damental differences in how PSA testing occurred and
linked this to considerations of how testing was orga-
nised. Both countries have factors within their structural
and organisational environments that seem to reinforce
each other in inﬂuencing practice in a particular direc-
tion. This combination of multiple factors appears to
explain the very different testing and incidence rates,
serving mostly to drive more PSA testing in Australia and
less PSA testing in the UK.
Australians have been shown empirically to have atti-
tudes broadly in favour of cancer screening.22 The
Australian media has been shown empirically to deliver
a generally pro-PSA-screening message.23 These two
combined seem likely to increase rather than limit
patient demand for PSA testing, and thus to promote
rather than retract a market for screening. A
fee-for-service payment system allows Australian GPs sig-
niﬁcant scope to routinely offer PSA testing, and gives
them a ﬁnancial incentive to provide this service to ﬁll
the demands of the market. Mixed messages in the
current Australian guidelines and some specialists pub-
licly advocating for PSA testing do little to curtail use of
the PSA test. In comparison, the medical training of GPs
in the UK to avoid PSA testing, strong discouragement
from the NHS, little patient demand, limited healthcare
resources, and zero ﬁnancial gains from screening for
Figure 1 Direction in which system factors described in table 2 drive PSA testing in Australia (black) and the UK (grey). Upward
arrows indicate drivers towards more PSA testing, downward arrows indicate drivers towards lower rates of PSA testing, circles
indicate neutral factors with no reported impact. PSA, prostate-specific antigen.
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GPs and public sector urologists were reﬂected in the
GPs’ explanations of low rates of testing in their respect-
ive practices.
What is being done in Australia to address divergent use
of the PSA test?
The provision of and access to PSA testing in Australia is
currently extremely heterogeneous, partly dependent on
the reasoning and preferences of individual doctors.
Newly released national evidence-based clinical guide-
lines aim to drive greater consistency in testing prac-
tices.24 The consensus guidelines, which include an
‘after the test’ component, may prompt more evidence-
based discussions and streamlined delivery of consistent
information, and standardise referral pathways in
Australia.
The authoritative consensus guidelines are a signiﬁ-
cant move in the right direction for ‘smarter screen-
ing’25 in Australia. An accompanying decision aid is
being designed to provide an opportunity to make more
informed decisions. Yet, the other drivers of screening
remain in the Australian setting compared with the UK
where PSA screening is discouraged at a system-wide
level. The Australian guidance has focused attention pri-
marily on prioritising individual choice. While the new
NHMRC guidelines represent a ﬁrst step in addressing
inconsistencies in what GPs are advised to do, and will
be a useful information resource to incorporate into
evidence-based discussions; they may not sufﬁce to
address what is arguably the most important objective:
to reduce unnecessary or harmful prostate screening.
Although reducing PSA testing rates in Australia is not
an explicitly agreed goal of the new NHMRC guidelines,
the comparable death rates despite considerably less
screening suggest it is likely that the lower rates of PSA
testing under the UK system are preferable. In the fol-
lowing section, we suggest areas for consideration and
evaluation (alongside the NHMRC guidelines), which
may potentially decrease use of the PSA test for screen-
ing purposes in Australian primary care.
What can be done in Australia to improve screening
practice?
By comparing Australia with the UK, we have identiﬁed
features of the context in which screening options are
offered that might not otherwise have been appreciated
as signiﬁcant in the Australian setting. Overall,
Australian men have fewer practical barriers to undergo-
ing a PSA test, alongside higher incentives for GPs to
perform the test. We suggest that, if reducing the rate of
PSA testing is a reasonable goal for Australian general
practice, the following strategies (structural and organ-
isational) may assist in achieving that goal.
Two-step consultations: Information provision that is sep-
arate from PSA testing availability via ‘staggered’
appointments, which incorporate a cooling-off period.
Tambor et al26 reported that when testing could be
obtained conveniently as ‘part of a battery of other tests’
approach as used in the Australian context, uptake was
considerably higher than when additional effort was
required to have a test.
Incentivise informed shared decision-making (SDM), as the
USA has introduced for lung cancer screening, for
example.27 UK GPs do not receive reimbursement spe-
ciﬁcally for engaging in SDM with patients; however,
they are accountable for their screening activity and use
of NHS resources. GPs in Australia may initially need
ﬁnancial encouragement to implement the NHMRC
guidance (provide information rather than offering
screening) if this is in contrast to their usual practice.
Australia’s fee-for-service GP payment system rewards
activity in primary care, such as testing, rather than the
giving of information to permit an informed choice
about whether to test.
Fund PSA testing differently: In the USA, Medicare has
considered imposing a penalty for physicians who
perform ‘non-recommended’ prostate cancer screening
with the PSA test as part of a federal effort towards value-
based care.28 Financial disincentives for GPs and men
over time will potentially diminish harm caused by
unnecessary screening (eg, of low-risk men or men with
a limited life expectancy), as a ﬁnancial barrier may
result in more considered decisions on the part of men
and their doctor. However, an ongoing and relevant
counterargument is that doctors should not be rewarded
for withholding a test that could help some men, nor
restrict the options of men with limited ﬁnancial means.
Welch and others have suggested introducing a small
cost to men for PSA testing.29 Introducing a small cost
for a PSA test with clearly communicated exceptions
(eg, men with strong risk factors for prostate cancer)
may be a reasonable option in Australia. There are plans
in Australia to consider changes to the Medicare Beneﬁts
Schedule item number to align with the new PSA testing
guidelines and only allow coverage for a PSA test every
second year, rather than annually. However, the PSA test
is currently in principle available free to men in Australia
and the UK, suggesting cost may not be a key factor
inﬂuencing more frequent testing in Australia. This
would be a pertinent topic for further research.
Why might achieving a shift in GP practice be difficult?
Although the varied structural and organisational condi-
tions in the respective healthcare systems of Australia
and the UK seemed to explain much of the difference
in GP accounts of their PSA testing practice—at the
patient and consultation level—another layer to the
decision-making environment was also evident. Gabbay
and le May’s theory of ‘mindlines’ is particularly relevant
to our analysis. We hypothesise from our data that GPs
from Australia and the UK are following different ‘mind-
lines’, shaped by their respective cultures, contexts and
experiential knowledge.
We propose that UK GPs have internalised an organ-
isationally embedded consistent mindline, based on
the evidence-based recommendations from a trusted
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authoritative voice. All GPs appeared to agree about
what practice was appropriate, implementing a relatively
similar version of evidence-based practice. There was
less room to move in their individual interpretations of
the evidence because the professional guidance was con-
sistent and not contested—UK GPs were advised which
evidence was appropriate, and provided with supporting
materials to distribute to men. Funding arrangements
also put explicit boundaries around what is considered
acceptable practice. The mindline used by UK GPs
seems to have developed during their training and was
subsequently collectively shared and reinforced via reli-
able professional networks, including urologists. It was
rarely challenged because of clear communication, a col-
lective understanding of requirements and expectations,
and limited exposure to men requesting prostate
screening.
We suggest that, in contrast to the UK, GPs in
Australia are accustomed to a noisy marketplace of con-
ﬂicting advice, including from urologists. As a result,
their mindlines appear to be more independently con-
structed based on individual experiences, and strongly
inﬂuenced by contextual considerations. Like the UK
GPs, the Australian GPs’ mindlines were developed and
reinforced via similar processes of experience, repetition
and interactions, but these occurred within local circum-
stances and macro systems that looked very different to
the UK situation. It is likely that Australian GPs’ mind-
lines vary considerably from one GP to the next as they
navigate and interpret the changeable conditions.
Australian GPs described a broad spectrum of men regu-
larly asking about PSA screening, each with very differ-
ent expectations. So, while an individual Australian GP
may have a relatively uniﬁed approach to PSA screening
decisions and discussions, speciﬁc contexts and patient
presentations could prompt temporary deviation from
this mindline in favour of an alternative.
While producing guidelines (such as the NHMRC
guideline) as a formal source of knowledge is essential,
against a background of clinicians’ diverse ingrained
habits and history, guidelines are unlikely to be enough
to alter established clinical practice in Australian GPs.
Nonetheless, consistent guidelines provide a much
needed foundation to build on. As Gabbay and le May
conclude, practitioners have a collective responsibility to
ensure their mindlines are based on research evidence
wherever possible,15 and the NHMRC guidelines provide
a consensus regarding the appropriate evidence base.
However, above all, our research has demonstrated the
overwhelming inﬂuence of local contexts on clinical
practice. GPs’ established mindlines and rules of thumb
appear to interact with the social and organisational
context. If policy leaders want to promote practice con-
sistent with the consensus guidelines, they are likely to
need to work actively, alongside providing ongoing
support for GPs, in directing how the NHMRC guide-
lines are received, implemented and used in practice.
The process should prioritise establishing GPs’ trust in
the guidelines as a reliable source of information for
supporting modiﬁed practice patterns among those
whose practice is not aligned with the new recommenda-
tions. Our ﬁndings and Gabbay and le May’s theory
suggest that guideline dissemination might be best tar-
geted through favoured sources of information, includ-
ing inﬂuential GP and specialist colleagues—although
conﬂicts of interest might make this challenging.
Future research might usefully explore the likelihood
and feasibility of a cultural shift around PSA screening,
examining men’s and broader public enthusiasm to screen
in Australia. Schwartz et al30 found that the majority of
American men they sampled would over-rule their physi-
cian’s recommendations for less frequent or no screening.
A closer look at urologists’ ‘mindlines’ may also be rele-
vant, as these appear to inﬂuence the mindlines of GPs.
Limitations
We interviewed a large number of highly informa-
tive participants (GPs) with diverse opinions and ap-
proaches; participation in the study was self-selecting. It
is possible that physicians with particularly strong opi-
nions about prostate cancer screening were more likely
to volunteer.
CONCLUSION
Important drivers of prostate cancer screening are
evident at a number of levels. PSA testing rates arise
from more than individual GP attitudes towards screen-
ing: current and historical structures, systems and rules
all play a signiﬁcant role in creating the mindlines that
GPs employ in their practice. It is likely that all of these
inﬂuences will need to be addressed if these mindlines,
and thus practice, are to change.
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CHAPTER SIX. 
Primary goals, information-giving and men’s 
understanding:                                                                          
A qualitative study of Australian and UK doctors’ 
varied communication about PSA screening 
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6. Overview of this chapter 
Communicating with men about the complexities of PSA screening is a challenging task for clinicians. 
Current international clinical guidance unanimously supports the concept of patient-informed decision 
making.  
In light of our prior findings on practice variation between the Australian and UK contexts, we set out in 
this study to better understand GP communication practices in particular. In this paper we report on an 
empirical analysis of how GPs in the two locations describe their communication with men about prostate 
cancer screening (Research Question 1.2), reasons given for communicating with men as they do 
(Research Question 2.4), and the consequences of varied communication approaches (Research Question 
3). It became apparent throughout the data collection process that GPs communicated with men about 
prostate screening in vastly different ways, and in some cases, not at all.  
6.1 Publication details 
Pickles, K, Carter SM, Rychetnik L, McCaffery K, Entwistle VA (2017). Primary goals, information-giving 
and men’s understanding: A qualitative study of Australian and UK doctors’ varied communication about 
PSA screening. BMJ Open, in press. 
6.2 Authors’ contributions 
All authors conceived the study and were involved in designing the study and developing the methods. SC 
& LR obtained funding and are CIs on the NHMRC funded project grant. KP conducted the interviews, had 
full access to all data in the study, and takes responsibility for the integrity of the data and the accuracy of 
the data analysis. KP drafted the manuscript. All authors contributed to the interpretation of the analysis 
and critically revised the manuscript.  
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6.3 Abstract 
In this grounded theory study we interviewed 69 general practitioners consulting in primary care 
practices in Australia and the United Kingdom. We present an analysis of how GPs explain their approach 
to communication with men about prostate cancer screening. GP approaches varied according to their 
goals for communication and specific practice situations. The reported consistency of PSA communication 
practices in the UK contrasted strongly with the significant variation reported in the Australian context. 
This analysis distinguished GPs’ primary communication goals as a central component of consultations 
about PSA screening, which influenced their information provision and the depth of patient understanding 
GPs sought to develop. Situational and relational factors were particularly important in the 
communication process for Australian GPs. We consider the significance of context and its influence on 
communication practice.  
6.4 Manuscript 
The version of the manuscript that is in press at BMJ Open follows. 
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Primary goals, information-giving and men’s understanding: A qualitative study of 
Australian and UK doctors’ varied communication about PSA screening 
Abstract  
Objectives:  
1. To characterise variation in general practitioners’ (GPs’) accounts of communicating with men 
about prostate cancer screening using the PSA test; 
2. To characterise GPs’ reasons for communicating as they do; and 
3. To explain why and under what conditions GP communication approaches vary. 
Study design and setting: A grounded theory study. We interviewed 69 GPs consulting in primary care 
practices in Australia (n=40) and the United Kingdom (n=29).  
Results: GPs’ explained their communication practices in relation to their primary goals. In Australia, 
three different communication goals were reported: to encourage asymptomatic men to either have a 
PSA test, or not test, or alternatively, to support men to make their own decision. As well as having 
different primary goals, GPs aimed to provide different information (from comprehensive to strongly 
filtered) and to support men to develop different kinds of understanding, from epidemiological to ‘gist’ 
understanding.  Taking into account these three dimensions (goals, information, understanding), and 
building on Entwistle et al.’s (2008) Consider an Offer framework, we derived four overarching 
approaches to communication: Be screened, Do not be screened, Analyse and choose, and As you wish. 
We also describe ways in which situational and relational factors influenced GPs’ preferred 
communication approach. 
Conclusion: GPs’ reported approach to communicating about prostate cancer screening varies 
according to three dimensions—their primary goal, information provision preference, and 
understanding sought—and in response to specific practice situations. If GP communication about PSA 
screening is to become more standardised in Australia, it is likely that each of these dimensions will 
require attention in policy and practice support interventions. 
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Introduction 
Worldwide, many men undergo regular prostate-specific antigen (PSA) screening for prostate cancer 
risk in primary care. We will use PSA screening to refer to PSA testing in ostensibly healthy men who 
are not considered to be at high risk of prostate cancer for their age; this contrasts with PSA testing in 
men who have a diagnosis of prostate cancer or are experiencing acute symptoms that may suggest 
prostate disease. Although the value of the PSA test as a screening tool is scientifically contentious, the 
public perception of prostate screening is reportedly positive, including an inflated sense of the 
benefits and underestimation of the harms (1). Access to a PSA test is often via General Practitioners 
(GPs). The large number of men screened in some countries, and the extent of public misperception 
and scientific contention, make the communication between men and their GPs about prostate cancer 
screening especially important.  
Communicating about screening is difficult. In-depth discussions about cancer screening can be 
complex, and may involve multiple statistical concepts, such as test sensitivity and specificity, and 
absolute and relative risk reduction figures from trial-based evidence. Chan et al. identified over 20 
specific informational items that experts and patients identified for inclusion in an ‘ideal’ discussion 
about prostate screening (2). The authors synthesised the items into a core set of key facts that 
clinicians should provide about PSA screening to their patients (Figure 1, developed by KP), however 
we note that even some of these items are contentious or inconsistent with the various national 
guidelines that we will discuss in the next section. 
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Figure 1. Proposed content for informed consent for PSA screening (Chan et al., 1998, figure developed by KP) 
 
 
Proposed communication standards for PSA screening discussions are reportedly challenging to 
implement in clinical practice e.g. (3-5). PSA tests are often ordered in the absence of any discussion; 
in the US, men report being unaware of being screened (6), not being asked for their screening 
preferences, and undergoing PSA testing without first discussing it with their doctor (7). Clinicians 
report offering screening without prior counselling (8). A survey of US physicians reported 20% 
acknowledged ordering PSA without telling patients (9). This can be for various reasons (10). Volk et 
al. surveyed US physicians and found that those physicians who reported ordering PSA tests without 
discussion were more likely to believe that patients wanted to be screened and that education is not 
needed. This was in contrast to those physicians who engaged patients in pre-screening discussion 
because they believed patients should know about the lack of evidence supporting screening (11). 
Physician beliefs about the limitations of the scientific evidence for PSA screening, the questionable 
utility of the PSA test, and ethical concerns regarding patient autonomy have also been identified as 
influencing the likelihood of discussions in US studies (10, 12). Physician beliefs can shape the content 
Basic minimum 
1. False positive PSA test results can occur. 
2. False negative PSA test results and false negative biopsies of the prostate can occur. 
3. Nobody knows whether regular PSA screening will reduce the number of deaths from prostate 
cancer. 
Conversation 
1. The PSA test is a blood test for prostate cancer. 
2. Done together, the digital rectal examination and the PSA test can screen for prostate cancer.  
3. The PSA screening test can detect prostate cancer sooner than the digital rectal examination 
alone. 
4. An elevated PSA test result may lead to other tests to see whether prostate cancer is present. 
5. The risk of getting prostate cancer is higher in a man who is older, has a family history of prostate 
cancer, or is African American. 
6. Prostate cancer may grow slowly and not cause any symptoms. That is why prostate cancer may 
not kill older men. They may outlive this cancer and die from something else. 
7. A man over age 70 is less likely to die from prostate cancer even though he is at higher risk to 
have it. 
Brochure 
1. The PSA screening test is controversial. 
2. There are advantages and disadvantages to taking the PSA test. One disadvantage is that a man 
could end up worrying about what an elevated PSA test result means. 
3. Done together, the PSA and DRE are most appropriate for men who have more than 10 years left 
to live. 
4. A man with early prostate cancer can choose watchful waiting, radical prostatectomy, or 
radiation therapy. 
5. There are side effects from prostate cancer treatment such as impotence, incontinence, 
narrowing of the urethra (strictures), trouble urinating, and rectal scarring. 
6. Nobody knows whether treating prostate cancer early is helpful or whether one treatment is 
better than another. 
7. Although a man thinking about taking the PSA test can consult a doctor, he should make the final 
decision himself. 
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of discussions; in a UK study, the strong personal views of clinicians against the value of PSA screening 
were reportedly clearly portrayed in their presentation of information about prostate cancer 
screening (13). 
In addition to this work on physician knowledge, values and attitudes, some researchers have studied 
patient and practice factors that may facilitate or preclude discussions about prostate cancer 
screening. For example, in one study US physicians were less likely to discuss screening if a patient 
had already made a decision about screening, or was perceived to have limited ability to understand 
the information (10). Other studies have reported on factors affecting the quality of discussions, 
including a lack of time and the complexity of the topic (9).  
Clinicians have cited clinical guidelines and scientific evidence about prostate cancer screening as 
factors guiding their practice e.g. (13). However this professional guidance varies widely, which may 
partly explain the observed variation in practice. Table 1 outlines the recommendations of key 
professional organisations in relation to communicating about prostate cancer screening, illustrating 
the main points of difference. “Informing” men about the benefits and harms of PSA screening is 
universally recommended; and use of decision support tools is recommended by half of the 
professional organisations. Only four of the ten guidelines advise whether GPs should raise the topic of 
PSA screening with men who do not ask about it in routine consultations. Medico-legal issues are 
referred to in only one, Australian, guideline. In practice, clinical guidelines may not always help GPs to 
decide how and what to communicate about PSA screening (14). 
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Table 1. The recommendations of professional organisations in terms of communicating about prostate screening 
Items included in recommendation and 
guidance 
Professional Organisation 
PCFA/CCA1  NHMRC2 RACGP3 USANZ4 NICE5 NHS/PHE6 USPSTF7 ACS8 NCI9 AUA10 
Is GP advised about whether to raise the 
topic with men if men do not raise it first? 
  ✓  ✓ ✓ ✓    
Is a decision aid recommended?  ✓ ✓ ✓  ✓     ✓ 
Is a decision aid provided?      ✓    ✓ 
Is IDMa recommended? ✓ ✓ ✓ ✓ ✓ ✓ ✓ ✓ ✓ ✓ 
Is SDMb recommended?   ✓   ✓  ✓   ✓ 
Is guideline accompanied by a clinician 
information sheet?c ✓ ✓    ✓ ✓    
Is guideline accompanied by a patient 
information sheet?d 
 ✓ ✓  ✓ ✓     
Does guideline recommend clinician to share 
their own PSA screening decision? 
      ✓    
Consider medico-legal responsibilities?   ✓        
1 PCFA/CCA: Prostate Cancer Foundation of Australia/Cancer Council Australia 
2 NHMRC: National Health and Medical Research Council 
3 RACGP: Royal Australian College of General Practitioners 
4  USANZ: Urological Society of Australia and New Zealand 
5 NICE: The National Institute for Health and Care Excellence 
6 NHS/PHE: National Health Service/Public Health England 
7 USPSTF: United States Preventive Services Task Force 
8 ACS: American Cancer Society 
9 NCI: National Cancer Institute of the National Institutes of Health 
10 AUA: American Urological Association 
a. Informed Decision Making (IDM): The patient is presented with all the information pertinent to making a decision and then assumes final authority for the decision (30). 
b. Shared Decision Making (SDM): The patient is provided with all the relevant information and works with the health care provider to reach a decision that reflects the health 
preference of the patient (30).  
c. A clinician information sheet is a fact sheet summarizing the evidence of benefits, limitations, and associated risks of prostate screening to help clinicians to accurately inform 
men. 
d. A patient information sheet is a fact sheet outlining the benefits, limitations, and associated risks of having a PSA test for prostate cancer risk. 
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Entwistle et al. characterised the two main ways that health care organisations communicate with the 
public about screening – Be screened and Analyse and choose – and proposed an alternative approach 
to communicating about screening, which they termed Consider an offer (15). The Consider an offer 
approach suggests health care providers should support people to assess an offer for screening, with a 
recognition that people may reasonably decline such offers. Consider an offer guides clinicians and 
patients to consider the source of screening recommendations and professional guidance. We return 
to the Consider an offer approach in the Discussion. 
This study draws on a larger body of work investigating clinician’s approaches to, and reasoning 
about, PSA screening in Australian and UK general practice. Despite similar levels of prostate cancer 
mortality, both PSA screening and prostate cancer incidence are lower in the UK than in Australia (16-
19). Previous analyses from this study have illuminated systemic variation between the two 
jurisdictions, including in payment models, the history of PSA screening policy, screening culture, and 
referral patterns (14). The authors have also published earlier findings from the empirical work about 
how clinicians manage the potential for overdiagnosis (20) and their responses to uncertainty in 
relation to prostate screening (21). Table 2 summarises our previous findings regarding differences in 
PSA screening in the two jurisdictions. Note that prostate cancer screening is not recommended in 
either location.   
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Table 2. The organisation and occurrence of PSA screening in Australia and the United Kingdom  
[Summary of findings, details reported in Pickles et al 2016] 
 Australia United Kingdom 
For men asking 
about prostate 
screening 
 PSA screening is available. GPs are 
advised to offer evidence-based 
decisional support to men 
considering whether or not to 
have a PSA test, including the 
opportunity to discuss the 
benefits and harms of PSA 
screening before making the 
decision. 
 PSA screening is available, but with 
conditions. The National Health Service 
Prostate Cancer Risk Management 
Programme (PCRMP) has 
recommended that screening for 
prostate cancer be available for 
asymptomatic men, on the 
understanding that they have been 
provided with full and balanced 
information about the advantages and 
limitations of the PSA test. 
Screening frequency  GPs reported frequently providing 
PSA screening within routine 
consultations. 
 GPs reported often initiating 
discussion of PSA screening; GPs 
reported commonly receiving 
requests for PSA screening. 
 GPs reported that PSA screening was 
rare in practice. 
 UK GPs reported not promoting PSA 
screening; they also reported that men 
rarely asked for PSA screening. 
Guidance for GPs  GPs are free to practice according 
to individual standards. 
 Australian guidance was mixed 
(see Table 1). The NHMRC has 
recently issued guidance to 
Australian GPs to drive greater 
consistency in practice. 
 Government-issued standards for PSA 
screening and communication 
processes in clinical settings are in 
place.  
 Guidance has been distributed to all GPs 
in England and Wales to assist in the 
provision of information to men. 
 GPs can choose to follow issued 
guidance but seem inclined to operate 
within the bounds of their health 
system. 
Preferred form of 
information 
provision 
 GPs reported generally informing 
men via a verbal discussion of PSA 
screening. 
 GPs reported relying on a standardized 
printed information leaflet. This was 
central to the consultation, sometimes 
alongside a brief verbal discussion. 
Appointment 
structure 
 PSA screening tests were usually 
discussed and ordered in a single 
appointment. 
 Information-giving occurred in a 
separate appointment to PSA screening 
itself. 
 
In the light of our prior findings on variation between the Australian and UK contexts, we set out to 
better understand GP communication practices in particular. The larger program of study examined 
the role of values, ethics, context, and evidence in cancer screening policy and practice. In this paper 
we present an analysis of how GPs in Australia and the United Kingdom explain their approach to 
communication with men about prostate cancer screening. We asked the following research questions, 
in respect of both settings: 
1. How do GPs describe their communication with men about prostate cancer screening? 
2. What are the reasons given by GPs for communicating with men as they do? 
3. Why and under what conditions do GPs communication approaches vary?  
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Methods 
Ethics approval 
Study procedures were approved by the Cancer Institute New South Wales and the University of 
Sydney Human Research Ethics Committee [#15245]. GPs had an opportunity to discuss the study 
with KP prior to participation; all GPs provided informed written consent to participate and were 
compensated for their time. Participation was voluntary, participants could withdraw at any time, and 
confidentiality was protected. All responses were anonymised before analysis and potentially 
identifying information removed.   
Design 
We applied the well-established, systematic qualitative research methodology of grounded theory 
(22). Grounded theory is a method of conducting qualitative research that focuses on creating 
conceptual frameworks or theories through building inductive analysis from the data. All study 
authors have been formally trained in qualitative research methods; SC has particular expertise in 
grounded theory methodology. 
Participants and Setting 
We identified clinicians working in primary care practices as being in the best position to provide 
insight on our research questions, and most likely to face the question of PSA screening as part of their 
everyday practice. We purposively recruited a sample of GPs first in the Australian health care setting, 
and later in the United Kingdom (England, Scotland, and Wales), as our study evolved. Sampling for the 
broader study was initially driven by existing quantitative evidence on characteristics of GPs, patients, 
and practice contexts associated with higher or lower PSA screening rates. We aimed to recruit a set of 
GPs likely to have diverse practices. See Pickles et al. (14) for a detailed description of the recruitment 
process.  
In Australia we advertised in newsletters and email lists of GP organisations, in mass and social media, 
medical journals, we phoned practice managers and via email and flyers distributed by rural GP 
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organisations. In the UK, academic colleagues distributed an invitation through their professional 
networks, we advertised to members of the Royal College of General Practitioners (RCGP), primary 
health care departments, university academic departments, and general practice and research via mail 
lists, and in organisational newsletters including the Society for Academic Primary Care (SAPC) and 
RCGP Scotland’s eBulletin. GPs were invited to contact KP if they were interested and willing to 
participate. An information sheet outlining the research project was emailed to all respondents. All 
GPs who expressed interest in participating were included. 
Overall, 69 GPs participated in this study, 40 GPs in Australia and 29 GPs in the UK. 44/69 of the GPs 
were male. The GPs ranged in clinical experience, working from 1-40 years in general practice, and 
were located in both metropolitan (n=32/69) and regional/rural (n=37/69) clinics, with varied 
patient populations. 
Data collection 
The field work for the prostate cancer element of this study was conducted by KP, a public health 
researcher, as part of a PhD degree. KP had no immediate personal or professional experience with 
prostate cancer or PSA screening. 
We generated data via in-depth semi-structured interviews. An interview guide was prepared to 
provide general direction and an overview of potential question routes. The interview guide covered a 
broad range of topics, including GPs’ recent clinical encounters involving PSA screening decisions, 
communicating information about the PSA test to patients; screening pathways; and overdiagnosis of 
prostate cancer. Example questions asked about communication included: 
 Describe a recent consultation with an asymptomatic man involving the PSA test…Can you take 
me right back to the beginning and tell me as much as you can about the consultation. Who 
initiated the conversation about the PSA test? 
 Should men be informed about overdiagnosis, false positives before having a PSA test? 
 How well do you think men understand PSA screening? 
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The schedule was reviewed and modified between interviews based on the developing analysis to 
enrich the data available to answer our research questions. All GPs were asked to think back to their 
most recent consultation involving a discussion about PSA screening or to describe a typical 
consultation where the topic was raised. 
Interviews took place between March 2013 and June 2014 (Australian GPs) and between September 
and December 2014 (UK GPs).  We continued to interview GPs until we judged we had reached 
theoretical saturation; that is, the point at which gathering more data ceases to yield any further 
insights about the emerging grounded theory. All interviews were conducted by KP, primarily by 
telephone or Skype, and ranged in duration from 18 to 70 minutes. With GP permission, the interviews 
were audio-recorded and transcribed verbatim by a professional transcribing service to produce data 
for analysis. Transcripts were not returned to participants for comment; all participants will receive a 
written summary of the research findings on study completion. 
Data coding and analysis 
The analysis was led by KP, who coded the transcripts. A subset of transcripts was read and coded by 
three authors independently to ensure interpretive rigor. We coded to capture the range of variation 
in the GP-reported discussions about PSA screening and for conditions that could explain that 
variation. Codes were kept as similar to the data as possible to preserve context and to ensure that all 
concepts derived directly from the data. Codes were compared and discussed to inform the 
development of the central concepts in the study. KP wrote detailed memos during data collection and 
analysis which were reviewed and discussed by the authors in analysis meetings.  
Results 
We observed considerable diversity in the ways that GPs’ described their communication about 
prostate cancer screening. Although the majority of variation occurred among Australian GPs, we also 
report on data from the UK because this helps illuminate the contrasting complexity of the Australian 
data, including the role of local context. 
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We first explain how Australian GPs varied in their descriptions of their communication. In the second 
section, we consider important ways in which UK and Australian GPs were similar and different. 
Australian GPs’ accounts of communicating with men about prostate cancer screening 
Australian GPs’ accounts varied greatly in how they introduced conversations about PSA screening 
with men, how screening discussions were framed, and their perceived informational obligations.  
Screening men with little or no prior communication 
A minority of interviewees reported ordering PSA tests for asymptomatic men with little or no prior 
communication with the patient. GPs were categorised as non-communicative if they reported (1) 
ordering PSA tests without explaining that to their patient, (2) ordering PSA tests at patient request 
with no further discussion, or (3) explaining PSA screening only after a positive PSA test result. We 
encountered occasional practices from which asymptomatic men were mailed pathology forms for a 
PSA test via practice recall systems, bypassing a GP consultation and opportunity for discussion.  
Several possible justifications were provided by non-communicative GPs: 
 Some GPs reasoned that because the information about PSA screening was ‘confusing’ 
‘complicated’ and potentially contradictory, it should not be provided.  
 Some GPs said their role was to ensure that men could be screened if they wanted, ‘I see 
doctors purely as enablers, of what people want…If you don't want to read about it [the test], then 
fine; I’ll just order one for you’ (AGP17).  
 Some GPs considered it ‘up to each patient to be informed appropriately’ (AGP14); if a man 
requested a PSA they would order a test assuming that man felt sufficiently informed from 
other sources.  
 Some GPs considered it unnecessary to provide information unless the man received a cancer 
diagnosis, ‘I don’t think they need all that information at the level of PSA testing. I think, that 
once you’ve got your cancer diagnosis, you can talk about what you want to do with that then’ 
(AGP26).  
 Some GPs did not appear to have a complete understanding of the epidemiological data, for 
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example, ‘someone was saying that a certain number of people had to have radiation and surgery 
and have impotence and incontinence, for one person’s life to be saved. I mean – I don’t know how 
you get those figures’ (AGP2).  
These were, however, minority views. We focus in what follows on the majority of GPs who did 
communicate with men in some way about PSA screening.  
Communicating with men, with variation on three key dimensions 
We identified three dimensions central to GP discussions with men about PSA screening: 
1. The GP’s primary communication goal. Some GPs had the goal of convincing the patient to 
screen, some had the goal of convincing the patient not to screen, and some had the goal of 
supporting decisions or facilitating patient choice; 
2. The type of information the GP provided; and  
3. The type of patient understanding the GP sought to achieve. 
It appeared that Dimension 1 was dominant; GPs communicated in accordance with their preferred 
goal or outcome of the communication. In most cases, the GP’s positioning on dimensions 2 and 3 was 
grounded in whether the GP felt strongly that patients should be screened or not, and the degree to 
which they directed men towards that preference. Below we explain these three dimensions, and GPs’ 
reasoning about them. 
Dimension 1. GP’s primary communication goal  
Some GPs aimed to convince men either to agree to be screened, or to agree not to be screened. These GPs 
had strong beliefs regarding whether or not PSA screening should occur routinely, and wanted patients to 
follow their advice, their ‘guide…down the path’ towards what they ‘thought was best’ (AGP29). GPs 
acknowledged ‘bias will creep into that’ (AGP29); ‘you can’t help yourself but…what you believe in is the 
way you push the consultation’ (AGP18). However this approach was justified by beliefs that, ‘…you can 
only do what you think is best for the patient’ (AGP29) and ‘a lot of people do want to be told what to 
do…doctors are their reference point’ (AGP31). GPs recognised that men sometimes chose not to take the 
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advised pathway, for example, ‘there are times when it wouldn’t matter what you said to a patient they’re 
still determined to have the test’ (AGP18). 
An alternative communication goal was to support men to make decisions about screening consistent with 
their own values and preferences. GPs with this goal aimed to facilitate an informed decision making 
process and were determined to provide information to all men ‘to make up their own mind’ (AGP16), 
because ‘with the PSA test, I can’t so easily say to myself, well, it’s in your best interests so I don’t need to inform 
you properly’ (UKGP9). GPs with this goal reasoned that a man ‘should be empowered to know everything’ 
(UKGP28); ‘should have the right and want to be able to make that decision for themselves about whether 
they have the test or not’ (AGP5). 
Dimension 2. GPs’ reported information provision   
Because GPs had different goals in communicating, they provided different information, in both quality 
and quantity. 
Some GPs claimed to provide men with ‘complete’ and ‘unbiased’ information, because they 
considered it their ‘ethical obligation’ as a health professional to do so; the patient, in this view, had a 
‘right’ to be fully informed, so GPs should ‘[put] all the information on the table’ (AGP31); ‘I’m very keen 
that people are well-informed about really what it means if they are to undertake a PSA rather than just 
simply agreeing to what their idea might be’ (UKGP23). This sometimes extended to teaching patients 
how to locate and interpret information for themselves. Informing patients was described by some 
GPs as serving a self-protective legal purpose, ‘I’ve informed the patient, the patient made his own 
decision, so he’s got to then accept the consequences’ (AGP19). 
In contrast to GPs who sought to provide comprehensive information, other GPs filtered information 
to ‘actually tell them [patients] what counts the most’ (AGP4). Here GPs aimed to explain their own best 
judgment about the evidence, framing the evidence according to the GP’s opinion regarding the value 
of PSA screening. This often took the shape of a personal recommendation either to have a PSA test or 
not. One GP, for example, said ‘[patients] don’t have that knowledge so you sort of, give an explanation 
why it needs to be done’ (AGP35); another, in contrast, thought ‘my discussing it has probably been 
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biased towards not getting it done’ (AGP16). Some GPs considered such advising to be best practice, 
because information provision alone was not enough to help men decide what to do. For example, one 
GP who favoured PSA screening reasoned, ‘If they really don’t know what to do then [after receiving 
information], any doctor would be a fool not to say look, get it investigated because, the most stupid thing 
anyone could do is say oh don’t bother about it…that’s just a total recipe for disaster’ (AGP31).  
Dimension 3. GPs’ reported ambitions for men’s understanding  
All GPs aimed to support the development of patient understanding. However there were two different 
conceptions of what constituted appropriate understanding of the information presented and 
available options:   
1) Sometimes GPs aimed to assist men to develop detailed population-level understanding of the 
evidence. They wanted men to understand all aspects of the information provided and described 
checking understanding, identifying gaps in patient knowledge, and clarifying misunderstandings, 
because ‘I don’t think their pre-existing understanding of the test is very good at all in most cases’ 
(UKGP21). Some of these GPs reported feeling personally and professionally responsible for 
presenting the ‘right amount’ and ‘right level’ of information for individual patients, ‘[achieving 
understanding is] really the doctor’s job, and our skill in trying to explain all that complicated evidence, 
as best as we can’ (AGP19). Some GPs commented they hoped men understood the detail of the 
evidence, otherwise it indicated they as a GP had done a ‘bad job of explaining it’ (AGP6), however they 
also explained ‘it’s a very difficult thing to formally confirm that they understand the implications of 
having the test done without kind of interrogating them’ (UKGP1). 
2) Alternatively, GPs might aim for men to develop overall ‘gist’ understanding. GPs committed to ‘gist’ 
understanding were satisfied if their patient had a less complete grasp on the intricacies of the 
evidence base, as long as they had an overall understanding of what the GP perceived to be core issues; 
‘I feel like as long as they can understand that basic concept [in this instance, that PSA is not a perfect 
test] …then I feel like it’s okay to still do the testing, even if they don’t understand all the detail…I feel like 
that’s a reasonable level of understanding, I don’t feel like people need to have an absolutely thorough 
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kind of understanding’ (AGP5). Those GPs who thought ‘gist’ understanding was acceptable thought it 
was reasonable for men to trust their doctor to advise them appropriately. 
Relationship between the dimensions  
When taking account of the three dimensions along which GPs varied, we identified four overarching 
approaches to communication: (1 & 2) Be Screened and Do not be screened (GPs who guided men towards 
screening or not screening); (3) Analyse and choose (GPs who aimed to ensure men made their own 
independent, informed decision, based on a detailed epidemiological understanding); (4) As you wish 
(GPs who simply facilitated the man’s stated preference to be screened or not screened). Two of these 
terms (Be Screened and Analyse and choose) align with Entwistle et al.’s characterization of 
communication approaches (15), as outlined in the introduction. Each GP we interviewed had a general 
preference to employ one of these four approaches in their everyday communication about PSA 
screening. In Table 3 we present an integrated illustration of the characteristics of each approach, 
ordered according to the 3 key dimensions evident in the GP accounts.  
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Table 3. Four GP approaches to communication about PSA screening in clinical interactions 
BE SCREENED interactions 
GP’s primary goal: 
 GP strongly believed that the man should be 
screened 
 GP goal is to convince the man to screen 
Information provided by GP: 
 GP’s personal judgment about the value of PSA 
screening 
 GP either tailored information provided to men to 
encourage men to be screened, or did not provide 
information (provided only encouragement to be 
tested) 
Type of understanding that GP considered 
adequate: 
 Gist understanding of information provided 
DO NOT BE SCREENED interactions 
GP’s primary goal: 
 GP strongly believed that the man should not be 
screened 
 GP goal is to convince the man not to screen  
Information provided by GP: 
 GP’s personal judgment about the harms 
/downsides of PSA screening 
 GP either tailored information provided to men to 
discourage screening, or did not provide 
information (provided only encouragement to 
avoid testing) 
Type of understanding that GP considered 
adequate: 
 Gist understanding of information provided  
ANALYSE & CHOOSE interactions 
GP’s primary goal: 
 GP may personally support testing or not testing 
 Despite their personal beliefs about testing, GP’s 
goal is to help the man to make his own informed 
decision 
Information provided by GP: 
 GP aimed to provide a comprehensive and 
impartial summary of best available evidence 
Type of understanding that GP considered 
adequate: 
 GP goal was to ensure men developed detailed 
understanding of their options, to make own 
informed decision 
AS YOU WISH interactions 
GP’s primary goal: 
 GP may or may not have a strong position on the 
value of PSA screening 
 GPs’ goal is simply to follow the man’s expressed 
preference  
Information provided by GP: 
 GP provided little information  
  
Type of understanding that GP considered 
adequate: 
 Ensuring men understood was not a priority for the 
GP. In some cases, GP perceived men to have 
already made a screening choice based on personal 
preference or gist understanding 
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Be Screened or Do not be screened interactions. If GPs had a strong preference that men should either 
be screened or avoid screening, they communicated in a directive way, oriented to encouraging the 
man either to screen or avoid screening respectively. This included offering personal judgment about 
the value – or harms – of PSA screening or framing the information they provided towards or away 
from screening. Some GPs gave a recommendation without offering men any further information. In Be 
screened and Do not be screened interactions, GPs considered it sufficient that men developed gist 
understanding of the information provided, because they thought it was reasonable for men to trust 
their doctor to advise them appropriately. These GPs strongly believed either that men should be 
screened routinely, or that they should not be screened at all, and they wanted patients to follow their 
advice. 
Analyse and choose interactions. If GPs aimed to support men to make their own decisions, consistent 
with the man’s personal preferences (i.e. a patient-directed decision), then they were not directive in 
their communication. In these interactions, GPs aimed to provide a comprehensive and impartial 
summary of the best available evidence; their goal was to ensure that men developed a detailed 
epidemiological understanding of their options in order to make an informed decision. They saw this 
as a neutral, educative role. For some, this approach was protective against potential medico-legal 
threats. GPs using this approach may personally favour either screening or not screening, but their 
primary commitment was to support the man’s decision, regardless of their own professional beliefs 
about screening.  
As you wish interactions.  Sometimes GPs acted on patient wishes to be screened or not screened 
without questioning. In these interactions GPs did not attempt to direct men in any particular 
direction, and often provided little information, ensuring that the man understood PSA screening was 
not a priority. In some cases, GPs perceived men to have already made a screening choice based on 
personal preference or gist understanding. These consultations typically involved men with an 
already-established screening preference, mostly for screening; the GP simply acted in line with the 
man’s instructions.  
 175 
 
How GPs negotiate communicating within specific contexts 
Many Australian GPs reported discussing PSA screening with men often, so had a prepared basic 
‘spiel’; as one reported, ‘the PSA is such a common question that you get asked and you just have to have 
some idea in your head what you’re going to say when they come in’ (AGP18). This spiel could be 
tailored to specific contexts as necessary. The interviews indicated that the GPs tended to have a 
preferred approach for most PSA interactions (to guide patient toward screening or not screening, to 
support men to make their own decision, or to act in accordance with the man’s expressed 
preference), or that they had maintained a particular communication style over time. However we 
identified eleven situational and relational factors (see Table 4) that GPs described as temporarily 
shifting their usual or preferred communication goals and processes. These factors predominantly 
arose from specific circumstances of individual consultations. GPs described modifying their provision 
of information and/or advice, depending on the eleven factors described in Table 4.
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Table 4. The effect of situational and relational factors on GPs’ approaches to communication in PSA screening interactions, as described by GPs 
Situations that encouraged particular approaches to 
communication about PSA screening, as described by GPs 
Examples of how GPs reported modifying their communication 
SITUATIONAL FACTORS…pertaining to patient and/or GP 
Patient was from an older or younger age group (particularly 
under 50 years or over 75 years), or had comorbidities  
 
 Some GPs paid closer attention to which direction they ‘coaxed’ patients in these age groups; for example, some would particularly 
emphasise false positives and the potentially harmful diagnostic pathway to younger men under 50 years (i.e. GP more likely to use 
Do not be screened approach). 
 Some GPs who usually communicated in Be Screened mode provided comparatively less detailed information for older patients, 
particularly those with declining memory or those they perceived as being cognitively unable to ‘handle the information’, and 
‘pick[ing] the details of the intricacies…and a lot briefer [conversation]’ (AGP17)  
 Some GPs described defaulting to providing stronger recommendations with elderly men. 
Patient had a family history of prostate cancer  Conversations with men with family history of prostate cancer were described as being slightly different; some GPs said their 
interactions with these men would be more ‘considered’ and ‘gentle’ despite the majority of the men knowing their decision before 
coming to the doctor. 
 Some GPs who generally communicated in a way to achieve screening (Be screened) or not screening (Do not be screened) changed 
their approach more towards Analyse and choose and As you wish in situations where a family history was implicated – for both 
those determined to be tested and those not wishing to be tested. 
Patient requested to receive a PSA test or was perceived to be 
determined to have a test 
 These patients were perceived to have positive preconceptions about PSA screening which pre-empt any GP discussion. 
 Some GPs who would usually communicate with a particular goal in mind (Be screened or Do not be screened) said any 
conversation counter to the man’s beliefs was not a productive conversation because their intentions could not be changed; ‘they 
see it as their right to have it [a PSA test]’ (AGP15); ‘he was so definite he wanted it’ (AGP6). GPs tended to take the As you wish 
approach in these situations, even if this was not their preference. 
 ‘I think that what changes in that situation is their determination to have the testing done, most of these men have made a decision 
before I’ve said anything, that they’re going to be tested, no matter what I say’ (AGP8). 
Patient was interested in finding out more about screening  Some GPs reasoned that a man’s interest in PSA screening would drive the discussion, ‘it tends to be very patient specific and 
tailored advice…and depends on what I think that they expect and hope to hear and are likely to do’ (AGP16). 
 GPs who usually took an As you wish approach, so did not communicate, would in some situations be required to shift to one of the 
other three approaches (Be screened, Do not be screened, Analyse and choose) because the man requested information. 
 Some GPs said the discussion would become ‘more complicated’ the more interested the patient was. 
SITUATIONAL FACTORS…pertaining to service characteristics 
Rural location with limited access to urology services 
 
 Some GPs were influenced by their access to a Urologist. Although they might prefer to recommend that men Be Screened or Do not 
be screened, they described instead shifting their approach towards Analyse and choose when based in a rural location; I ‘just might 
try to explain the test, do a bit more pre-test counselling with the patient when I was in the country, just because I knew that I’d then 
be managing the result rather than just sending them onto a Urologist, like it’s easy to do in Sydney’ (AGP5). GPs described how in 
rural locations it is common for GPs to have to manage abnormal PSAs for a longer period before they can access urologists for a 
second opinion. Some GPs were uncomfortable with this situation and consequently aimed to involve men more in the decision 
from the beginning. 
 Some GPs would talk to patients after PSA screening if it was abnormal but not before; i.e. they would take either a Be Screened or 
As you wish approach before testing, and provide counselling if needed after testing. These GPs perceived some men as resistant to 
seeing a GP at all, so thought it important to be seen to do a test because it was ‘something’ proactive for them while they were 
there, rather than simply talking. 
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Time available for the consultation (GP short of time) 
 
 
 Some GPs who preferred an Analyse and choose approach engaged in less detailed discussion with patients about PSA screening 
when they were short of time. They described selecting out the information to include in discussions with men when they were 
time poor, more in line with the Be Screened or Do not be screened approaches. 
 Some GPs said it is often simply impractical to provide full information and support patients to develop detailed population-level 
understanding at each appointment so on occasions they ‘just haven’t had time to give a full spiel so I order it and I will have the 
discussion later with them, if it’s positive’ (AGP13). 
RELATIONAL FACTORS…pertaining to patient and/or GP 
GP made a judgement that the patient ‘starting point’ in terms 
of grasping the information was low and it would be difficult 
for them to understand PSA screening 
 
 Some GPs who usually favoured Analyse and choose, reverted to a Be Screened or Do not be screened approach when 
communicating was difficult, ‘If I had a patient who is extremely unintelligent and I tried to explain it and I didn’t seem to be getting 
through to him, and I felt it was in his best interests, I might go ahead and do the test [or not do the test] anyway’ (AGP29)  
 Some GPs tailored the content accordingly; ‘it really depends on the population you’re dealing with … what you perceive they are 
capable of understanding’ (AGP31); ‘You’ve got to target it at the level of the patient basically’ (AGP4). 
 ‘If a man thinks PSA is just a blood test, then I mentally go oh dear, we need to go through this in more detail’ (AGP4). 
Patient was perceived to be anxious, and so not receptive to 
information  
 
 Sometimes GPs provided minimal information to manage anticipated patient anxiety; ‘if you put too much information out 
there…most of it doesn’t go in…there’s too much information…‘it’s not possible for people to take that stuff in, they don’t even want to’ 
(AGP7). 
 In such cases, GPs who would usually communicate in Analyse and let choose mode, acted in what they saw as their patient’s ‘best 
interests’ (toward Be screened or Do not be screened), which could involve no communication, or being selective with the 
information they shared. 
GP made a judgement that the patient was ‘very switched on’ 
and had ‘done their homework’ 
 GPs were often more inclined to take the option of As you wish in situations involving well-informed men, regardless of the GP’s 
usual practice.  
 Alternatively, GPs might take an Analyse and choose approach and tailor content accordingly; ‘it really depends on the population 
you’re dealing with … what you perceive they are capable of understanding’ (AGP31); ‘You’ve got to target it at the level of the patient 
basically’ (AGP4). 
GP aware of patient history of screening  
(GP has screened patient in the past or has discussed 
screening with patient previously, GP knows patient’s 
screening preferences, or GP knows patient has been 
screened previously) 
 Some GPs who would prefer the Analyse and choose approach said they ‘may not give a full spiel’ (AGP13) to men who have been 
screened before and ‘often do it [discuss] a little more quickly, because it is clear that they remember it from the year before. And if 
they are men who made the decision last year to have the test done, then they are often going to make the same decision this year…so 
it’s a quicker conversation, but it’s not a non-conversation. And it depends on the patient and how well I know them’ (AGP30). In these 
situations, GPs tended to shift to an interaction more like one of the other three approaches. 
 Some GPs were more likely to initiate screening with men who had had PSA screening with them in the past or had had many PSA 
tests, because ‘generally a lot of my patients by now have had the spiel so many times that they often will, come in and say “It’s time 
for my yearly prostate test’ (AGP29).  
RELATIONAL FACTORS…pertaining to service characteristics 
Patient was the usual patient of another GP, and patient asked 
for a PSA test 
 
 
 
 Sometimes GPs who preferred an Analyse and choose approach were consulted by patients who were routinely tested by another 
GP. In this situation, the GP would assume that the man had heard the talk before. They responded to this situation in several ways: 
o Some GPs shifted to either the Be screened or As you wish approach and ordered PSA tests without discussing it with the 
man, reasoning that the discussion could be revisited if the PSA was abnormal. 
o Some GPs maintained Analyse and let choose mode and actively engaged patients in a discussion, because they did not 
know what men had heard from previous GPs. This was sometimes with a view to changing the patient’s mind: e.g. ‘I am 
trying to create permission and faith for me to open the discussion up again, rather than just keep redoing the test’ (AGP30). 
 Some GPs found this position incredibly challenging if they preferred not to test (i.e. Do not be screened); ‘because you have to undo 
the patient’s expectations…you’ve got to decide whether you just go with the flow…or you sit down and ascertain what their appetite 
for negotiating is. Some of them are just locked into it and it’s too late’ (AGP23). 
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GPs also shifted between the four communication approaches more readily when they were presented 
with complex cases; producing more fluid, responsive, and sometimes ‘quite inconsistent’ (AGP16) 
conversations. Many GPs did have a primary goal when communicating (to encourage or discourage 
screening, or to support the man to make his own decisions) but these could change in different 
situations. Also, some men did not take the advised pathway – either toward screening or not 
screening, or some men preferred the GP to direct the decision, not wanting to engage with 
information or to make their own decision.  
Comparison of communication approaches in Australia and the UK 
UK GPs generally did not communicate about PSA screening unless men asked about it, so they often 
neither communicated about it as a screening test, nor ordered it. When men asked for a PSA test, 
information provision was central to consultations in the UK context, and most UK GPs commonly 
practiced according to the Analyse and choose or Do not be screened approaches. Few UK GPs described 
adjusting their conversations about PSA screening with patients.  
The reported consistency of PSA communication practices in the UK contrasted strongly with the 
significant variation reported in the Australian context (Tables 3 and 4). The contextual factors 
considered in Table 4 were uncommon in UK GPs’ accounts, due to fewer men requesting and fewer 
GPs suggesting prostate screening. UK GPs mostly reported giving the same standard information 
leaflet to all men who expressed interest in PSA screening, regardless of their personal circumstances. 
Many GPs practicing in Australia tended to filter information, and commonly practiced according to 
the Be Screened approach, but no UK GPs reported using this approach. 
We identified different versions of the Do not be screened approach adopted by Australian and UK GPs. 
For the Australian GPs, this approach took the form of a personal recommendation against screening, 
directed by the GP and according to their personal – negative – perspective of PSA screening. For UK 
GPs, the Do not be screened approach also involved the GP recommending that the man should not be 
screened. However UK GPs explained this as enactment of a collective standard of care recommended 
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and issued by the UK National Health Service irrespective of their own personal preferences for or 
against screening. 
Discussion 
This analysis suggests that GPs’ primary communication goals are a central component of 
consultations about prostate screening. Four distinct communication approaches – Be Screened, Do not 
be screened, Analyse and choose, and As you wish – were identifiable from the GP accounts of their 
preferred practice.  
The terms Be Screened and Analyse and Choose align with Entwistle et al.’s Consider an Offer 
framework. We identified two additional ways of communicating unique to our empirical data, which 
we labeled Do Not Be Screened, and As you wish. The need for inclusion of a Do not be Screened element 
is likely a product of the Australian context where the PSA test is available and widely promoted for 
screening purposes in the media, despite the majority of relevant public health and health professional 
groups recommending against routine screening of asymptomatic men. This meant Australian GPs 
were regularly consulted by men expecting to be screened, and some reported feeling obligated to 
actively direct men away from wanting a PSA test for that purpose. 
The As you wish category is also likely to be, in part, a reflection of the somewhat market-driven 
Australian health care system. As you wish interactions occurred when GPs’ believed men had already 
made up their minds about their preferred choice, and could not be swayed by information presented 
by the GP. This led GPs to implement the man’s choice and order the test, despite the lack of an 
evidence base to support that decision. There was no evidence of As you wish interactions in the UK 
data. As we previously reported (14), in the UK there is strong guidance to GPs to practice in a 
particular way. GPs are expected to steward limited NHS resources, and the PSA test is not publicly 
promoted to the same extent, limiting consumer expectations for screening. All of these are 
conceivable explanations for why As you wish interactions were less commonly reported in UK 
interviews. 
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The main issues raised by this analysis 
The four variants raise important questions about patient-centered care, consumer demand, and the 
role of the health professional. It is well established in the literature that both patients and clinicians 
are rarely entirely rational, and may not necessarily know what is in the patient’s best interest, 
particularly when faced with scientific uncertainty e.g. (23, 24). Humans tend, for example, to become 
sensitised to worst-case scenarios and disregard objective risk probabilities; this makes us vulnerable 
to pursuing, recommending, or accepting potentially harmful treatments (25). If this is so, an As you 
wish approach could mean patients are more exposed to increased harms, and that leaving patients to 
make decisions about their health care needs without professional guidance is potentially maleficent, 
or at least negligent. This problem is further complicated by the wide availability of possibly 
misleading information, provided by sources that have an interest in inflating perceptions of cancer 
risk. Some authors highlight that increased patient involvement in decision-making has potential for 
negative social consequences such as increasing patient demand for unproven services (26). Cribb and 
Entwistle reasonably argue that in some circumstances it may be ethically legitimate for health 
professionals to question and even influence the preferences of patients for these reasons (27).  
Most current recommendations encourage GPs to discuss the benefits and harms of prostate cancer 
screening with patients. However, there may be considerable variation in what patients want and 
expect from GPs prior to making a decision about PSA screening. Degeling et al. ran three community 
juries on the topic of how GPs should communicate about PSA screening. Juries heard extensive expert 
evidence about PSA screening, consent and general practice. Two juries of general citizens (i.e. mixed 
gender and age) concluded that GPs should ensure men have enough knowledge to make their own 
decision. One jury of only men of PSA screening age concluded that men should be able to trust their 
GP (or a specialist) to provide just enough information at just the right time, expressed concern about 
the potential for information overload, and thought the degree of patient involvement depended on 
the patient (28). This suggests that citizens who are (atypically) well informed about the benefits and 
harms of prostate cancer screening may take different views and have different expectations on how 
GPs should communicate about PSA screening. If this is the case, it may be appropriate for GPs to have 
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at least a range of communication strategies available, to suit the needs of different patients. Men 
eligible for, or already receiving, PSA screening, may well prefer for GPs to direct the decision (Be 
screened or Do not be screened approaches) to avoid uncertainty. However men’s preferences are 
arguably an insufficient guide; other considerations, including clinical practice guidelines, medical law 
and clinical ethics requirements, are relevant to determining what GPs should do.  
A large component of this analysis is about awareness of and sensitivity to context and the importance 
of interpersonal relations and their influence on communication practice (see Table 4). Some of the 
GPs’ communication decisions, based on situational or individual factors, were easily justified, because 
the situation presented was either clinically relevant (e.g. family history, older age), or professionally 
justified (e.g. low literate patient, patient request). While most guidelines advising on PSA screening 
suggest informed or shared decision making, they do not consider what may be a ‘best’ approach to 
situations involving the many local factors that GPs face in day to day practice, including relational 
factors, implicated in screening decisions (and the complexities of general practice). We identified a 
subtle web of relational issues that influenced GPs to move between communication options and 
particular types of decision pathways. These included managing colleague associations (what are GPs 
to do about patients who have come from a pro-screening GP to a GP who does not support PSA 
screening?), managing business, including patient lists (patient request, time pressures), and 
maintaining patient trust. These issues made the decision making process particularly complicated, 
and in addition to vague guidance on such matters, perhaps account for why many GPs appeared to 
have multiple, dynamic approaches. Accounting for relational variables as identified in this study can 
facilitate nuanced assessment of the different types of support clinicians might offer people who may 
struggle with particular decisions (29), and allows scope for professional expertise: the ‘art’ of 
medicine.  
 
Implications for policy and practice 
There are variable approaches to communication about PSA screening, some of which may be 
considered better than others. Guidance about communication - not just about the PSA test itself, but 
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also about how best to facilitate the decision – may be useful; we suggest there is a need for further 
higher level professional discussions about what the primary goals of GPs should be when 
communicating about PSA screening. Coming to an explicit agreement on what that purpose should be 
may assist in improving communication and providing clearer guidance for GPs working in the 
Australian context. For instance, one endpoint (that could be evaluated) may be that men can 
demonstrate they have a sense of their values in relation to the available options, to show evidence of 
rational, thoughtful, and informed decision making.  
Limitations 
As this is a qualitative study, we cannot infer the prevalence of the reported approaches to 
communication; the results of this study could be extended into quantitative survey research with 
whole populations of GPs to test prevalence. It is also possible that those GPs who did not participate 
were in some way different to those who did (that is, that these data are subject to selection bias), 
however the diversity in our respondents suggests that it is very unlikely that our sample was biased 
towards a particular view of PSA screening or corresponding communication style. 
Conclusion 
This empirical study produced evidence documenting varied approaches to communication. In the 
Australian setting, some flexibility in communication seems justified. Further, because of (a) the large 
number of men implicated, (b) the known harms of the screening process, and (c) that PSA is not a 
routine screening program, we argue that PSA screening is a particularly pressing case to necessitate 
dedicated effort to facilitate conversations that include but go beyond potential harms and benefits 
with men. This would include encouraging and enabling men who ask for screening to look carefully at 
why PSA screening is not recommended (to increase awareness of why a Do not be screened approach 
is justified). Assisting GPs to facilitate these conversations with patients should offer the advantage of 
supporting men’s autonomy and reducing harm.  
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CHAPTER SEVEN.  
Discussion & Conclusions 
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7. Overview of this chapter 
In this final Chapter I synthesise my analysis of how prostate cancer screening works in clinical 
practice in Australia and the United Kingdom, from the GPs’ perspective. I present a practical model 
illustrating the core components of the screening process including its outcomes, derived from 
clinicians’ accounts. Informed by this model, I draw some conclusions and make recommendations in 
the final section of this chapter. 
Prostate cancer screening is a complex clinical decision regularly encountered by a large number of 
men and GPs in Australia. It is controversial due to the finely balanced benefits and harms, including 
harms incurred by overdiagnosis and overtreatment, and attracts substantial media coverage and 
attention. Recommendations on PSA screening are highly contested and politically charged 
(particularly in Australia), the right course of action remains unresolved, and conflicted interests are 
increasingly recognised.  
These factors collectively raise important ethical questions and have direct implications in clinical 
care. Yet, as highlighted in the literature review presented in Chapter 1, little was known about GPs’ 
views and experiences in relation to PSA screening of asymptomatic men. I wanted to know how GPs 
are thinking about PSA screening. Are they concerned? What are they prioritising? 
In chapters 3-6 of this thesis I documented extensive variation in GPs’ accounts of prostate cancer 
screening. This is the first study to systematically map GPs’ reasoning and understanding of prostate 
cancer screening using the PSA test. These findings offer guidance for future policy and practice, 
grounded in the experiences of clinicians at the frontline of PSA screening. 
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To summarise my main findings: 
 Australian GPs use one of four heuristics to decide what to do about PSA screening, based on 
different reasoning about over- and under- diagnosis (Chapter 3). There were GPs who (1) 
prioritised avoiding underdiagnosis; (2) weighed underdiagnosis and overdiagnosis case by case; 
(3) prioritised avoiding overdiagnosis; and (4) did not engage with overdiagnosis at all; 
 GPs experience significant and diverse uncertainty about PSA screening and manage and respond 
to different types of uncertainties encountered with three different strategies (Chapter 4): they 
take charge of uncertainty; engage others in managing uncertainty; and/or transfer responsibility 
to other parties; 
 From the GPs’ perspective, the difference in screening practices in Australia and the UK is mostly 
explained by the history of prostate screening policy; organisational structures; and funding 
models (Chapter 5); and, lastly, 
 GPs communicate with men about PSA screening using one of four approaches, which depend on 
the GPs’ primary goals for the interaction in combination with specific practice situations (Chapter 
6): these approaches can be summarized as (1) Be screened; (2) Do not be screened; (3) Analyse 
and choose; and (4) As you wish. 
In Table 12 I provide a summary of key concepts I used in the earlier chapters of this thesis. I refer to 
these throughout this discussion.
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Table 12: Key concepts used in this thesis and the meaning of the concept in context 
What is the concept How was the concept used 
Chapter in which the 
concept was/will be 
described 
Asymptomatic Those men attending clinical practice with no prior indications associated with prostatic disease #5: Comparison 
Symptomatic Men who have symptoms that could be related to locally advanced or metastatic prostate cancer #5: Comparison 
Values 
The relatively sedimented evaluative attitudes of GPs: what they evaluated as important or unimportant in a relatively stable 
way 
#7: Discussion 
Underdiagnosis 
Failing to diagnose in a situation where diagnosis would have been beneficial for the patient (e.g. through early detection of 
a cancer that would otherwise have caused death) 
#3: Overdiagnosis 
Overdiagnosis 
A diagnosis that meets the pathological criteria for prostate cancer but does not benefit the patient because the cancer 
would not have become symptomatic in the patient’s lifetime and/or would not have caused the patient’s death 
#3: Overdiagnosis 
Personal burden 
GPs’ experiences of negative cognitive and emotional consequences as a result of being responsible for what feels like an 
impossible choice: including feelings of worry, guilt, self-blame, regret, insecurity, and anxiety 
#3: Overdiagnosis 
Heuristics Intuitive cognitive shortcuts that people often use to form judgments and make decisions   #3: Overdiagnosis 
Routine practice A GP’s usual practice in regards to screening, communication, and response to patient requests #3: Overdiagnosis 
Practice outcome GPs’ experiences of the consequences of their PSA screening decisions #3: Overdiagnosis 
Probabilistic uncertainty 
Uncertainty generated from the indeterminacy of a phenomenon’s future outcome, such as the probability of benefit (or 
harm) from a test or treatment (1) 
#4: Uncertainty 
Ambiguity uncertainty 
The lack of reliability, credibility, or adequacy of information about a phenomenon of interest: includes imprecision, 
conflicting opinions/evidence, and lack of information (1)  
#4: Uncertainty 
Complexity uncertainty 
Uncertainty arising from complex aspects of a phenomenon itself, which make it difficult to comprehend, such as numerous 
potential outcomes, and/or multi-morbidity (1)  
#4: Uncertainty 
Scientific uncertainty Disease-centred. Uncertainties about diagnosis, prognosis, causal explanations, treatment recommendations (1)  #4: Uncertainty 
Practical uncertainty System-centred. Uncertainties about the structures and processes of care (competence, quality, responsibilities) (1) #4: Uncertainty 
Personal uncertainty GP/patient-centred. Uncertainties about psychosocial and existential issues (1) #4: Uncertainty 
GPs “taking charge”  
(of uncertainty) 
Describes circumstances when GPs recognised uncertainty, tolerated it, and accepted it as a lasting presence in their practice #4: Uncertainty 
GPs “engaging others” 
(managing uncertainty) 
Describes circumstances when GPs took uncertainty as a challenge and engaged others (medical profession, colleagues, 
patients) to make decisions in a context of shared uncertainty 
#4: Uncertainty 
GPs “transfer responsibility” 
(for uncertainty) 
Describes circumstances when GPs perceived uncertainty as problematic and sought out other parties to reduce their 
experience of uncertainty (e.g. urologists, health system, legal authority) 
#4: Uncertainty 
Mindline 
Collective, internalised, tacit guidelines (2), mainly grown and collectively reinforced via training, experience, and 
interaction with trusted sources, and mediated by features of primary care organisations 
#5: Comparison 
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Consider an offer 
An approach to communicating about screening that suggests health care providers should support people to assess an offer 
for screening, with a recognition that people may reasonably decline such offers (3) 
#6: Communication 
Be Screened  
communication approach 
GP guided man towards screening #6: Communication 
Do not be screened 
communication approach 
GP guided man towards not screening #6: Communication 
Analyse and choose 
communication approach 
GP aimed to ensure man made own independent, informed decision #6: Communication 
As you wish  
communication approach 
GP facilitated man’s stated preference to be tested or not tested #6: Communication 
Interpersonal trust Trust placed in an individual or personal relationships (4) #7: Discussion 
Institutional trust Trust placed in a system or institution (4) #7: Discussion 
Distal knowledge 
Knowledge created and derived from outside of the care environment (for example, research evidence, clinical guidelines) 
(5) 
#7: Discussion 
Proximal knowledge 
Knowledge created and derived from within a specific care environment, and dependent on contextual issues within that 
environment (5) 
#7: Discussion 
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Earlier in this thesis, my goal was to understand and report on the range of positions taken by the GPs 
in this study, including the influence of those positions on screening practice. In this chapter, I 
synthesise and interpret these findings. The observed range of practice variation points to the 
necessity of understanding these issues beyond face value. In parts, I take a critical position, 
particularly on those beliefs and practices reported by GPs that are strongly in contradiction to agreed 
standards or the body of evidence, and thus arguably associated with doing more harm than good.  
A model of PSA screening practices from the perspective of GPs 
Throughout this chapter I will present and discuss a conceptual model of GPs’ perspectives on their 
reasoning and use of the PSA test as a screening tool, and some of the key factors that influence their 
prostate screening practice.  The model in its entirety is presented in Figure 9. Sections 7.1 to 7.3 
inclusive systematically explain the components of the model: I provide an overview here.  
The three intersecting circles in the centre of Figure 9 represent three background conditions which 
appeared to be central to GP descriptions of their screening approach: GPs (1) develop or receive an 
interpretation of the research evidence; (2) hold relatively stable values and goals about PSA 
screening; and (3) form an intuitive typology of “PSA patients”. 
GPs described four relevant factors external to the clinic that influenced and shaped these background 
conditions, which I will refer to as Sources of knowledge: (1) personal and practice experiences, (2) 
organisational values, (3) relational factors, and (4) research evidence. GPs evaluated the four sources 
of knowledge via two filters – trust and uncertainty – which further determined to what extent they 
were integrated into the GP’s screening approach.  
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Two key elements of screening interactions – communicating and making a final decision – mediate 
the final outcome. Here, GPs either engaged or did not engage patients and/or the profession in the 
process. There were relevant consequences for both the GP and the patient. 
Sections 7.1 to 7.3 present a different component of the model; each of these sections also addresses 
one of my three central research questions. In Section 7.4 I provide reasons for why the PSA screening 
environment in Australia may be the way that it is. In Section 7.5 I suggest ways in which GPs might be 
better supported to respond to current practice demands, including challenges that might present. 
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Figure 8: An integrative model of how PSA screening works in primary care  
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7.1 Research Question 1: How do GPs approach PSA screening? 
In answering my first research question, I arrived at a model that was both similar and different to 
commonly-used models of evidence-based medicine (EBM). This model is at the core of Figure 9 and 
will be explained and referred to throughout this section.  
EBM (ostensibly) provides a central framework for the contemporary practice of clinical medicine 
(Chapter 1).  When EBM was first established, evidence-based clinical decision making was 
represented in Sackett’s now well-known three-circle model (6). The three intersecting circles in the 
model (Figure 10) represented the types of knowledge that should be integrated when making clinical 
decisions: clinical expertise, research evidence, and patient preferences.  
A fundamental assumption in establishing EBM was that superior patient care would be provided by 
clinicians whose practice was concordant with the best available evidence (7). It was hoped that 
disseminating high-quality evidence to practicing physicians would help reconcile different views on 
the practice of medicine, and in turn, result in less variation in practice (8). 
Figure 9: Sackett’s early model (1996) of the key elements for evidence-based clinical decisions (7) 
 
 
 
 
 
Over time, EBM arguably emphasised more strongly that clinical expertise was a central factor in 
clinical interactions, and a necessary complement to research evidence (6). This was reflected in an 
updated model (Figure 11) (9). Thus the new model acknowledged that an ‘evidence-based’ decision 
will vary according to both patient preferences and the individual clinical circumstances. 
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Figure 10: Haynes’ updated model (2002) for evidence-based clinical decisions (7) 
 
 
 
 
Both of these idealised models of EBM aim to promote a transparent, rational decision-making process 
(10). EBM encourages clinicians to aim to prioritise information from rigorous clinical trials in their 
work, to recognise agreed standards of evidence, and to increase uniformity and efficiency by limiting 
idiosyncrasies in medical care (11). However, consistent with many authors (e.g. (12, 13), my analysis 
suggests that the EBM model is an ideal: in the clinic GPs face human and evidentiary complexities that 
make doing ‘pure’ EBM very difficult.  
Comparing my model to the traditional EBM model 
Resonances between my model (Figure 9) and traditional EBM models are immediately evident, most 
obviously the three intersecting circles at the centre, which represent three central background 
conditions that GPs described bringing into any PSA screening situation. GPs (1) develop or receive an 
interpretation of the evidence; (2) hold relatively stable values and goals about PSA screening; and (3) 
form an intuitive typology of “PSA patients” (Figure 12). 
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Figure 11. Three background conditions central to GP descriptions of their screening approach 
 
 
 
 
 
Sackett’s model was intended to be prescriptive: it represented what, according to the authors, should 
occur in clinical practice: about how decisions should be made (7). My model represents not how GPs 
should be practicing, rather, how 69 GPs in Australia and the UK explained that they are practicing and 
how decisions are made. I will describe each of the three background conditions in turn.  
GPs develop or receive an interpretation of the evidence about PSA screening 
Research evidence has always been central to models of EBM (Figures 10 and 11). To some extent, 
these models were intended to centralise and institutionalise the synthesis of evidence, such that all 
clinicians should be accessing the same evidence base, potentially via clinical practice guidelines or 
evidence summaries. However, as previously described, the evidence base for PSA screening is 
contested, and clinical guidelines are discordant (Chapter 1).  
GPs’ interpretations of the research evidence (whether individually developed or received via 
guidelines) were central to whether and how evidence was applied in clinical practice. Chapters 3-6 
suggest that GPs were more or less receptive to evidence-based recommendations and practice 
depending on their perceptions of the evidence. 
 Different GPs perceived the evidence very differently. Some claimed the evidence showed that 
PSA screening was on-balance harmful, some that it was on-balance beneficial, some that the 
evidence was not guiding and decisions needed to be made case by case, and some seemed not 
to perceive the evidence to be important to their decision making (Chapter 3); 
Interpreted 
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 GPs experienced varying degrees of uncertainty about the PSA screening evidence base. For 
example, some GPs accepted the nature of current evidence and managed decision making on 
their own, some engaged others to help them to make sense of the evidence, and some 
transferred responsibility for interpreting the evidence to others (Chapter 4); 
 Different GPs had more or less guidance in interpreting the evidence base, and support to 
apply the best available evidence in practice. UK GPs received a clear evidence-based 
recommendation from government against PSA screening and directed care accordingly (and 
with resources to do so). Some Australian GPs felt uncertain and even despondent about the 
evidence base because of the ambiguous and contested versions of ‘evidence-based’ expert 
advice in their context. They practiced in ways consistent with their individual perceptions of 
the evidence, and with significant scope to do so within the Australian healthcare system 
(Chapter 5); 
 Different GPs communicated with men about the evidence differently. Some had strong 
personal judgments about the evidence and framed conversations accordingly; some 
communicated epidemiological perspectives on the evidence; some did not feel it necessary, or 
appropriate, to share comprehensive details of the evidence base with patients (Chapter 6). 
GP perceptions of the evidence thus directly impact on the care and advice that men receive, and on 
GPs personally. I return to these issues in Section 7.4. 
GPs hold relatively stable values and goals about PSA screening 
In Table 12 I described ‘values’ in line with Andrew Sayer’s viewpoint (14), as the relatively 
sedimented evaluative attitudes of GPs: what they evaluated as important or unimportant in the 
context of PSA screening in a relatively stable way. I have denoted values in this way throughout this 
chapter and I discuss them in relation to the literature in Section 7.4. Here in Table 13 I present a 
range of values held by GPs in this study and the types of goals that GPs pursued towards achieving 
those values.  I categorised the values into 2 main types. Type 1 were values that GPs deemed as 
important to a good clinical process or important outcomes in a patient. Type 2 were values that GPs 
deemed as important in their role as a GP.  
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There was wide variation in the interpretation of common core values (Table 13). For example: two 
GPs, each arguing that they should “minimise harm to patients” may avoid screening to avoid 
overdiagnosis, or promote screening to avoid underdiagnosis (Chapter 3). Similarly, many GPs valued 
“facilitating informed decisions”, but GPs had very different views of what information should be 
provided or what patients should understand (Chapter 6).  
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Table 13: Values held by GPs and the types of goals that GPs pursued towards achieving those values 
 
Values held by GPs 
Range of goals that GPs pursued, motivated by that value  
(the same value could inform very different goals,  
depending on how it was interpreted)  
 
Chapter in which the 
value or goal was 
described 
What did GPs 
value as an 
outcome in a 
patient? 
 
‘Preventing death’ of patients  To identify cancer risk early (to diagnose cancer early) 
 To advocate screening; to talk men into having a PSA test 
 To minimise potential legal ramifications 
#3: Overdiagnosis 
#4: Uncertainty 
#6: Communication 
Minimising harm to patients  To prioritise avoiding screening to minimise risk of harming (via 
overdiagnosis) 
 To prioritise screening to minimise risk of harming (via underdiagnosis) 
#3: Overdiagnosis 
 
Supporting patient autonomy  To support men to make their own decisions 
 To provide the PSA test if a man wants it 
#6: Communication 
Facilitating informed decisions   To provide men with comprehensive information  
 To provide the right amount and right level of information 
 To provide the GP’s interpretation of the information 
 To seek ‘epidemiological’, in-depth patient understanding of the 
evidence 
#6: Communication 
Facilitating shared decisions  To encourage patient engagement 
 To understand patient reasons for wanting screening 
 To understand patient preferences for screening or not screening 
 To educate patients about how to do their own research about PSA 
screening 
 To share personal screening practice with patients 
#3: Overdiagnosis 
#4: Uncertainty 
#6: Communication 
Fostering patient trust in GP  To not confuse men with complicated information 
 To provide the GP’s interpretation of the information 
 To seek ‘gist’ patient understanding (leave intricacies of evidence to GP) 
 To follow established and consistent organisational protocol  
#3: Overdiagnosis 
#4: Uncertainty 
#6: Communication 
Wanting to have information about their 
male patients’ prostate cancer risk 
 To screen men, to better predict risk  
 To attain reassurance (of GP and patient) by screening 
#3: Overdiagnosis 
#4: Uncertainty 
#6: Communication 
Keeping male patients healthy  To ensure men stayed engaged with the health system 
 To comprehensively screen for overall health – smoking, weight, mental 
health, prostate cancer 
 
 
 
#3: Overdiagnosis 
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What did GPs 
value in their 
role as a GP?  
 
 
Being responsive to patient preferences  To provide the PSA test if a man wants it  
 To make screening decisions in interaction and case-by-case 
#3: Overdiagnosis 
#6: Communication 
Applying the ‘art of medicine’ to decide 
‘right’ approach  
 To advise patients according to situation and/or individual 
circumstances 
 To act in patient’s best interests 
#3: Overdiagnosis 
#4: Uncertainty 
#6: Communication 
Following ‘best practice’   To practice according to clinical guidelines and recommendations #3: Overdiagnosis 
#6: Communication 
Providing confident screening decisions 
or opinions 
 To make decisions about the evidence, with or without uncertainty 
(some GPs thought all GPs should have the capacity to do this) 
 To not burden patients with uncertainty 
#4: Uncertainty 
#6: Communication 
Managing uncertainty   To manage uncertainty by screening 
 To manage uncertainty by not screening in the first place (UK GPs) 
#4: Uncertainty 
#5 Comparison 
Preserving professional legitimacy and 
reputation 
 To avoid being judged as inadequate or ineffective 
 To build and maintain rapport with patients 
 To maintain patient lists 
 To avoid potential legal ramifications 
#3: Overdiagnosis 
#4: Uncertainty 
#5 Comparison 
Practicing in line with personally and/or 
professionally-established norms  
 To practice in the way one always has, or in the way one’s institution has 
always encouraged  
#5 Comparison 
#6 Communication 
Protecting health care resources  To minimise screening of asymptomatic men (UK) 
 To not prioritise conversations about PSA screening with asymptomatic 
men unless they ask 
#4: Uncertainty 
#5: Comparison 
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GP values, and how GPs assigned value, served as powerful anchors for their practice, and were in this 
way action-guiding (15). Value positions also provide perspective on GPs’ sub-optimal practice, or 
practice contrary to that suggested by the epidemiological evidence. For example, some GPs justified 
talking men into PSA screening because the GP strongly valued ‘preventing death’, and believed that 
more screening would prevent more deaths.  
GPs form an intuitive typology of “PSA patients” 
The EBM model suggests that patients’ preferences should be considered first whenever it is possible 
to do so (7). Some GPs’ core values (Table 13) were about being responsive to patients; they 
considered the circumstances of each patient and shifted their screening rules accordingly (Chapter 3 
& 6). However I refer to a GP’s intuitive typology of “PSA patients” in this section. This is because it was 
relatively uncommon for GPs to describe individual cases of men telling them about their specific 
preferences or concerns.  
Rather, GPs’ descriptions of patient preferences appeared to be understandings based on a general 
sense of what patients collectively want and need. GPs referenced patient ‘types’ and what they tended 
to prefer, gathered from broader populations of patient preferences. In practice, they engaged and 
communicated with patients according to those generalised assumptions. The centrality of heuristics 
in human reasoning has been well recognised since the 1970s so it is not surprising that GPs would 
rely to some extent on heuristics for clinical decision making. However an approach that relies on 
broadly perceived ‘patient types’ is out of keeping with models of patient centred care and shared 
decision making that emphasise engagement with the particular patient and their individual values. If 
a GP assumes that a patient, and their values, will conform to a particular ‘type’, and so do not ask 
patients about their personal values, they may a) be incorrect; and b) miss an opportunity to discuss, 
and possibly influence, a patient’s knowledge and values about screening. I return to “PSA patient” 
types in Section 7.3. 
To re-cap, I have explained the relevance of GPs’ interpretations of the evidence, variation in values 
and goals, and patient typologies to the PSA screening process. The following section focuses on four 
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sources of knowledge which further shaped GPs’ interpretations, values, and practice. Note that these 
sources had influence independently of GPs seeing patients in the clinic. 
7.2 Research Question 2: What factors influence GP approaches to PSA 
screening? 
I synthesised the findings of my empirical work (Chapters 3-6) to discuss in this final chapter. When 
doing so, I noticed that GPs were talking about different types of ‘evidence’, which they called on 
(explicitly and implicitly) to help them to decide what to do about PSA screening. I consolidated my 
observations from Chapters 3-6 and produced four categories, which I labelled ‘sources of knowledge’. 
I describe them here.  
 
Figure 12: Four sources of knowledge (personal and practice experiences; organisational values; relational factors; research 
evidence) and the type of knowledge that each source provided (experiential, tacit, relational, formal) 
 
 
 
 
Relational 
knowledge
Tacit  
knowledge
Formal 
knowledge
ORGANISATIONAL 
VALUES
RELATIONAL 
FACTORS
RESEARCH 
EVIDENCE
PERSONAL & 
PRACTICE 
EXPERIENCES
Typology of 
PSA Patients
GP values 
& goals
Interpreted 
evidence
Experiential 
knowledge
 202 
 
 
Four sources of knowledge influence GP decisions and approach to PSA screening 
The first type of knowledge that GPs drew on was experiential knowledge. The source of this 
knowledge was the GP’s unique set of personal and practice experiences, particularly those related to 
PSA screening and prostate cancer. The second type of knowledge was tacit knowledge – a knowing 
how knowledge – provided by the GPs’ organisational contexts (e.g. professional expectations, 
conditions of practice, and professional responsibility) and reinforced by organisational values. The 
third type of knowledge I have labeled relational. Unlike the two types of knowledge already presented 
– knowledge from clinical experience, and knowledge of organisational values – relational knowledge 
is knowledge from and about interpersonal interactions: about social and professional relationships, 
expectations, and status. The final type of knowledge that GPs accessed was formal knowledge. The 
source of this knowledge was the research evidence, translated into practice guidelines and 
recommendations from professional bodies. 
Table 14: Sources of knowledge that shaped GP evaluations, the type of knowledge provided by that source,  
and how the type of knowledge was synthesised 
Source of knowledge 
Type of knowledge 
provided 
How was the knowledge synthesised? 
(by GP or for GP) 
Personal and practice 
experiences 
Experiential knowledge Heuristics  
(synthesised by GP) 
Organisational values Tacit knowledge Mindlines  
(synthesised by GP) 
Relational factors Relational knowledge Heuristics and/or mindlines 
(synthesised by GP) 
Research evidence Formal knowledge Guidelines  
(synthesised for GP) 
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Sometimes the knowledge provided by each source was explicitly consolidated in practice by the GP 
themselves; in the form of heuristics, or rules of thumb – for example, when a GP established a 
preferred practice orientation, based on a particular experience/s. Sometimes the knowledge was 
implicitly/tacitly consolidated by the GP themselves; in the form of mindlines – for example, when a GP 
internalised a way of practicing consistent with the norms of their organisation. And sometimes 
knowledge was synthesised for the GPs by external authorities, in the form of guidelines summarising 
the research evidence (Table 14).  
Now I will explain how the four sources of knowledge interacted with the three central background 
conditions (interpretations of the evidence, GP values and goals, and typology of “PSA patients”) 
described in Section 7.1. 
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Table 15: The four sources of knowledge were integrated and used by GPs, with variable influence, when considering PSA screening 
 INTERPRETED (GP or other) EVIDENCE GP VALUES & GOALS GP TYPOLOGY OF “PSA PATIENTS” 
P
E
R
S
O
N
A
L
 &
 
P
R
A
C
T
IC
E
 
E
X
P
E
R
IE
N
C
E
S
  Experiences provided tangible, 
experiential evidence of ‘appropriate’ 
care 
 Warranted particular ways of practicing 
 Not necessarily evidence-based or in 
accordance with guidelines 
 Values constructed, de-constructed, confirmed, and 
disconfirmed by experiences 
 Particular experiences shaped practice goals 
 Personal screening behaviour influential (based on 
personal values) 
 Experiences provided information about 
general patient preferences  
 GPs formed perceptions about specific 
patient types: “PSA patients” 
O
R
G
A
N
IS
A
T
IO
N
A
L
 
V
A
L
U
E
S
 
 Organisations guided what counted as 
relevant evidence 
 Organisations created environments 
encouraging (or discouraging) the 
utilization of evidence  
 Policy agendas of organisations 
influenced evidence use in clinical care 
 Organisational contexts shaped/enabled particular GP 
roles, values, and corresponding goals for practice 
 Varied by origin and context  
UK GPs: 
 Shared values and goals professionally-derived, 
collective, and relatively aligned with other GPs and 
organisation 
 Organisational values – and goals – internalised by GPs 
(mindlines) as personal 
Australian GPs: 
 Most influenced by individual values and goals, derived 
from experiences and independent of organisation 
 Organisational values ambiguous and expected GP role 
(and corresponding goals for practice) unclear 
 Institutional norms and infrastructure 
shaped what Australian and UK GPs 
prioritised as an outcome for a patient  
 Provided context for GP formation of 
mindlines about what patients want and 
need 
R
E
L
A
T
IO
N
A
L
 
F
A
C
T
O
R
S
 
 Judged relevance of evidence in 
interaction with patients 
 Discounted or re-shaped evidence to fit 
relational expectations 
 Values constructed in context of relationships and social 
interactions 
 Personal and professional values sometimes conflicted 
 Some relational factors influenced practice discordant to 
GP values and goals 
 Preferences and characteristics of “PSA 
patient” derived in interaction 
 Established starting point for patient 
engagement (information and 
understanding) 
R
E
S
E
A
R
C
H
-
B
A
S
E
D
 
E
V
ID
E
N
C
E
  Uncommon for GPs to engage directly 
with research evidence to inform 
screening practice 
 GPs could practice different versions of EBM depending 
on their values and goals 
 Some GPs framed evidence to fit with valued outcomes 
 Guidelines are largely context-free until 
integrated and applied by GPs in clinical 
contexts 
 Research-based evidence cannot 
provide specific guidance for individual 
patients without interpretation 
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The first column of Table 15 illustrates how the four sources of knowledge were integrated and used 
by GPs, with variable influence, when considering PSA screening. GPs had very different 
interpretations of the evidence arising from experiences, organisations, relationships, and research 
respectively. They rarely discussed relying on research, or syntheses of research, as a source of 
knowledge: they were far more likely to rely on evidence available from the other sources to guide 
their practice.   
Australian GPs commonly relied upon experiential knowledge as the most direct form of ‘evidence’ for 
decision-making. A one-off experience, like a man ‘saved’ by PSA screening or a man dying of prostate 
cancer when not screened (Chapter 3), trumped all other sources of evidence. GPs perceived 
experiential evidence as ‘real’; experiences were easily recalled and intuitively meaningful, in contrast 
to the epidemiological research evidence. However this approach to clinical reasoning makes GPs 
prone to certain biases, as will be discussed in Section 7.4.  
GPs acquired tacit knowledge from their respective organisations, which indirectly shaped their 
appraisals of the evidence. In Chapter 5 I drew on data from my comparative work to argue that 
organisational arrangements that provide or limit opportunity for evidence-based screening 
pathways, partly direct how and which guidelines are received and implemented, and facilitate 
‘appropriate’ evidence utilisation in practice via resources and support. I return to the influence of 
practice conditions in Australia and the UK throughout this chapter.  
In some contexts, relational factors prompted GPs to discount or re-shape the evidence to ‘fit’ with 
situational demands. In Chapter 6 I described how particular patient types, for example, strongly 
influenced whether GPs utilised evidence in screening decisions, and if they did use evidence, how that 
was done. Relational factors and consumer demand are closely associated and had important 
implications for GP outcomes and informing future practice (see Section 7.3). 
As shown in the second column of Table 15, GPs prioritised particular values depending on 
experiential knowledge. The GP’s professional context shaped the degree to which those values 
translated into goals for practice. UK GPs described practice goals in line with organisational values 
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that they shared with others in the profession, and internalised as their own. Most GPs in Australia, on 
the other hand, constructed individual practice goals in line with their personal values, and 
independent of their organisation. Experiential and relational types of ‘evidence’ thus factored 
particularly highly in the Australian context. Because the GPs had significant scope to practice in 
accordance with personal values, ‘good’ screening practice was sometimes in direct contrast to that 
supported by research-based evidence (formal knowledge) against screening (Chapter 3). 
As shown in the last column of Table 15, the four sources of knowledge interacted with how GPs 
constructed typologies of “PSA patients”: most implicitly developed a set of patient ‘types’. GPs 
customised their approach to each patient, or developed a relatively uniform approach to apply to all 
patients depending on the guidance received from their organisation and how appropriate the GP 
thought it was to follow this guidance. For example, UK GPs accessed an information resource that 
facilitated and encouraged a standardised approach to all patients, while what Australian GPs came to 
know about “PSA patients” (experientially and/or interpersonally) often trumped formal guidance. 
Some GPs’ constructions of a “PSA patient” were very basic and automatic: “male, 50 years or older”. 
Other GPs’ “PSA patients” were very detailed and considered and demonstrated finely-tuned ways that 
GPs distinguish men; for example, “male, 50 years or older, no family history, requests PSA test after 
friend diagnosed with prostate cancer, anxious, low health literacy, may not be interested (or able to 
understand) detailed discussion…”. Similar constructions of patients translated into markedly 
different outcomes, depending on GPs’ values, organisational values, and context. An asymptomatic 
“male, 50 years or older” type in the UK context had significantly different implications in practice than 
a “male, 50 years or older” in the Australian context: Australian GPs commonly raised PSA screening 
(and/or screened) opportunistically with this type of patient, unprompted, while UK GPs consistently 
did not discuss the PSA test with any patient.  
Next I describe two ‘knowledge filters’ (trust and uncertainty) through which GPs evaluated the 
incoming knowledge. Table 16 illustrates how components of the filters relate to the sources of 
knowledge. 
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Table 16: Sources of knowledge that shaped GP evaluations, the type of knowledge provided by that source, how the type of 
knowledge was synthesised, and the knowledge filters which shaped how that knowledge was received and utilised in practice 
Source of knowledge 
Type of 
knowledge 
provided 
How was the 
knowledge 
synthesised? 
(by GP or for GP) 
Filter: Type 
of trust 
Filter: Type of 
uncertainty 
Personal and practice 
experiences 
Experiential 
knowledge 
Heuristics 
(synthesised by GP) 
Interpersonal Personal 
Organisational values Tacit knowledge 
Mindlines 
(synthesised by GP) 
Institutional Practical 
Relational factors 
Relational 
knowledge 
Heuristics and/or 
Mindlines 
(synthesised by GP) 
Interpersonal 
Practical 
Personal 
Research evidence Formal knowledge Guidelines 
(synthesised for GP) 
Institutional Scientific 
 
Knowledge filters 
GPs consciously or unconsciously judged the usefulness of each source of knowledge: asking, does the 
knowledge provided by this source align with or challenge my values? Does this knowledge help me to 
apply or understand the evidence, or provide more evidence? Knowledge was more likely to be 
integrated into screening considerations over other types if the source of knowledge was trusted, 
increased certainty about making a particular decision, or supported practicing in a particular, 
preferred, way.  
Trust and uncertainty are represented as circular in the model (Figure 14) to indicate that deciding 
whether to trust and responding to uncertainty were ongoing processes, and responsive to changing 
conditions. 
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Figure 13: GPs evaluated the four sources of knowledge through two knowledge filters: trust and uncertainty 
 
Filter one: How much do I trust this knowledge?  
GPs more or less explicitly evaluated whether sources of knowledge were to be trusted to inform a 
good decision, or to help provide the best possible care. Here I consider trust – the ‘mutual confidence 
that no party to an exchange will exploit the other’s vulnerability’ (16) – in terms of its function as a 
medium of interaction between social systems and individuals, after Niklas Luhmann (17). Trust is 
commonly conceptualised as being of two types: institutional (trust placed in the system or institution) 
and interpersonal (trust placed in the individual or personal relationships) (4). Both institutional and 
interpersonal types were relevant to the PSA screening process as I describe it in my model.  
Longstanding trust in the NHS institution translated to minimal onus on individual GPs in the UK to 
interpret the evidence, the authenticity of practice recommendations, or to consider underlying 
interests. When GPs trusted their professional body (i.e. institutional trust) they had confidence in 
practicing to that guidance – derived from formal research-based knowledge – and in line with 
organisational values. In contrast, low trust in institutional guidance in the Australian context was 
common (Chapter 4); GPs found it challenging to locate the best advising authority in which to place 
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trust due to inconsistent advice, perceived conflicted interests, and ‘experts’ lack of relevant first-hand 
experience of the issues. Confusion and uncertainty undermined their overall trust in the system and 
formal knowledge. In response, many Australian GPs trusted the knowledge provided by individual 
experiences and relationships (i.e. interpersonal trust) to direct their care. 
Filter two: How certain or uncertain is this knowledge? 
GPs more or less explicitly evaluated the usefulness, or burden, of incoming information (they asked, 
how much uncertainty is this source of knowledge likely to introduce or resolve?), particularly whether it 
was perceived to provide more certainty or uncertainty. 
Filtering knowledge according to the degree to which it was uncertain was more necessary for 
Australian GPs, and less so for UK GPs. This is because in the UK, the healthcare structures and systems 
were far more strongly guiding than in Australia (Chapter 5). Paul Han conceptualises this kind of 
uncertainty as ambiguity uncertainty (system-centred)(1). This meant that UK GPs could take the 
direction from the NHS as a proxy for relative certainty: because GPs in this study perceived the NHS 
as trustworthy and its guidance as relatively certain, they could assume that the evidence was certain 
enough. In contrast, because the working environment of Australian GPs has historically contained so 
much ambiguity uncertainty, with different authorities constantly contradicting one another, they 
were more likely to perceive the evidence as uncertain, and to feel responsible for confronting this 
alone. 
In the clinical encounter 
So far I have focused on the central resources available when GPs were faced with the possibility of 
PSA screening in general practice. GPs drew on interpretations of the evidence, on values and goals, 
and their typologies of patient preferences. They could use any of four types of knowledge 
(experiential, tacit, relational, and formal), from four different sources, and varied their use of these 
depending on their view of how uncertain that knowledge was, and degree to which the GP trusted 
institutions and individuals to guide them.   
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Once the GP had, intuitively or explicitly, mobilised this set of resources available to them, there were 
several actions they may or may not take once faced with a patient. The solid horizontal line in Figure 
15 represents the point at which a GP and patient came together in the clinic. Actions available to GPs 
included communicating with the patient about PSA screening, making a final decision about PSA 
screening, and finally doing or not doing a PSA test.  I will now explain these three actions. 
Figure 14: Most GPs engaged patients in communicating and making a final decision 
 
Communicating and Making a final decision about PSA screening 
At this stage, GPs engaged others in communicating and decision making or used their individual 
judgment to arrive at a decision. Consultations typically involved some degree of communicating and 
decision making. What that involved exactly, and by whom, depended on how the GP evaluated and 
was influenced by preceding factors, like relational information (Chapter 6) or uncertainty (Chapter 
4). When a patient requested a PSA test, for example, a GP could take several pathways: the GP might 
(a) have a careful, impartial discussion about the evidence, (b) tell the patient why they should or 
should not be screened, from a personal or professional viewpoint, (c) issue an information leaflet 
with more or less talking around it, or (d) do as the patient wishes with no further discussion. Here, 
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GPs could change a patients mind about wanting a PSA test – some did – but this was mostly limited to 
those GPs who were highly engaged with the issues, had high trust in their institution to support them 
to do so, and/or had a patient interested in making an informed choice (Chapters 3, 5, 6). 
Clinical guidelines were not necessarily useful in aiding communicating or making a final decision. GPs 
found it challenging to have conversations with men about overdiagnosis for example (Chapter 3), and 
felt conflicted about involving patients in making decisions based on uncertainty (Chapter 4). At times, 
GPs determined that not all patients wanted to be active participants in the process (Chapters 3, 6). I 
have accordingly shaded Communicating and Making a final decision grey in the model because they 
are actions that sometimes happened and sometimes did not before a man was screened or not 
screened. The screening context determined their relevance (Chapters 5, 6): some institutional 
arrangements create more or less opportunities for discussion and involvement, from mailed 
pathology forms without a consultation in the Australian context (no opportunity) to staggered two-
step appointments in the UK (ample opportunity) (Chapter 5). 
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7.3 Research Question 3: What are the consequences of this process? 
Screening or not screening (Do GPs screen, or do they not?) 
The point of this analysis is to help explain how and why a GP does or does not order a PSA screening 
test. While the outcomes might seem simple (yes/no, do they or don’t they test) as the model shows 
there are many factors that can influence whether or not the test occurs, and even the degree to which 
the GP considers whether or not to test, or alternatively simply tests, or not, out of habit.  
Figure 15: Screening outcome: Do GPs order a PSA test or do they not? 
 
There were GPs who carefully weighed up the consequences of screening versus the consequences of 
not screening, and were deeply engaged in the process. They located this decision in the broader 
context of additional testing and treatment and associated harms (Chapter 3), and decided on the 
‘best’ trade-off of risks and harms for the patient and/or the GP personally, in interaction. Having 
intimate knowledge of the fundamental issues did not make screening or not screening any easier 
(Chapter 3, 4). It is conceivable that some GPs will value early detection while others might want to 
avoid screening and treatment harms (Chapters 3, 4, 6). 
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A number of GPs were not necessarily thinking about ordering a PSA test in an evidence-based or 
patient-centred way. They were highly concerned about missing cancers and aimed to uniformly 
screen all men (Chapter 3), they felt anxious about legal ramifications, maintaining business, or 
preserving relationships with urologist colleagues (Chapters 3, 6), or screened in the pursuit of some 
certainty in this inherently uncertain situation (Chapter 4).  
A relatively common scenario in the Australian context was where a GP’s screening behaviour was 
habitual, a routine, or the PSA test was constructed as “just another test”. GPs who did not engage with 
issues of overdiagnosis or underdiagnosis, or who ordered a PSA test in a battery of routine blood 
tests (Chapter 3, 4) illustrate the routine approach described. This process may represent (a) an active 
coping strategy to simplify the complexity, (b) an automatic process that may or may not involve 
internal reflection on the part of the GP, or (c) GP ignorance. These actions had direct implications for 
patients (Chapter 6) including patient satisfaction with the process, understanding of the issues, and 
health outcomes. I discuss patient outcomes in the following section. 
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Patient outcomes  
Figure 16: GPs valued and prioritised different outcomes for patients 
 
Whether, on balance, a man is likely to benefit or be harmed by PSA screening, remains a debated 
issue. Thus a GP, policymaker, or epidemiologist’s conceptualisation of a ‘good’ patient outcome may 
differ to that valued by a patient. One patient’s ‘ideal’ outcome might entail accessing a PSA test with 
little resistance; another’s might be receiving reassurance (personally, or for a concerned partner or 
family member) about why screening is not warranted (Chapter 6). However GPs commonly reverted 
to intuitive “PSA patient” types to help them to decide whether to involve patients in the process and if 
they did, how that should be done (Section 7.1). Processes of care thus could transpire according to 
GPs’ heuristics of patient values, rather than actual patient values. The Be Screened (or Do not be 
screened) and As you wish approaches described in Chapter 6 are good examples of the spectrum of 
patient involvement. In As you wish interactions GPs were led by the patient and their stated 
preferences, without questioning those wishes, while GPs strongly directed care in Be screened and Do 
not be screened interactions.  
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Some GPs did describe practicing to patient-centred values: valuing patient autonomy, facilitating 
informed or shared decisions, and fostering patient trust (Table 13), but the same espoused values 
could translate into very different practice from one GP to another. Because patients in Australia do 
not have the kind of continuity of care that is more typical in the UK, any given man could potentially 
see a range of possible GPs with a range of values. I have shown throughout this thesis that GPs are 
likely to vary widely in their PSA screening practices: some GPs’ routines reduced, and some 
increased, the probability of negative patient outcomes such as false positives, overdiagnosis, worry 
and anxiety, or limiting opportunity for patient consent. 
GP outcomes – personal burden 
The emotional and cognitive personal burden borne by some clinicians identified in this study was 
significant, particularly for GPs practicing in Australia (which I explain below), and is likely a neglected 
issue in mainstream coverage of the topic. Personal burden will be the focus of this section and Table 
17 below.  
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Figure 17: Personal burden was a significant and taxing outcome for some GPs in this study 
 
I am using the term ‘personal burden’ to group GPs’ reports of having to cope with feelings of worry, 
guilt, self-blame, regret, insecurity, and anxiety. The underlying source of the burden experienced 
appeared to be about confronting tension created between what the GP was able to do or wanted to do 
(e.g. order a PSA test, not order a PSA test, do an ‘effective’ job, avoid over or under diagnosis), and 
what the GP ought to do according to advice from professional organisations (Table 17). A good 
example of the experience of personal burden is the GPs who were torn between balancing 
overdiagnosis and underdiagnosis, reported in Chapter 3.  
Personal burden was not a universal experience: not all GPs reported burden and there was diversity 
in the experience of it in those who did report it. This experience was unique to GPs practicing in 
Australia when compared to GPs practicing in the UK (Chapter 4). There are conditions in the contexts 
of GPs practicing in Australia that produced or shaped an emotional response, and conditions in the 
practices of GPs practicing in the UK that buffered GPs from potential burden (Chapter 5). The UK 
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comparison is an important reference because it demonstrates that it is possible to have a system 
response to PSA screening that does not burden GPs or have implications for their emotional 
wellbeing. I return to this argument in Section 7.5.  
GPs who engaged with the most troublesome and contentious issues ultimately suffered the most 
burden. GPs who did not engage with the issues in any depth were mostly relieved of burden. This is 
the great paradox of PSA screening: the harder a GP tries to locate answers or certainty (turning to the 
evidence, professional guidance, or via more screening and investigation), the more uncertainty they 
will find or introduce and the more burden they are likely to experience (Chapter 4). 
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Table 17: GP experiences of personal burden 
 
 
Source of personal burden  Characteristics of GPs who experienced this type 
of burden the MOST 
Characteristics of GPs who experienced this type 
of burden the LEAST 
Chapter in which personal 
burden was described 
 No clear ideal, evidence-
based course of action 
 
 GP wanting to practice consistent with 
recognised ‘evidence-based’ standards 
 GPs concerned about overdiagnosis, who 
prioritised less screening 
 GPs who tried to understand or resolve 
uncertainty 
 GPs who tried to engage others in managing the 
issues 
 GPs concerned about underdiagnosis, who 
prioritised screening  
 GPs who believed that screening saves lives  
 GPs not engaged with the issues 
 GPs who shared or transferred responsibility to 
others 
#3: Overdiagnosis 
#4: Uncertainty 
#6: Communication 
 
 
 Discordant and ambiguous 
advice from the medical 
profession and professional 
organisations 
 
 Australian GPs who sought ‘best practice’ 
guidance 
 GPs who engaged with the issues  
 GPs practicing within the UK health system 
 GPs who followed their own screening protocol 
 GPs not engaged with the issues 
 GPs who did what patients wanted 
#3: Overdiagnosis 
#4: Uncertainty 
#5: Comparison 
 Concern about burdening 
patients (with uncertainty, 
complexity, negative 
outcomes) 
 GPs who tried to engage men in discussion 
about the issues 
 GPs who sought informed decision making and 
consent 
 GPs who made decisions on behalf of patients  
 GPs supporting the attitude that GPs don't have 
to have the answers to everything  
 GPs who felt supported in their chosen 
screening approach 
#4: Uncertainty 
#6: Communication 
 Consumer demand  GPs practicing within the Australian health care 
system 
 GPs who did not support screening 
 GPs who ordered PSA tests when they did not 
want to  
 GPs practicing within the UK health care system 
 GPs who did what the patient wanted 
 
#5: Comparison 
#6: Communication 
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Outcomes and experiences informed GPs’ future practice  
Sayer acknowledges that sedimented values are not completely stable, and can be recursively re-
shaped by particular practices, persons, relationships, or institutions – which might affect our future 
valuations and influence how we act (14). The outcomes and experience of GPs’ practice became 
important sources of knowledge for GPs’ future practice, implicitly and explicitly. These ‘feedback 
loops’ provided knowledge for practice and knowledge from practice (represented in Figure 19 as 
broken lines bordering the model). GPs developed new rules and acted in particular ways in response 
to outcomes observed and experienced in the clinic (Chapters 3, 6).   
Figure 18: Broken lines illustrate ways in which outcomes and experiences informed GPs’ future practice 
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GPs confirmed, validated, or modified their screening behaviour based on the ‘new’ evidence gained in 
practice from a decision or approach that ‘worked’. For example, GP experiences of personal burden, 
or having a patient ‘saved’ from PSA screening. GPs directed subsequent practice towards avoiding or 
achieving that experience or outcome.  
Outcomes and experiences are not necessarily a source of reliable information, primarily because PSA 
screening provides false certainty. Normal PSA results, and biopsy-confirmed prostate cancer 
following screening (even if indolent), provide ‘evidence’ supporting the benefits of PSA screening. 
Both examples can erroneously reassure GPs, and patients, that screening is worthwhile, create 
consumer demand, and prime GPs to screen more if they find more prostate cancers.  One GP did not 
screen and had a man die of prostate cancer; subsequently that GP screened all men; then a patient 
suffered a perioperative stroke following treatment. The GP was left in a position of feeling she/he had 
personally contributed to both outcomes. This case demonstrates that reasoning for all patients based 
on single cases is flawed. It seems likely that GPs’ chance case experiences can skew their perceptions 
of the evidence generally depending on what cases they confront. I return to GP reasoning and 
cognitive biases in the following section. 
Some ‘feedback loops’ indirectly encourage dubious screening practice; for example, financial 
incentives, healthcare system incentives (including to fill demand), and perceived threat of 
malpractice. Other system features block important feedback and create the opportunity for less than 
ideal practice, such as practice recall systems. 
7.4 How can we explain current prostate cancer screening practice?  
Each empirical chapter of this thesis offered a focused explanation of current PSA screening practice, 
from the perspective of GPs, drawn from the developing analysis: GP reasoning about under- and over- 
diagnosis, experiences of uncertainty, structural and organisational differences between screening 
contexts, and GP goals for the screening interaction. This section draws on and extends those 
discussions, informed by my empirical findings in combination with existing literature about 
knowledge, values, trust, uncertainty, and clinician wellbeing. I focus on four explanations: (1) GPs 
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implicitly or explicitly prioritise knowledge derived from their local environment (proximal 
knowledge); (2) GP reasoning, like all human reasoning, may be prone to cognitive bias; (3) there are 
complex layers to the screening process, each infused with values; and (4) GPs feel personally 
responsible for adverse consequences. 
GPs implicitly or explicitly prioritise proximal knowledge 
The four sources of knowledge that I described throughout this Chapter represented important points 
of reference for screening decisions; the knowledge provided by each source is not necessarily formal 
or “evidence”-based. Clarke and Wilcockson (2002) distinguish between two kinds of knowledge: 
distal knowledge created and derived from outside of the care environment (for example, research 
evidence, clinical guidelines) and proximal knowledge, derived from within a specific care 
environment, and dependent on contextual issues within that environment (5). When making 
decisions about PSA screening, GPs in this study prioritised and applied proximal knowledge – 
acquired from personal and practice experiences and organisational and relational contexts – over 
distal knowledge. Each source of knowledge was synthesised either by the GP (proximal) or for the GP 
(distal) to make sense in clinical practice. 
Distal knowledge indicates professional standards of care, and is generally expected to drive evidence-
based practice (18, 19). However you will recall in Chapter 5 that I proposed that GPs construct 
‘mindlines’ from their specific care environments, after Gabbay and le May (2). Mindlines fit a view 
that knowledge is created and re-created in different contexts by a process of reduction and 
prioritisation of potentially relevant knowledge of different kinds (20). All GPs accessed diverse forms 
of proximal knowledge meaningful to their local context – not all conscious and explicit – and 
practiced in a way that made sense to their practice.  
UK GPs primarily drew on tacit, proximal knowledge from their organisation. Because medical practice 
is fixed in externally legitimised knowledge and practices under the UK’s NHS system (21), their 
mindlines and practices were strongly influenced by distal knowledge embedded in their organisation. 
For Australian GPs, proximal knowledge from experiences and relationships seemed intuitively 
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trustworthy, provided relative certainty when compared to distal sources, and enabled GPs to practice 
in a way consistent with their personal values. Clarke and Wilcockson argue that there is instability in 
decision making based on rapidly fluctuating proximal knowledge compared to the relative stability of 
distal knowledge (5). However, as I have explained, proximal and distal knowledge were not entirely 
separate entities. Some forms of proximal knowledge incorporated elements of distal knowledge and 
were thereby relatively stable and consistent sources. Individually interpreted proximal sources were 
more prone to personal biases, which I will now explain. 
GPs’ reasoning may be more or less subject to cognitive biases 
Relatively judicious clinical reasoning is preferred over intuitive judgment in EBM (8) but was not 
common practice for GPs in this study. Rather, GPs synthesised knowledge from proximal sources via 
heuristics and mindlines and these played an integral role in helping GPs to navigate the complexities 
of PSA screening decisions and actions.  
As noted, some knowledge may be more affected by cognitive biases and arbitrary reasoning than 
others. Heuristics are shortcuts in reasoning: intuitive cognitive processes that ignore parts of 
information to make decisions more quickly (22), and often develop beyond one’s awareness (23). In 
this study heuristics were constructed by individual clinicians from specific interactions and related to 
their own clinical activity. For example, “this patient is the same type of patient as Mr Jones”. Heuristic 
reasoning has been dismissed as undermining clinical thinking and heuristics as unreliable shortcuts 
(24, 25). Anchoring to single experiences, for example, can leave GPs susceptible to chance events and 
the influence of feedback loops. If a GP received evidence from a single experience that “screening 
saves lives”, then they could overestimate the benefits of PSA screening, and maintain that initial 
impression once formed (26). Other authors suggest that heuristics are often at least as accurate as 
complex statistics in pointing to the right decision (27), and advantageous for professional practice 
(28). Making clinical decisions on the basis of heuristics and mindlines reflects the realities of clinical 
practice, rather than undermining the scientific foundation of medicine (29) or good clinical practice 
(30). They offer important insight into clinician values, reasoning, and judgments. Heuristics have 
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limitations, particularly when not adaptive to reflective thought, but are a useful function of clinical 
expertise, especially under uncertain conditions. 
Values, mostly implicit, are embedded in every stage of the PSA screening process  
There is often an assumption that research evidence – the epitome of EBM – is value-free. In reality, it 
is laden with judgments. Politicians, lobbying groups, the pharmaceutical industry, and researchers 
and universities themselves, influence the defining of research priorities, what counts as evidence, and 
how knowledge is distributed (20). GPs and patients bring their own values to the clinic. So although 
evidence is very important in making choices about PSA screening, it is evidence in the context of 
values, which are equally important.  
There are researchers who argue that unacknowledged values are forms of psychological heuristics 
(31) that act as short cuts and provide immediate answers to problems we choose not to explore in 
detail (23). Some proponents of EBM argue that values can and should be controlled for as removable 
sources of bias for this reason (32). Sayer, on whom I have relied for my conception of values, takes a 
middle position, arguing that values are neither arbitrary, nor beyond the scope of reason. Rather, 
Sayer describes values as relatively stable (‘sedimented’) valuations: we evaluate practices, persons, 
relationships, or institutions based on sedimented values and usually act, at least in part, consistently 
with those values (14). On this view, values have normative force: they represent judgments about the 
things that matter – in this case, to GPs – and give decisions and actions meaning, significance, and 
moral worth (23, 33). They are both normative and potentially reasonable.  
In this study, values helped explain why GPs had different priorities and why they made different 
kinds of judgments: they practiced in a way consistent with their values. There are writers who argue 
that the values of clinicians inevitably become prescriptive guides to what kinds of doctors they should 
be and how they should act (34, 35). Australian GPs had diverse ideas about what constituted a good 
GP and the corresponding ‘right’ course of action (both generally and particularly in respect of PSA 
screening), and were strongly guided by their personal (often conflicting) value systems. UK GPs were 
more strongly guided by values embedded in collective commitment to their profession, which left less 
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room for an independent effect of their personal values. The UK-based GPs I spoke to appeared to 
practice the way they did not mostly because they were prohibited from practicing otherwise, but 
because they had internalised a set of commitments and trusted the institution in which they were 
practicing to support that expected standard of care. Australian GPs had low institutional trust, for 
reasons outlined previously, high uncertainty about professional expectations, and expressed a strong 
sense of personal responsibility (and anticipated burden) for their actions. Because of discordant 
opinion, GPs in Australia could reasonably claim a professional commitment to different authoritative 
bodies to justify different practices, as there was authoritative advice available to support or reject 
many different courses of action with regard to PSA screening. 
GPs’ sense of personal responsibility for adverse consequences creates burden 
The complexity of the screening process has been obscured by research and debate focused on the 
flaws in PSA screening evidence and policy, with little consideration for the GPs involved. The prostate 
screening literature tends to neglect the fact that many GPs who are not adequately supported 
experience considerable emotional and cognitive burden as a result of having to manage the PSA test. 
Literature from other healthcare contexts, such as emergency departments, similarly suggests that the 
wellbeing of those working in the ‘helping professions’ can be seriously compromised if they are not 
supported to perform their role (36). Yet compassionate and empathetic appreciation of the social, 
ethical, and emotional challenges faced by doctors in their routine daily work is often lacking (37). 
This study highlights the existence of a number of factors – ambiguous advice, uncertain expectations, 
and patient demand – that contributed to emotional and cognitive burden for GPs. To fully understand 
the practice of PSA screening in Australia requires understanding and taking seriously that burden. 
Health outcomes for patients are always a priority, but the wellbeing of practitioners is also important 
for a number of reasons including the sustainability of the healthcare system, the safety and quality of 
patient care (38), and simply what they are owed as fellow human beings. If the health system is to 
take doctors’ wellbeing seriously, then those with agency in the health system will need to intervene, 
and to do so in ways that will not only improve outcomes for patients but also support GPs.  
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7.5 How might GPs be best supported to respond to current practice 
demands?  
Throughout the empirical chapters I described a range of GP perspectives on these issues and drew on 
that information to make suggestions for policy and practice. Each chapter called for a considered 
response to current prostate screening practice as a priority, informed by GP insight about the 
challenges presenting in the clinic: GPs feel personally burdened making screening decisions under 
conditions of considerable uncertainty (Chapter 3 & 4); GP values and goals for practice determine 
men’s (unequal) access to information and consent to PSA screening (Chapter 3, 4 & 6); and healthcare 
system factors, including social and funding structures, incentivise particular ways of practicing, which 
are not necessarily consistent with evidence-based or ethical practice standards (Chapter 5).  
There are several ways in which explanations of the PSA process produced in this study can aid both 
GPs and those who wish to influence their practice. My findings suggest that to be effective, strategies 
must: (1) take account of the unique conditions of clinical interactions, including the different 
motivations (values and goals) of GPs and the consequences of importance to them (Section 7.1); (2) 
recognise the range of ‘evidence’ sources informing practice (Section 7.2); (3) consider the significant 
influence of trust, uncertainty, and patient engagement (Section 7.2); (4) account for the way in which 
case experiences can shape future practice (Section 7.3); and (5) acknowledge the substantial 
challenges faced by GPs, including the experience of personal burden (Section 7.3). In this final section 
I propose strategies at the level of the healthcare system, GPs’ local practice environments, and 
targeting individual GPs, to offer important guidance for future policy and practice.  
At the healthcare system level 
In Australia currently, GPs receive extensive pressure to screen (Chapters 1, 3-6). There is an 
established screening culture, mostly in favour of PSA screening. Screening enthusiasm is perpetuated 
by mainstream media, creating significant patient demand. My UK comparative work illuminated – by 
contrast – features of the Australian healthcare system that encourage more rather than less screening 
(Chapter 5). Payment systems and a corresponding market for screening provide incentives to screen 
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in combination with less stringent conditions for providing the PSA test. GPs can refer borderline 
uncertain ‘grey’ PSA results to urology with no consequence, and urologists profit from this process. 
Australia has perhaps inadvertently established a system over the years that makes it much easier for 
GPs to order PSA tests than not, and with ample opportunities to do so.  
There are no or few feedback loops that are negative or discouraging for clinicians who routinely 
screen patients in Australia (39). GPs receive credit for ‘curing’ disease that would never have harmed, 
positive feedback from patients for ‘saving their life’, and alarming feedback from patients with missed 
diagnoses (40). There is little reward for GPs avoiding overdiagnosis (Chapter 3). Patients can feel 
they have missed out, have not had enough care, or feel frightened about not knowing, and GPs are left 
with uncertainty and anticipated decisional regret (Chapter 4). GPs receive no feedback from patients 
whose cancer was overdiagnosed. 
Inbuilt feedback mechanisms in the Australian healthcare system, such as these, require immediate 
attention: they conflict with goals of reducing unnecessary or harmful prostate screening, have 
considerable ethical and public health implications, and substantial cost to the healthcare system. 
Although individual GPs undoubtedly have a role to play in reducing the prevalence of PSA screening, 
it is (1) difficult for individual GPs to find solutions alone because of the dominant social, financial, and 
political factors contributing to the current situation, and (2) arguably beyond the professional 
responsibility of individual GPs because these complicated circumstances – creating demand, 
expectation, and uncertainty – are not typically addressed in EBM directives (41).  
Debate over the appropriate healthcare system response to PSA screening has been controversial for 
decades (Chapter 1). My UK comparison case provides good evidence that system-level changes could 
effectively influence a different and arguably ‘better’ way of practicing. I suggest ‘better’ because UK 
GPs rarely experienced the uncertainty or personal burden described by Australian GPs, in 
combination with documented comparable death rates despite considerably less screening. In Chapter 
5 I suggested that systems-level features such as the two-step screening process described in the UK 
may help to avoid overuse, ensure adequate information provision, and ultimately maximise 
opportunities for GPs to create evidence-based mindlines. Financial incentives, penalties, funding 
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arrangements, tort reform and clarification, and established consent protocols may put additional 
explicit boundaries around what is considered acceptable practice. For instance, GPs in Australia can 
currently order PSA tests routinely, without discussion, or in a battery of other blood tests, with or 
without patient knowledge. Structural intervention, with insight from this study, may gradually 
influence a shift in GPs’ default screening positions (e.g. ‘tick box’ screening) by strongly discouraging 
or preventing particular approaches while providing pathways encouraging more evidence-based 
care.  
It is necessary that strategies are sensitive to context if policymakers want them to be applicable and 
utilised. Some interventions will be effective in some contexts but not in others. Adopting practice 
from the UK model will be futile if those strategies cannot work in the Australian context because of 
the challenges I have presented, the different healthcare systems, and established clinical practice 
(fewer men in the UK request a PSA test and fewer GPs suggest a PSA test). PSA screening is accepted 
as routine care in Australia; many will not see any problem with the status quo, and some have a 
vested interest in maintaining this. The UK has taken a consistent, blanket approach that is rarely 
complicated by individual patient request or contested professional guidance; thus it works in that 
context. In 2012, the RACGP advised its members not to raise the issue of PSA screening unless 
requested by a man. This is likely an ineffective approach to addressing routine screening (and many 
GPs reported it to be so) because too many men and GPs know about the PSA test and are actively 
using it in practice. If men know the test is available - GPs said it is hard not to bring it up.  
The two health systems are historically significantly different, but it seems reasonable, given that the 
evidence is international and the cultures of the two countries similar, that there should be similar 
expectations of GPs in terms of practical and ethical obligations, and that they can in turn expect to be 
supported by the system (with resources) to practice within that framework, regardless of their 
starting position. The challenge is to intervene in the system to provide them with the supports and 
structures that will facilitate this. Australian policymakers, medical organisations, and individual GPs 
could be implementing small, targeted changes in numerous places to collectively impact on screening 
attitudes and default screening positions, with a particular focus on the feedback mechanisms built 
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into the Australian healthcare system. Future generations of men and GPs should be able to have the 
opportunity to decide what is best, without being influenced by the current culturally- and market-
driven screening enthusiasm. Some efforts to intervene have begun in the Australian context, such as 
the impending release of a patient decision aid and a push to publicly fund PSA tests with screening 
intent every two years, rather than annually, to align with the recently revised prostate screening 
recommendations. An informed understanding, and consideration for the broad and local 
circumstances contributing to screening patterns is imperative to influencing sustainable and effective 
changes; I propose possible solutions at the local level in the following section. 
In the practice environment 
Addressing the specific care environments in which decisions take place and where heuristics and 
mindlines are formed can alter the organisational routines in which GPs’ personal routines are 
embedded (2). Many of the issues identified and questions raised in this study are not resolvable with 
scientific clarity or explanations, and guidelines (formal, distal knowledge) in isolation seem incapable 
of offering a simple solution to the ‘swampy lowlands’ (42) – the confusing, ‘messy’ human concerns - 
of this clinical problem. Guidelines commonly attach no value to many things that matter to GPs, in 
particular, those things that may be undermining GPs’ perceptions of the usefulness of the scientific 
evidence. These include avoiding underdiagnosis, preserving professional legitimacy (Chapter 3), or 
responding to everyday clinical realities such as patient demand (23). Mindlines have also been largely 
ignored by those responsible for the development of guidelines (20). I have shown that GPs perceive 
there to be a proliferation of mutually contradictory formal guidelines in this area, which consequently 
has undermined trust in formal guidelines in general on PSA screening; I have also shown the 
relevance of mindlines to GPs’ practice in this area. These two findings suggest that what may be more 
pressing than the development of yet another prescriptive guideline may be the additional provision 
of clear guidance, taking account of the significant diversity in GP approaches and the considerable 
ambiguity uncertainty they described. I have argued throughout this thesis that it is not unreasonable 
for GPs to expect that expert bodies will provide clear guidance wherever possible, with explicit 
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acknowledgement of the challenges faced by GPs when balancing these issues. Professional guidance 
would focus on process, in combination with explicit endpoints outlined in guidelines.  
I suggest a collective effort from medical authorities to deliver guidance – involving open and 
transparent professional discussions – to clarify expectations, obligations, and to support GPs to make 
it possible to provide the best possible care, to practice to expected professional standards, and in 
specific local environments. This guidance may entail a suite of best approaches – to match the 
multiple, dynamic approaches of GPs (Chapters 3-6). For instance, flowchart guidance for GPs unclear 
about the screening process as a whole (especially relevant to those GPs treating the PSA as just 
another blood test); or professional training with GP educators to guide GPs not confident with 
application of knowledge or with resisting deeply (historically) ingrained attitudes and practice that 
are not aligned with current recommendations. The Journal of the American Medical Association 
(JAMA), for example, followed publication of new cholesterol guidelines with a pragmatic article on 
how to apply the guideline in clinical practice and when to consider ignoring it (43). Detailed ‘how to’ 
resources built into online systems accessible in the clinic, including less conventional issues (e.g. ‘how 
to’ – ethically and legally – discourage men who ask for a PSA test), might be useful starting points to 
support GPs, and create opportunities for reflective critical dialogue amongst clinicians and the 
profession. Integrated process evaluation (to identify inconsistencies in implementation) and outcome 
evaluation (to monitor effectiveness in practice, including unanticipated consequences) of the 
suggested interventions would be essential. For instance, educational visits for GP training purposes 
may be well received and increase GP knowledge, but effect little change in their screening behaviour. 
Even with clear and consensual professional guidance, there is always likely to be some range of 
variation in practice. However some types of variation will be reasonable, while others will arguably 
be unacceptable. Conditions that would justify variation include GP and patient values, specific 
practice conditions, and the unpredictable realities of general practice. Reasons for variation that 
could reasonably be rejected include practice motivated by profit or protecting reputation; or 
indiscriminate, defensive, or automatic screening due to clinician disengagement with the central 
issues. This is because screening is not inconsequential: there is potential to cause considerable and 
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irreversible harm to men (e.g. overdiagnosis and overtreatment) and to the healthcare system (e.g. 
financially, resources, trust in the profession). I suggest ways in which policymakers and the 
profession can intervene on individual GPs or groups of GPs – perhaps practicing in this way – in the 
following final section. 
At the individual GP level 
Behavioural researchers propose strategies like facilitated workshops, role-play with clinician 
educators, and self-monitoring activities in clinical decision making to stimulate behaviour change in 
health practitioners (44). However my model of PSA screening practices, from the perspective of GPs, 
suggests (1) it is not reasonable to just intervene on GPs and expect them to change, without also 
changing the many elements of the system that permit or even press GPs into screening; and (2) it will 
be important to consider not just end points (behaviours) but also the many parts of the process that 
lead to the behaviours: sources and types of knowledge (proximal and distal, formal and informal, 
explicit and tacit), trust and uncertainty, and the set of resources – interpretations of the evidence, GP-
held values and goals, typologies of patients – that a clinician brings into the consultation.  
Although in this section about implications I focus on PSA screening because this was the focus of my 
research, it seems important to note that, as generalists, GPs are faced with a wide array of patients 
and clinical presentations each day, and need somehow to remain across the practice 
recommendations for each of these presentations. Thus any of the recommendations below need to be 
considered in light of the many demands on any individual GP’s expertise and time.  
Nevertheless, given that PSA screening is prevalent in Australia, is generally thought to generate 
considerable harm, and could be otherwise (as demonstrated by the UK case), it seems reasonable that 
PSA screening should be one of the priorities for practice improvements in Australia. Prostate cancer 
screening is one issue in a collection of current challenges to primary care. It has been recognised as 
one of several key areas requiring attention under the international ‘Choosing Wisely’ programs, 
which are centered on reducing overuse and overprescribing, iatrogenic harms, and wasted resources. 
PSA screening is a good case study to draw from to question problematic practices that have become 
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ingrained in the health care system and in clinicians’ routine care, for challenging the way we think 
about healthcare, and designing for a more sustainable health care system delivering more effective, 
necessary care. Recent policy shifts would suggest that PSA screening is an ongoing public health 
priority in the Australian context. 
Sources and types of knowledge  
Key skills for processes conducive to evidence-based knowledge translation include first knowing who 
to trust for useful and reliable advice; and being able to question that advice (i.e. critical appraisal 
skills) (30). Tonnelli argues that institutions need to facilitate training of doctors in critical appraisal of 
all sources of evidence, equivalent to the training they receive for appraising scientific evidence (45). 
Individual clinicians also need to have capacity (with institutional support) to question professional 
advice. Current medical education reportedly rarely teaches students how to manage and/or resolve 
potential conflicts of interest, for instance, despite their being ubiquitous in the profession (46). 
Researchers have designed social models to train clinicians to recognise social and cultural forces 
shaping evidence, decisions, and policies when making clinical decisions (e.g. (47)); and the Consider 
an Offer framework described in Chapter 6 entails critically evaluating professional guidance (3).  
Continuous and critical evaluation of one’s own and others’ medical practice is important to ethical 
and evidence-based practice. A great deal of unreflective practice, and acceptance, was evident in both 
Australia and the UK: GPs reached decisions before being able to explain their reasoning for doing so, 
and/or ceased to register any conflicting evidence. Paying specific attention to intentional and 
meaningfully engaged practice is warranted, with a focus on developing more nuanced clinical 
expertise and ethical judgment (48).  
Clinicians will continue to use shortcuts in reasoning like heuristics to manage the cognitive load of 
medical decision-making; some are essential to clinicians’ understanding and practice of the ‘art’ of 
medicine. But as noted, they can be biased by availability and memorability. Further research into 
intuitive and heuristic reasoning and how evidence might be incorporated into such reasoning is 
necessary; Gigerenzer et al argue that if the profession can formalise and understand heuristics then 
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their use can be effectively taught, leading to less practice variation and more efficient medical care 
(22). Greenhalgh et al proposes that deeper study of mindlines, to determine how best to produce 
expert clinicians and expert patients, is key to preventing further harm (49). 
Trust and uncertainty  
In Australia currently, there are many voices of authority advising GPs on ‘best practice’, creating 
confusion and uncertainty about expected standards of care and longstanding distrust in the overall 
system because of ongoing disagreement (Chapter 4 & 5). In addition, GPs perceive there to be much 
at stake for them individually in relation to prostate screening and scope to take a ‘wrong’ course of 
action. GPs feel uncertain, distrust the evidence and authorities, and experience burden when 
grappling with the difficult value and normative judgments under these conditions. Building 
institutional trust is of high priority in taking seriously issues of trust, uncertainty, and the cognitive 
and emotional burden experienced by GPs, as well as cultivating evidence-based approaches. 
Institutional trust includes trust in groups of people like doctors, and in systems of knowledge, like 
science (50).  
In building institutional trust, the aim is to establish trust founded on professional roles, rules, and 
norms. This could include, for example, the introduction of formal conversations amongst clinicians in 
a clinic with the aim of agreeing on collective norms and targets and accepting mutual responsibility 
for achieving them (30). The goal of such endeavors is not only to build institutional trust, but to in 
turn bring individual GP values in line with those of their organisation (or to provide support for GPs 
to practice in a way that is somewhat discordant with their personal values if this serves other, 
arguably more important, values such as reducing harm or maintaining trust). Other goals include to 
reduce dissonance, uncertainty, and burden at the individual level, and to reduce reliance on 
unreliable sources of knowledge at risk of cognitive bias and jeopardising patient care, such as one-off 
experiences.  
Institutional trust underpinned UK practice. The challenge for Australian doctors is to locate where to 
place trust with good judgment, and to avoid the groupthink that might arguably come with trusting. It 
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should be noted that I am not advocating blind obedience, which leads people to stop thinking when 
confronted with an apparent source of authority, whether human (e.g. a charismatic urologist who 
advises GPs to start screening all men at 40 years) or technological (e.g. a PSA test result) (51), making 
people less rather than more critical (50). I am instead proposing that institutions seek to provide a 
consistent trustworthy platform from which GPs can confidently take direction in combination with 
applying individual clinical reasoning and expertise.  
Central set of resources 
In this last section I return to the three background conditions (interpretations of the evidence, GP 
values and goals, and patient typologies), which were central to GPs’ descriptions of their screening 
approach, and propose how individual GPs might be supported to more effectively utilise these 
resources in clinical practice. 
Interpretations of the evidence. Although it is reasonable to expect GPs to have varying statistical 
literacy; it is their professional responsibility to be familiar enough with the best current research 
evidence about PSA screening (not necessarily a detailed epidemiological account) to have an 
informative evidence-based conversation with patients. Clinicians also have a recognised collective 
responsibility to ensure their mindlines are concordant with research evidence where possible (2). 
Some GPs interviewed were already attentive to epidemiological evidence: such GPs might be trained 
or encouraged to share evidence and uncertainty with patients using decision aids (52), to practice to 
a consistent standard. Greenhalgh et al note that few clinicians are aware that decision aids, like 
infographics and options grids, exist (49), so active support is likely to be necessary if they are to be 
used more often. There is, however, an issue regarding equal access to good quality care for men 
regarding PSA screening. While GPs may be differently motivated to act in accordance with the 
evidence and to explain the evidence to their patients, it seems difficult to justify men receiving advice, 
clinical care, and opportunity for consent more or less arbitrarily, as a result of the GP they happen to 
see. Thus, over time, and given the high public profile and demand for PSA screening, it does seem 
important to aim to bring all GPs up to an equivalent standard in their interpretations and 
communication of the evidence. Main et al (53) describe ‘core information sets’ which might be useful 
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to ensure consistent information is provided. Core information sets are constructed by clinicians, for 
example, and include baseline information which they consider pertinent to a specific clinical problem 
or process (encompassing values, beliefs, goals) but which is not typically discussed or included in 
guidelines and decision aids, with their focus on outcomes.  
GP-held values and goals. Acknowledging GP values and exploring them seriously and in a formal way 
should be of high importance in this context: they helped to explain practice variation and the GP 
experience. Ascertaining and integrating values is an important part of several movements in health 
care, including EBM (15). Values-based practice (VBP) is a relatively new skills-based approach to 
working with complex and conflicting values in health care; its proponents emphasise that it can 
support both evidence-based and ethical practice (15). There are examples of policy and service 
developments in values-based practice in the UK including a national framework for values-based 
practice supporting a number of initiatives, particularly in mental health (15). A key starting point in 
VBP is providing clinicians with opportunities to become more aware of their own values and how 
they influence their practice (54). Learnable clinical skills – such as communication skills – are also at 
the heart of VBP, and are essential to arriving at shared understandings of different values and of what 
matters for effective decision making (15). Given the centrality of values in determining practice 
variation in this context, any attempt to intervene is likely to benefit from incorporating the principles 
of VBP. 
GP typologies of PSA patients. Identifying and acknowledging patient values is similarly as important 
and relevant to VBP, but as noted many times throughout this thesis, were not commonly elicited or 
prioritised in screening decisions. Like GPs, patients will attach different value to different processes 
and outcomes. A focus on ways to make the values of all parties involved explicit, for reflection, 
collective deliberation, and ongoing critical appraisal (55), may thus help to locate shared solutions to 
the complexities of PSA screening.  
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To summarise: 
Target How might GPs be best supported to respond to current practice demands? 
System   Financial incentives, penalties, funding arrangements, tort reform/clarification 
 Consider supporting a two-step screening process 
Practice 
environment  
 A collective effort from medical authorities to deliver guidance, for example: 
o Flowchart guidance for GPs unclear about the screening process as a whole 
o Professional training with GP educators to guide GPs not confident with application 
of knowledge or with resisting deeply (historically) ingrained attitudes and practice 
that are not aligned with current recommendation 
o Detailed ‘how to’ resources built into online systems, including less conventional 
issues (e.g. ‘how to’ – ethically and legally – discourage men who ask for a PSA test) 
Individual GP   Training doctors in critical appraisal of all sources of evidence and to support individual 
clinicians to have capacity to question professional advice 
 Teach medical students how to manage and/or resolve potential conflicts of interest (social 
models have been designed to assist) 
 Continuous and critical evaluation of one’s own and others’ medical practice to facilitate 
intentional and meaningfully engaged practice 
 Build institutional trust 
 Aim to bring all GPs up to an equivalent standard in their interpretations and communication 
of the evidence 
 Acknowledge GP values and explore them seriously and in a formal way 
 Values-based practice as a way forward, currently utilised in mental health in the UK 
 
Evidence-based medicine will rightly remain at the core of clinical practice, guidelines, and policies, 
and healthcare systems, and is ideally the central component of public debate and clinical discussions 
about PSA screening. However EBM mechanisms alone seem unlikely to be able to influence the future 
of PSA screening in Australia. Rather than focusing solely on translating research evidence into 
practice, which to date has been the apparent focus of the NHMRC in this area, it is equally if not more 
important to think about how GPs can be supported to balance multiple, potentially conflicting, types 
of knowledge (including that from the research evidence), and to put structures and processes in place 
to support the informational and emotional needs of GPs. This study has demonstrated the multiple 
forms of knowledge and resources that are developed over time and mobilised in a PSA screening 
decision. Given this complexity, it seems important to address the range of influences on PSA 
screening at the same time, rather than expecting another synthesis of the evidence to do the work. A 
multi-pronged approach seems more likely to increase effective support for GPs and in turn, to 
influence reasoned care, curtail inappropriate use of resources, prevent patient morbidity from 
unnecessary intervention, and reduce GP burden. With recent policy shifts, it is an opportune time to 
commit seriously to addressing these wide-ranging issues.  
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In the following section I outline strengths and limitations of this study; in the final section I conclude 
this chapter, and the thesis. 
7.6 Strengths and limitations 
Limitations of this study: 
It is possible that those GPs who did not participate were in some way different to those who did (that 
is, that these data are subject to selection bias). However I heard a very wide and conflicting range of 
views, expressing very different perspectives on PSA screening, and have been able to report 
significant differences in the range of practice. This diversity suggests that it is, at least, unlikely that I 
inadvertently sampled a cohort with uniform and unusual reasoning and screening practices.  
As in any qualitative study, I am not able to infer prevalence of reported practices, beliefs, attitudes or 
values. The results of this study could be extended into quantitative survey research with whole 
populations of GPs to test prevalence. As with any interview-based study, I relied on GPs’ own 
accounts of their reasons, values and practices. These accounts came from Australia and the UK during 
2013 and 2014: policy and practice changes over time may change the perspectives of GPs, and my 
findings may not be transferable to all contexts.  
Public and patient perspectives were not included in this study; additional qualitative research might 
explore their perspectives on interacting with clinicians about PSA screening, to further inform policy 
and practice. 
Strengths of this study: 
An empirical synthesis across all PSA screening practice is the unique contribution of this study: it 
provides a nuanced analysis of how and why GPs test the way they do. I identified what matters to GPs 
and issues that encourage, prevent, and justify practicing in particular ways. These findings highlight 
the central place of values, interpretations of the evidence, and the number of divergent value 
judgments that can be made based on the same evidence-based ‘facts’.  
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I have showed diversity in what GPs considered to be good practice or a good decision or outcome, 
and the unique influence of informal sources of knowledge, trust and uncertainty, context, and 
“feedback loops” that are implicated in the process.  
Data were derived from a large mixed sample of GPs practicing in two countries; with the inclusion of 
various practice types and locations. Data may therefore apply to similar settings with similar health 
care systems. The process model that was generated from this data might have value as a workable 
model for any primary care encounter, not limited to PSA screening. Future work could investigate 
whether, for example, the model has relevance when applied to similarly contentious public health 
issues, such as breast cancer screening: Do the three background conditions apply? Are the four 
sources of knowledge relevant and if so, how are they balanced? It might also be of interest to examine 
whether issues of trust and uncertainty are integrated into the decision-making processes of clinicians 
practicing in different contexts with diverse health care systems, such as the United States. Do 
clinicians in the US also experience burden? Lastly, quantitative work, integrating elements of the 
model, could usefully ascertain the prevalence of the concepts evident in my analysis, in larger 
populations of GPs. 
7.7 Conclusions 
This research provides an in-depth comparative analysis of important drivers of prostate cancer 
screening reported from the perspective of GPs in two locations with diverse screening rates. For 
Australian GPs on the frontline, decision-making about PSA screening is extremely difficult and 
complex, and often personally burdensome. GP perspectives on PSA screening of asymptomatic men 
have not been considered in any great detail. The considerably diverse interpretations of ‘best’ 
practice illuminated in this study – based on GP values, trust, uncertainty, and context – is important, 
because GPs are the key reference point for advising on prostate screening. The questionable utility of 
the PSA test, the recognised harms of the screening process, and the lucrative business of PSA 
screening are central to considerations. Many GPs in this study felt uncertain, burdened, and/or 
unsupported, with little professional guidance, in knowing how to respond to these specific demands, 
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and limited in their capacity to make changes at the clinical level. I began this research project in 2012, 
the same year that the USPSTF recommendation discouraging PSA-based screening was released. 
Recently (April 2017), the Task Force proposed an updated recommendation in light of developments 
in the evidence (see Chapter 1). Policy continues to evolve, and attract substantial debate, in this field, 
and GPs are unlikely to feel less uncertain now than they did when my PhD research began. Given that 
past attempts to intervene in PSA screening practice in Australia seem to have had limited effect, a 
new approach that better reflects the complexity of this issue seems warranted. The model I have 
developed is one attempt to elucidate how PSA screening can and should be managed in primary care; 
it is my hope that it will make a contribution to finding more effective solutions.
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J PCancer screening is an important component of prevention and early detection in public health
and clinical medicine. The evidence for cancer screening, however, is often contentious. A
description and explanation of disagreements over the evidence for cervical, breast, and prostate
screening may assist physicians, policymakers, and citizens faced with screening decisions and
suggest directions for future screening research. There are particular issues to be aware of in the
evidence base for each form of screening, which are summarized in this paper. Five tensions
explain existing conﬂicts over the evidence: (1) data from differing contexts may not be
comparable; (2) screening technologies affect evidence quality, and thus evidence must evolve
with changing technologies; (3) the quality of evidence of beneﬁt varies, and the implications are
contested; (4) evidence about harm is relatively new, there are gaps in that evidence, and there is
disagreement over what it means; and (5) evidence about outcomes is often poorly communi-
cated. The following principles will assist people to evaluate and use the evidence: (1) attend
closely to transferability; (2) consider the inﬂuence of technologies on the evidence base; (3)
query the design of meta-analyses; (4) ensure harms are deﬁned and measured; and (5) improve
risk communication practices. More fundamentally, there is a need to question the purpose of
cancer screening and the values that inform that purpose, recognizing that different stakeholders
may value different things. If implemented, these strategies will improve the production and
interpretation of the methodologically challenging and always-growing evidence for and against
cancer screening.
(Am J Prev Med 2015;49(2):274–285) & 2015 American Journal of Preventive MedicineIntroductionCancer screening is well established in high-income countries, but its evidence base is con-stantly evolving and often contentious. This
leaves physicians and policymakers in a difﬁcult position,
forced to act in the context of methodological complexity
and substantive disagreement.1,2 Three cases of screening
for cancer or cancer risk are considered: cervical,
prostate, and breast screening. The unique characteristics
of the disease, test, and program in each case are outlined
in Table 1. Tables 2–4 catalogue sources of controversy inre for Values, Ethics and the Law in Medicine, University of
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rev Med 2015;49(2):274–285 & 2015 Ameeach case; these are discussed in more depth below. The
concluding section presents ﬁve common themes that
may help explain the ongoing controversies.
The aim is not to synthesize the evidence but to
provide the “backroom” story of the evidence on cancer
screening and better illuminate why experts so often
disagree.Cervical Screening
Cervical screening is one of the best-supported and least
controversial forms of cancer screening. Nonetheless,
there are potentially contentious features of the cervical
screening evidence base. These are as follows: (1)
dependence on observational data; (2) understanding,
communicating, and managing the balance of beneﬁt and
harm; and (3) the uncertain future impact of new
technologies.
The ﬁrst challenge in the cervical screening evidence
base is the status of the existing evidence. Screening wasrican Journal of Preventive Medicine  Published by Elsevier Inc.
Table 1. Disease, Test, and Program Characteristics in Each Case
Cervical cancer Prostate cancer Breast cancer
Tests used Pap smear using conventional
and/or liquid based cytology 
computer-assisted reading; HPV
DNA testing increasing 
cytology; visual inspection with
acetic acid/liquid iodine (VIA/
VILI) in LMICs
PSA test; new testing methods,
including use of biomarkers, are
being developed; DRE also used
Mammogram; ﬁxed or mobile
mammogram unit; recently
widely upgraded to digital
technology
When test was invented Pap test developed late 1930s First commercial PSA test
released in 1986
X-ray used for breast disease
1910s; ﬁrst screening RCT
1963–1975
When test was ﬁrst
used for screening
Used to screen asymptomatic
women from the 1940s
USFDA approved PSA test for
prostate cancer screening in
1994
Ad hoc screening from mid-20th
century3; population screening
programs 1980s onwards (based
on publication of results from
early RCTs)
What test is designed to
detect
Abnormal cells on the cervix
(cytology, VIA/VILI) or presence of
oncogenic HPV strains (HPV test)
Raised serum PSA levels Variations in soft tissue
radiolucency; originally
diagnostic
Relationship between
test and target disease
HPV-caused lesions are potential
precursors for cervical cancer
Poor; test not developed to
screen for cancer; elevated PSA
may not indicate cancer risk
Cancers have characteristic
(often subtle) soft tissue
appearances on x-ray
What results of
screening are reported
Lesions: nature and severity
(grade) of changes; reporting
standards differ; HPV reported by
type
PSA levels, expressed as
nanograms of PSA per milliliter
(ng/mL) of blood
Apparent presence of masses
and lesions suspicious for
invasive and/or in situ cancer
Contention over test
itself
Cytology is prone to human error;
terminology and reporting
standards vary; sensitivity and
speciﬁcity estimates vary widely4
There is no meaningful “normal
range” for the PSA test in
screening
There is variation in what degree
of suspicion constitutes a
positive screen
Variations between
jurisdictions that may
change the evidence
base regarding beneﬁt
and/or harm
IARC recommends 3-yearly
cytology screening from 25 years;
evidence base pools data from
widely varied programs:5 start-
age ranges from 18–30 years,
interval 1–5 years; reporting
standards, terminology and
treatment vary
Differences in target age,
recommended ﬁnishing ages,
screening intervals, deﬁnition of
“abnormal,” biopsy thresholds
Differences in target age,
screening intervals, thresholds
for recall and biopsy; service
studies may differ in participant
population age (and therefore
underlying cancer risk), follow-up,
out-of-study screening
Developments in the
test
Tests that detect oncogenic-type
HPV may supersede cytology as
primary screening test
New test rules in development;
variations proposed (free:total
PSA ratio, PSA density, velocity,
doubling time, prostate health
index) for clinical signiﬁcance; no
evidence these improve health
outcomes2
Increasing use of tomosynthesis
(integrated 2/3D mammography)
and MRI, which may contribute to
both beneﬁt and harm
DRE, digital rectal examination; HPV, human papillomavirus; IARC, International Agency for Research on Cancer; LMICs, low- and middle-income
countries; MRI, magnetic resonance imaging; PSA, prostate-speciﬁc antigen; USFDA, U.S. Food and Drug Administration; VIA, visual inspection of the
cervix using acetic acid to highlight precancerous lesions; VILI, visual inspection of the cervix using Lugol’s iodine to highlight precancerous lesions.
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between the late 1940s and early 1960s, and data from
those programs, rather than from controlled trials,
provide the evidence base for cervical screening effective-
ness. Observational studies compared screened and
unscreened populations and showed reduced cervical
cancer incidence and mortality in the former.5,30,31 This
evidence base clearly shows that cervical screeningAugust 2015reduces morbidity and mortality: what is less clear is
who to screen, when, and how to optimize beneﬁt and
minimize harm.
The cervical screening evidence base is susceptible to the
well-known biases of any observational study.1 It is not clear
how these biases should be taken into account. In addition,
the observational data about cervical screening cross juris-
dictions in which there are substantially different programs
Table 2. Main Issues in Cervical Cancer Screening
Issue Explanation
Incidence and mortality of cervical cancer is low in
high-income countries
The incidence of cervical cancer is much lower than, e.g., breast or
prostate cancer, so number needed to screen over many years to avoid
one death is high.6
Cervical screening reduces morbidity and mortality from
cervical cancer
Early Nordic observational studies suggest a mortality beneﬁt from
screening using the Pap test.
Organized programs confer greater beneﬁt than opportunistic screening.5
There is no RCT evidence from high-income countries Because Pap test screening for cervical cancer was introduced so early, it
was not possible or ethical to conduct an RCT of its effectiveness.
RCTs are being conducted in LMICs These will be a useful evidence base for LMICs.
It is easy to overstate the beneﬁts of cervical cancer
screening because the underlying mortality rate is low
Because incidence is low, number needed to screen is high and absolute
risk reduction low.
Statements of beneﬁt may obscure the relatively small absolute number
of people affected. E.g., mortality is often said to have halved in the
decade following commencement of organized screening in Australia: this
is accurate, but the absolute change was from only 4/100,000 to
2/100,000 women.
Most cervical lesions regress It has been recognized since the 1970s that most cervical lesions will not
progress to cervical cancer.
It is not clear what proportion of lesions regress, or which
lesions will regress
It may never become clear which lesions will regress or what proportion of
them will regress.
CIN3 progression to cancer has been estimated at 12%,7 20%,6 and 30%8
in different studies.
Overtreatment is difﬁcult to measure and to manage The majority of treatment is overtreatment, but as it is not possible to
identify which lesions will regress, this may not be resolvable with the
technology currently available.
There are vastly more abnormal results than there are invasive cancers,
especially in women aged o25 years; e.g., in Australia in 2010 the
incidence of invasive cancer in women aged o25 years was 1.5/
100,000, but 40,000 of the 250,000 screens in women agedo25 years
returned an abnormal result.9
Perinatal morbidity in treated women is the main iatrogenic harm of
concern.10
The evidence base is affected by differences in program
design between countries
Evidence about cervical screening comes mostly from monitoring data
from screening programs. However, different countries run their programs
differently. They use different tests, screening ages, and screening
intervals. They classify and report on their programs using different
terminology and standards. Then the data from these very different
contexts are combined. This has implications for the evidence base.
Screening technology is changing Because of HPV vaccination, a move away from cytology seems likely; an
alternative future might be mass HPV screening with cytological
examination of those with positive HPV tests.
It is unclear what the incremental beneﬁts and costs of these new
technologies over existing screening programs will be. This is a rapidly
evolving part of the evidence base in cervical screening.
CIN3, Cervical intra-epithelial neoplasia; HPV, human papilloma virus; LMICs, low- and middle-income countries.
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nal data from different settings may not be as easily
comparable as is often assumed (Table 1). To minimize
bias, meta-analysis of RCT evidence is the preferred method
for estimating beneﬁt and harm in screening. RCT evidence
of different screening technologies, and combinations of
technologies, is emerging. This may add more certainty tothe cervical screening evidence base, although some of the
ﬁndings from RCTs in low- and middle-income countries
(LMICs) may not be transferable to other settings.32–35
The second challenge in this evidence base concerns
understanding, communicating, and managing the bal-
ance of beneﬁt and harm; this problem has several
dimensions. It is easy to inadvertently overstate thewww.ajpmonline.org
Table 3. Main Issues in Prostate Cancer Screening
Issue Explanation
Most prostate cancer is not life threatening Although prostate cancer can be life threatening, the vast majority of cases are
indolent.
Early trials of PSA screening were of poor quality Early trials—which reported very positive ﬁndings—had serious methodological
problems, including low participation in screening, failure to randomize, and
failure to analyze by intention to screen.
Large RCTs are currently underway The ERSPC trial11 and the USA PLCO12 trial have made interim reports but are
ongoing. These are the only large, methodologically sound trials of PSA
screening conducted to date.
There is controversy over the design of the current
large RCTs
ERSPC included different countries using different screening tests and
procedures. Those screened in the trial were more likely to be treated in a
University hospital. The Swedish subset of ERSPC compared volunteer
screenees (probably a healthier group) to whole-population controls
(particularly signiﬁcant because Sweden was one of only two, out of seven,
subgroups to report statistically signiﬁcant reductions in prostate cancer
mortality after 11 years). These patterns are likely to bias results in favor of
screening.
In PLCO,450% of controls were screened during the trial, and 44% of
participants had previously been screened.
Methodologists disagree on whether these biases are fatal to the results of the
trials.
PSA screening may decrease prostate cancer death Some trials suggest reductions in incidence of prostate cancer death.
Observational studies in highly screened populations suggest lower prostate
cancer mortality.
PSA screening is unlikely to decrease all-cause
mortality
Only ERSPC has reported a mortality beneﬁt, which was very small in absolute
terms. 1,055 men would have to be screened to prevent one death from
prostate cancer over 11 years.13
The PSA test is not prostate cancer-speciﬁc PSA test has poor sensitivity and speciﬁcity for detecting prostate cancer.
A PSA44.0 ng/mL produces a 6.2% false positive rate but detects only 20.5%
of cancer cases.14
PSA test cannot distinguish increased cancer risk from other common
conditions, e.g., benign prostatic hyperplasia, prostatitis.
Certain medications (e.g., ﬁnasteride), ejaculation, and prostate manipulation
can also increase PSA levels.
PSA test manufacturers and PSA thresholds vary
between studies, laboratories, and clinicians
Studies and laboratories employ more than one kind of PSA test and different
abnormal thresholds.
The evidence base is thus hard to interpret because of lack of comparability.
Conventional threshold for further investigation is 4 ng/mL, but men with PSA
levels 4–10 ng/mL may not have prostate cancer,15 and men with resultso4
ng/mL can show histological evidence of prostate cancer.16,17
Lowering the threshold below 4 ng/mL would increase overdiagnosis and
overtreatment of clinically unimportant disease.18,19
A meaningful threshold for screening may not exist because of the test’s poor
sensitivity and speciﬁcity; i.e., the PSA test has little utility as a screening tool
for prostate cancer. There is currently no alternative test available.
PSA screening can increase the likelihood of receiving
treatment
In the U.S., e.g., up to 90% of men with prostate cancer diagnosed as a result
of PSA testing receive treatment.20
Prostate cancer treatment can produce considerable
negative consequences
Treatment can result in erectile dysfunction or impotence, anxiety, urinary
incontinence, bowel dysfunction, or death.
ERSPC, European Randomized Study of Screening for Prostate Cancer; PLCO, Prostate Lung Colorectal and Ovarian Cancer trial; PSA, prostate-speciﬁc
antigen.
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high-income countries. This is because mortality from
cervical cancer in high-income countries is considerably
lower than for cancers such as breast and prostate. This
was true even prior to widespread Pap testing. ForAugust 2015example, the age-standardized mortality rate from cer-
vical cancer in the United Kingdom was approximately
8/100,000 in 1971, compared to 37.5/100,000 for breast
cancer and 20/100,000 for prostate cancer.36 Thus, even
substantial proportional (or relative risk) reductions in
Table 4. Main Issues in Breast Cancer Screening
Issue Explanation
Mortality beneﬁt exists Most studies show mortality beneﬁt from organized mammographic screening—
especially for women aged 50–70 years—of approximately 20%.21–24
The extent of mortality beneﬁt is contentious Estimates of beneﬁt vary considerably.
Different study types are used, including RCTs, observational studies, and
modelling.
Meta-analysis of RCTs is widely regarded as the best way to identify population
beneﬁts, but different meta-analyses include or exclude different RCTs because
of differing judgments about study quality.21–24
Mortality beneﬁt is less than originally thought Recent meta-analyses of RCTs suggest that beneﬁt is lower than suggested by
the earliest studies.
This can be partly attributed to problems in quality with some of the RCTs.
It has been hypothesized that treatment improvements in recent decades may
leave less room for screening to have an effect and make older trial data less
relevant.21–24
The harm from false positive screening tests varies
between programs and populations
The rate of false positives varies as a result of factors such as the following:
 Test factors, e.g., equipment quality; skill of the clinicians reading the
mammograms
 Differing policies and standards regarding acceptable levels of false positives
and false negatives
 Frequency of screening in the program (increased frequency tends to
increase the absolute number of false positives)
 Individual participant factors (e.g., greater breast density in some women,
including pre-menopausal women and women taking hormone replacement
therapy [HRT]) that can make mammogram interpretation more challenging
(and false positives more common)
 Population factors: the frequency of false positives in part depends on the
positive predictive value of the test, which depends on the prevalence of
disease in the screened population. This depends on population risk proﬁle
(e.g., younger women have lower incidence).25
The extent of overdiagnosis is contentious Estimates of overdiagnosis vary as a result of factors including the population
studied; research questions asked (e.g., total cancer or invasive cancer only);
methods used (e.g., comparing incidence in intervention and control arms of
RCTs, comparing observational annual incidence data, comparing observational
cumulative incidence data, using simulated population models); correction for
possible biases such as lead time; and fundamental assumptions when
estimating overdiagnosis in models.1,10,26,27
Biological consequences of in situ disease is
unclear
Before the onset of screening, in situ disease was mostly diagnosed in
conjunction with an invasive cancer. It was not anticipated to be a common
isolated ﬁnding on screening.
It is unclear what the right response to increased diagnosis of in situ disease
should be.
Knowledge of the natural history of in situ breast diseases is improving but still
incomplete.
Diagnosis and management are controversial, especially for less aggressive
diseases (e.g., low-grade DCIS), where risk of death is only slightly increased but
surgery to negate the risk may be extensive.21–24
There are small radiation harms of screening Harm from radiation during mammography is generally agreed to be real and
may be greater in women screened more often (e.g., those identiﬁed as carrying
potentially harmful mutations in the BRCA1 or BRCA2 genes).28,29 However, in
screening of the general population, these risks are extremely small and likely to
be further reduced by the implementation of digital mammography.
BRCA1/BRCA2, BReast CAncer susceptibility gene 1 and 2; DCIS, ductal carcinoma in situ.
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small reductions in the absolute number of deaths
prevented in well-resourced countries (Table 2). Cervical
cancer, however, remains a signiﬁcant burden and
leading cause of cancer mortality in some low-income
regions.37In addition, the treatments triggered by screening may
be unnecessary and harmful in some cases. Cervical
screening reduces cancer incidence as well as mortality.
This is because it detects cellular abnormalities on the
cervix, or pre-cancerous lesions, caused by human
papillomavirus (HPV) (Table 1). Cervical cancer is awww.ajpmonline.org
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However, cellular abnormalities are common: there is an
estimated lifetime incidence of 40% in women born since
1960.6 Also, progression appears to be less linear than
originally thought,38 and most HPV infections regress
spontaneously. This means that four of ﬁve women with
dysplasia may be treated unnecessarily,6 but at present it
is not possible to identify which individual high-grade
lesions will regress, and can be left untreated, or will
progress, and require treatment (Table 2).
The evidence does suggest a solution, however: to focus
on minimizing harm, particularly in women aged o25
years. The evidence shows that (1) HPV infection is most
likely to spontaneously regress in this group; (2) paradoxi-
cally, these women also experience more abnormal cytol-
ogy, treatment, and cervical incompetence and perinatal
morbidity as a result of treatment; and (3) crucially, there is
no mortality beneﬁt in screening this age group. 10,39 As a
result, many countries are delaying commencement of
screening until age 25 years (Table 1), recommending
screening thereafter only every 3–5 years, or both.40,41
Although this change is supported by the evidence, in
many jurisdictions women continue to be screened earlier
and more often than these guidelines would support.5,42,43
Finally, it is important to anticipate the future impact of
new technologies on the evidence base and on practice.44,45
Research increasingly supports screening women aged
Z30 years using an oncogenic-type HPV test instead of
or in addition to cytology.32 The U.S. Preventive Services
Taskforce (USPSTF), for example, now recommends that
women aged 30–65 years can screen with a combination of
cytology and HPV testing every 5 years if they wish, rather
than with cytology alone every 3 years.33 The U.S. Food
and Drug Administration (FDA) has recently approved the
use of HPV testing alone as a primary screening test,46
which seems likely to result in further revision of recom-
mendations. The recommendations are somewhat ahead of
the evidence—with the exception of an Indian cluster
RCT,34 primary HPV testing has not yet shown mortality
beneﬁt. Similarly, comparative beneﬁts and harms of
different sequential combinations of HPV and cytology
testing are not yet clear. However, RCTs of newer screening
technologies (e.g., HPV tests, including self-testing and
testing in vaccinated populations, and computer-assisted
cytology reading) are underway. HPV vaccination will
further reduce underlying risk in the population and
thereby potentially reduce the relevance of the existing
evidence on cervical screening.
Screening for Prostate Cancer
Unlike cervical screening, prostate-speciﬁc antigen (PSA)
testing for prostate cancer risk is intensely contested47;August 2015this includes contention over the relationship between
evidence and practice. Important issues include (1)
inconsistency between the ﬁndings of different trials
(and tension over the interpretation of observational
ﬁndings); (2) variation in tests and thresholds for
abnormality within and between studies; and (3) evi-
dence suggesting that the PSA test performs poorly for
screening purposes.
The ﬁrst challenge is the quality and interpretation of
research about the efﬁcacy and effectiveness of PSA
testing. Observational data from highly-screened com-
munities are sometimes used to argue that testing reduces
prostate cancer mortality.16,48,49 However, as noted ear-
lier, ﬁndings from observational studies may be mislead-
ing because of characteristic biases such as lead time,
length time, and selection bias.2,18 Early RCTs were of
poor quality (Table 3).2,18 Since then, two ongoing RCTs
have reported results: the European Randomized Study
of Screening for Prostate Cancer (ERSPC) and the U.S.
Prostate, Lung, Colorectal, and Ovarian Cancer (PLCO)
Screening Trial. PLCO has shown no effect on prostate
cancer–speciﬁc or all-cause mortality.50 ERSPC reported
reduced prostate cancer mortality in screened men but
no change in all-cause mortality.11 There is considerable
controversy over trial design (Table 3). Although difﬁcult
to quantify, frequency of testing and follow-up and type
of treatment provided after diagnosis are likely to affect
outcomes reported from trials.12,13,51
Expert bodies increasingly advise against PSA screen-
ing. The USPSTF concluded that the mortality beneﬁt is
very small and outweighed by risk of harm.52 The
American College of Preventive Medicine has similarly
concluded that populations should not be routinely
screened with the PSA test, owing to insufﬁcient evi-
dence.53 The Australian National Health and Medical
Research Council evidence guideline on PSA testing in
asymptomatic men has recently concluded that there is
no effect of PSA testing on all-cause mortality and that
no conclusions can be drawn about prostate cancer
mortality.54 These decisions are consistent with the
evidence, which suggests that PSA testing may reduce
the short-term risk of dying from prostate cancer by a
very small amount, at the cost of a much greater risk of
harm, including from false positive results, overdiagnosis,
and overtreatment. The question this raises is: If a
screened man will not die any later than an unscreened
man, is it meaningful to prevent him from dying of
prostate cancer in particular? And at what cost (harms to
the man as well as expense to the man and the health
system) should this goal be pursued? This question seems
to divide experts, not least according to whether they care
for men with the disease or have experienced it
themselves.
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interpretability and comparability of PSA results. This is
an issue for many screening tests (Table 1), but especially
for the PSA test. Manufacturers and laboratories employ
divergent PSA calibrations, producing different readings
from the same sample.55 Even when identical methods
are used, thresholds set to separate “normal” from “high-
risk” PSA levels often differ. Within and between studies,
different standards are often combined, potentially
invalidating conclusions.16,56 Tests and thresholds used
by different countries participating in large trials often
vary (Table 3), and trial study groups have been unable to
identify acceptable PSA cut offs for prostate cancer
screening. This makes it difﬁcult to compare study results
and apply them to real-life settings.
The ﬁnal problem with interpreting the evidence about
PSA testing is addressing the potential for harm. The
evidence suggests that sensitivity and speciﬁcity of the
test are poor (Tables 1 and 3), which means cancers are
missed (poor sensitivity) and false positives are common
(poor speciﬁcity). The evidence suggests that PSA testing
increases diagnosis of indolent disease, frequently cas-
cades to diagnostic biopsies and follow-up treatments,
and produces physical and psychological harms and
costs: for every life saved by the PSA test, up to 48 men
may be overtreated (Table 3).57 Determining whether
this is acceptable requires difﬁcult debate over the nature
of a good outcome, and what harm or expense that
outcome might justify.
Screening for Breast Cancer
Like the evidence for PSA testing, the evidence for breast
screening has been controversial. Important features of
this evidence base include (1) uncertainty regarding the
extent of breast cancer mortality reduction beneﬁt; (2)
uncertainty regarding the extent of harm; and (3)
disagreement about managing in situ disease.
The ﬁrst challenge for the evidence on breast screen-
ing is that despite a considerable body of research, the
degree to which breast screening reduces breast cancer
mortality remains unclear. The evidence base includes
11 RCTs (1971–2006), numerous observational studies,
and mathematical models. It is probable that an invita-
tional program of breast screening by mammography
offers a population breast cancer mortality beneﬁt,
particularly for women aged 50–70 years. If poorer-
quality RCTs are removed from meta-analyses, this
beneﬁt is reduced, but by how much is unclear
(Table 4). Absolute and relative beneﬁts are lower in
women aged o50 years.58 Also, treatment has greatly
improved in recent decades, so including RCTs from the
1970s–1990s may overstate the beneﬁt of screening(Table 4).1,21–24,26 The degree to which widely observed
declines in breast cancer mortality are attributable to
improvements in treatment remains contested.59 It is
unclear how this can be resolved. Incremental changes in
technology—from ﬁlm mammography to digital mam-
mography, tomosynthesis (integrated two-/three-
dimensional [2/3D] mammography) and magnetic res-
onance imaging (MRI) to screen high-risk women—may
also affect the balance of screening beneﬁts and
harms.60,61
The second concern is the extent of harm that is
caused. Invitational mammography programs cause
harm, including false positives and overdiagnosis. The
absolute rate of false positives can vary according to the
equipment used, skill and experience of ﬁlm readers, test
thresholds, and screening frequency (Table 4).25
Although the rate of false positives per screen may be
low, they accumulate; thus the chance of false positive
recall or biopsy over a lifetime is much higher. Increas-
ingly, evidence suggests that breast screening produces
overdiagnosis of both invasive and in situ breast cancer.
Although experts agree that mammography screening
causes overdiagnosis, there is disagreement on its extent.
A recent meta-analysis suggests that, in women invited
to screening, there is an 11% lifetime risk of over-
diagnosis as a proportion of cancers that are diagnosed,
and a 19% risk during the active screening period.21,24
Harms, especially overdiagnosis, may tend to outweigh
beneﬁts in women aged 470 years as they age.62
However, the relevant evidence is highly contentious
for methodological and other reasons explained in
Table 4.26,27
The ﬁnal challenge in this evidence base concerns
ductal carcinoma in situ (DCIS), which represents
approximately 17%–34% of screen-detected cases and
20%–25% of all newly diagnosed cases of breast cancer in
the U.S.63 Women are rarely diagnosed with DCIS
because they experience symptoms: DCIS is diagnosed
almost entirely as a result of screening. Overdiagnosis of
DCIS is widely considered an important harm of
mammographic screening. However, the evidence is
not clear on either the natural history of DCIS or how
aggressively DCIS should be treated. More research is
needed to evaluate treatments for in situ disease.21,26What Characteristics of the Screening
Evidence Base Could Explain Expert
Disagreement?
In high-income countries, cancer screening is a familiar
feature of preventive medical care. Screening is expected—
with good reason—to be informed by evidence. Across thesewww.ajpmonline.org
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three more explicit tensions that help to explain why
interpreting the evidence is such a difﬁcult task.Tensions in the Evidence Base That Are
Discussed Less Often
Two tensions in the evidence base are under-examined: the
comparability of data between studies and contexts, and
the impact of technological developments. These tensions
are also difﬁcult to resolve and potentially destabilizing.
Data from different contexts may not be comparable,
particularly for observational data from monitoring
studies. As shown, the evidence base contains data from
different times, countries, and programs, and from
populations with varying event rates (Table 1). Trans-
ferability of this evidence is difﬁcult for several reasons.
Because screening trials are particularly large and need
long follow-up to show effects, they can be especially
susceptible to the passage of time. When early trials were
conducted, screening techniques were less developed,
treatments less effective, cancer incidence lower, and
cancer mortality often higher. Breast screening evidence,
for example, includes decades-old trials; treatment has
progressed substantially since they were conducted.
Evidence from screening trials is also susceptible to local
variation (e.g., in disease biology, event rates, and age
distribution), not least because screening is applied to
whole populations, not just people who are ill. As HPV
vaccination is implemented differently around the world,
for example, the underlying event rate for cervical cancer
will change dramatically. The resource intensiveness of
cancer screening trials also means that (1) few trials are
done (leaving less evidence to interpret); (2) trials are
often funded by industry (changing the research ques-
tions); and (3) trials are somewhat dependent on local
screening and treatment practices (e.g., target age,
screening intervals, testing techniques, follow-up time,
available treatment). The variability and transferability of
screening evidence is a challenge for methodologists, and
even more so for clinicians and policymakers, as the
characteristics on which the evidence depends are not
always made clear in reporting.
The second under-examined tension is that screening
technologies affect evidence quality; thus, evidence must
evolve with changing technologies. Cancer screening
relies on complex cascades of technology for collecting,
imaging, analyzing, and interpreting possible changes in
human bodies. Without the technology, there is no
screening, but as technology evolves, it potentially makes
existing evidence obsolete.64
The evidence on PSA is hampered by poor technology.
The PSA test has limited sensitivity and speciﬁcity,August 2015studies and laboratories use multiple test types and
different thresholds, there is no meaningful “normal
range,” and new test rules do not appear to change
patient outcomes. Some propose using test results only
within, rather than between, patients, but the poor test
characteristics of PSA make even this problematic. It is
understandable that clinicians want to retain some tool to
measure prostate cancer risk.65 However, given the test
characteristics of the PSA, it may not be possible to
generate a meaningful evidence base about its use in
populations.
The cervical screening evidence base is shifting
because of changing technology; tests that detect
oncogenic-type HPV may become the primary form of
screening in vaccinated populations. Mammography
remained relatively constant in the 20th century, chang-
ing only incrementally from ﬁlm to digital mammog-
raphy. In the 21st century, we face substantial
technological change, with moves to tomosynthesis
(integrated 2/3D mammography) and MRI screening of
high-risk women. Although tomosynthesis is receiving
considerable attention in the lay press and peer-reviewed
literature, attempts to estimate its effects have been based
on opaque assumptions and limited evidence. It seems
possible that both MRI and tomosynthesis will enhance
both the beneﬁts and harms of screening, but at present
this is unknown.60,61Acknowledged Tensions in the Evidence Base
Three other, more explicit, tensions are over the quality
of evidence of beneﬁt, the relatively new evidence
regarding screening harm, and risk communication.
The quality of the evidence of beneﬁt from screening
varies, and the implications of this evidence are con-
tested. When one expert says to another, “You are wrong
about the evidence on screening,” she is likely to mean
this: “I disagree with the criteria that you have used to
separate good-quality studies, which should be included,
from poor-quality studies, which should be excluded.
I therefore disagree with your conclusion.”
The cancer screening evidence base contains observa-
tional studies, RCTs, and modeling of widely varying
quality and with disparate results. Early studies of
screening generally suggested greater beneﬁt, and later
studies less beneﬁt, which may be because early trials
were poorly designed (e.g., PSA) or because recent
treatment improvements leave less room for screening
to provide beneﬁt (e.g., breast screening). Even new trials
contain methodological ﬂaws (e.g., PLCO, ERSPC), and
methodologists often disagree about study design, par-
ticularly over whether screened and unscreened groups
are comparable.
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and so are rare. Thus, new conclusions generally arise
from re-analyses of existing research ﬁndings rather
than from new trials. Researchers performing meta-
analyses must decide on criteria for including and
excluding studies. The recent Marmot review of the
evidence on breast screening demonstrates that this is
possible,21 even in high-proﬁle situations, but disagree-
ment over criteria is likely to remain. And when new
analyses produce new ﬁndings, those whose settled
beliefs are challenged may perceive the chosen criteria
as arbitrary or incorrect. This highlights the importance
of transparency regarding how and why meta-analyses
are conducted.
The second acknowledged tension is that evidence
about harm is relatively new, and there are gaps in that
evidence and disagreement about what it means. Initially,
cancer screening researchers focused on measuring
screening beneﬁts; they have only recently turned to
potential harm. For all three cases—cervical, prostate,
and breast cancer (including DCIS)—there is limited
evidence about which instances of disease or pre-disease
are aggressive and require treatment, and which will be
indolent or regress. Because of this, many people will be
overtreated and may be harmed. Researchers are trying
to address this gap by studying the mortality beneﬁt of
treatment for small, Grade 1, node-negative breast
cancers, for example, or the genetic proﬁle of aggressive
versus indolent prostate cancers. This work may assist in
the future. In the meantime, existing knowledge suggests
opportunities to reduce harm. For example, there is
currently no way to determine which cervical lesions will
regress or progress. However, epidemiological data
demonstrate that women aged 18–25 years are most
likely to have unnecessary treatment, experience harm
from treatment, and fail to beneﬁt from treatment. This
has led some jurisdictions to restrict cervical screening to
women aged 425 years.
Even when evidence about screening harm emerges,
experts often disagree about what it means and how to
respond. This may be in part because public health and
medical professionals have learned to think in a
particular way, and have taught citizens to think
similarly, of cancer and pre-cancer as progressive and
life-threatening, and screening as one of few defenses
against this threat. For the ﬁrst several decades of
screening research, harm was rarely measured.
Although later research suggested that screening may
harm, it may be difﬁcult for this evidence to reach public
attention given the powerful cultural meaning of cancer
death.66,67 New facts about screening harm are hotly
contested, with regard both to their accuracy and their
implications. And screening programs continue to beevaluated primarily against increasing participation
targets, rather on the likely balance achieved between
beneﬁt and harm.
For example, it is generally accepted that prostate
biopsies and prostate cancer treatments are likely to
produce harm. This is taken as a fact, but that fact is
interpreted very differently. Some argue that most
screen-detected prostate cancers are indolent, so most
diagnosis is overdiagnosis, and most harm done is
unnecessary. They conclude that insurers or policy-
makers should constrain clinicians who test healthy
men, thus preventing harm. Others take a different view,
that without PSA testing, clinicians have no way of
diagnosing tumors that would develop or metastasize.
These experts tend to take the view that insurers or
policymakers should leave testing open to clinicians and
allow the possibility of harm to be dealt with via more
judicious decisions about treatment. Their opponents
might counter with studies showing that men diagnosed
with prostate cancer generally proceed to treatment
rather than “watching and waiting.”20 Although each
party can present data of some kind to support their
claims, it is worth remembering that data become
evidence only through interpretation and that experts
are susceptible to biases in this interpretive process.68,69
The ﬁnal acknowledged tension is that evidence
about outcomes is often poorly communicated, despite
the evidence about communication. Researchers and
programs tend to express outcomes using relative risks,
which incorporate baseline risk and are easier to
generalize across contexts. However, research shows
that relative risks encourage lay people and clinicians to
overemphasize beneﬁts and minimize harms. This has
been acknowledged as ethically problematic, poten-
tially biasing or manipulating people’s perceptions,
misleading them, and undermining their autonomy.70
If experts are obliged to communicate honestly with
citizens—an obligation that seems supportable—this
becomes an urgent issue to address for all forms of
cancer screening.
Conclusions
The beneﬁts and harms of screening are often ﬁnely
balanced—more than anticipated when screening was
established. There are both unique and shared character-
istics of cervical, prostate, and breast screening that help
to explain the challenge of balancing beneﬁt and harm.
These include the incomparability of data from different
times, places, and programs; the instability of the very
technology on which screening is based; disagreement on
which studies are sufﬁciently well designed to be taken
seriously; gaps in knowledge; and disagreement aboutwww.ajpmonline.org
Carter et al / Am J Prev Med 2015;49(2):274–285 283how to understand newly emerging evidence of harm.
This suggests ﬁve principles for evaluating and using the
evidence:1.Auattend closely to transferability;
2. consider the inﬂuence of technologies on the
evidence base;
3. query the design of meta-analyses;
4. ensure harms are deﬁned and measured; and
5. improve risk communication practices.However, even more fundamental are questions about
the purpose of screening and who should make decisions
about screening. Should insurers or policymakers leave
screening options open for clinicians and patients to
choose? Or should they be directive, promoting some
forms of screening and limiting others to minimize
harm? Should community engagement and deliberation
guide screening policy and practice? And what should the
purpose of screening be? There are many potential aims
of cancer screening, including preventing cancer death,
reducing all-cause mortality, minimizing anxiety, max-
imizing cost efﬁciency, and minimizing avoidable harm.
These different aims reﬂect different values, which may
differ between patients, clinicians, funders, and policy-
makers. Questions about the evidence base need reso-
lution. This should be complemented with clear thinking
about the aims of screening. Only when the aims of
screening are clear will researchers be able to generate an
evidence base sufﬁcient to assist decision making, and
clinicians be able to best support their patients to make
good screening decisions.This work is supported by the Australian National Health and
Medical Research Council (NHMRC), under Project Grant
number 1023197. SC is supported by NHMRC Career Devel-
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doi: 10.5694/mja15.00164Research“What should happen before asymptomatic
men decide whether or not to have a PSA test?”
A report on three community juriesrostate-speciﬁc antigen (PSA) Abstract
testing of asymptomaticObjectives: To elicit the views of well informed community members on
the ethical obligations of general practitioners regarding prostate-speciﬁc
antigen (PSA) testing, and what should be required before a man
undergoes a PSA test.
Design and setting: Three community juries held at the University of
Sydney over 6 months in 2014.
Participants: Forty participants from New South Wales, of diverse social
and cultural backgrounds and with no experience of prostate cancer,
recruited through public advertising: two juries of mixed gender and ages;
one all-male jury of PSA screening age.
Results: In contrast to Royal Australian College of General Practitioners
guidelines, the three juries concluded that GPs should initiate discussions
about PSA testing with asymptomatic men over 50 years of age. The
mixed juries voted for GPs offering detailed information about all
potential consequent beneﬁts and harms before PSA testing, and favoured
a cooling-off period before undertaking the test. The all-male jury recom-
mended a staggered approach to providing information. They
recommended that written information be available to those whowanted it,
but eight of the 12 jurors thought that doctors should discuss the beneﬁts
and harms of biopsy and treatment only after a man had received an
elevated PSA test result.
Conclusions: Informed jury participants preferred that GPs actively
supported individual men in making decisions about PSA testing, and that
they allowed a cooling-off period before testing. However, men of screening
age argued that uncertain and detailed information should be
communicated only after receiving an elevated PSA test result.Pmen remains controversial.1
Testing may improve prostate can-
cer survival rates,2 but can also lead
to harms, such as repeated inves-
tigations and the unwanted effects of
treatments, including incontinence
and impotence.3-5 Evidence re-
garding beneﬁts and harms alone has
not resolved tensions over PSA
testing.6 Disagreement among ex-
perts and in guidelines has confused
public communication in Australia
and internationally.7,8
In December 2014, the Prostate Can-
cer Foundation of Australia (PCFA)
and the Cancer Council Australia
(CCA) released clinical consensus
guidelines for general practitioners
for public comment,9 after the Na-
tional Health and Medical Research
Council (NHMRC) had published
information on the topic for health
practitioners.10 These documents
established criteria for identifying
men more likely to beneﬁt than to be
harmed by PSA testing. However, it
remains unclear if and when GPs
should introduce the subject of PSA
testing in consultations with indi-
vidual men. The Royal Australian
College of General Practitioners
(RACGP) advises GPs not to broach
the subject of PSA testing, but to
provide full information regarding
the beneﬁts, risks anduncertainties of
testing and treatment if patients spe-
ciﬁcally ask about it.11
In this article,we report the outcomes
of three community juries convened
in 2014 to consider the dilemmas
associated with PSA testing. A com-
munity jury is a group of citizens
brought together to receive detailed
evidence about a speciﬁc problem
and to then deliberate on this prob-
lem.12 Our aimwas not to capture the
opinions of the broader community,
but to ascertainwhat awell informed
citizenry would accept as legitimate
PSA testing policy and practice, andthe reasons for their views. Commu-
nity juries are an established, appro-
priate method for investigating such
questions.12 Community juries have
been used inAustralia and elsewhere
to consider questions related to can-
cer screening.13,14Unlike surveys and
focus groups, they involve extensive
provision of information, construc-
tive and structureddialogue between
ordinary members of the public and
experts, and adequate time for
consideration of the problem. The
process is similar to a legal proceed-
ing, but the outputs are not legally
binding; they instead provide evi-
dence for policy making.
We consulted major stakeholders
(consumer organisations, GPs, epi-
demiologists, urologists, the CCA) to
design the questions that the juries
would consider. All agreed that the
key issues to be explored were:MJA 203 (8) whether GPs should initiate dis-
cussions with asymptomatic men
about the PSA test;
 when men should be given in-
formation about the potential
beneﬁts and harms of testing,
biopsy and treatment.
Valid consent for interventions is in-
tegral to an ethical health care sys-
tem, and providing adequate and
timely information is fundamental to
valid consent. While this has been
noted in relation to PSA testing,15,16 it
is not yet clear what should happen
before men decide for or against
taking a PSA test. Noting the work
currently being undertaken by the
NHMRC,CCAandPCFA,we sought
information on what selected groups
of members of the public consider to
be the obligations of GPs regarding
informing men about PSA testing,
and what else might be requiredj 19 October 2015 335.e1
1 The questions addressed to the three juries, and the options available
335.e2
Researchbefore aman could validly consent to
a PSA test.for their verdicts
Jury 1 deliberated and drafted recommendations on the open question:
Consent and PSA testing for prostate cancer: “What should happen before
men decide whether or not to be tested?”
Juries 2 and 3 were asked to vote on two questions:
Part A. Select 1 or 2:
1. Should GPs introduce the topic of PSA testing during appointments with
male patients who have no symptoms?
OR
2. Should they wait until men ask about it?
Part B. Which of these options do you endorse? (Please give your reasons):
1. Men without symptoms should get all the information about the possible
beneﬁts and harms of testing, and biopsy and treatment, before they decide
whether or not to have a PSA test.
OR
2. Men should not get information about possible beneﬁts and harms of
biopsy and treatment before PSA testing. Instead, the doctor should wait
until they know the test result. If the test result is raised, then the doctor
should give information.
Jurors were asked to endorse either B1 or B2, and to give reasons for their
decisions. The juries were repeatedly reminded that the questions were
speciﬁcally about PSA testing for asymptomatic men.uMethods
Community jury research is a delib-
erative method, with the following
general characteristics:
 a group of citizens is convened
for 1 to 3 days;
 they are asked to consider a spe-
ciﬁc problem;
 they hear evidence from (often
opposed) experts, and ask the
experts questions;
 they are given time for delibera-
tion and to come to a docu-
mented conclusion.
There are two main approaches in
community jury research: partici-
pants draft open recommendations
as a group, or vote on options speci-
ﬁed by the researchers.17 We used
both approaches in our investigation:
Jury 1 tested anopen approach,while
Juries 2 and 3 were asked to vote on
speciﬁc options (Box 1).Recruitment and selection
We recruited three community juries
in 2014 — two of mixed gender and
ages (Juries 1 and 2), and one of men
of PSA screening age (Jury 3) — by
placing advertisements and articles
in the mass and social media in Syd-
ney. Of 119 respondents, 42 were
unavailable on the days scheduled
for the juries; 37 with recent personal
or close familymember experience of
prostate cancer treatment, biopsy or
active PSA monitoring were also
excluded. We sought socioeconomic
and cultural diversity for our juries.
Juries 1 and 2 were socioculturally
diverse but of above-average educa-
tional attainment; the all-male Jury 3
was also socioculturally diverse, but
its educational attainments broadly
matched those of the general Aus-
tralian population. Forty participants
were thus recruited according to their
eligibility, sociodemographic char-
acteristics and availability (Box 2).
Each jury commenced with an eve-
ning orientation session (Day 0),
during which the questions and the
jury process were introduced andMJA 203 (8) j 19 October 2015consent was obtained. Jury Day 1
focused on interrogating the evi-
dence and understanding the ethical,
legal and practical aspects of the
problem. Testimony on the following
themes was prerecorded by selected
experts and shown to jurors in a
video presentation:
 basic biology, diagnosis, treat-
ment and prognosis of prostate
cancer;
 qualitative empirical evidence on
how Australian GPs manage PSA
testing in their practices;
 ethical and legal aspects of pa-
tient consent (in general, and
with regard to screening);
 potential harms of screening
asymptomatic men for prostate
cancer; and
 potential beneﬁts of screening
asymptomatic men for prostate
cancer.
Each presentation lasted about an
hour. Prerecording ensured that the
evidence presentedwas standardised,
although some experts slightly modi-
ﬁed their presentations for Juries 2 and
3 according to the more speciﬁc op-
tions considered by these juries. The
biographical sketches of the experts
and the video presentations shown to
Juries 2 and 3 are available online.18Immediately after each video, the
relevant expert was available for
questions through a conference calling
system. Facilitated by a researcher,
these question-and-answer sessions
allowed jurors to clarify or challenge
the arguments presented. Facilitation
focused on promoting constructive
dialogue and fair interaction between
jurors. Our observations of unstruc-
tured deliberations and the transcripts
indicated that this inclusivity was
maintained during non-facilitated
periods.
For theﬁrst hour of JuryDay 2, jurors
reﬂected on, discussed and debated
the evidence, aided by a researcher
acting as facilitator. Juries then
deliberated for an hour without the
researchers, and either reached a set
of recommendations (Jury 1) or ma-
jority verdicts on the questions
posed (Juries 2 and 3). The recom-
mendations or verdicts, the under-
lying reasoning, and dissenting
views were reported to the research
team in a ﬁnal, facilitated feedback
session.
Data collection and analysis
The three deliberative groups (juries)
were the units of analysis in this
study. All jury deliberations (facili-
tated and non-facilitated) and expert
question-and-answer sessions were
2 Characteristics of the jury participants
Jury 1 Jury 2 Jury 3
Number 13 15 12
Age
<40 years 2 5 1
40e70 years 10 8 9
>70 years 1 2 2
Researchaudio-recorded and transcribed.
During the ﬁnal session, the verdicts
and reasons were recorded by a
researcher on a ﬂipchart. Each point
was reviewed by the jury to ensure
accuracy. Transcripts were subse-
quently reviewed to identify key
reasons why jurors supported or
rejected the presented options.Range, years 28e70 19e75 37e74
Median, years 52 49 57
Gender
Male 9 9 12
Female 4 6 0Ethics approval
Our study was approved by the
Cancer Institute NSW Population
and Health Services Research Ethics
Committee (HREC/12/CIPHS/46).Highest educational attainment
High school 2 3 1
Trade or diploma 0 1 7
Bachelor degree 4 7 3
Postgraduate degree 7 4 1
Cultural background/ethnicity*
Australian 11 11 7
Southern/eastern European 0 1 0
Southeast Asian 1 0 1
Northeast Asian 1 2 2
Southern/central Asian 0 1 1
Northwest European 0 0 1
Socioeconomic status of suburb†
Low 1 1 2
Middle 1 4 4
High 11 10 6
*Based on the Australian Standard Classiﬁcation of Cultural and Ethnic Groups (ASCCEG).22
†Based on Socio-Economic Indexes for Areas (SEIFA).23uResults
Jury 1
In response to the question, “What
should happen before men decide
whether or not to be tested?”, Jury 1
recommended that:
 GPs should initiate discussions
about PSA testing with 50e70-
year-old asymptomatic men,
and provide information about
the limitations of the test and the
potential beneﬁts and harms of
biopsy and treatment;
 these discussions should be
encouraged but not mandatory;
 discussions should inform a
man’s decision making rather
than be constrained by formal
procedures (eg, signing a form);
 GPs should consider a cooling-off
period, so that men need to wait
1 to 2 days after the discussion
before being tested; and
 the community should be in-
formed about expert uncertainty
regarding the PSA test, to stimu-
late discussion between men and
their GPs.
Problems discussed by Jury 1
without reaching a consensus were:
 the appropriate content for a pa-
tient information sheet;
 how to communicate to men that
they can opt out of PSA testing;
and
 whether to discourage PSA
testing by charging a fee.Juries 2 and 3, part A
Similar to Jury 1, themajority view of
both Juries 2 and 3 was that GPs
should introduce the topic of PSA
testing to asymptomatic men aged
50e70 years (Box 3). Prostate cancer
was seen as a legitimate health
concern for older men, so that PSA
testing was an appropriate topic for
general health discussions. Jury 3 (all
males) also argued that GPs were
best placed to informmen about PSA
testing, as GPs were a more reliable
point of access to medical advice;
relying on other information sources
would be “leaving it to chance”. All
men, they said, should have equal
access to the same information.
A minority in both Juries 2 and 3
voted that GPs should not raise thetopic of PSA testing with asymp-
tomatic men because other, more
important health issues should
receive priority, and because men
might bemore inclined to have a PSA
test if GPs raised the topic. Theywere
particularly concerned about the un-
reliability of the test and the risks of
unnecessary treatment ensuing.Juries 2 and 3, part B
Like Jury 1, the majority of Jury 2
(mixed gender) voted that detailed
beneﬁteharm information about
PSA testing and prostate biopsy
and treatment should be provided
in advance to support informed
decision making. This was a mi-
nority position in the all-male Jury 3
(Box 3).MJA 203 (8) j 19 October 2015 335.e3
3 The outcomes of the deliberations of the three juries
Jury 1 recommendations
GPs should:
< initiate discussions with 50e70-year-old asymptomatic men about PSA
testing;
< be prepared to provide men with information about all the potential harms
and beneﬁts;
< consider instituting a cooling-off period so that men need to wait before
taking the test.
Juries 2 and 3 verdicts
Part A
1. Should GPs introduce the topic of PSA testing during appointments with male
patients who have no symptoms?
OR
2. Should they wait until men ask about it?
Jury 2 (mixed gender, n ¼ 15) voted 12e3 for option 1;
Jury 3 (all men, n ¼ 12) voted 10e2 for option 1.
Part B
1. Men without symptoms should get all the information about the possible
beneﬁts and harms of testing, and biopsy and treatment, before they decide
whether or not to have a PSA test.
OR
2. Men should not get information about possible beneﬁts and harms of biopsy
and treatment before PSA testing. Instead, the doctor should wait until they
know the test result. If the test result is raised, then the doctor should give
information.
Jury 2 (mixed gender, n ¼ 15) voted 13e2 for option 1;
Jury 3 (all men, n ¼ 12) voted 8e4 for option 2.u
335.e4
ResearchThe reasons given by members of
Juries 2 and 3 for their views
included:
 men have a right to know rele-
vant information before making a
decision; and
 after an elevated PSA test result,
it might be difﬁcult to refuse
subsequent biopsy and treat-
ment, and men may not obtain
the information needed to decide
about the next steps.
Similar to Jury 1, Juries 2 and 3 sup-
ported a cooling-off period so that
men could reconsider their decision
before testing.
The majority of Jury 2 (13 of 15) sup-
ported providing all information
before PSA testing. However, 10 of
the 13 objected that our wording
(especially “should” and “all”) was
too prescriptive. They wanted GPs
to be free to provide information
tailored to an individual’s level of
interest and personal requirements.
Two-thirds of the all-male Jury 3
voted that information about the
beneﬁts and harms of biopsy andMJA 203 (8) j 19 October 2015treatment should be provided only
after an elevated PSA test result had
been received. These jurors argued
that the PSA test alone was not
intrinsically harmful, and favoured
staggering the delivery of informa-
tion, with written information avail-
able to those who wanted it at any
particular point. Jury 3 members, in
particular, were concerned about
“information overload”. They felt
that most men would not want to
understand the harms and beneﬁts of
prostate biopsy and treatment until it
was directly relevant to them. They
trusted GPs to tell them what they
needed to know in a timely manner,
avoiding unnecessary anxiety.
Notably, some participants argued
that details about the risks of biopsies
and treatment options should be
provided to men by urologists
because of their specialist expertise.Discussion
After two days of deliberation, all
three community juries recom-
mended that GPs should discuss the
PSA test with asymptomatic menover 50 years of age as part of routine
care. Jurors felt GPs were best placed
to consistently inform men about
PSA testing, rather than relying on
their being informed (or not) by other
sources. All three juries wanted GPs,
if prompted, to provide information
about the limitations, beneﬁts and
risks of testing, biopsy and treatment,
and to offer to providemore details if
desired by the patient. The concept of
a cooling-off period to allow men to
think about whether or not they
wanted a PSA test was also highly
valued.
All Jury 3 members were men, and
many were having, and appeared
committed to, routine annual PSA
tests. They also reached different
conclusions to the other juries about
when information should be pro-
vided. While Juries 1 and 2 focused
on what would be good for men
generally, members of Jury 3 often
focused on their own personal expe-
riences and preferences, including a
shared inclination to rely on a doc-
tor’s assessment of the particular in-
formation that was required to
inform a patient’s decisions. This
suggests that, although an informed
public prefers GPs to take an active
role in educating men about the
PSA test, some men of screening age
may not wish to be burdened with
uncertain and detailed information
about the consequences unless they
have received an elevated PSA test
result.
There are valid reasons why GPs
might resist raising awareness of the
PSA test. Simply mentioning it may
encourage men to favour being
tested; patients differ in their infor-
mation needs;19 and communicating
the potential harms of PSA screening
is difﬁcult.20,21 The new consensus
recommendations and NHMRC-
developed information resources
promise to support GPs in the chal-
lenging task of discussing the topic.
Models for communicating informa-
tion about screening in a balanced
and patient-centred way have also
been described in the literature. The
“consider an offer” model,19 for
example, suggests that GPs helpmen
consider and evaluate recommenda-
tions or offers of screening, while
explicitly acknowledging that the
Researchoffer might reasonably be refused.
Rather than encouraging screening
or expecting people to analyse
detailed evidence, whether they felt
ready to do so or not, such patient-
centred approaches could help indi-
viduals decide how much informa-
tion they wish to receive, and to
reﬂect on their values and prefer-
ences regarding beneﬁts and harms
when deciding whether or not to be
screened.
A limitation to this study is that
community juries are comprised of
small groups of engaged citizens
whose viewsmaynot represent those
of the general public. However,
as all three juries came to similarconclusions, it is likely that our ﬁnd-
ings are replicable. Our unit of ana-
lysis was the deliberative group, but
we note that the ﬁndings from the
all-male jury differed from those of
the mixed-gender juries, and that the
men in the mixed juries endorsed the
ﬁnal recommendations of the juries
in which they participated. This
suggests that gender-related factors
may inﬂuence jury processes.
The juries were clear: GPs should
raise the topic of PSA testing and
explain the beneﬁts and harms, but
tailor their information to the indi-
vidual patient. Timing of informa-
tion provision was less clear. PSA
testing, the juries concluded, is ahealth issue that matters to men, and
GPs are a reliable, trustworthy
source of advice on health issues.
These jury outcomes invite critical
reﬂection by professional bodies
about how GPs should actively
support individual men making de-
cisions about PSA testing.
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Walking the tightrope: communicating overdiagnosis
in modern healthcare
Communication that empowers the public, patients, clinicians, and policy makers to think differently
about overdiagnosis will help support a more sustainable healthcare future for all, argue Kirsten
McCaffery and colleagues
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Overdiagnosis and overtreatment have serious implications for
individuals, healthcare systems, and society,1 2 and effective
strategies are urgently needed to help the public, clinicians, and
policy makers address this problem. Communication about
overdiagnosis has been highlighted as essential for moving
forward but presents several challenges, such as the potential
to confuse the public, undermine trust, and adversely affect
people who already have a diagnosis. Various communication
based strategies offer real promise; we describe what is known
and what we need to know to communicate effectively and
safely about overdiagnosis and overtreatment.
What are the key messages to be
communicated?
Understanding of overdiagnosis among the general public and
health professionals is limited, so it is essential to communicate
what it means for individuals, the health system, and society
(box 1). By definition, overdiagnosis will not improve prognosis
andwill probably harm individuals (for example, by unnecessary
intervention) or society (opportunity costs). For individuals, it
is important to communicate the nature (physical or
psychological), likelihood, and duration of the harms. For
societies with free public healthcare, the financial strain and
opportunity cost are usually at system level—resources wasted
on unnecessary tests and treatments are unavailable for people
in greater need. But in private healthcare systems, overdiagnosis
can be a huge personal financial burden, even for those with
insurance.
Communication is further complicated because it is usually
impossible to know whether an individual has been
overdiagnosed or benefited from the diagnosis—overdiagnosis
can only be observed at the aggregate level. Recent efforts to
communicate the concept and likelihood of overdiagnosis in
breast screening have had some success, albeit with much room
for improvement. When given a patient decision aid including
an infographic and icon array (figure⇓), 29% of women
understood both the concept and quantitative outcomes of breast
screening (including deaths avoided, false positive results, and
overdiagnosis); 59% of women understood the conceptual
information alone.3
Communication based strategies to
mitigate overdiagnosis
Several communication based strategies have been applied in
the areas of overtesting and overtreatment and directed at
individual, community, or policy levels (box 2).
Strategies for individuals
Shared decision making is a consultation process where a
clinician and patient jointly make a health decision. It changes
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Box 1: Overdiagnosis and its consequences1 2
Overdiagnosis occurs when a diagnosis is “correct” according to current professional standards but when the diagnosis or associated
treatment has a low probability of benefiting the person diagnosed.2 It is caused by a range of factors such as:
• Use of increasingly sensitive tests that identify abnormalities that are indolent, non-progressive, or regressive (overdetection)
• Expanded definitions of disease—for example, attention-deficit/hyperactivity disorder and dementia—and lowering of disease thresholds,
such as osteoporosis (overdefinition)
• Creation of pseudodiseases (also called disease mongering), such as low testosterone and restless leg syndrome
• Clinicians’ fear of missing a diagnosis or litigation
• Public enthusiasm for screening or testing and desire for reassurance
• Financial incentives
Potential consequences of overdiagnosis
• Psychological and behavioural effects of disease labelling
• Physical harms and side effects of unnecessary tests or treatment
• Quality of life affected by unnecessary treatment
• Hassles of unnecessary tests and treatments
• Increased financial costs to individuals
• Wasted resources and opportunity costs to the health system
• Overmedicalisation of society
the way decisions are framed by identifying that there is a
decision to be made (not an obligatory test or default treatment),
and explaining the range of options available and their benefits
and harms. It also involves deciding with patients “what is most
important to them” in terms of their values, preferences, and
circumstances.4 Importantly, the option of doing nothing or
active surveillance can be discussed as a deliberate or positive
action5 to counter people’s bias for tests and treatment, especially
in cancer.6Consumer led interventions that teach patients to ask
about benefits and harms of different options have shown some
success.7 Shared decision making is increasingly part of clinical
training, often combined with evidence based healthcare,8 and
this should be enhanced to include understanding and
communicating about overdiagnosis.
Patient decision aids support shared decision making. High
quality evidence from 115 trials shows that they improve
patients’ knowledge and understanding of options and their
risks and benefits, and increase consistency between patients’
values and choices.9 Decision aids have successfully informed
women about overdiagnosis in breast screening,3 reduced men’s
desire for prostate specific antigen (PSA) testing10 or surgical
management for prostate cancer, and reduced preferences for
potentially unnecessary elective surgery.9 A trial of a decision
aid communicating overdiagnosis in breast screening (879
women approaching age 50) increased informed choice
compared with controls and did not increase anxiety; worry
about breast cancer decreased (box 2).3A pilot study of a breast
screening decision aid for women over 75 years (n=45) including
information on overdiagnosis had similar findings.11 12However,
information on the harms of overdiagnosis and overtreatment
is rarely presented.13 14Consumers consistently overestimate the
benefits of screening, tests, and treatments and underestimate
the harms,13 and although shared decision making is widely
espoused, it is not often implemented.15
Strategies for communities
Mass media and direct to consumer campaigns can influence
large numbers of people simultaneously and promote sustained
beneficial changes in behaviour.16 For example, a mass media
campaign about back pain, driven partly by concerns about
unnecessary back imaging, changed both community and general
practitioner beliefs about management, resulting in reduced
imaging, work insurance claims, and healthcare usage.17 Scaled
down versions of the programme have been replicated in several
countries.16 Other important initiatives include the Choosing
Wisely campaign, now operating in nine countries (www.
choosingwisely.org), and the UK’s “do not do” list.
Policy directed strategies
Deliberative democratic methods (such as community juries)
support policy decisions by gathering informed public responses
about disputed issues, such as what services are available or
reimbursed by health funds. Because overdiagnosis is
scientifically and politically contested, this topic is ideal for
deliberative democratic methods. Deliberative methods must
meet exacting standards and are time consuming.18 Community
juries have considered PSA testing in Australia19 20 and
mammographic screening in New Zealand, where participants
changed their recommendation at least partly because of
potential harms from overdiagnosis.21 Disseminating findings
from juries could enhance community health literacy, leading
to better informed citizens and more transparent decision
making.
Changing terminology:Behaviours can be influenced bymedical
terminology, and changing the names for medical conditions
may help reduce the effect of overdiagnosis. In one study,
describing ductal carcinoma in situ as “non-invasive cancer”
resulted in 13-16% more women choosing surgical treatment
(rather than medication or active surveillance) compared with
calling it a “breast lesion” or “abnormal cells.”22 Similar findings
were reported in Australia.23 24 Independent experts convened
by the US National Cancer Institute25 and National Institute of
Health have proposed dropping the word “cancer” entirely in
this case, arguing for it to be reserved for lesions likely to
progress if untreated.25 26 Similar arguments exist for thyroid
and prostate cancer,27 but effects of disease labels extend beyond
cancer. Parents were more likely to accept medication when
“gastro-oesophageal reflux disease” (compared with no label)
was used to describe excessive irritability in infants, even when
told the drugs would not control the symptoms.28
Potential challenges to effective
communication
Low levels of awareness: Awareness of overdiagnosis is low,
particularly for cancer screening with few people understanding
overdiagnosis of cancer is even possible.29 30 In one study, 18%
of Australian men and only 10% of women said they had been
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Box 2: Examples of effective communication strategies for overdiagnosis or overtreatment
Community back pain campaign (three year campaign 1997-99)17
• Significant improvements in community (n=4730) beliefs about back pain over three years in Victoria (where campaign was run) versus
New South Wales (no campaign)
• General practitioners’(n=2556) knowledge improved—for example, time when patients can to return to work, not prescribing complete
bed rest. In a patient scenario, GPs in Victoria were 2.51 times less likely to order tests for acute low back pain and 0.40 times as
likely to order lumbosacral radiographs. Over the duration of the campaign insurance claims for back pain reduced by 15%
Patient decision aids9
• Cochrane review of 115 randomised controlled trials reported that decision aids reduced number of people choosing major elective
surgery in favour of more conservative options (relative risk 0.79) and reduced number of men choosing PSA testing (RR 0.87) in
nine studies
• A randomised trial of a decision aid for women approaching 50 years (n=879), which explicitly explained the concept of overdiagnosis
and presented quantitative information on its likelihood, found that it increased informed choice by 9% (intervention24% v control
15%), reduced intentions to screen by 13% (74% v 87%)3
Changing disease terminology
• Study of 394 women compared the commonly used cancer term for ductal carcinoma in situ (non-invasive cancer) with non-cancer
terms (breast lesion, abnormal cells). Results showed 47% preferred surgery when cancer term was used compared with 34% and
31% respectively22
Citizen juries
• 27 men randomly allocated to PSA screening community jury (12 men) or control (15 men). The jury concluded that the Australian
government should not invest in PSA testing and recommended an education programme for GPs with better quality and consistent
information about PSA for doctors and patients. After the jury, men had significantly lower intentions to screen compared with controls24
told about overdiagnosis in screening for prostate and breast
cancer respectively.31 Similarly, a US survey reported only 9.5%
of men and women (aged 50-69 years) said they had been
informed about overdiagnosis when discussing cancer
screening.32 Further US and UK studies reported that only about
half of respondents had heard of “cancers that grow so slowly
that they are unlikely to cause [you] problems in [your]
lifetime.”33 34 There are few publications reporting clinician
awareness, but one recent survey among 126 university affiliated
clinicians in the US found 28% listed overdiagnosis as a
potential harm of PSA testing, and 56% listed unnecessary
treatment.35
Cognitive biases and counterintuitive messages: Longstanding,
prominent public health messages have emphasised the benefits
and ignored the harms of early diagnosis for many diseases.36 37
This makes the concept of overdiagnosis unfamiliar,
counterintuitive, and difficult to understand. There is widespread
faith in the importance of early detection,38 39 and people may
choose cancer screening because it is the apparent default
decision, even if their informed preferences would be
different.40-42 Furthermore, when people are predisposed towards
an intervention, they may perceive benefits to be high and risks
low, even when explicitly told otherwise.43 Suggesting a
reduction in tests that are popular with the public can provoke
emotionally charged, even hostile responses,44 reflecting
cognitive dissonance.45
Uncertainty and trust: Intolerance of uncertainty and anxiety
about missing rare cases underpin much medical excess.46
Communicating about overdiagnosis requires us to acknowledge
the inherent uncertainty in the size and extent of the problem
and its consequences. These issues are often hotly contested.47
Communicating uncertainty adds complexity and may lead to
confusion and avoidance of decision making48 and can
undermine trust in the healthcare provider.49 However, distrust
can also arise when patients discover that information about
harms has been withheld. Clinicians often avoid discussing
uncertainty with patients,48 but studies of breast and prostate
screening show that people want to be told about
overdiagnosis.19 29
Vested interests and persuasive communication: Vested interests
may influence how information is presented in the media and
the scientific arena. Pharmaceutical and device manufacturers
have direct interests in maximising product sales. Industry
funded disease awareness campaigns often increase the numbers
of people portrayed as patients.50Narrowing the boundaries that
define disease or raising diagnostic thresholds is a threat to
turnover, profit, and professional interests.51 Similarly patient
advocacy groups, often also industry funded, can have interests
in portraying their condition as widespread, severe, and treatable
to optimise media, professional, and policy attention and to
attract resources.52 Politicians too have seen mileage in
supporting screening programmes without offering more
nuanced assessments of their benefits and harms, including risks
of overdiagnosis.53
Further research directions
We need studies about what the public, patients, and clinicians
currently know, understand, and want to know about
overdiagnosis and their attitudes, reactions, and choices when
provided with such information. Then we can research effective
communication—how to increase understanding among all
parties and the effectiveness and acceptability of such strategies.
Once effective interventions are identified, we need to
understand how to implement them within healthcare systems
that currently reward overdiagnosis. However, research must
also consider potential harms of communicating overdiagnosis,
and herein lies the tightrope. Possible harms include cognitively
overburdening and confusing the public, adversely affecting
patients already diagnosed and treated, and creating distrust in
conventional medicine.29 A careful evidence based approach is
essential.
Achieving widespread understanding about overdiagnosis will
take time, but we have some tools to move forward. Given that
high health anxiety is largely a consequence of the health system
itself, the health community must be patient with and
sympathetic towards those who do not share this concern about
overdiagnosis. Successful communication that empowers the
public, patients, clinicians, and policymakers to think differently
about overdiagnosis will help support more sustainable
healthcare for all.
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Figure
Infographic and icon array explaining overdiagnosis in breast screening in a patient decision aid developed by Hersch et
al3
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